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Abstract 
Chinese Hamster Ovary (CHO) cells are the most common mammalian cell line used 
around the world and are considered the “workhorse” for production of recombinant 
proteins in the pharmaceutical industry.  
Efforts have been made to optimise the production process through advancements in media 
formulation and improving process control strategies like bioreactor design, fed-batch 
feeding and temperature shift approaches, increasing batch titres from 50 mg/L to 5-10 g/L. 
However, it is believed that there is still room for improvement in the advent of media and 
process optimisation reaching a plateau. An alternative route to overcome this plateau is 
through engineering of the CHO host cells themselves.  
The overall aim of this PhD project was to identify and exploit endogenous CHO promoters 
to enhance heterologous protein expression.  
Having obtained ~ 30 CHO putative promoter sequences of varying length from 9 target 
genes from PCR, we screened and cloned 4 priority CHO promoter fragments into a variety 
of reporter vectors (GFP, Luciferase, p27 and EPO) to test their strength and utility. We 
have identified 3 novel temperature responsive promoters fragments from Cirbp SSu72 and 
Mdm2 genes and one constitutive promoter from a miRNA cluster [miR-17-92].  
These promoters can permit moderate to high expression of a desired protein similarly to 
viral commercial ones such as cytomegalovirus (CMV) and simian virus (SV40) as well as 
boost expression levels of reporter proteins upon a temperature shift to 31
o
C. As a result, 
these novel tools are particularly advantageous in a bioprocess where reduced temperature 
is used already to increase protein production. In addition, we reported a ~94% decrease in 
clonal GFP stability of a CMV viral promoter versus our endogenous promoters over a 3 
month timecourse experiment proving that viral promoters cannot sustain prolonged 
activity in culture like our novel endogenous promoter sequences. 
We have also shown that CHO clones overexpressing human XIAP exhibited 2/3-fold 
increased resistance to apoptosis and survival in extended culture settings compared to 
control cells. A secondary aim was to identify potential interacting miRNAs by utilising a 
novel pulldown method (miR-Capture), to isolate miRNAs targeting the anti-apoptotic 
XIAP mRNA in two different cell types, using a biotinylated anti-sense oligonucleotide 
capture affinity technique.  
Thus, identifying miRNAs which may impact on favourable phenotypes such as anti-
apoptosis and increased growth rate may provide a means of improving CHO cell lines 
used for biopharmaceutical production.  From the miR-Capture, there were 26 miRNAs 
detected in the human lysates and 14 in the CHO lysates. Four miRNAs (miR-124, miR-
526b*, miR-760 and miR-877) were shown to be common from parallel CHO and human 
miR-Capture’s, using oligos designed against XIAP. Functional validation provided further 
evidence that miR-124 targets XIAP mRNA in CHO and human cells and may be a suitable 
target for miRNA engineering in CHO. 
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In conclusion, we demonstrate the potential utility of novel endogenous, temperature 
sensitive promoters and the overexpression of XIAP in conjunction with existing 
production processes to ameliorate bioprocess performance further. 
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NHA  - Normal Human Astrocytes 
nt  - Nucleotides  
OD  - Optical Density 
Oligos  - Oligonucleotides 
p53  - Protein 53 (tumor suppressor protein) 
PBS  - Phosphate Buffered Saline 
PCD  - Programmed cell death 
PCR  - Polymerase Chain Reaction 
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PM (-)  - Pre-Mir (neg control) 
PS  - Phosphatidylserine 
p.s.i  - Pressure per square inch (Ψ) 
PVDF  - polyvinylidene difluoride membranes 
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TE  - Tris-EDTA 
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TSS  - Transcription/Translation Start Site 
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1.1: Introduction to Biotechnology in Bioprocessing 
The birth of recombinant DNA technology in 1973 by Cohen and Boyer made possible the 
emergence of Biotechnology and its continuation into mainstream business (Cohen et al. 
1973). Biotechnology bridged the gap between drug development and manufacturing of 
recombinant proteins as new therapeutic medicines by allowing the application of DNA 
cloning methods for commercial purposes.  
Over the last 4 decades, we have witnessed a change in genetic engineering from simple 
artificial plasmid constructs in microorganisms to more elaborate mammalian recombinant 
protein technology. Now recombinant protein therapeutics which are primarily produced in 
mammalian cells, constitute a $108 billion global market (Wuest, Harcum and Lee 2012). 
More recently the number of recombinant technologies has increased globally with Chinese 
Hamster ovary (CHO) mammalian host cells becoming the leading mammalian platform in 
the production of biopharmaceuticals. They account for over 60% or entire global 
production (Hernandez Bort et al. 2012) (Fussenegger et al. 1998) (Kim and Lee 2012). 
In the last few years we have seen the yield and titres of batch production reach record 
highs, going from milligrams to grams per litre (Zhou et al. 1997) (Lim et al. 2010). This 
was due to many factors such as; bioreactor design and improved materials, optimisation of 
media, improved expression systems and selection of high-producing CHO clones. As a 
result, some believe the maximum output of these little protein super factories has been 
reached whereby the cells can’t actually make anymore due to the limits of the cellular 
machinery.  
The next generation of improvements in bioprocessing may come from genetic engineering 
approaches such as; vector engineering, the use of endogenous promoters and anti-
apoptotic regulation (topics which will be covered in the succeeding introduction sections), 
as tools with the overall aim to allow more efficient protein production by overcoming this 
capacity bottleneck (Wurm 2004).  
Improving productivity may not be the only goal but infact, recent years have shown that a 
level of control is thought to be just as if not more desirable than maximum protein yield. 
This control is often dependant on the bioprocess in question, or the nature of a particular 
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protein (ex: protein product versus an engineering target or toxic versus non-toxic product) 
and represents another avenue to use engineering tools.  
The focus of the work described in this thesis is about identifying and implementing some 
novel genetic tools in the form of promoters to gain greater control over CHO cell 
behaviour and performance within a bioreactor. 
 
1.2: Chinese Hamster Ovary Cells 
Chinese Hamster Ovary (CHO) cells were derived from the ovaries of Hamsters as the 
name suggests. In 1957, Theodore T. Puck obtained a female Chinese Hamster from Dr. 
George Yerganian's laboratory at the Boston Cancer Research Foundation and used it to 
derive the original Chinese Hamster ovary cell line.  
Since then, CHO cells have become the workhorse cell-line of choice for recombinant 
protein production because of their rapid growth and high protein production capacity 
necessary for large scale biopharma production increasing production of the drug of interest 
(Jayapal et al. 2007) (Mead et al. 2009).  
A variety of cellular expression systems have been used over the years including; bacteria, 
yeast, insect and plant cells which can produce valuable recombinant proteins. The majority 
of new protein products are made in mammalian cells, in fact among the 58 biopharma 
molecules approved from 2006 to 2010, 32 are produced by mammalian systems (Walsh 
2010). This is due in part to the fact that only mammalian cells can facilitate post-
translational modifications (PTMs) such as folding and glycosylation on the protein of 
interest, to be fully biologically active in other mammalian cells.  
Take the three major therapeutic proteins on the market today, erythropoietin (EPO), tissue-
type plasminogen activator (t-Pa) and β-interferon. All require appropriate glycosylation 
made possible by the PTMs offered by CHO cells (Kim and Lee 2012).  
Furthermore, the first approval of t-Pa in 1986, paved the way for mammalian cells to be 
the emerging workhorses in an expanding field, with CHO cells being the most valuable 
due to the following characteristics; 
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 Easy to handle and robust in culture  
 Perform PTMs for full protein functionality 
 Relatively safe – (as they do not propagate most human pathogenic viruses) 
 Fast growing cell line (fast turnaround times) 
 Accept foreign/exogenous DNA readily when transfected 
 They can be grown and adapted in a multitude of medium types 
 A broad range of commercial sub clones exist 
 They can grow in suspension or adherent/attached cultures 
 
As CHO cells gained popularity for being safe hosts, FDA approval became more 
widespread, offering a big advantage to multinational pharmaceutical companies and of 
course the patients. In addition, CHO cells did not suffer from the disadvantage of a low 
specific productivity (Qp) like other mammalian expressers at the time, as it could be 
overcome with gene amplification systems such as dihydrofolate reductase (DHFR) and 
glutamine synthetase (GS) (Lim et al. 2010). 
 
1.3: Media Optimistation 
Before any genetic alterations were even conceived, media formulation and composition 
was of utmost importance in the maintenance and growth of mammalian cells. It was 
important because they are a more complex biological entity than bacteria and fungi and 
thus survival is harder outside a favourable environment. Once a basal growth medium is 
established additional amino acids, lipids, salts, vitamins growth factors etc can be added to 
satisfy all the nutritional needs of the cells in culture.  
Cellular productivity is proportional to biomass and cell viability/health of producer cells 
(Kumar et al. 2007). Each cell line will have a defined growth medium in which it performs 
best and in the case of CHO cells over the last 20 years, tweaking the media composition 
often through trial and error, has yielded excellent titer results up to a g/L scale (Jayapal et 
al. 2007). However, culture media should not increase the osmolality or encourage 
generation of excess metabolic waste products as these affect both quantity and quality of 
the protein product (Castro et al. 1992). 
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Three main categories for existing media formulation are; (1) Serum supplemented media, 
(2) Serum-free media and (3) Protein-free media. Ideally nutrient formulations totally free 
of exogenous proteins containing no materials of animal origin to be used for high density 
cell culture and biological production are the holy grail in media optimisation (Jayme 
1999). 
(1) Serum is an ill-defined non cellular portion of blood that remains after removal of blood 
cells and clotting proteins and is one of the most important basic requirements for 
mammalian cells during ‘in vitro’ culture. Serum can protect the cells from shear-stress and 
has been shown to delay the onset of apoptosis and increase viability in culture. Zanghi et 
al, report that using 5% FBS reduced the specific cell death rate by 65% during a 3-d 
lactate-consumption phase and a 10% FBS supplement increased cell viability to >99% 
during exponential growth from ~75-90% compared to protein-free media (Zanghi et al. 
1999). However, high batch-batch variations of isolated serum and risk of contamination 
from prions and viruses resulting in transmissible spongiform encephalopathy (TSE), have 
led to developments of formulations free of serum. 
(2) Eradication of serum from culture medium is necessary when a protein product is for 
therapeutic purposes, as mentioned to avoid cross contamination with pathogens and 
immunogenic responses. Also important are the costs of downstream processing to purify 
the target protein/drug once the process is complete, which otherwise can be complicated 
by the presence of protein-rich serum.  
(3) The elimination of proteins such as growth factors, from media is also beneficial in 
much the same way as elimination of serum, mainly allowing further reduction in 
downstream process costs in the pharmaceutical industry when producing recombinant 
proteins.  
However, care is needed when sourcing of non-protein additives (e.g., geographic location, 
endemicity and species) and then use trusted validation methods before supplementation 
(Jayme 1999) (Jayme and Smith 2000). An example of a chemically defined protein-free 
formulation would be the CDM-HD by FibercellSystems™ and is optimised for use in their 
hollow fiber bioreactor systems. 
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In conclusion, while media optimisation has been beneficial and a vital cog in improving 
bioprocess production using mammalian cells. Some believe improvements have reached a 
plateau and alternative means are being sought such as host cell and vector engineering 
(Lim et al. 2010) (Kim et al. 2012). Altering cell genetics through engineering approaches 
and using specific molecules/genes involved in certain pathways within the cell could 
influence proliferation and apoptosis for example, allowing the cells to perform beyond 
their natural characteristics and thus drive more beneficial protein production. 
 
1.4: Strategies in Mammalian Cell Engineering 
To improve characteristics of recombinant CHO (rCHO) cells in regard to cell growth and 
foreign protein production, numerous strategies have been targeted mainly to increase the 
time integral of viable cell concentration (IVCC) and/or specific productivity of each 
individual cell (Qp). Enhancing Qp is the common goal for biotechnologists with many 
engineering methods being used in various ways, which will be discussed over the course 
of this section. 
 
1.4.1: Stable recombinant clone generation in CHO (rCHO) 
The generation of a producing cell line is through the introduction of a transgene encoding 
the protein product into host CHO cells. This is usually followed by gene copy number 
amplification to increase its transcript level and subsequent intensive screening to isolate 
the high-producers capable of increased secretory capacity (Seth et al. 2006) (Kantardjieff 
and Zhou 2014).  
By transfecting a plasmid encoding a GOI, external DNA is incorporated into cells via 
transient (short term) transfection or integrated into the genome of the cells via stable 
transfection (permanent).  
Only the cells which contain the integrated GOI and selective marker in their genome can 
survive under selective pressure, this facilitates a high degree of heterogeneity where all 
resultant progeny to display the same behaviour characteristics. Routinely then, the next 
step is to identify the best performers over extended periods, often screening for 
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characteristics related to bioprocessing such as; high growth rate, slow death rate and high 
specific cell productivity (Qp). 
A common method to construct recombinant CHO cell lines is to transfect dihydrofolate 
reductase (DHFR) negative (dhfr
−
) CHO cell lines such as the DG44 (Urlaub et al. 1983), 
with the cDNA genes for DHFR and the protein of interest. Initial transformants are 
selected for growth in the absence of glycine, purines, and thymidine. The transfected genes 
are then amplified by stepwise increasing the concentration of methotrexate (MTX), a 
competitive inhibitor of DHFR, in the culture medium (Kaufman 1990). During this 
process the transfected genes are amplified several 1000-fold resulting in an increased 
production rate for the recombinant protein (Crouse et al. 1983). 
However, screening can be laborious and slow. In recent times other selection technologies 
to isolate production standard cell lines have come to fruition. See table 1.4.1, for an 
overview of these selection technologies. 
 
Table 1.4.1: Clonal selection methods coupled with their advantages/disadvantages. 
Selection Method Advantages Disadvantages 
Limited dilution single cell 
cloning 
Simple, cost effective Time-consuming, Isolation not 
guaranteed of high expressors, 
low throughput 
Fluorescent activated cell 
sorting (FACS) 
High throughput, common 
industrial method 
Toxicity issues from GFP 
expression, stressful to cells, 
expensive instrument 
ClonePix (Genetix) Automated / fully sterility Expensive / needs trained 
person 
Laser-enabled analysis and 
processing (LEAP) 
Automated / time saving Potential damage to cells 
(irradiation) 
Gel microdrop technology Safety from product diffusion 
over time 
Low frequency of bead 
occupancy (~15%) 
Matrix-based secretion assay Protein secretion measured on 
a cell by cell basis 
Difficulty in sorting/laborious 
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In conclusion, random integration and gene amplification still represent the standard 
approach in industrial application for generating production strains (Kramer, Klausing and 
Noll 2010). Additional avenues such as, introduction and overexpression of genes and site-
specific integration techniques which can facilitate insertion of a product gene in contrast to 
random integration are discussed in the coming sections. 
 
1.4.2: Overexpression engineering 
Probably the most traditional way to engineer cell lines is based on overexpression of 
certain genes. It usually involves the isolation of a native DNA sequence (often the cDNA 
of a full gene), this fragment is then subsequently cloned into a mammalian expression 
vector/plasmid for transfection into a host for propagation. The stable integration into the 
cell genomes is promoted by applying antibiotic selective pressure. Furthermore, it is 
possible to increase the expression of the amplified gene by raising the selective pressure 
(Kramer et al. 2010) (Klausing and Noll 2010). 
Studies have shown that overexpression of proliferative and anti-apoptotic genes can lead 
to improved bioprocess phenotypes, for example, overexpression of the bcl-2 and Beclin-1 
genes and their homologues represents a frequent overexpression strategy to increase 
viability and inhibit apoptosis in CHO (Figueroa et al. 2003)(Ifandi and Al-Rubeai 2005, 
Lee et al. 2013). While Omasa et al, report that overexpression of the growth arrest DNA 
damage inducible protein 34 (GADD34) could improve recombinant human antithrombin 
III product concentrations by ~40% (Omasa et al. 2008). Additionally, overexpression of 
HSPs (HSP27 and HSP70) was found to extended culture times and increase productivity 
in CHO cultures (Lee et al. 2009). 
Overexpression and manipulating genes or regulatory pathways can be a valuable approach, 
however, problems can arise. These modifications could destabilize the metabolic balance 
within the cells and impair other functions and cause unexpected side-effects (Kramer, et 
al. 2010). For example; overexpression of Bcl-2 resulted in down-regulation of DNA repair 
and NHEJ (non-homologous end-joining) leading to abnormal chromosomal formation in 
approximately 30% of cell divisions in metaphase (Wang et al. 2008). 
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Although site-specificity is not a prerequisite for introduction of transgenes into a host for 
overexpression, the success of integration can be boosted by more specific insertion 
methods, particularly into favourable areas of the genome permitting high transcription 
rates. Targeted integration also may avoid unwanted disruption of coding sequence. It is a 
powerful tool to have more control of targeted integration of an exogenous sequence into a 
predetermined genomic location. 
Methods such as site-specific recombination (SSRs) have come to prominence to tackle the 
issues of sub-optimal expression of transgenes at unfavorable chromosomal loci. Strategies 
such as using site-specific nucleases, recombinase-mediated cassette exchange (RMCE), 
for example the Cre/LoxP system, and cis-acting elements have all been shown to increase 
efficiency of site-specific insertion of a transgene. 
 
1.4.3: Site-specific targeting techniques 
1.4.3.1: Site-specific nucleases for genome editing 
Gene targeting and knockout are useful tools to study gene function and modify features of 
a cell. Early methods revolved around using chemical agents, radiation and transposons 
(Remy et al. 2010). The outcome of these non-targeting methods was based on chance and 
screening for cells with the desired mutation was time and labour intensive.  
Using more accurate methods like homologous recombination to induce mutations at 
specific locations was explored. To increase the occurrence of HR, double-stranded breaks 
(DSBs) can be introduced at certain sites within the genome (Kramer, Klausing and Noll 
2010).  
This can be achieved by using site-specific nucleases such as; Zinc-finger nucleases 
(ZFNs), Transcription activator-like effector nucleases (TALENs), Meganucleases and 
more recently the emergence of Clustered regulatory interspaced short palindromic repeats 
(CRISPRs) all comprise powerful classes of tools that are redefining the boundaries of 
biological research (Gaj et al. 2013), and could hold the key for improved gene therapy. 
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Chronologically, the first engineered nuclease technology, Zinc-Finger nuclease, was 
presented in a 1991 publication by Pavletich and Pabo (Pavletich and Pabo 1991). ZFNs 
recognise specific DNA sites in the genome based on a unique specifically designed zinc-
finger DNA binding motif attached to a cleavage domain (FokI restriction enzyme). The 
DNA is cleaved and then relies on the ability of cellular repair machinery to use extra-
chromosomal DNA (donor DNA) as a template to enhance homologous recombination 
(HR).  
The development of ZFN-mediated gene targeting provided molecular biologists with the 
ability to site-specifically and permanently modify both plant and mammalian genomes 
including the human genome via stimulation of homologous recombination (HR) (Durai et 
al. 2005). A study by Cost et al, in CHO ZFN engineering, recently where they reported 
that by knocking out the pro-apoptotic genes Bak and Bax in CHO cells, generated clones 
were more resistant to apoptotic stress induced by starvation, staurosporine, and sodium 
butyrate (Cost et al. 2010). 
As genome editing became more prominent in cell engineering, more cost effective 
competing technologies have arisen. A similar class of nucleases termed ‘TALENs’ 
(Transcription-Activator-Like Effector Nucleases), employ a similar FokI domain design 
and show promise in a range of species (Mussolino and Cathomen 2012) (Hockemeyer et 
al. 2011).  
Meganucleases, homing endonucleases capable of recognizing long DNA sequences 
(~45bp) are divided into five sub-families (Kramer, Klausing and Noll 2010) (Paques and 
Duchateau 2007). Limitations in recognition motifs are one concern, but engineered 
meganucleases can be constructed by domain swapping. An example of an engineered 
meganuclease is the knockout of RAG1 gene locus in 293H cells (Grizot et al. 2009). 
However, they have drawbacks such as lower mobility owing to being quite large compared 
to the more motile smaller ZFNs and TALENs (Epinat et al. 2003).  
CRISPRs were first discovered in the 1980s, but their function wasn’t confirmed until 2007 
by Barrangou and colleagues. They are a distinctive feature of the genomes of most 
bacteria and archaea. Termed RNA-guided endonucleases (RGENs), they are derived from 
the prokaryotic adaptive immune system involved in resistance to bacteriophages which 
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integrates a genomic fragment from an invading infectious agent into its CRISPR locus 
(Barrangou et al. 2007). Approximately 40% of sequenced bacterial genomes, and ~90% of 
those from archaea, contain at least one CRISPR locus, furthermore the availability of a 
public database which is regularly updated called ‘CRISPRdb’ is accessible at 
http://crispr.u-psud.fr/crispr (Grissa et al. 2007). 
Using CRISPR instead of the other site-specific nucleases eliminates the need to construct a 
completely customized endonuclease for each target, something that is still required by 
TALEN and Zinc Finger. As a result of this the entry barrier to genome editing has been 
lowered significantly, allowing for more users and more innovation (Gratz et al. 2013).  
Three types of CRISPR mechanisms have been identified (Figure 1.4.3.1), type II is the 
most studied to date. DNA from viruses or foreign agents are digested and incorporated 
into a CRISPR locus amidst a series of short (~20bp) repeats. These loci are then 
transcribed and processed into RNAs (crRNA), which is then used to guide effector 
nucleases to target invading DNA sequence further based on sequence complementarity 
(Jinek et al. 2012).  
18 
 
 
Figure 1.4.3.1: The 3 stages of CRISPR-Cas action. CRISPRs act in three stages: 
adaptation, expression and interference. In type I and type II CRISPR-Cas systems, but not 
in type III systems, the selection of proto-spacers in invading nucleic acid probably depends 
on a proto-spacer-adjacent motif (PAM) (Koonin and Makarova 2013). 
In summary, genetic engineering using the various methods above are useful for a number 
of applications. These include; targeted gene mutations, chromosomal rearrangement, and 
the creation of transgenic animals. While applications such as gene therapy, allele disabling 
and editing (editing an organisms DNA by altering, removing or adding nucleotides to the 
genome) are possible, however they can suffer from drawbacks such as; off-target 
effects/cleavage (wrong digestion site) and immunogenicity issues, as is the case with many 
foreign proteins/molecules inserted into a living organism. 
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 Recently, improvements in zinc-finger nuclease design (Ramalingam et al. 2011) and 
TALEN design (Joung and Sander 2013) are being sought to decrease immunogenicity, 
cytotoxicity and subsequently increase efficacy regarding genome editing. These 
mechanisms can contribute to the development of precise targeting within a cells genome 
and they all combine to expand the tailored engineering toolbox further. 
 
1.4.3.2:  Cre/LoxP system 
The Cre/LoxP site-specific recombinase method can also be used for gene targeting and 
DNA manipulation via insertions, deletions, and inversions. First reported by Kito et al, the 
system was utilised for reproducible monoclonal antibody production using CHO cells. 
They showed that after gene-targeting of loxP in clone MK2 with selective gene 
amplification with methotrexate (MTX), the MTX-resistant colonies showed high levels of 
antibody production (Kito et al. 2002). Placing Lox sequences appropriately allows genes 
to be activated, repressed, or exchanged for other genes. 
Kameyama et al described an accumulative gene integration system (AGIS), in which 
target gene cassettes could be repetitively integrated into a pre-determined site on a plasmid 
or cellular genome by recombinase-mediated cassette exchange (RMCE), using Cre and 
mutated LoxPs. The equilibrium and specificity of the recombination reaction can be 
controlled using mutated LoxPs (Kameyama et al. 2010). 
Two advantages of the Cre/LoxP technology include; insertion of a cassette in the correct 
orientation and it being of higher efficiency than random integration methods. The 
properties of site-specific recombinases in combination with other biotechnological tools 
(Inducible systems, shRNA/siRNA mediated gene silencing) make them useful instruments 
to induce precise mutations in specific cells or tissues in a time-controlled manner (Garcia-
Otin and Guillou 2006). 
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1.4.4: RNA interference engineering  
RNA interference (RNAi) is an evolutionarily conserved phenomenon for sequence-
specific gene silencing. RNAi was first described by Fire et al, 1998 in C. Elegans where 
dsRNA was introduced into worms and specific mRNA silencing was seen. After injection 
into adult animals, purified single strands had at most, a modest effect, whereas double-
stranded mixtures caused potent and specific interference (Fire et al. 1998).  
In the RNAi pathway (Figure 1.4.4), RNAi is induced by small interfering double-stranded 
RNA molecules (siRNAs) which are approximately 21 to 23 nucleotides in length and 
serve as the regulatory molecules that guide and induce sequence-specific gene silencing. 
This leads to negative regulation of gene expression at a post-transcriptional level and is 
termed post-transcriptional gene silencing (PTGS) (McManus and Sharp 2002) (Sakurai, 
Chomchan and Rossi 2010) (McManus and Sharp 2002) (McManus and Sharp 2002).   
RNAi-mediated gene silencing can be performed using artificially synthesised siRNA 
molecules (native siRNAs were originally found in plants) or via the endogenous 
expression of short hairpin RNA molecules (shRNAs) encoded by plasmids or viral vectors 
(Amarzguioui et al 2005). However, unlike chemically synthesised siRNAs which have 
been shown to only cause a transient knockdown of a target gene after transfection (3-5 
days), shRNA vectors can induce a longer term and more stable expression of RNAi 
silencing in target cells after transfection (Wu 2009). 
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Figure 1.4.4: Pathway of siRNA. ShRNA is processed by Dicer into siRNA duplexes that 
are then bound by the RISC. Each duplex consists of a guide strand (red) which remains 
bound to RISC and a passenger strand (blue) which is degraded. Target mRNAs are 
recognised by base pairing and are subsequently silenced by different mechanisms. The 
m
7
G structure of the mRNA depicts the eukaryotic 5′-Cap structure, (A)n stands for the 
polyadenylation of the 3′-end (Kramer, Klausing and Noll 2010). 
 
Furthermore, arising from shRNA vector-mediated silencing are another class of small non-
coding RNAs called microRNAs or miRNAs, which are produced by the cell naturally 
(unlike siRNAs which are generally artificially made by chemical synthesis), to further 
regulate gene expression. Both siRNA and miRNAs are commonly used to induce RNAi in 
mammalian cells for functional studies. 
Typically, RNA interference can be subdivided into three main pathways by the biogenesis 
of the small RNAs mediating the silencing: short interfering RNAs (siRNAs), microRNAs 
(miRNAs) and PIWI-interacting RNAs (piRNAs), respectively (Siomi and Siomi 2009). 
Despite their distinct functions, the boundaries between their pathways are not well 
defined; but the general mechanism is applicable to all three types. Additionally, the key 
role of the piRNAs seems to be the protection of the germ line genome (Choudhuri 2009) 
(Siomi et al. 2011). 
RNAi technology has become a novel reverse genetic tool for silencing gene expression in 
mammalian cells for a number of potential benefits including; developing new therapeutics 
for certain diseases like cancer (Takeshita and Ochiya 2006). Additionally, because of the 
ability of RNAi to silence disease-associated genes in tissue culture and animal models, the 
development of RNAi-based reagents for clinical applications such as HIV replication 
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inhibition (Berkhout and Liu 2014) and personalised cancer treatment is gathering pace, as 
technological enhancements that improve siRNA stability and delivery in vivo, while 
minimising off-target and non-specific effects, are developed (Leung and Whittaker 2005) 
(Wu et al. 2014). 
More related to the work presented in this project, is using siRNA-mediated silencing as a 
tool for investigating gene function. For example, the knockdown of pro-apoptotic factors 
using RNAi like Alg-2 and caspases 3 and 7 (caspase suppression has been shown to lead 
to increased viability and subdued autophagy). The zinc finger transcription factor 
‘Requiem’ has also been reported to improve cell viability and more importantly increase 
recombinant protein production such as interferon-γ in CHO cells by targeting the apoptosis 
cascade (Lim et al. 2010) (Wu 2009).  
Additionally, siRNAs are attractive to regulatory authorities as they have not induced any 
toxic reactions to date as shown in vivo studies in mammals and many have been developed 
as therapeutics over the last decade aiding in personalised cancer treatment (Hong et al. 
2007) (Rossbach 2010) (Wu et al. 2014). For example; Song et al showed that by silencing 
the Fas gene through intravenous injection of Fas siRNA with RNAi holds therapeutic 
promise to prevent liver injury by protecting hepatocytes from cytotoxicity (Song et al. 
2003). In addition, Brummelkamp et al reported that viral delivery of small interfering 
RNAs can be used to target the oncogenic K-RAS (V12) allele in human tumor cells 
allowing for tumor-specific gene therapy to reverse the oncogenic phenotype of cancer cells 
(Brummelkamp et al. 2002).  
In summary, small RNA molecules such as siRNAs and miRNAs were once deemed too 
small to impinge on large complex organisms. Ironically they are now considered as 
attractive biological tools to control regulation by sequence-dependent degradation of 
mRNA with more development being made in the area of small molecule engineering than 
any other field in genetics at present (Jadhav et al. 2012). 
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1.4.5: Cis-regulatory elements 
Other important cell engineering elements for augmenting gene expression include; 
S/MARs, UCOEs, and IRES elements. ‘Cis’ meaning “on the same side as” as derived 
from latin. They are essentially DNA/RNA regulatory sequences that are located generally 
in the same location or on the same chromosome and close to the coding sequence they 
regulate. 
 
1.4.5.1: Scaffold/matrix attachment regions (S/MAR)  
S/MARs are one of the most widely used cis-acting elements outside of native promoters; 
they organise the chromatin into structural domains and can be mapped to non-random 
locations in the genome by using stress-induced DNA duplex destabilization (SIDD) or 
when placed under negative superhelical tension (Bode et al. 2006).  
S/MARs do not have a clear-cut consensus sequence; the characteristics that define their 
activity are thought to be structural, they occur at the flanks of transcribed regions, in 5´-
introns, and also at gene breakpoint cluster regions (BCRs) (Benham, Kohwi-Shigematsu 
and Bode 1997). They are believed to define boundaries interfacing heterochromatin and 
euchromatin domains (two structural forms of chromatin, heterochromatin is more tightly 
packed than euchromatin and therefore euchromatin is more transcriptionally active) 
thereby acting as epigenetic regulators (Harraghy et al. 2011). 
Regarding use in CHO cells, S/MARs have been tested to evaluate their performance in 
rCHO cells, with Harraghy et al, reporting increases in recombinant antibody production 
and reducing the number of clones to be screened and time to production by as much as 9 
months after incorporating MARs into suitable expression vectors (Harraghy et al. 2012). 
Girod et al reported that the chicken lysozyme MAR interestingly mediates a dual effect by 
working as a cis-acting element as well as working as a trans-acting element for a separate 
co-transfected plasmid (Girod, Zahn-Zabal and Mermod 2005). 
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Locus control regions (LCRs) and Boundary elements (BEs) are two other chromatin 
elements and these were screened for their ability to augment the expression of 
heterologous genes in mammalian cells even though LCRs composition and locations 
relative to their cognate genes are different (Li et al. 2002). Of all chromatin elements 
assayed, the chicken lysozyme matrix-attachment region was the only element to 
significantly increase stable reporter expression (Zahn-Zabal et al. 2001).  
 
1.4.5.2: Ubiquitous Chromatin Opening Elements 
Similar in function to S/MARs, UCOEs are promoter-like elements associated with 
endogenous house-keeping genes. They contain extended CpG islands found to be resistant 
to methylation and the effects of transgene silencing (Nair et al. 2011). 
A study by Benton et al, showed the results of combining the cytomegalovirus (CMV) 
promoter with fragments derived from UCOE, a vector with 8kb UCOE sequence, resulting 
in a much improved number of clones expressing high levels of GFP after flow cytometry 
analysis – thus reducing the level of screening necessary to isolate such high producing 
clones perhaps (Benton et al. 2002).  
Additionally their mode of action has relative experimental ease of use, which is combined 
with vector engineering, which can subsequently be readily transfected into mammalian 
cells. UCOEs are useful additions to mammalian engineering to improve desirable 
phenotypes without using the more potentially disruptive and damaging genetic 
manipulations like directed mutagenesis for example. 
Where there were size concerns for transfection efficiency, smaller sequences of UCOE 
(1.5-4kb) from human were utilised by (Brooks et al. 2004) (Boscolo et al. 2012). Both 
have shown great potential regarding recombinant productivity increases with quick 
implementation into production systems.  
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1.4.5.3: IRES elements 
Internal ribosomal entry segments (IRES) are elements that affect the outcome of gene 
expression in a cell based on interaction with other elements present and have varying 
degrees of efficiency. These sequences allows for translation initiation to take place in the 
middle of a messenger RNA (mRNA), thus going against the convention where 5’cap 
recognition is need to initiate translation. They are typically of viral origin but recently 
found in the mRNA of the tumor suppressor p53 gene (Sharathchandra et al. 2014).  
IRES elements are particularly useful for creation of bicistronic mRNAs that encode both a 
gene of interest and a selectable marker for stable transfection (Martinez-Salas et al. 1996) 
(Koh et al. 2013). 
Fussenegger and co-workers created a technology called ‘pTRIDENT’, it involves a series 
of tricistronic vectors that utilise three IRES segments to link 3 genes which normally 
would not be expressed in unison (Fussenegger et al. 1998) (Fux et al. 2004). Although 
overall the process seems to be less efficient than natural cap-dependant translation, there is 
an argument that selection is actually improved due to impairment of the marker expression 
downstream whereby creating better-expressing transfectants and false positive clones may 
be reduced. 
On the contrary, targeting IRESs by silencing or knockdown can be a suitable avenue for 
therapeutic development as IRES-mediated hepatitis C (HCV) and polioviruses (PV) that 
infect humans use the IRES mechanism for synthesis of viral proteins (Dasgupta et al. 
2004).  
After critical examination of IRES publications over the last decade, flaws were uncovered 
leading to alternative interpretations, such as the possibility that IRES elements might 
function using other mechanisms such as cryptic promoters, splice sites, or sequences that 
modulate cleavage by RNases. In short, the focus on IRES-binding proteins has gotten us 
no closer to understanding the mechanism of internal initiation (Baranick et al. 2008). The 
uncertainty about these mechanisms might underlie what-appears-to-be internal initiation, 
and Kozak et al offer a temporary solution, where it might be beneficial to redefine IRES to 
mean "internal regulatory expression sequence.  
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This compromise would allow the sequences to be used for gene expression studies, for 
which they sometimes work, without asserting more than has been proven about the 
mechanism (Kozak 2003). 
 
1.4.5.4: Other engineering strategies 
In addition to all engineering methods described previous, there are many more strategies 
that expand further than the scope of this project. Due to the increasing demand for quality 
recombinant proteins the interest in alternative strategies has grown in recent years.  
Other strategies used to engineer mammalian cells include; glycosylation engineering (Park 
et al. 2012), chaperone engineering, (Josse, Smales and Tuite 2012), unfolded protein 
response (UPR)-based engineering (Chien et al. 2014), metabolic engineering (Le et al. 
2013) and secretion engineering (Peng et al. 2010). 
 
1.5: The CHO Genome Project 
Until recently, the absence of a publicly available CHO genomic sequence was a hindrance 
to many researchers interested in studying CHO cell lines. Although genetic heterogeneity 
among CHO cell lines is well documented, a systematic, nucleotide resolution 
characterisation of their genotypic differences has been hindered by lack of a unifying 
‘Gold standard’ sequence resource for CHO cells as a whole. 
As the most common mammalian cell line used in biologic production processes, the CHO 
genomic sequence along with its mapping and annotating, became a research priority in the 
field of biotechnology. As a result of explicitly identifying the CHO genetic code, 
biotechnologists aimed to improve the efficiency and understanding of cell culture 
bioprocessing overall (Wuest et al. 2012). 
In 2010 there were only a few known institutes in possession of entire or at least partial 
CHO genome sequences or resources (Kramer et al. 2010). Among them were the 
“Consortium for Chinese Hamster Ovary Cell Genomics” group and they have amassed a 
sequence repertoire of more than 68,000 expressed sequence tags (ESTs), representing 
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more than 28,000 unique CHO transcripts (Kantardjieff et al. 2009). Furthermore, the 
Chinese Hamster genome database at http://www.chogenome.org/ is another online 
resource for the CHO communities (Hammond et al. 2012). 
In July 2011, a consortium group led by Beijing genomics institute (BGI) based in 
Shenzhen, China released the first draft of the CHO-K1 ancestral cell line (Xu et al. 2011). 
The assembly comprised 2.45 Gb of genomic sequence, with 24,383 predicted genes 
annotated from scaffold assembly’s and made available to the public on GenBank and the 
resource at www.chogenome.org. The information within will facilitate genome-scale 
science for the optimisation of biopharmaceutical protein production for years to come and 
in 2012 they were nominated for Upstream Collaboration of the Decade at the BPI awards 
in Rhode island, USA. 
More recently, Lewis et al reported their findings upon analysing six CHO cell lines 
derived from CHO-K1, DG44 and CHO-S lineages. More importantly, they published the 
Chinese Hamster sequence as a reference to compare all cell line sequences to. They 
identified genes missing in the different lines and detected >3.7 million SNPs, 551,240 
indels (an insertion or deletion event) and 7,063 copy number variations (Lewis et al. 
2013).  
Up until these sequences were released, the isolation and identification of promoter 
sequences and gene sequences in CHO was slow and tedious. Cross species alignments 
based on sequence comparisons in other rodent species such as rat and mouse were used to 
make educated guesses and roughly map the region of promoter upstream of the target 
genes used in this study (see results section 3.2). So with the advent of the fully assembled 
CHO-K1 sequence, this process was simplified approximately midway through the project. 
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1.6: Gene Promoters 
A promoter is a segment of DNA (usually occurring upstream from a gene coding region) 
that acts as a controlling element in the expression of that gene by initiating transcription. 
The typical organisation of a promoter and gene segment is shown in figure 1.6. Vectors 
used in bioprocessing and gene therapy require an expression cassette. The expression 
cassette consists of three vital components: promoter, therapeutic or product gene and 
polyadenylation signal. The promoter is chiefly responsible for controlling expression of 
the gene and is therefore a potential tool in driving protein production (Zheng and Baum 
2008) (Preker et al. 2008) 
Crucial to the activity of a promoter is its ability to recruit RNA polymerase (RNAP), to 
initiate transcription. RNA polymerase enzymes are essential to life and are found in all 
organisms and many viruses. There are 5 distinct types; each type is responsible for 
synthesis of a different molecule. RNAP I is involved in ribosomal synthesis (rRNA) 
(Grummt 1999). RNAP II is involved in synthesising precursors of mRNA (including 
snRNA and miRNA) and is the most studied type owing to its strong control over 
transcription (Hahn 2004). RNAP III synthesises transfer RNA (tRNA) present in the 
cytosol (Geiduschek and Tocchini-Valentini 1988). RNAP IV and V are less studied but are 
involved in siRNA-directed heterochromatin formation and synthesis in plants (Wierzbicki 
et al. 2009). 
All common polymerase II promoters share similar sequence structures; a core promoter 
consisting of either a conserved TATA box-enriched well defined region or more 
expansive, evolvable CpG islands, an initiator element and a downstream promoter element 
(Kadonaga 2004) (Carninci et al. 2006), and a proximal promoter (Heintzman and Ren 
2007). 
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Figure 1.6: DNA structure and configuration surrounding a TATA-based promoter locus. 
The regulatory proteins and specific transcription factors recruit the RNA polymerase II to 
the transcription start site (TSS) to initiate transcription. 
 
Promoters contain specific sequences and response elements which allow RNA polymerase 
and other transcription factors’ (TF’s) to bind securely to the transcription start site (TSS) 
of the DNA to begin transcription and ultimately protein synthesis. A promoter’s ultimate 
function is to facilitate expression of different gene products at various times in their 
biological pathways in order to maintain homeostasis (Gagniuc and Ionescu-Tirgoviste 
2012). 
Promoters can have proximal and distal regions, and the expression of a particular gene 
may be regulated by the concerted action of both cis and trans-acting elements related to 
that promoter. The boundaries between proximal and distal regions are ill-defined and the 
entire mapping of promoters and the interactions between proximal and distal sequences 
can be complex (Sanyal et al. 2012) (Davydova et al. 2011). 
Proximal sequence is taken to be adjacent to the gene of interest and usually embodies 250-
300 nucleotides (nt) upstream of the TSS, and contains all primary regulatory elements and 
transcription factor binding sites. The distal promoter region can be anywhere from 300 
base pairs (bp) to many Kilobases (Kb) away. Signal transduction occurs due to the 
foldable nature of DNA to bring distal elements into close proximity with complexes bound 
at the proximal region.  
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1.6.1: Types of Promoters 
Eukaryotic promoters are diverse and can be difficult to characterise, with the general 
consensus being that there are two major classes, namely TATA and CpG island based 
promoters. However, a recent study divided them into 10 sub-classes by analysing 
thousands of promoter sequences using novel methodologies termed the ‘Kappa index of 
coincidence’ method and a specialised data entry method based on an electronic conversion 
of images into electronic signals using a ‘Optical Character Recognition’ (OCR) neural 
network (Gagniuc and Ionescu-Tirgoviste 2012).  
However, here we have sub-classed the types of promoters into four more amenable types 
based on their mode of driving gene expression;  
 
1.6.1.1: Constitutive promoters 
These are promoters that can drive expression in almost all tissues and cellular 
environments; they are largely and oftentimes entirely independent of environmental 
factors and stimuli. Reports have shown functionality across species and those derived from 
viruses; CMV, RSV, LTR, adenovirus MLP and SV40 are examples of compact high-
expressing constitutive promoters frequently used in cell engineering (Mulligan and Berg 
1981) (Makrides 1999). 
Qin et al carried out a systematic comparison of eight commonly used constitutive 
promoters (SV40, CMV from viruses, UBC, EF1A, PGK and CAGG from mammals, and 
COPIA and ACT5C from Drosophila). They found that these promoters vary considerably 
from one another in their strength when tested in various cell lines from different species. 
While most promoters have fairly consistent strengths across different cell types, the CMV 
promoter can vary considerably from cell type to cell type (Qin et al. 2010). 
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1.6.1.2: Tissue-specific or development-stage-specific promoters 
More relevant to gene therapy and therapeutics are tissue-specific promoters. Gene therapy 
is used to correct genetic defects or to deliver new therapeutic functions to the target/patient 
cells. A tissue-specific promoter is a promoter that has functionality in only certain cell 
types. Use of a tissue-specific promoter in the expression cassette can restrict unwanted 
transgene expression as well as facilitate persistent transgene expression in the target organ. 
Therefore, choosing the correct promoter, especially a tissue-specific promoter, is a major 
step toward achieving successful therapeutic transgene expression (Zheng and Baum 2008). 
A tissue-specific promoter directs the expression of a gene in specific tissue(s) or at certain 
stages of development and can be useful tools to drive expression in combination with other 
expression strategies such as RNAi. For example, Wolff et al combined the use of tissue-
specific promoters with miRNA silencing expression in antigen-presenting cells (APCs) to 
increase the probability of long-term expression and establish transgene tolerance in liver 
and skeletal muscle (Wolff, Wolff and Sebestyen 2009). 
As different promoters have variable the optimal dose of a therapeutic transgene product 
over time may be achieved by varying the promoter utilised to avoid promoter activity 
attenuation and extinction post-delivery as reported by Qin et al. They also reported that the 
cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) 
inhibit transgene expression from certain widely used viral promoters/enhancers 
(cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus 
long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro (Qin et 
al. 1997). 
Many tissue specific promoters are also seen in plants, promoters that control the 
expression of plant genes to improve areas such as tobacco manufacture and genetically 
modified foods. However, for the purpose of this literature review plant promoters are not 
discussed. A good database of promoter and cis-transacting elements from plants are on 
PLACE (http://www.dna.affrc.go.jp/PLACE/). 
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1.6.1.3: Inducible promoters 
As their name suggests, this type of promoter can be induced by various factors such as; 
small molecules, environmental stimuli aswell as artificially controlled by biotic and abiotic 
factors like oxygen levels, heat, cold, chemical compounds like biotin, copper, cumate, 
alcohol, gases, steroids which subsequently can facilitate control via induction.  
Pertinent to this entire study, by harnessing such induced control, fine tuning gene 
expression via inducible promoters may potentially improve biopharma processes. This 
might be achieved by regulating certain pathways like apoptosis and growth by controlling 
favourable or unfavorable genes involved in the pathway.  
Furthermore, the synthesis of difficult to produce or toxic proteins requires inducible 
expression systems with low basal expression strength and high induciblity after a triggered 
event/stimulus. Certain proteins, such as kinases, transmembrane receptors, or transporters 
are inherently toxic to the producer cell and can only be produced using transient or 
inducible expression systems (Boorsma et al. 2002). 
Another concern is clonal instability during CHO cell line development. There are several 
underlying causes, the most prominent of which are DNA copy number decrease and 
transgene silencing, while in some cases it has been shown that unstable cell lines are more 
prone to apoptosis (Dorai et al. 2012). Clonal instability can also manifest due to the 
toxicity of the therapeutic protein(s) that the cells express. To circumvent such product-
induced instability, Misaghi et al developed an inducible vector based on doxycycline 
induction.  Their findings suggest that this regulated expression system could be suitable 
for production of difficult proteins that would normally trigger instability (Misaghi et al. 
2014). 
Initial advances in inducible expression methodology were made using prokaryote cells, 
whereas more recently focus has been on mammalian cells. The E.coli lac promoter (lac 
operon) was the flagship mechanism for providing inducible gene expression via interplay 
between lactose substrate and IPTG induction (a lactose metabolite that binds to the lac 
repressor). However, due to it having relatively weak expression strength meant that very 
high levels could not be achieved as lac genes are not transcribed to a significant level in 
the absence of induction (Davies and Jacob 1968) (Gronenborn 1976).  
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Berkner et al identified a range of inducible and constitutive promoters to be used in S. 
acidocaldarius, where genetically modified stable shuttle vectors were developed based on 
low molecular weight carbohydrates that don’t impede the bioprocess (Berkner and Lipps 
2008). Findings showed that the most suitable inducible promoter was a maltose inducible 
promoter (266bp sequence), with induction feasible with either maltose or dextrin at 
concentrations of 0.2-0.4% (Berkner et al. 2010). 
In another example Valdez-Cruz et al, report the use of a temperature inducible expression 
system, based on the pL and/or pR phage lambda promoters regulated by the thermolabile 
cI857 repressor has been widely use to produce recombinant proteins in prokaryotic cells 
(Valdez-Cruz et al. 2010). 
Some of the bacterial based systems suffered irregular expression and relied on toxic 
inducer molecules when used in mammalian cells, however, the Tet-on/off system was 
shown to be exempt from these issues (again utilising E.coli via its tetracycline repressor). 
Inducible expression systems such as the tetracycline responsive system (Gossen and 
Bujard 1992) and early binary systems used chimeric transactivators from insect hormones 
to drive responsive target promoters. This typically involved the binding of a ligand-
dependant transactivator to its cognate promoter (Fussenegger 2001) (Vilaboa et al. 2005). 
Their use in bioprocess development strategies has been limited as a result of the 
combination of low or leaky expression, costs and side effects of chemical regulators, time-
consuming construction of stable cell lines, and difficulties in managing levels of the 
regulating agent. Furthermore, regulatory authorities such as the FDA, prefer bioprocess 
strategies that do not make use of antibiotics or hormones (Boorsma et al. 2002) (Weber et 
al. 2007). 
Boorsma et al developed the first novel temperature-regulated DNA expression system, 
designated ‘pCytTS’. This layered system based on Sindbis virus cDNA carries the gene 
for a non-cytopathic and temperature-sensitive replicase and a gene of interest. The titres of 
β-IFN were shown to be highly glycosylated while the β-IFN mRNA did not show any 
accumulation of mutations under viral replicase amplification even after 10 days in culture 
at 29
o
C. This highlighted that ‘pCytTS’ system has applicability in bioprocessing and has 
the ability to produce high-quality glycoproteins (Boorsma et al. 2002). 
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Other existing inducible based promoters include Heat-shock protein promoters, 
particularly the powerful human chaperones ‘hsp27’ and ‘hsp70’, which have been used for 
gene therapy strategies because of their efficiency and the possibility of induction by dose-
dependent external heat. (Garrido et al. 2006) (Rerole et al. 2011).  
Spatial and temporal control of transgene expression using hsp70 promoters provides a 
non-invasive method of accurate control using temperature (Rome, Couillaud and Moonen 
2005). Hsp70 was found to be strictly inducible having little or no basal expression levels 
in most cells. Noonan et al observed that Hsp70B' appeared transiently in response to heat 
stress whereas interestingly another heat-shock protein tested ‘Hsp72’ levels persisted for 
many days measured by a GFP-reporter and flow cytometry. Finally they showed that 
‘Hsp70B' was optimally induced by temperature when cell numbers were low, whereas 
‘Hsp72’ levels were greatest at higher cell number, so there is some ambiguity to the 
induciblity of heat-shock promoters even in the same protein family (Noonan et al. 2007). 
In addition, Rohmer et al reported on two novel adenoviral vectors designed with an 
insulated human ‘hsp70B' promoter and they showed stringent heat-inducible gene 
expression with induction ratios up to 8000-fold, but required an upstream insulator 
sequence to avoid sub-optimal performance of the promoter (Rohmer et al. 2008). 
Another useful inducible promoter is the mouse mammary tumor virus (MMTV) 
originating from murine models. Its control over gene expression has been shown to be 
regulated by glucocorticoids and its sequence contains a hormone response element (HRE) 
located between -202 and -59 upstream of the start of transcription in the long terminal 
repeat (LTR) region of proviral DNA and is necessary for this induction (Cato, Henderson 
and Ponta 1987). James et al engineered CHO cells to overexpress a secreted protein 
(SEAP) upon induction of the MMLV promoter using dexamethasone. They achieved ~10-
fold higher SEAP titres compared to the constitutive SV40 promoter after CHO cells were 
grown for up to 9 days (James et al. 2000).  
This again highlights a useful system of regulation control; however it still needs an 
external receptor to function fully and also it can it can be difficult to maintain 
reproducibility when using external components. 
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In 2004, Running-Deer and Allison reported the first use of CHO regulatory sequences (not 
called promoter as the sequences used were flanking on the 5’ and 3’ of the gene) from the 
Chinese Hamster elongation factor 1α (CHEF-1α) gene for use in the high level expression 
of proteins such as the CCR4 chemokine receptor. They cloned a 19kb fragment containing 
the gene as well as 12kb of the 5’ flanking sequence and 4kb of the 3’ flanking sequence 
into six reporter gene constructs and transfected into CHO-DG44 cells.  
As a comparison, CHO cells were also transfected with the same six reporter genes inserted 
into commercial vectors utilising either the immediate early promoter from 
cytomegalovirus (CMV) or the human EF-1alpha promoter and the average expression 
levels from pooled, stable transfectants were 6- to 35-fold higher in the CHEF-1 vectors. 
Finally they also used the CHEF-1α vectors to express a membrane-bound protein in stably 
transfected non-CHO cell lines such as Jurkat, K562 and HEK-293, suggesting that CHEF-
1α vectors may be useful for high-level protein expression not only in CHO cells, but also 
in a variety of other mammalian cell lines (Running Deer and Allison 2004). 
More recently, Thaisuchat et al identified one temperature sensitive promoter S100a6 
(Calcyclin) that was capable of temperature inducible transgene expression of luciferase. 
Calcyclin and its flanking regions were identified from a genomic CHO-K1 lambda-phage 
library and then various constructs were investigated for promoter activity at 37°C and 
33°C after transfection into DHFR-deficient CHO cells. Upon a shift to 33°C, a two to 
three-fold increase of basal productivity (already higher than SV40 promoter) was 
achieved. This CHO S100a6 promoter can be characterised as a cold-shock responsive 
promoter with the potential for improving process performance of mammalian expression 
systems, of particular advantage for a process with reduced expression during initial cell 
growth followed by the production phase at low temperature with a boost in expression 
(Thaisuchat et al. 2011). 
In conclusion, inducible promoters can serve as genetic switches for fine tuning gene 
therapy proteins or for maximal performance and productivity in bioprocesses. 
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1.6.1.4: Synthetic promoters 
Promoters can also be manufactured by synthetic means and combined to make a multi-
purpose promoter with all essential components to drive gene expression. Promoter 
engineering often uses components like transactivating proteins and enhancers (DNA 
sequence that controls the efficiency and rate of transcription of a specific promoter) to 
boost their potential for expression.  
The various configurations of transcriptional components have enabled the creation of 
genetic networks that are strongly analogous to the architectural design and functionality of 
electronic circuits. Toggle switches which possess "memory' so as to remember transient 
administered inputs and oscillatory networks which produce regularly timed expression 
outputs, are two examples of networks that have been constructed using such properties 
(Greber and Fussenegger 2007). 
Furthermore, many synthetic promoter systems are controlled and induced by using 
components that are responsive to external stimuli such as heat and many are generated to 
study gene function in plant and mammalian models (Venter 2007).  
Although synthetic promoters seem attractive in that you can pick and choose specific 
components to make a ‘super’ promoter, a drawback is that many regulatory bodies, like 
the FDA, do not like promoting such artificial gene therapy approaches. This is perhaps due 
to lack of data relating to the potential side-effects and immune response issues resulting 
from using exogenous synthetic sequences (Tigges and Fussenegger 2009) (Jain 2013).  
This gave rise to the construction of synthetic promoter libraries and it has represented a 
major breakthrough in systems biology. Systems biology represents an area of combined 
biology and mathematics, where all functional parts of cellular pathways and interactions 
are studied. It now enables the subtle tuning of important regulatory pathway activities. A 
number of tools are now available that allow the modulation of gene expression and the 
detection of changes in expression patterns (Mijakovic et al. 2005) (Hammer et al. 2006).  
More specifically for CHO engineering, Brown et al describe the first library of ~140 
synthetic promoters specifically designed, by harboring 7 repeats of discrete transcription 
factor binding site sequences upstream of a minimal CMV, to regulate the expression of 
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recombinant genes at varying levels in three CHO cell lines (CHO-S, CHO-K1 and CHO-
DG44) and offering precise control of recombinant transcriptional activity (Brown et al. 
2014). 
A successful example of a synthetic mammalian promoter construct was reported by 
Hartenbach and Fussenegger. They introduced specific mutations into a synthetic internal 
ribosome entry site (IRES(GTX)) derived from the GTX homeodomain protein creating a 
novel synthetic P(GTX) promoter, resulting in additional transcriptional activity. It 
mediated high-level expression of a variety of transgenes like SEAP and human vascular 
endothelial growth factor 121 (VEGF-121) in CHO-K1 cells, thus outperforming 
constitutive phosphoglycerate kinase (P(PGK)) and human ubiquitin C (P(hUBC)) 
promoters in comparison (Hartenbach and Fussenegger 2006).  
Precise regulation advancements in systems biology via inducible and synthetic sequences 
can assist other areas like drug discovery and therapeutics, plus they can generate biological 
meaningful in vivo data, that can be flexibly and repeatedly reproduced. Using 
combinations of synthetic and inducible regulatory sequences can benefit bioprocess 
productivity and allow control over complex host cells (Aubel and Fussenegger 2010). 
Other common mammalian expression systems used in industrial protein production are 
shown in table 1.6.1.4. 
Table 1.6.1.4: Existing CHO/mammalian promoter systems. 
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1.7: Promoter engineering  
So why the interest in promoter engineering? Based on current trends in bioprocessing, 
gaining control over protein production using inducible promoters is an attractive avenue 
for researchers. Some of the early developments utilised the Tet on/off inducible system, 
Mazur and colleagues reported on the cytostatic cell-cycle-arresting gene (p27) under 
control of a single tetracycline-repressible Tet (off) promoter system. They showed that the 
behavior of the engineered CHO cell lines could be controlled by the addition or 
withdrawal of the exogenous agent tetracycline to or from the cell culture medium (Mazur 
et al. 1998) (Mazur et al. 1999).  
Systems and synthetic biology have made significant leaps over the past decade, they 
enable rational and predictable reprogramming of cells to conduct complex physiological 
activities (Wieland and Fussenegger 2012). Weber and Fussenegger have reviewed ways to 
utilise metabolite, hormone, and light-triggered genetic switches to control cellular activity 
and gene circuits (Weber and Fussenegger 2010). 
Analogous to the engineering of electronic circuits, there now exists an extensive repertoire 
of artificial regulatory elements that has further enabled the ambitious reprogramming of 
cells to mimic spatiotemporal dynamics such as the oscillation of circadian clocks (Wieland 
and Fussenegger 2012), as well as the design of artificial ecosystems for implementation of 
time- and distance-dependent bioprocesses through ‘quorum-sensing’ (inducible responses 
correlated to population density) (Weber and Fussenegger 2011). 
There are potentially as many if not more promoters as there are genes. This cannot be fully 
elucidated owing to the complexity within cells but is partly due to discovery of 
bidirectional promoters (Trinklein et al. 2004) (Hartenbach and Fussenegger 2005). A 
‘bidirectional gene pair’ refers to two adjacent genes coded on opposite strands, with their 
5' ends oriented toward one another (Piontkivska et al. 2009). They are often functionally 
related, this can be beneficial and harmful as modifications of their shared promoter region 
allows them to be co-regulated and thus co-expressed.  
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In conclusion, thanks to the knowledge and insight resulting from the CHO-K1 draft 
sequence now being available, this will aid in identifying promoter sequences of more 
housekeeping genes for example, accelerating cellular promoter designs for more dynamic 
expression control (Datta, Linhardt and Sharfstein 2013). 
 
1.8: Exogenous Inducer Molecules (IMs) and building a promoter catalogue 
The design and construction of synthetic gene circuits with complex spatiotemporal 
dynamics was pioneered in bacteria, but it took almost a decade until biologists were able 
to construct synthetic genetic circuits with complex spatiotemporal dynamics in 
mammalian cells (Weber and Fussenegger 2010). In the next section we will discuss 
synthetic promoters further within the context of precise inducible expression for 
developing bioprocessing plus the broad area of synthetic systems biology providing scope 
for novel therapeutic strategies. 
There are existing technologies that utilise systematic inducer molecules (IM’s) researched 
and tested by a group headed by Martin Fussenegger, Wifred Weber and co-workers. They 
have published numerous articles documenting the use of synthetic switches and atypical 
combinations of interaction compounds (Ehrbar et al. 2008) (Weber et al. 2007, Weber and 
Fussenegger 2011, Weber et al. 2009a, Weber and Fussenegger 2007) (Kramer et al. 2004). 
For example, by using the induction of various molecules one can build a portfolio of 
mutually compatible systems that can adjust therapeutic transgene levels in response to 
antibiotics, hormone analogues, quorum-sensing messengers and secondary metabolites 
(Weber and Fussenegger 2004). Other compounds which have been explored include; 
gaseous acetaldehyde (Werner et al. 2007), Biotin (Weber et al. 2009b), Cumate (Gaillet et 
al. 2010), drug sensing hydrogels (Ehrbar et al. 2008), all of which have had varying levels 
of success.  
The IMs used to transmit information in their experiments have a multitude of isoforms, 
bioconjunctants, hybrid molecules of biology and metal ligands, vitamin H/Biotin, L-
arginine sensors, and even a food additive vanillic acid has shown to be capable of inducing 
transgene expression.  
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Furthermore, groups have devised methodology to design synthetic networks based around 
these interacting molecules (Greber and Fussenegger 2007) (Aubel and Fussenegger 2010) 
(Wieland and Fussenegger 2010) (Weber and Fussenegger 2009). 
In early publications, Weber and colleagues reported significant differences in the 
regulation performance in diverse cell lines using macrolide- (E.REX system) and 
streptogramin- (PIP system) responsive gene regulation systems in mouse and CHO cells 
(Weber et al. 2002). They also showed that the implantation of microencapsulated DT40 
cells engineered for TIGR-controlled expression of the human vascular endothelial growth 
factor A (hVEGF121) provided low-temperature-induced VEGF-mediated vascularisation 
in chicken embryos (Weber et al. 2003).  
However, they reported a more stringent tunable time-delay circuit where the tetracycline-
responsive transactivator (tTA) induced expression of the pristinamycin-responsive 
repressor PIP-KRAB representing a biologic building block for emulating a fundamental 
circuit topology in integrated artificial synthetic gene networks (Weber, Kramer and 
Fussenegger 2007).  
Huang et al showed the use of the metallothionein (MT) expression system as an inducible 
metal induction method producing recombinant human growth hormone (hGH) in CHO 
cells.  The setup was successful in increasing cellular productivity. It was shown that a fed-
batch process could increase the maximum cell numbers two-fold, from 3.3x10
6
 to 6.3x10
6 
cell/mL, over those obtained in normal batch fermentations. This, coupled with extended 
fermentation times, resulted in a fourfold increase in final hGH titer, from 135 +/- 15 to 670 
+/- 70 mg/L at a specific productivity q(hGH) value of 12 pg cell(-1)d(-1). The addition of 
NaBu further increased specific productivity of hGH in cells to a value of approximately 48 
pg cell(-1)d(-1) (Huang et al. 2004). But once again the use of a metal is not attractive for 
large scale industry bioprocessing. 
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1.9: Viral versus Endogenous CHO promoters in bioprocessing 
Although viral promoters are examples of strong promoters capable of robust constitutive 
expression, they can trigger the undesired silencing phenomenon due to DNA and histone 
methylation of the promoter region (Brooks et al. 2004) (Williams, Christensen and Helin 
2011). They can also induce stress responses which impact on the unfolded protein 
response (UPR) and Endoplasmic-reticulum-associated protein degradation (ERAD) 
pathways, leading to incorrect protein folding or even cell death in worst cases. Parkinson’s 
disease and cystic fibrosis both have been linked to ERAD malfunction as the pathways are 
no longer able to stabilize aberrant proteins and can accumulate and damage the cells 
(Vembar and Brodsky 2008) (Mehnert, Sommer and Jarosch 2010). 
Studies on viral promoters and enhancers began in the mid-80s and at an early stage were 
recognised as useful biological tools (Foecking and Hofstetter 1986). While Zarrin et al 
concluded that CMV and RSV promoter/enhancers contain stronger regulatory elements 
than do SV40 and V/lambda1 for expression of genes in lymphoid cell lines showing 10- to 
113-fold increases (Zarrin et al. 1999).  
Another issue seen commonly is the cell-cycle dependence of these promoters that causes 
high cell to cell variation in the amount of protein produced at a given time and 
heterogeneity in a population (Thaisuchat et al. 2011). They do not routinely allow 
induciblity or any control once the expression process begins. Further evidence showed 
these viral promoters having the greatest transcriptional activity during S Phase 
(replication) between G
1
 and G
2
, this may lead to undesired cell and protein heterogeneity 
(Pontiller et al. 2010). 
Due to some of these shortcomings, endogenous cellular promoters have been investigated 
for the purpose of recombinant protein expression aswell. The idea of using endogenous 
promoters is appealing from a regulatory point of view.  
As mentioned previously, examples of such endogenous CHO promoters at present are the 
constitutive CHO-derived elongation factor-1 (CHEF-1α) gene and the inducible S100a6 
(calcyclin). Both can drive high expression of several genes and in a variety of cell lines 
including CHO (Running Deer and Allison 2004) (Thaisuchat et al. 2011). More recently, 
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Le et al isolated a CHO-specific promoter (~800bp fragment) of the Thioredoxin-
interacting protein (Txnip) gene and demonstrated its ability to drive transgene expression 
synchronous with the CHO host cells natural rhythm. This gene was chosen by the group 
because it was previously shown to be dynamically expressed, based on transcriptome and 
proteome analysis of Chinese hamster ovary cells under low temperature and sodium 
butyrate treatment and subsequent gene set enrichment analysis (GSEA) (Kantardjieff et al. 
2010). 
Strong cellular promoters may also be sourced from housekeeping genes. Two other 
constitutive promoters Chinese Hamster Cofilin (CHCF) and the CHO CH1433e epsilon 
promoter confer high expression and outperformed a CMV viral promoter in driving GFP 
and luciferase expression (Chan et al. 2008) (Datta, Linhardt and Sharfstein 2013). 
Although displaying no inducible expression attributes, constitutive promoters like these 
have a niche in the genetic toolbox for recombinant protein production.  
 
1.9.1: Endogenous promoters responsive to temperature inducibility 
The previous section described numerous ‘artificial’ inducible systems that have been used 
in various biotech applications. Many of these require some sort of exogenous inducer 
molecule or trigger to be added to the system which may not always be possible or 
desirable. It is this challenge that led our group and others to consider the possibility of 
using endogenous gene expression patterns to design more ‘natural’ inducible methods of 
control to drive protein expression in response to a process-related 
trigger/signal/input/stimulus. 
A discrete process trigger that can be capitalised on is the use of temperature shift to adjust 
protein expression and will be detailed further in section 1.11.2. There are several well 
characterised genes whose expression is responsive to temperature called CSPs. They are 
known to increase their genetic expression in response to moderate, but not severe drops in 
temperature. The first and best characterised one of these is Cirbp. 
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1.9.2: Cirbp – The classical temperature inducible gene 
Cirbp the first cold-shock protein identified in mammalian cells (Fujita 1999)(Nishiyama et 
al. 1997) has been extensively studied. Although its exact function is not known, it is 
believed to operate as a RNA chaperone (Al-Fageeh and Smales 2009). It facilitates mRNA 
translation upon exposure to cold stress. Being composed of one consensus carboxyl-
terminal region containing several AGG motifs, it is structurally very different to bacterial 
CSPs (Sumitomo et al. 2012). 
Although the Cirbp gene sequence is well characterised in mouse and human models, 
Nishiyama et al demonstrated that Cirbp expression is down-regulated at elevated 
temperature (37
o
C) in male germ cells of mice and humans. Additionally, a high level of 
Cirp protein was detected immunohistochemically in the nucleus of primary spermatocytes. 
(Nishiyama et al. 1998). Furthermore, De Leeuw et al showed that Cirbp modulates cell 
cycle progression to protect the host from various stresses and possibly acts as an 
oncoprotein as it shuttles from the nucleus to the cytoplasm, and affects the stability and 
translation of its target mRNAs (De Leeuw et al. 2007). 
Interestingly, the Cirbp gene has alternative promoters, as shown in mouse NIH-T3T cells 
(Al-Fageeh and Smales 2009), which result in splice variants which can impact on the 
promoter’s sensitivity and strength. Alternative splicing results in three major CIRP 
transcripts varying in size due to different transcription start sites. Two of these transcripts 
showed varying levels of expression, with the longest transcript (detected at 32
o
C) showing 
a discrete expression and stability profile under mild hypothermic conditions and exhibited 
internal ribosome entry segment (IRES)-like activity (Al-Fageeh and Smales 2009).   
Another well reported CSP is Rbm3 which is another member of the glycine rich RNA 
binding family. It has been suggested that Rbm3 is involved in regulation via the alteration 
of miRNAs (Dresios et al. 2005). The 5’UTR of Rbm3 has been extensively investigated 
by Mauro and co-workers and they have identified 13 ORFs from a 720nt cDNA leader 
sequence and an IRES element, both of which may contribute to cold stress responsiveness 
(Chappell et al. 2001) (Chappell and Mauro 2003). 
The presence of an IRES element was revealed after deletion and mutation studies and 
demonstrate 4 cis-acting elements within this 5’UTR that most likely bind different 
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cyotoplasmic proteins. When comparing IRES activity between 37
o
C and 33
o
C it was 
shown to be enhanced up to 5-fold depending on the cell line. They also showed that Rbm3 
enhanced cap-dependant mRNA translation at 33
o
C compared to 37
o
C (Chappell et al. 
2001).  
 
1.10: Promoter Analysis – Bioinformatics 
Integrated genome databases--such as the UCSC, Ensembl and NCBI MapViewer 
databases - and their associated data querying and visualisation interfaces (e.g. the genome 
browsers) transformed the way that molecular biologists, geneticists and bioinformaticists 
analyse genomic data (Schattner 2009) (Teufel et al. 2006).  
As sequence entries in the major genomic databases currently rise exponentially, the gap 
between available, deposited sequence data and analysis by means of conventional 
molecular biology is rapidly widening, making new approaches of high-throughput 
genomic analysis necessary. At present, the only effective way to keep abreast of the 
dramatic increase in volume of sequence information is to apply bio-computational 
approaches (Ecker et al. 2012).  
How DNA regulation can be accomplished over long distances has long been intriguing. 
Current data indicates that although the mechanisms by which these diverse regulatory 
elements affect gene transcription may vary, an underlying feature is the establishment of 
close contacts or chromatin loops (Dean 2011). These elements were shown to be often 
separated from target genes by distances that can reach 100 kb (Dean 2011), therefore it is 
difficult to analyse promoter sequences that have no defined boundaries.   
When subjecting a promoter sequence to experimental scrutiny, whether it is a putative 
promoter segment, enhancer or any proposed regulatory sequence, subsequent analysis 
revolves around finding out answers to various questions.  
Some examples include; why and how does it drive expression, which important 
transcription factors (TFs) bind to the promoter sequence, why does that arrangement work 
in one organism and not in another, why do some promoters regions have TATA boxes 
while some have CpG islands architecture. 
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When a protein is needed the cell machinery signals transcription, this is facilitated by 
transcription factors. As TFs play an essential role in promoter regulation a natural question 
to ask is what transcription factors (TFs) bind to a promoter sequence to gain an insight into 
promoter-TF interactions and functionality (Stewart et al. 2012). We now know that the 
tissue-specific expression of a particular gene is the result of the presence of a particular 
constellation of TFs in the cell nucleus.  
But how do the transcription factors themselves come to be expressed in a tissue-specific 
manner? In many cases, the genes for transcription factors are activated by other 
transcription factors and now we know that transcription factor cascades are responsible for 
coherent expression (Nagore et al. 2013) (Handstad et al. 2012). 
The aim in deciphering the landscape of the promoter is to establish what the minimal 
sequence is, that allows functionality, or can mutations be introduced along the promoter 
region to hinder or indeed increase transcriptional rates and can these promoters and their 
cognate TFs be further engineered. 
Traditional methods like gel retardation, electrophoretic mobility shift assay (EMSA) or 
DNA footprinting have been used to identify a region of DNA which a transcription factor 
can bind, but they suffer due to TFs binding to ill-defined sites/motifs. One way to 
circumvent this is through Chromatin Immunoprecipitation (ChIP), in which a cross-
linking fixing agent such as formaldehyde is used to covalently-link proteins and DNA 
complexes. After cross-linking, cells are sonicated and sheared to generate ~500bp 
fragments which can be separated using a specific antibody. Then these antigen-antibody 
interactions can then be precipitated using beads with an affinity to the chosen antibody. 
Lastly, reversing the cross-links with a heat step 65
o
C for 12-18 hours typically releases the 
DNA (Handstad et al. 2012). 
Ding and co-workers have developed novel approaches such as (ChIPModule and 
SIOMICS) to systematically discover transcription factors and their related cofactors from 
ChIP-seq data. Some methods heavily rely on well annotated motifs even though the 
number of established motifs is limited. Interestingly, de novo motif discovery methods 
often neglect underrepresented motifs in ChIP-seq peak regions. To address this the group 
created SIOMICS and it was shown to be advantageous in terms of speed, increasing the 
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number of known cofactor motifs predicted in experimental data sets and reducing the 
number of false-positive motifs predicted in random data sets. The SIOMICS software is 
freely available at (http://eecs.ucf.edu/∼xiaoman/SIOMICS/SIOMICS.html) (Ding et al. 
2013) (Ding, Hu and Li 2014). 
Other previous web-based tools such as MEME and DREME, that can process large 
eukaryotic datasets in a timely manner, were described by Bailey and Machanick and they 
run two complementary motif discovery algorithms on the input data and use the motifs 
they discover in subsequent visualisation platforms, binding affinity and identification 
steps. DREME is available as part of the MEME Suite of motif-based sequence analysis 
tools (http://meme.nbcr.net) (Machanick and Bailey 2011) (Bailey 2011). 
Many genes have been extensively studied and co-regulated gene networks have been 
experimentally and computationally researched in the ways mentioned. Now entire 
websites and software packages exist whereby genes and indeed more importantly for this 
project, their adjacent promoters can be analysed. Furthermore, there are only two 
promoter-specific landscape studies (Carninci et al. 2006) (Sanyal et al. 2012), they report 
extensively across various mammalian cells, however, neither were CHO specific. 
Performing comparisons between these unknown sequences against known regulatory 
motifs, putative cis-elements and consensus sequences can aid the mapping an unknown 
promoter region.  
See table 1.10 for a list of existing bioinformatic tools. This is all made possible by the 
revolutionary ChIP-seq and Ref-seq strategies (Mimura et al. 2014). 
 
 
 
 
 
  
47 
 
Table 1.10: List of existing online bioinformatics tools available. 
Motif Search Tools Promoter analysis databases 
Motiffinder from TAIR UCSC  
Weeder Web AGRIS 
MotifSampler AtProbe 
GeneSprings AthaMap 
MEME/DREME DoOP 
TAIR Pattern Match PlantCare 
Genomatix PLACE 
BioProspector Transfac 
Improbizer CBRC 
Toucan 2 CSHL 
ALGEN:PROMO RSAT 
 
 
1.10.1: Identifying and locating transcriptional elements 
Enhancers, silencers, insulators and transcription factors are DNA elements that play 
central roles in regulation of the genome that are crucial for appropriate control of gene 
expression but unfortunately, as mentioned, can be located many kb from the genes that 
they regulate (Raab and Kamakaka 2010, Bondarenko et al. 2003), making it difficult to 
identify these elements. 
Building or mapping a framework for promoter architecture can identify conserved 
sequences and may constitute vital regulatory sequence. The aim in searching the promoter 
landscape for transcription factor bind sites (TFBS) is to establish what sequence confers 
functionality. In silico programs look for TFBS motifs in DNA sequence from several 
species, upstream of the start codon ATG.  
The specificity of a transcription factor can be described by pattern matching. Two 
alternative formats are currently used to describe regulatory signals: strings (including the 
IUPAC alphabet for ambiguous nucleotides) or position-specific scoring matrices (PSSM) 
(van Helden 2003). 
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A particular program can identify common TFBS in those sequences using their specific 
search tools and algorithms. The common TFBS must obey various criteria e.g.: be on the 
same strand or be within a certain distance of other TFBS in order to constitute a possible 
promoter framework (Figure 1.10.1 A). 
 
 
Figure 1.10.1: (A) Illustration of bioinformatic framework building for promoter regions, 
by cross-referencing other species to identify common consensus sequence motifs 
facilitated through ChIP-Seq/Ref-Seq strategies. Conserved sequences identified may 
constitute essentially regulatory sequence. (B) Examples of four well-established consensus 
elements with annotation and sequence are shown. 
 
Many elements can be present either proximally or distally while the configuration of these 
elements can vary greatly among species. Imperative to discerning full promoter 
functionality is locating important regulatory elements such as; 
49 
 
 CAAT box - A consensus sequence close ~80 bp from the TSS start point (+1). It 
plays an important role in promoter efficiency, by increasing its strength, and it 
seems to function in either orientation. This box is replaced in plants by a consensus 
sequence called the AGGA box 
 TATA box - A sequence usually located ~25 bp upstream of the TSS. The TATA 
box tends to be enclosed by GC rich sequences and binds RNA polymerase II and a 
series of transcription factors (TFII and TBP) to form an initiation complex 
 GC box - A sequence rich in guanidine (G) and cytosine (C) nucleotides, is 
regularly found in multiple copies in the promoter region and the ubiquitous SP1 TF 
usually binds to it  
 CAP/TSS site - A transcription initiation sequence or start point defined as +1, at 
which the transcription process actually starts 
 Enhancers – No defined locus and orientation independent but crucial to full 
functionality and activity diversity by binding to multiple TFs at any given time.  
There is currently an interest in studying and isolating enhancers, which can be 
attached to heterologous promoter regions to augment transcriptional activity and in 
some cases to provide additional levels of control (for example; to confer tissue-
specific or stage-specific expression of a gene) 
 
The sequencing of a large number of genomes has greatly stimulated the development of 
computational methodology (in silico) for the identification of signals and patterns in DNA 
preserved over evolution as they can be indicative of functionality (Farre et al. 2003). 
The web resource Regulatory Sequence Analysis Tools (RSAT) (http://rsat.ulb.ac.be/rsat) 
offers a collection of software tools dedictated to the prediction of regulatory sites in non-
coding DNA sequences. These tools include sequence retrieval, pattern discovery and 
genomic scale matching, map drawing, random sequence generation plus many more. It 
currently holds >100 fully sequenced genomes which are updated regularly from Genbank 
(van Helden 2003).  
 
1.11: Engineering of important cellular pathways 
Having explored the various means of controlling gene expression using promoters, 
regulatory elements and exogenous inducible molecules, we now explore the pathways they 
can be used to control. 
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1.11.1: Engineering of cellular proliferation and cell cycle arrest 
It has been shown that recombinant protein yields from CHO cell fermentations are 
correlated to cell number and longevity (Sunley and Butler 2010). The four phases of 
growth for any cell in culture [lag, log, stationary, decline] can be targeted to increase the 
longevity of batch cultivation. Ideally, a short lag phase where cells are acclimatise to the 
environment, followed by a rapid log/exponential growth phase, where the cells grow to 
maximum density as fast as possible so that you get a longer stationary phase. During this 
extended stationary phase they can concentrate their metabolic energy to increasing specific 
protein productivity and not on other cellular functions.  
Care must be taken to monitor the possibility of uncontrolled proliferation beyond a certain 
density where nutrient depletion and toxic metabolite waste can cause cell death and 
degrade the valuable protein product (Zeng, Deckwer and Hu 1998). The transfer of a 
population of cells from a typical cell cycle to a temperature shifted biphasic cycle (Figure 
1.11.1) involves reducing the lag and exponential phases, getting to high cell density 
(HCD) quickly. This extends the stationary phase, which is the main production phase, as 
cellular energy is being utilised for protein synthesis and not cellular growth (Fox et al. 
2005) (Fogolin et al. 2004) (Tan et al. 2008) (Kim and Lee 2007) (Schatz et al. 2003). 
 
 
Figure 1.11.1: Typical and more idealistic biphasic growth curve of cells in culture.              
[1=Lag, 2= Exponential, 3= stationary and 4= Decline/death phases].  
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Sunley et al, reported an increase in volumetric titer of beta-interferon in stationary cultures 
and furthermore more than twofold after application of a temperature-shift strategy 
involving a switch from growth to production phase (Sunley, Tharmalingam and Butler 
2008).  
Furthermore, productivity can be linked to cell cycle stage (Table 1.11.1). G1 phase is 
considered to be an ideal time to increase production and subsequent studies have shown 
G1 arrest to contribute to increased protein production in hybridoma cells and CHO cells 
(Sonna et al. 2002) (Al-Fageeh and Smales 2006). 
 
Table 1.11.1: Typical Eukaryote/Mammalian cell cycle summary. 
 
 
Researchers first developed proliferation control strategies to enhance protein production 
over extended stationary phase over a decade ago (Mazur et al. 1999) (Kaufmann et al. 
2001). For example; Mazur et al, used a multicistronic expression unit encoding the product 
gene and a cytostatic cell-cycle-arresting gene (p27) under control of a single tetracycline-
repressible (Tet-(off)) promoter. This allowed induction of p27 expression and subsequent 
growth control during a well-defined, highly viable physiological cellular state resulting in 
enhanced heterologous protein production (Mazur et al. 1998).   
Cell cycle regulating factors such as p27 and p21 have been used in CHO cells to induce 
cellular arrest (Fussenegger et al. 1997) (Sunley and Butler 2010) (Fussenegger, Mazur and 
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Bailey 1997) (Fussenegger, Mazur and Bailey 1997). Bi et al, reported that in p21 (CIP1)-
arrested cells production of antibody from a stably integrated lgG4 gene was enhanced 
approximately fourfold more than in proliferating cells (Bi et al. 2004). Conversely, factors 
such as E2F-1 and the oncogenic protein c-myc responsible for cell cycle progression have 
been successfully applied to develop rCHO cell lines capable of robust growth and 
maximum IVCC (Kuystermans and Al-Rubeai 2009). 
In addition to the cell cycle genes mentioned, other gene targets such as; valosin-containing 
protein (VCP) knockdown was shown to be detrimental to cell viability in CHO and has 
since been used as in in-house control when testing cellular viability (Doolan et al. 2010). 
Whereas overexpression of malate dehydrogenase II (MDH II) in CHO cells resulted in 
increases in intracellular ATP and NADH, and up to 1.9-fold improvement in integral 
viable cell number (IVC) (Chong et al. 2010).  
Van Opstal et al reported that addition of a growth inhibitor during mitosis and up to 2 
hours after mitosis resulted in arrest of CHO cells in early G1 phase. This was deduced 
from the expression of cyclins A and D post-addition. After 24 h of cell cycle arrest, cells 
highly expressed the cleaved caspase-3, a central mediator of apoptosis. These results 
demonstrate that protein kinase B (PKB) activity in early G1 phase is required to prevent 
the induction of apoptosis (van Opstal et al. 2012). This leads us onto the next potential 
engineering pathway. 
 
1.11.2: Programmed cell death (PCD) engineering 
Another strategy in mammalian engineering is the manipulation of programmed cell death 
(PCD) which is important, as it affects the viable cell concentration as well as the product 
quality and quantity (Arden and Betenbaugh 2004).  
Cellular turnover and death occurs as either necrosis (more sudden and passive) or two 
types of PCD; apoptosis (PCD type I) and autophagy (PCD type II). However, inhibition of 
apoptosis does not necessarily guarantee the blocking of autophagy-mediated cell death due 
to the independency between both processes (Kim, Kim and Lee 2012) (Nikoletopoulou et 
al. 2013).  
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Mammalian cells often undergo programmed cell death upon exposure to stresses 
encountered in bioreactors. Cell death is triggered by numerous factors like nutrient 
depletion, shear stress, elevated osmolarity and accumulation of toxic by-products. The 
implementation of strategies to control PCD through apoptosis, prevent the onset of these 
stresses and enhance culture productivities represents a major goal of biotechnologists. 
Research in apoptosis has increased substantially since the early 1990s and is highly 
examined strategy at present (Krampe and Al-Rubeai 2010). 
Apoptosis is a biochemical process of programmed cell death (PCD type I). It is a natural 
process whereby cellular population homeostasis is maintained by eradicating damaged or 
ill-functioning individual cells. Approximately 50-70 billion cells undergo apoptosis in a 
human adult daily, which involves complex signaling pathways. This apoptotic signaling is 
mediated by a caspases-cascade system in two main networks, which is a series of 
proteolytic cascades activated by cleaved caspases (Figure 1.4.2). Caspases can be divided 
into two types, effector caspases and initiator caspases (Kim, Kim and Lee 2012). 
Apoptotic engineering, be it pro or anti-apoptotic based continues to be a highly desirable 
method to control via the various pathway proteins (caspases, Bcl-proteins) and is linked to 
mitochondria permeability. The pro-apoptotic Bcl-2 proteins Bad, Bid, Bax, and Bim may 
reside in the cytosol but translocate to mitochondria following death signaling, where they 
promote the release of cytochrome c (Ow et al. 2008).  
Links between cancer and apoptosis have been apparent for some time, the discovery of an 
agent that selectively kills tumor cells and not normal cells is the holy grail for cancer 
researchers. Even links between transcription factors and apoptosis have been made. For 
example, more recently the role of Pokemon (POK erythroid myeloid ontogenic actor), 
transcription factor with proto-oncogenic activity was identified. Zhang et al, demonstrated 
that it might serve as an important mediator of crosstalk between intrinsic and extrinsic 
apoptotic pathways in hepatocellular carcinoma (HCC) cells (Zhang et al. 2013).  
Gillissen et al reported that XIAP targeted therapy can be used to overcome TRAIL-
resistant (after the loss of Bak/Bax function) carcinoma cells. This can be achieved by 
direct or indirect inhibition of XIAP by RNAi, Mithramycin A or by the SMAC mimetic 
LBW-242 as well as inhibition of the proteasome by the drug Bortezomib (Gillissen et al. 
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2013). With all this considered, pathway knock-outs, not just the apoptosis pathway, is 
obviously a viable avenue for manipulation and has the potential to create new stable cell 
line specific phenotypes post screening. For example APAF-1, COX-2, Akt and p300 have 
all been manipulated to observe different phenotypes such as decreased proliferation using 
the anticancer properties of melatonin to modulate pathways (Wang et al. 2012).  
There are a lot of subsidiary components and molecules involved in apoptosis and just as 
much scope for engineering improvements relating to these components. Mimicking the 
internal signaling without alerting the host cell to trigger any kind of abnormal behavior 
would be a key advantage in maintaining cellular homeostasis. 
 
 
Figure 1.11.2: Schematic diagram illustrating the caspase-cascade in the apoptotic 
pathway. Two pathways can be initiated to complete apoptotic PCD, all molecules within 
these pathways can be potential engineering targets in order to manipulate bioprocess 
relevant apoptosis cellular behaviour. 
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Because caspases play a vital role in apoptosis regulation including induction, transduction 
and amplification of these signals, then suppression of caspase activation is a promising 
strategy. We will discuss in more detail the role of various apoptotic–related genes and 
single gene specific engineering targets in section 1.9.  
In addition, defective apoptotic processes have been implicated in an array of diseases 
(Eschenburg et al. 2012) (Saleem et al. 2013) (Ndozangue-Touriguine et al. 2008). 
Disproportionate apoptosis levels causes atrophy (partial wearing of bodily components), 
while a deficient amount results in uncontrolled cell proliferation, leading to cancer in 
extreme cases.  
Autophagy is a catabolic process that takes place through a caspase-independent lysosomal-
mediated degradation pathway and is distinguished from apoptosis (Kim and Lee 2012). It 
is a conserved pathway that delivers intracellular materials into lysosomes for degradation, 
is involved in development, aging, and a variety of diseases. Up until recently, the focus of 
cell death engineering was on apoptosis solely, whereas now more studies involving 
engineered CHO cells are being explored, for example; Hwang et al observed the 
accumulation of a common autophagic marker, a 16 kDa form of LC3-II and was found to 
take place in two antibody-producing CHO cell lines, Ab1 and Ab2 (Hwang and Lee 2008). 
They also show that overexpression of Bcl-xL or Akt could delay the autophagic cell death 
induced by nutrient exhaustion (Hwang and Lee 2009). 
Hyperosmotic stress was found to trigger autophagy also. Han et al studied two rCHO cell 
lines, producing antibody and erythropoietin and both were subjected to hyperosmotic 
stress resulting from NaCl addition (310-610 mOsm/kg). They found elevated amounts of 
caspases 3 and 7, fragmented chromosomal DNA. Concurrently, hyperosmolality increased 
the level of accumulation of LC3-II, a widely used autophagic marker measured by western 
blot analysis and confocal microscopy (Han et al. 2010).  
In summary, by combining information on the interplay between necrosis, apoptosis and 
autophagy so we can obtain more specific data of their interwoven roles which can perhaps 
prove useful to increase CHO cell performance in future studies. For example, a recent 
report by Zou et al reveal a previously unidentified role for autophagy in protection against 
necrosis triggered by pathogenic bacteria in C. Elegans and implicate that such a function 
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of autophagy may be conserved through the inflammatory response in diverse organisms 
(Zou et al. 2014). 
 
1.11.3: Effect of low Temperature on culture performance 
It has been well documented that cultures grown at 37
o
C and are then shifted to mild 
hypothermic temperature of 32-28
o
C, slows growth and metabolism of CHO cells, which 
permits extended viable culture times. As a result, the cellular machinery can direct its 
energy on protein synthesis and thus potentially increase productivity (Lim et al. 2010, 
Fussenegger, Mazur and Bailey 1997, Kaufmann et al. 1999) (Recillas-Targa 2006). 
Additionally, improved cell viability, specific productivity and reduced nutrient uptake rate 
are other beneficial culture traits that have been reported (Furukawa and Ohsuye 1998) 
(Yoon, Hwang and Lee 2004) (Schatz et al. 2003) (Fogolin et al. 2004). Although, some 
early reports did demonstrate the opposite or no significant increase at all. For example; the 
cultivation of hybridoma cells at low temperatures resulted in a decrease of specific 
monoclonal antibody productivity (Sureshkumar and Mutharasan 1991). 
Although this may appear to be a clear cut mechanism of control over cellular growth and 
consequently productivity, it can vary hugely depending on cell type/line and the protein 
product being expressed. The underlying effects of temperature shift at a cellular and 
molecular level remain poorly understood (Recillas-Targa 2006) (Recillas-Targa 2006). 
The effects caused to cell from lowering temperature on CHO culture performance which 
doesn’t require any additional genetic engineering on the cell, makes it an attractive from 
the outset in improving mammalian cell bioprocesses. Many cells respond favourably in 
culture, even before any genetic manipulation is undertaken. Two studies on protein 
productivity showed that, at reduced temperature CHO cells exhibited a state close to that 
of growth arrest and increased protein production levels in SEAP and EPO were 
reproducible (Kaufmann et al. 1999) (Yoon, Song and Lee 2003).  
Mammalian cells respond to low temperature (mild hypothermia) by synthesising/up-
regulating cold-shock proteins (CSPs) to aid in cellular function. During this change in 
environmental temperature, other proteins that work at the customary physiological 
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temperature of 37
o
C, have been shown to have their transcription and translational 
machinery suppressed (Underhill and Smales 2007).  
Cold-shock proteins (CSPs) such as CspA, Rbm3, Cirbp, RecA, quickly became targets for 
biotechnologists. Two notable CSP genes from the glycine-rich protein (GRP) family are 
CIRBP (cold-inducible RNA binding protein) and RBM3 (RNA binding motif protein 3) 
which showed upregulation at low temperature (Nishiyama et al. 1997). CSPs share the 
cold-shock domain (CSD) as a common motif and are believed to function as RNA/DNA 
chaperones, assisting replication and translation via protein folding at low temperatures 
(Jiang et al. 1997). 
As mentioned in section 1.9.2, Cirbp has since become a standard model for inducible 
expression strength in reduced temperature culture experiments and thus could be used as a 
tool to assess the prospective temperature induciblity of other genes (Underhill and Smales 
2007) (Hong et al. 2007) (Al-Fageeh and Smales 2009). However, CSPs are not fully 
conserved across species and their effects are quite variable between cell lines. There are 
~30 identified CSPs in E.coli (Gualerzi et al. 2003).  
Fox et al hypothesised that improving total production of recombinant protein should be 
achieved by stimulating cells to actively grow at low temperature. They reported 7.7 and 
4.9-fold increases in total interferon-gamma protein production in CHO cells grown under 
stimulated (fibroblast growth factor or insulin supplemented in the serum) hypothermic 
conditions compared with the control cultures grown at 37
o
C (Fox et al. 2005). In another 
study by the same group, Tan et al, report that following stable overexpression of Cirbp, 
final IFN-gamma titre by production CHO cells was increased by 40% compared with 
current temperature-based strategies alone. Furthermore, there was no decrease in cell 
growth or recombinant-protein glycosylation quality (Tan et al. 2008).  
Much still remains to be discerned about cold adaption at a molecular level. Recent efforts 
topics include; measuring the effects of different acclimation periods (duration of cold-
adaption), the effects of lower temperature on aggregate formation in cultures of IgG 
producers and how an irregular unfolded protein response (UPR) caused by cold-shock 
correlates to misfolding of proteins (Gomez et al. 2012).  
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The response of cells at a genomic level, although poorly understood, dominates the 
literature rather than studies into the proteome of a cell. Kaufmann et al were one of the 
pioneers in examining the CHO proteome. They saw distinct changes in protein expression 
by 2-D polyacrylamide electrophoresis of cells grown at 37
o
C and 30
o
C. These changes in 
the proteome suggest that mammalian cells respond actively to low temperature by 
synthesizing specific cold-inducible proteins and support the hypothesis that stress signals 
must be converted into biochemical signals to alter gene expression patterns of CSPs, 
presumably resulting from changes in post-translational protein modifications (Kaufmann 
et al. 1999).  
Recent studies from researchers within the NICB have reported a number of differentially 
expressed proteins and RNAs involved in temperature shift culture over timecourse 
experiments (Kumar et al. 2008b) (Kumar et al. 2008a). The resulting dataset has been very 
useful for creating target lists for follow up functional validation of important temperature 
related proteins.  
In parallel with these findings, we aim to combine the already positive intrinsic attributes of 
mild hypothermic shifting of culture temperature shift seen above with the isolation of 
temperature-sensitive CHO specific promoters in this project, which can be used in parallel 
for increased bioprocess performance. In conclusion, although poorly understood, interest 
in the cold-shock/temperature shift as a method of increasing bioprocessing, therefore is 
really heating up. 
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1.12: MicroRNA roles in gene regulation and engineering potential 
1.12.1: Background and scope 
Since the discovery of RNAi (section 1.5.4) major attention has focused on studying 
miRNA (microRNA) and siRNA (small interfering RNA). Basically hidden in the genome 
until recently, miRNAs like siRNAs are non-coding small RNAs and are typically 19-25 
nucleotides long. MicroRNAs have a major impact on most biological processes and their 
ability of to influence gene expression is now recognised as a fundamental layer of 
regulation within the cell (Barron et al. 2011).  
MicroRNAs (miRNAs) are strongly implicated in the global regulation of gene expression, 
and, in this regard, they consequently affect metabolic pathways on every regulatory level 
in different species.  
This characteristic makes miRNAs a promising target for cell engineering, while a key 
advantage of miRNAs, in contrast to most cell-engineering approaches that rely on 
overexpression of regulatory proteins, is that they do not compete for the translational 
machinery that is required to express the recombinant product (Muller, Katinger and 
Grillari 2008) (Hackl et al. 2011). Furthermore, Maccani et al showed that mature 
microRNAs were predominantly upregulated in the producing cell lines compared to non-
producer lines (Maccani et al. 2014). 
MicroRNAs with their ability to regulate complex pathways that control cellular behavior 
and phenotype have been proposed as potential targets for cell engineering in the context of 
optimisation of biopharmaceutical production cell lines and for improving understanding of 
mammalian cell physiology.  
They are also attractive because of the ability of a single miRNA to influence more than 
one target gene. This is due to imperfect base-pairing exempt of seed region; the seed 
region constitutes 2-7 nucleotides from the 5’ end of the miRNA which binds with full 
complementarity to a target mRNA. It has become apparent that the miRNA molecules 
themselves are subject to sophisticated control during biogenesis and degradation (Jadhav 
et al. 2013). 
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At present, around 16,000+ miRNAs have been identified across all species. These are 
documented in online databases such as ‘mirBase’ and ‘mirWalk’ and used in a plethora of 
software algorithms for miRNA:mRNA binding prediction in silico such as; ‘TargetScanS’ 
and ‘miRNAnda’. There are ~1700 miRNAs in the human genome estimated to be 
targeting approximately 60% of genes.  
In parallel, CHO miRNA identifications have been growing (Wu 2009)(Hernandez Bort et 
al. 2012, Gammell et al. 2007) (Doolan et al. 2012). Furthermore, Hackl et al identified 387 
miRNAs in CHO after extensive profiling and next-generation sequencing and  numbers 
are sure to increase in the future (Hackl et al. 2011).  
An interesting feature of miRNA genomic structure (Figure 1.12.1) is that many miRNAs 
exist in clusters that are co-expressed. miRNAs are predominantly transcribed by RNA 
PolII though some are PolIII-dependent with A/B boxes being identified upstream. It is 
estimated that ~50% of all miRNAs are located within introns of protein encoding genes 
with the remainder residing in intergenic regions (Barron et al. 2011).  
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Figure 1.12.1: Genomic organisation of miRNA genes. There are four classes of 
organization. (1) Intergenic miRNAs, are located in isolation from other genes and occur as 
either a monocistronic (a) or polycistronic unit (b). Their transcription is driven by their 
own promoter upstream and may be either RNA PolII- or PolIII-dependent. (2) Intronic 
miRNAs are located within an intron of a protein-coding gene, again as monocistronic or 
polycistronic units. They may be under the control of their own independent promoter or 
may be co-transcribed with the host gene. In the latter case they are processed into pre-
miRNAs by the microprocessor complex subsequent to intron splicing. (3) Mirtrons exist in 
short introns and differ from other intronic miRNAs in that they by-pass processing by 
Drosha and are exported directly to the cytoplasm to engage Dicer. They are co-expressed 
with the host gene. (4) Exonic miRNAs are located in an exon and are independently 
transcribed from their own promoter. [Black arrow = host gene promoter start site, Black 
arrow with lines = miRNA promoter start site, Diamond-shapes with lines = introns, E1/2 
= exons] (Barron et al. 2011). 
 
To study the role of miRNAs in the regulation of CHO cell growth, qPCR, microarray and 
quantitative LC-MS/MS analysis were utilised for simultaneous expression profiling of 
miRNA, mRNA and protein (Clarke et al. 2012). This was the basis for the sampleset used 
in this project, where 51 miRNAs were identified to be associated with increased growth 
rate (35 miRNAs upregulated and 16 miRNAs downregulated). For other specific miRNAs 
for used in engineering recently (Table 1.12.1).  
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Table 1.12.1: Functional roles of miRNA engineering targets (Barron et al. 2011). 
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1.12.2: The miR-17-92 cluster  
Clusters of miRNAs are perhaps a result of evolutionary duplication events (Lim et al. 
2003) (Yu et al. 2006), more specifically, they are closely linked to early evolution of the 
vertebrate lineage (Tanzer and Stadler 2004). Clustering and conservation patterns reported 
by Altuvia et al raised the proportion of clustered human miRNAs that are less than 3000 nt 
apart to 42%. This suggested that the clustering of miRNA genes was higher than currently 
acknowledged at the time (Altuvia et al. 2005). Identification of miRNA family members 
could be an important requirement for understanding the full mechanism of post-
transcriptional regulation as they share the same vital seed sequence. 
One of the better characterised oncogenic miRNAs is the polycistronic miR17-
92/oncomiR-1 (Olive et al. 2009). It has been identified as a powerful cancer driver that 
coordinates the activation of multiple oncogenic pathways, such as the PI3K and NFκB 
pathways (Jin, Lai and Xiao 2014).  
The pre-miR transcript contains 6 stem-loop hairpin structures that ultimately generate 6 
mature miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b1 and miR-92-1, with 
miR-19a acting as an internal brake that opposes the oncogenic activity of the others in 
some cancer contexts (Zeitels and Mendell 2013). Furthermore, Olive and co-workers have 
done considerable work on this cluster and its molecular dissection in many oncogenic and 
apoptotic (interacts with PTEN and Bim apoptotic components) settings with results 
suggesting that miR-17-92 can be harnessed to enhance the efficacy of T cell-based tumor 
therapy (Olive et al. 2009) (Jiang et al. 2011) (Olive et al. 2013). 
Relating to this project Clarke et al, identified the miR-17-92 as differentially expressed in 
fast growing CHO cell lines compared to slow cell lines, each of the cluster members being 
positively correlated with increasing growth rates (Clarke et al. 2012). 
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1.13: XIAP is an important gene in apoptosis regulation  
1.13.1: Background 
There exists a family of apoptosis inhibitors called IAPs (inhibitors of apoptosis) that are 
well documented. During the process of programmed cell death or apoptosis, caspases 
become activated and cause a cascade of events that eventually destroy the cell. X-linked 
inhibitor of apoptosis or XIAP is the most potent caspase inhibitor encoded in the 
mammalian genome and has the most potential from a cellular engineering perspective in 
apoptosis prevention in mammalian engineering (Wilkinson et al. 2004).  
Recent evidence showed that inhibitor of apoptosis (IAP) proteins are frequently 
overexpressed in cancer and their expression level is implicated in contributing to 
tumorigenesis, chemoresistance, disease progression and poor patient-survival. 
In addition, Gyrd-Hansen et al showed that IAPs contain an evolutionary conserved 
ubiquitin binding domain that regulates NFκB (Gyrd-Hansen et al. 2008). Another example 
by Smolewski et al, found elevated cellular levels of cIAP1, cIAP2, XIAP and Survivin 
correlated with a progressive course of chronic lymphocytic leukemia. Thus, targeting IAPs 
with small-molecule inhibitors by their antisense approaches or natural IAP antagonist 
mimetics may be an attractive strategy of anti-cancer treatment (Smolewski and Robak 
2011). 
One of these IAPs became the focus of the second part of this thesis, XIAP. XIAP is 
translated by a cap-independent mechanism of translation initiation that is mediated by a 
unique internal ribosome entry site (IRES) sequence element located in its 5' untranslated 
region which facilitates its anti-apoptotic function during any kind of induced-cellular 
stress like radiation and chemotherapy, making it an attractive therapeutic target (Devi et al. 
2004). This also allows XIAP mRNA to be actively translated during conditions of cellular 
stress when the majority of cellular protein synthesis is inhibited (Holcik 2003).  
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1.13.1: Structure and Function 
The XIAP gene encodes a protein that belongs to a family of 8 apoptotic suppressor 
proteins. Members of this family share a conserved motif termed the baculovirus IAP 
repeat, which is necessary for their anti-apoptotic function. This protein was first shown to 
function through binding to tumor necrosis factor receptor-associated factors TRAF1 and 
TRAF2 and inhibits apoptosis induced by menadione, a potent inducer of free radicals, and 
interleukin 1-beta which is a converting enzyme (Song et al. 1996). 
The XIAP protein consists of 3 major types of structural domains. Firstly, there is the 
baculoviral IAP repeat (BIR) domain consisting of roughly 70 amino acids, which 
characterises all IAPs. Secondly, there is a UBA domain, allowing XIAP to bind to 
Ubiquitin (a regulatory protein found in most tissues and important regulator of 
degradation, promotion and prevention of interactions between molecules) (Blankenship et 
al. 2009). And lastly, there is a Zinc-binding domain, or a ‘Carboxy-terminal RING Finger’ 
(Duckett et al. 1998) (Deveraux and Reed 1999). 
XIAP stops apoptotic cell death that is induced either by viral infection or by 
overproduction of caspases. XIAP binds to and inhibits caspases 3, 7 and 9. The BIR2 
domain of XIAP inhibits caspase 3 and 7, while BIR3 binds to and inhibits caspase 9 
(Deveraux and Reed 1999). The UBA domain utilises E3 ubiquitin ligase activity and 
enables IAPs to catalyse ubiquination of innate caspase-3, or caspase-7 by degradation via 
proteasome mode of action (Delhalle et al. 2003).  
The most widely used strategy for targeting IAP proteins is based on mimicking the natural 
IAP antagonist, Smac/DIABLO. XIAP was shown to be inhibited by DIABLO (Smac) and 
HTRA2 (Omi), two death-signaling proteins released into the cytoplasm by the 
mitochondria (Eschenburg et al. 2012). Smac/DIABLO is a mitochondrial protein and has 
been shown to be a negative regulator of XIAP enhancing apoptosis by binding to XIAP 
and subsequently preventing it from binding to caspases (Wilkinson et al. 2004). 
Mutations in XIAP mRNA sequence have been shown to result in X-linked 
lymphoproliferative syndrome. X-linked lymphoproliferative disease (XLP) is an inherited 
immunodeficiency, involving primarily T and natural killer (NK) cells, which in the 
majority of cases exacerbates following exposure to Epstein-Barr virus (EBV)(Schuster and 
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Kreth 2000). Furthermore, alternate splicing resulted in multiple transcript variants while 
pseudogenes of this gene are found on chromosomes 2 and 11 (Bassiri et al. 2008). 
However, mutations affecting the RING finger do not noticeably affect apoptosis, 
indicating that the BIR domain is sufficient for the protein’s function. When inhibiting 
caspase-3 and caspase-7 activity, the BIR2 domain of XIAP binds to the active-site 
substrate groove, blocking access of the normal protein substrate that would result in 
apoptosis (Eckelman, Salvesen and Scott 2006, Huang et al. 2001). XIAP distinguishes 
itself from the other human IAPs because it is able to effectively prevent cell death due to; 
TNF-α, Fas, UV light, and genotoxic agents (Duckett et al. 1998). 
 
1.14: Identifying miRNAs that regulate bioprocess-relevant phenotypes 
Combining miRNA engineering with anti-apoptotic engineering is an attractive prospect in 
bioprocessing and therapeutics, especially considering the role of the XIAP gene within 
cancer disease states becoming more recently publicised (Ren et al. 2014). Developments 
combining both have been promising, for example Liu et al reported that miR-7 targeted 
and downregulated XIAP. Subsequent ectopic expression of XIAP then rescued the effects 
induced by miR-7 on HeLa and C-33A cells (Liu et al. 2013).  
Another study by Druz et al used nutrient depleted spent media, to induce apoptosis in 
order to identify resultant miRNA expression post-induction using microarrays and 
bioinformatics analysis. They reported up-regulation of the mouse miR-297-669 cluster and 
focused on the pro-apoptotic role of mouse specific miR-466h and its capability to 
modulate the apoptotic pathway in mammalian cells (Druz et al. 2011). 
In a separate study, it was found that expression of miR-23b was reduced in brain cancer 
Glioblastoma cells (GBMs). CHO cells were transfected with miR-23b mimics 
subsequently leading to down-regulation of XIAP. Combined exposure of GBM cells with 
Docetaxel and miR-23b mimics resulted in significantly increased apoptosis compared to 
the drug alone. Reduced expression of miR-23b in GBMs, and subsequent deregulated 
expression of XIAP may contribute to the ability of GBMs (especially faster growing lines 
like SNB-19) to evade apoptosis at least partially. This highlighted that miR-23b may be a 
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promising candidate for the development of targeted treatment options in human Glioma 
(Griffith, Kinsella et al, in preparation). 
In summary, as a consequence of these findings plus other literature links between XIAP, 
miRNA and apoptosis in human disease states (Gillissen et al. 2013) (Saleem et al. 2013) 
(Ndozangue-Touriguine et al. 2008) (Smolewski and Robak 2011), we wanted to bridge a 
connection between XIAP and the miRNAs that control its regulation in both human and 
CHO as a means to improve bioprocessing based on anti-apoptotic engineering, in addition 
to using endogenous promoters to improve transgene expression and will be explored in a 
in the second part of this project.  
 
1.14.1: Methods for identifying mRNA:miRNA interactions 
A recent publication from Bort et al, detailed an extensive database of miRNAs. By using 
clustering analysis they revealed groups of genes with similar expression patterns, which 
were subjected to functional pathway analysis. In total, over 1400 mRNAs and more than 
100 miRNAs were differentially regulated (p<0.05) in the batch culture at the beginning 
relative to the end of the culture. Therefore, during batch or fed-batch cultivations it can be 
expected that the transcription pattern of genes will change and that such changes may give 
indications on the cellular state in terms of viability, growth, and productivity (Hernandez 
Bort et al. 2012).  
Although numerous bioinformatics tools exist (Watanabe et al. 2007) (Li et al. 2010) to 
predict possible miRNA:mRNA interactions, true experimental validation of such 
interactions can be difficult and laborious. See table 1.14.1 for a list of existing methods.  
Due to the low degree of complementarity between the miRNA and its target region of 
mRNA 3’UTR, in silico prediction programs are often imprecise and therefore not very 
reliable for validation. In order to bridge the gap, iterative interactions between in silico and 
experimental methods are being explored and are beginning to play a vital role in the 
biological study of miRNAs (Chaudhuri and Chatterjee 2007). 
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Table 1.14.1: Methodology, description and reference for current miRNA isolation and 
identification methods. 
Method Description References 
Gene Reporter Assays 
3’UTR analysis with transcriptome/proteome using pre-
miRs and anti-miRs after modulation 
(Orom and Lund 2010) 
IP of Ago2 proteins Pulldown using highly specific monoclonal antibodies (Beitzinger and Meister 2011) 
Let-7 - Approach 
Using an endogenous Let-7 to isolate cDNA via base pair 
complementary in vivo 
(Andachi 2008) 
Biotinylated tagged miRNAs 
Bead Affinity purification using tagged miRNAs and 
analysis with RT-qPCR  
(Orom and Lund 2007) 
Digoxigenin (DIG) labelled 
miRNAs 
Another in vitro LAMP method, using anti-DIG antiserum 
to isolate from Zebrafish and C.Elegans 
(Hsu and Tsai 2011) 
TAP-Tar 
Tandem affinity method where miRNA:mRNA complexes 
are IP’d using anti-Ago Ab and streptavidin beads in vitro 
(Nonne et al. 2010) 
HITS-CLIP 
In vitro cross-linking of miRNA:mRNA complexes and 
Ago2 proteins 
(Chi et al. 2009) 
PAR-CLIP 
Photoactivatable-ribonucleoside enhanced cross-linking 
and IP, can be used to assess regulatory impact of miRNAs 
(Hafner et al. 2010, Hafner et 
al. 2012) 
p21Cip1/Waf1 - 3’UTR 
targeting 
To try isolate a single mRNA of interest, but must be 
transfected into cell line leading to laborious complications 
(Wu et al. 2010) 
lncRNA:PAR-CLIP 
Systematic transcriptome wide analysis of lncRNA-miRNA 
interactions, combination of recently discovered lncRNA 
and PAR-CLIP technique 
(Jalali et al. 2013) 
miR-133a-HAND2  
MS2-GFP fusion tag approach to empirically identify 
miRNAs in the 3'UTR of the mRNA encoding cardiac TF 
‘Hand2’  
(Vo et al. 2010) 
 
Unexpectedly, besides 3’UTR binding sites, these above studies highlighted that a large 
proportion of miRNA targets were actually mapped within the mRNA coding sequence. 
Furthermore, miRNAs regulate target mRNA expression in a moderate way and can work 
synergistically or additively with other miRNAs. It is recommended that additional assays 
are implemented to independently confirm observations from any affinity capture (Hassan 
et al. 2013). 
The small size of miRNAs provides a limited amount of sequence information for 
specificity. Furthermore, as partial pairing between a miRNA and a target site is often 
sufficient, a wide net can be cast for genes that are subject to regulation. This property not 
only means that a single miRNA can regulate multiple mRNAs but also that predicting 
those targets is not straightforward (Pasquinelli 2012).  
As different degrees of base pairing mediate target recognition by microRNAs exist, 
Pasquinelli detailed these modes of binding across plants, mouse, C. Elegans and human 
(Figure 1.14.1). Prediction algorithms can be exempt from accounting for miRNA and 
target interaction via these 5 broad pairing criteria.  
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Most cases, in animal models involve duplexes that contain mismatches and multiple 
nucleotide bulges. The most common motif is perfect pairing between nucleotides 2 and 7 
at the 5′ end of the miRNA, which is called the 'seed' region, and the target site (Thomas, 
Lieberman and Lal 2010) (Shukla, Singh and Barik 2011).  
There are rare examples of near-perfect complementarity between a miRNA and a target 
site that enables cleavage of the mRNA, such as in the case of miR-196 and a sequence in 
the HOXB8 mRNA (Yekta, Shih and Bartel 2004). Like any rule of thumb in science there 
are exceptions, there are also numerous examples of functional miRNA target sites that do 
not readily fit any of the previously described patterns (Rigoutsos 2009), and follow the last 
example in figure 1.14.1. 
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Figure 1.14.1: The different degrees of base pairing mediate target recognition by 
microRNAs (Pasquinelli 2012). 
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1.14.2: MiRNA pulldown using biotinylated mRNA capture technique 
Despite their biologic importance, determining miRNA targets represents a major 
challenge. The problem stems from the discovery that functional mRNA regulation requires 
interaction with as few as 6 nucleotides (nt) of miRNA seed sequence (Lim et al. 2005). 
Bioinformatic analysis has greatly improved the ability to predict, however, different 
algorithms produce divergent results with high false positive rates commonly seen 
(Bentwich 2005) (Watanabe, Tomita and Kanai 2007) (Baek et al. 2008). 
First described by Hassan et al, ‘miR-Capture’ can be used to identify specific miRNAs 
that target any chosen mRNA (Figure 1.14.3). This involves a biotinylated anti-sense 
oligonucleotide (designed against any mRNA exonic sequence) that is captured on 
streptavidin beads along with its bound mRNA and associated bound miRNAs (Hassan et 
al. 2013).  
Beitzinger et al reported the first biochemical identification approach of miRNA targets 
from human cells using antibodies specific to the argonaute (Ago) protein complexes 
involved in the miRNA/RISC pathway (Beitzinger et al. 2007). They went on to generate a 
full protocol for isolation and immunoprecipitation validation a few years later (Beitzinger 
and Meister 2011).  
Interestingly, Zisoulis et al developed a similar biochemical method to identify on a large 
scale the target sequences recognised by miRISC in vivo using live animal models. The 
bound RNA molecules were trimmed to the regions protected by Argonaute, and subjected 
to a series of isolation and linker ligation steps and identified by high-throughput 
sequencing methods (Zisoulis et al. 2011). 
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Figure 1.14.2: MiR-Capture Affinity technique with miRNA:mRNA. (1) CHO adherent 
cell culture source. (2) GOI in cytoplasm and cellular environment, (3) MiRNA-n denotes 
any target miRNAs within the mRNA locality either latent (grey) or signalled (green). The 
capture oligo was designed against an exposed loop structure determined from M-Fold 
software. 
 
Although there is an abundance of other experimental methods see table 1.14.1, all have 
varying advantages and disadvantages, with none being the standard bearer. However, as 
most of the competitive techniques are limited to 3’UTR targeting, miRNAs within the 
5’UTR or coding region will not be identified. Thus, the miR-Capture technique has the 
added benefit of being able to target a single specific genes mRNA transcript but also to 
potentially identify miRNAs anywhere along the full length of an mRNA transcript, XIAP 
in this case (Hassan et al. 2013). 
 
 
 
 
 
 
 
 
73 
 
1.15: Thesis aims 
1) Identify CHO genes that exhibit difference in expression between 37oC and 31oC. 
2) Identify whether differential expression is a result of changes in mRNA 
transcription or stability. 
3) As a result then to generate temperature shift/inducible promoters that could be 
used in conjunction with a routine temperature shift phase in a bioreactor as a tool 
to control transgene expression. 
4) Manufacture a promoterless reporter GFP plasmid host to enable quantitative and 
qualitative promoter studies in a reproducible manner. 
5) Isolate constitutive promoters to drive expression at a defined level, not influenced 
by temperature and other external stimuli, in particular directing our efforts towards 
a novel miRNA cluster identified from microarray expression profiling. 
6) Test the utility of promoters which display inducible and constitutive expression as 
alternatives to CMV promoters to be used in bioreactor and protein production 
settings. 
7) Test stability of expression between viral and endogenous promoters over a 
timecourse of 3 months, using a GFP reporter stably transfected into CHO-k1 
parental cells. 
8) Characterise and map various transcription factor binding sites present in the CHO 
promoters using bioinformatic approaches. 
9) Based on a parallel study (undertaken in collaboration with Dr. Paula Kinsella), 
whereby we showed that XIAP/miR-23b influences proliferation of Glioblastoma 
cells, examine XIAP as a potential anti-apoptotic engineering target in CHO 
studies.  
10)  Creation of XIAP specific CHO-K1 stable clones, perhaps observing increased 
growth densities and reduced sensitivity to apoptosis and which may be used in 
protein production settings. 
11)  Utilise a novel pulldown method (miR-Capture) to isolate cell-specific 
microRNAs targeting XIAP messenger RNA using a biotinylated anti-sense 
oligonucleotide capture affinity technique 
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12)  Compare the CHO and human XIAP sequence and the milieu of miRNAs that bind 
to the full length mRNA from each species and see which miRNA are common, if 
any. 
13)  Validate the most promising miRNA candidates targeting XIAP from the miR-
Capture approach (12). 
14)  Identify potential miRNAs that may be used to facilitate beneficial phenotypes in a 
bioreactor for increasing protein production in the future. 
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Section 2.0  
 
 
 
 
 
 
Materials and Methods 
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2.1: Ultra Pure Water 
Ultra high purity (UHP) water was used, where applicable, in all media and preparation of 
solutions during this project. The water was purified in house by a reverse osmosis system 
(Elga USF Maxima water purification system) to a standard of 12-18MΩ/cm resistance.  
 
2.2: Sterilisation 
Water, glassware and all thermolabile solutions were sterilised by autoclaving at 121°C for 
20 mins under 15 p.s.i. pressure. Thermolabile solutions were filtered through a 0.22um 
sterile filter (Millipore, SL6V033RB), with low protein binding filters used for all protein-
containing solutions. 
 
2.3: Glassware 
All glassware was washed and sterilized routinely. A deproteinisation agent RBS-25 (AGB 
scientific, 83460) was used to remove proteineous material and eliminates cellular debris 
from glassware. UHP was then used to rinse meticulously with a final sterilisation 
performed using an autoclave.  
 
2.4: Preparation of cell media 
Using clean water and glassware, ATCC medium was routinely made by combining stock 
500ml DMEM and F-12 Ham basal media (Sigma, 56495C) containing glutamine and 
sodium pyruvate (Gibco-Invitrogen 11360-035). This was finally supplemented with either 
FBS or FCS to a desired concentration of usually 2-10% FBS/FCS, depending on 
experiment.  
In addition, sterility checks were done for all complete culture media and cell culture 
related solutions by incubating a small aliquot at 25-37
o
C for a period of 5-7 days to ensure 
that no bacterial or fungal contamination was present at the time of usage. 
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2.5: Routine Management of Cells 
2.5.1: Precaution measures 
All routine cell culture work was carried out in a class II laminar air-flow cabinet (Nuiaire 
Biological Cabinet) or (Holten). Strict aseptic techniques were adhered to at all times (see 
NICB SOP No. 000-01). Laminar flow-biological safety cabinets (BSCs) were switched on 
at least 15 minutes prior to use and swabbed with 70% IMS prior to and following all work. 
Additionally, IMS was used on all equipment placed within the BSC. Experiments were 
performed using only one cell line at any given time in the BSC to avoid cell line cross-
contamination. Each week, cell culture cabinets and any incubators that were used were 
cleaned with industrial detergents (Virkon), IMS and UHP. A separate lab coat was worn 
during aseptic work and nitrile gloves were worn at all times during cell culture work. 
 
2.5.2: Sub-culturing of cell lines 
Over the course off the project, cells where grown in either suspension or adherent formats. 
The following was how each where subcultured and grown continuously. 
2.5.2.1: Anchorage dependant cells 
Adherent cell lines were grown in T25cm
2
 or T75cm
2
 tissue culture flasks and typically fed 
every 2-3 days. The spent media was either discarded to waste or sterile filtered (0.22μm) 
to be used as conditional media for future experiments. Cell culture flasks were rinsed with 
pre-warmed (37°C) trypsin/EDTA solution (0.25% trypsin (Gibco, cat # 15090), 0.01% 
EDTA (Sigma, cat # E4884) solution in PBS in order to remove any naturally occurring 
trypsin inhibitors present in residual serum.  
Fresh trypsin was then aliquoted in volumes dependant on flask size (1ml – 3ml) and left in 
the incubator at 37
o
C for 5-10 mins, until cells were detached from the respective flask 
under the microscope. This cell suspension was then transferred to sterile 20ml universals 
(Greiner, cat # 201151) for centrifugation at 1000rpm for 4-5 mins. Cell pellets were 
resuspended in fresh ATCC media and counted (see section 2.5.3) and subsequently 
reseeded to desired concentration depending on experiment. 
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2.5.2.2: Suspension Cells 
Cell lines used throughout the project had been adapted to suspension growth were either 
grown in 250ml disposable flasks (Corning, cat # 431144) with a 50ml working media 
volume or disposable 50 ml spin-tubes (Sartorius, cat # DF-050MB-SSH) using a 5ml 
media working volume. 
When subculturing cells, typically a sample was counted (see section 2.5.3) and the 
necessary volume extracted and centrifuged at 1000rpm for 4-5mins in a 20ml universal 
(Greiner, cat # 201151). The resulting pellet was resuspended with fresh ATCC media and 
seeded as desired, depending on the experiment.  
 
2.5.3: Cell counting 
Prior to cell counting samples were taken from one of the sub-culturing methods described 
in section 2.5.2. Cell numbers and viability estimations were carried out using a method 
where the culture sample was mixed at a 1:1 ratio with trypan blue (Gibco, cat 525). The 
mixture was incubated at room temperature for a 2-3 minutes and then an aliquot (~10μl) 
was applied to a chamber of a haemocytometer.  
Within the haemocytometer, there are sixteen squares making up a grid. We calculated the 
cell number per mL in the original cell suspension flask by counting individual cells 
contained in four grids under the microscope. This was done by dividing the cell count by 
four to get the average cell number of a sample then multiplying the average by a factor of 
10
4
 (volume of grid) and finally multiplying by the dilution factor (if original ratio wasn’t 
1:1). 
The volume occupied by the sample chamber is 0.1cm x 0.1cm x 0.01cm (i.e. 0.0001cm
3
); 
therefore the average cell number was multiplied by 10
4
 which is equivalent to cells per 
mL. Viable cells were differentiated from non-viable based on their membrane remaining 
intact and healthy and not allowing uptake of the trypan dye. The percentage viability can 
be calculated then by dividing viable versus non-viable cells to get a percentage viability of 
a sample population. 
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2.5.4: Cryopreservation of cells/Cell freezing 
To allow long term storage of cell lines and stocks, cells were preserved with 5% DMSO 
(Sigma, cat # D8418), a known cryoprotectant and submersed in liquid nitrogen at a 
temperature below -180
o
C. Note: This can be done from plates or culture flasks. 
Cells for cryopreservation were harvested in the log phase to ensure they were in a healthy 
state and counted as per section 2.5.3. Samples were then centrifuged and the resultant 
pellet was resuspended with a suitable volume of fresh media. An equal volume of 2x 
freezing medium (10% DMSO and neat FBS) was added drop-wise (to prevent toxic shock) 
to the cell suspension providing a final concentration of 5% DMSO. Finally, aliquots of this 
suspension were placed into 1.5ml cryovials (Greiner, cat # 12279), labelled and 
immediately placed at -80
o
C, after 6-12 hours cryovials were transferred to liquid nitrogen. 
 
2.5.5: Reviving cell lines from cryopreservation/Cell thawing 
Prior to the removal of a cryovial from liquid nitrogen, fresh media was pre-warmed at 
37
o
C in a sterile container. The cryovial was removed, and working as quickly as possible, 
placed into a sterile water bath at ~35-40
o
C for 1 minute. The thawed cells were then 
transferred to the pre-warmed media and centrifuged at 1000rpm for 4 minutes. The 
supernatant was removed and the cell pellet was resuspended in additional pre-warmed 
fresh ATCC and transferred to a T25cm
2
 flask. Small aliquots of this sample were assessed 
for viability and sterility checked using tryptone soya broth (TSB) and thioglycollate broth 
(Thio) and incubated at 37
o
C for 7 days to ensure no contamination occurred during the 
cryopreservation or revival steps. 
 
2.5.6: Mycoplasma testing 
Routine mycoplasma examinations were carried out on all cell lines used in this study by a 
trained in-house technician. This was to ensure all experiments and cultures remained 
contamination free and results obtained were not affected by the presence of mycoplasma 
in any of the CHO cell cultures used during experimentation. 
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2.6: DNA manipulation and other techniques 
Throughout this project, many unique plasmids were generated with various inserted DNA 
fragments that were needed for further experiments; this DNA cloning forms part of the 
general project workflow (Figure 3.1.3.1). To incorporate a foreign DNA sequence into a 
plasmid requires the manipulation of a few techniques.  
Target sequences were amplified via PCR (section 2.6.2) using specific gene primers which 
bind to a complementary section within a genomic DNA template (section 2.6.10). These 
PCR products were then purified using agarose gel electrophoresis (section 2.6.3).  To 
facilitate insertion, restriction sites were manually designed on the 5’ and 3’ ends of primer 
sets (forward and reverse) as complementary sequences matching the corresponding 
reporter plasmids used for cloning. Both the PCR product and report backbone were 
digested via restriction endonuclease enzymes (section 2.6.4) to fashion ‘sticky’ ends for 
performing ligation reactions (section 2.6.5). This facilitated the creation of unique reporter 
plasmids which allowed insertion of any DNA inserts with complementary restriction sites 
for future work. 
Once these constructs were successfully cloned and sequenced (2.6.9), these plasmids were 
then transformed into bacteria cells (section 2.6.6). To generate more copies of these 
plasmids, Mini or Midi preps were used to generate the higher concentrations necessary for 
performing transfections into mammalian cells (section 2.6.7 and 2.6.8). 
  
2.6.1: Designing and Ordering Primers 
Primers are small (18-25nt) strands of nucleic acid, which serve as a starting point to DNA 
synthesis in PCR applications. They are required for DNA replication because the enzymes 
that catalyze this process, DNA polymerases, can only add new nucleotides to an existing 
strand of DNA. Primers and oligos can be used interchangeably. Primers were designed 
from sequence homology to either CHO or mouse. By using the software at 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) this allowed us to check the 
melting temperature (Tm) and % GC content and ensure these sequences were kept within 
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the general design criteria deemed good practice by molecular biologists. The sequences 
were then ordered from a company based in Germany called MWG Eurofins™.  
 
2.6.2: Polymerase Chain Reaction (PCR) 
This technique has become commonplace in molecular labs around the world ever since 
1983, when Kary B.Mullis developed the technique. It is a thermal cycling reaction, which 
can generate thousands of copies of a DNA sequence from a single piece of starting DNA, 
called a template. Using specific primers as mentioned in section 2.6.1, varying lengths of 
DNA sequence can be amplified based on primer location within the template and by 
following the typical reaction cycling show in table 2.6.2.1.  
Essential to the success of PCR is the ‘Taq polymerase’, a heat stable enzyme capable of 
assembling new DNA strands from single building blocks called nucleotides (nt), then as 
PCR progresses, the DNA generated is itself used as a template for replication.  
Many companies offer various PCR kits and master-mixes which can benefit the researcher 
in numerous ways, some reduce non-specific amplification, some are used as master-mixes 
to reduce reagent waste and errors from pippetting, while some have faster cycling 
capabilities.  
Three main PCR reagents used over the project were; a Redtaq
(TM)
 2x master mix (cat # 
BIO-25043) a Platinum
(R)
 high-fidelity Taq polymerase (cat #11304-011) and Velocity
(R)
 
DNA polymerase (cat # BIO-21098).  
Each PCR cycling protocol varies depending on PCR mix used and what size amplicon is 
to be generated. The general PCR reaction volumes and components can be seen in table 
2.6.2.1.  
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Table 2.6.2.1: Typical PCR components and volumes. 
Component Volume (μl) 
10x Polymerase buffer
 
5 
2mM dNTP 5 
Taq Polymerase 0.4 
Forward Primer
 
(10nM) 1 
Reverse Primer (10nM)
 
1 
Template DNA
 
1 
H20 9.5 
Total Volume 50 
 
PCR master-mixes were added to thin-walled 0.2ml PCR tubes and kept on ice till the 
thermal cycler was pre-heated and the general conditions were as follows; 
 
Table 2.6.2.2: Typical cycling conditions for a PCR run. 
Stage Temperature Time Cycle Number 
Initial Denaturation 95°C 2 mins  
Denaturation 94°C 30 secs 
25 cycles Annealing (primer specific) 30 secs 
Elongation 72°C 1 min/kb 
Final elongation 72°C 10 mins  
 
Throughout the project, PCR had to be modified from these general conditions due to 
efficiency issues and hard to isolate sequence targets. Having varied many conditions and 
cycler settings for optimisation, it was difficult to fully exemplify them all. However, we 
will describe the frequently used types of PCR and the theory behind them.  
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Nested PCR: 
This method involved using two sets of primers that were used in two rounds of successive 
PCRs. In the first reaction, one pair of primers were used to generate DNA products, which 
may additionally create non-specifically amplified DNA fragments, but ideally copies of 
the correct sequence to be amplified were also present. This first PCR reaction sample was 
then used as the template in a second PCR reaction with a set of primers whose binding 
sites are completely or partially different from each of the primers used in the first reaction 
but are located within the first amplified sequence and are thus nested within the first 
amplicon created from the PCR round 1. This allowed a more efficient PCR due to having a 
much more specific template in the second round of PCR Note: Nested PCR is often more 
successful in specifically amplifying long DNA fragments than conventional PCR, but it 
requires more detailed knowledge of target sequences. 
Touchdown PCR:  
Touchdown PCR was another variant of PCR that was used to reduce non-specific bands 
being generated/amplified. This was achieved by gradually lowering the annealing 
temperature as PCR cycling progressed. The annealing temperature in the initial cycles was 
usually a few degrees (3-5°C) above the Tm of the primers used and although this sounds 
excessive, it has been shown that PCR’s can be successful with exaggerated temperatures. 
Even if only a few copies are initially created at higher temperatures, then in later cycles, as 
the temperature drops below the Tm, the few copies generated previously are subsequently 
used as templates in the lower temperature rounds of cycling. In other words, the higher 
temperatures give greater specificity for primer binding, and the lower temperatures permit 
more efficient amplification from the specific products formed during the initial cycles. 
While the above two types of PCR were used in the generation of promoter fragments used 
in this study other types were also utilised such as; In-silico PCR, Inverse PCR and reverse-
transcriptase PCR (RT-PCR) at different stages. 
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2.6.3: Analysis of DNA samples using agarose gel electrophoresis 
After a PCR run, we wanted to test and visualise the target fragments created. We 
performed agarose gel electrophoresis and the protocol used was as follows; 
1. First, a stock of 50x TAE buffer was created (242g Tris Base, 57.1ml Glacial Acetic Acid, 
100ml 0.5M pH8.0 EDTA, to 1L with UHP water). This was diluted to 1x stock with UHP 
water and Agarose (Sigma, cat # A9539) added to a final concentration of 1% w/v. This 
percentage was chosen to run and visualise most fragments on the gel matrix, however this 
percentage could be increased or decreased to achieve better resolution on smaller or larger 
fragments respectively. 
2. This solution was then heated in a microwave until dissolved; Ethidium Bromide was then 
added to a final concentration of 0.5 µg/ml and poured into the appropriate mould with a comb 
to allow for sample wells. 
3. Once solidified the gel was placed in an electrophoresis tank filled with 1x TAE buffer. DNA 
samples, mixed with a suitable loading buffer, were then added to the wells and current applied 
to the gel. 90-100V was generally used for visualisation; however greater resolution could be 
achieved at a lower voltage applied for a longer period. 
4. A reference DNA ladder sample was also generally run alongside samples to measure and 
compare visualised band sizes. 
5. Once sufficiently separated, bands could be visualised in a UV light box at a 254nm 
wavelength. If the reaction has non-specific bands along with the correctly sized one, it was cut 
it out of the gel with a scalpel and purified.  
 
 
2.6.4: Cloning of DNA: Endonuclease restriction digestion of DNA 
Two combined molecular methods were used in the cloning of nucleic acids as needed over 
the course of the project. Restriction enzyme digestion was performed using specific 
endonucleases and ligation using a T4 ligase (Roche cat: 10481220001) enzyme. From the 
outset of primer design, suitable restriction enzymes (Acc65i + Xho1) were chosen. The 
complementary sequence for these restriction sites to allow DNA cleavage was included 
with every primer set ordered. As a result, when PCR generated the correct fragment, they 
contain sticky ends to permit cloning via the T4 ligase in a ligation reaction.  
Primers were designed with ‘Acc65I’ restriction sites on all forward primers and an ‘Xho1’ 
on all reverse primers (with additional bases to allow for anchorage of enzyme). This 
allowed us to perform a restriction digest to create ‘sticky ends’ at 5’ and 3’ ends of the 
amplified PCR fragments. These fragments were then ligated into two reporter 
plasmids/vectors (pEGFP + pGL3). These plasmids in parallel were also subjected to 
restriction digestion using the same enzymes (thus generating compatible ends for ligation).  
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A standard restriction digest reaction is outlined below; 
 
This reaction was incubated at 37°C for at least 3-4 hours and often up to 24 hours to 
ensure complete digestion. Furthermore, multiple restriction enzymes can be used in single 
reactions, provided a suitable NEB buffer was available. There are four existing NEB 
buffers and all have varying efficiencies depending on the restriction enzymes used. For our 
needs, the Acc65i and Xho1 enzymes were found to function best in NEB buffer 3 and 
therefore was used in all restriction digests, as it has 100% activity for both enzymes. Note: 
Keeping the volume of enzyme below 5% of the total reaction volume is important for full 
reaction activity also. 
 
2.6.4.1: Alkaline Phosphatase (AP) treatment  
Before any ligation there was an intermediary step performed. After digestion and 
purification of the plasmid backbone and the PCR product (eluted with nuclease-free water 
into ~45μl), we wanted to prevent the re-circularisation of digested plasmid backbone 
samples.  
The purified plasmid samples were treated with alkaline phosphatase (AP) which 
dephosphorylates the phosphodiester bonds in DNA decreasing the probability of sticky 
ends (generated from restriction digests) from re-joining undesirably. This was performed 
to improve the efficiency of future ligation reactions.  
 
 
 
 
 
Component Volume 
DNA 1μg 
NEB Buffer (10x) 2μl 
Bovine Serum Albumin 0.2μl 
Restriction Enzyme(s) 1μl 
H20 to 20μl 
Total volume 20μl 
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The following reaction was performed at 37
o
C for 1 hour: 
 
 
Finally, to remove any traces of enzyme that may damage DNA or inhibit further reactions; 
we purified samples using the MinElute
TM
 PCR Purification Kit (Qiagen, cat # 28006). 
 
2.6.5: Cloning of DNA: Ligations 
Once plasmid backbones and inserts were ready to be ligated, an enzyme called ‘ligase’ 
was used to anneal the DNA fragment insert to the backbone. We used a T4 ligase from 
Roche, (cat: 10481220001). 
Next, we used an open source ligation calculator found online (http://www.insilico.uni-
duesseldorf.de/Lig_Input.html), which uses the following formula to work out amounts of 
nucleic material (in nanograms) needed for preparing efficient ligation concentrations;  
 
 
Table 2.6.5: Typical ligation components and volumes. 
 
*Note: The insert DNA volume was variable depending on the sample concentration. Volume used was 
sufficient in each case for a minimum of 1:5 vector: insert ratio. 
Component Volume 
Purified Plasmid 44.6μg 
AP Buffer (10x) 5μl 
AP (Roche, cat. 11097075001) 0.4μl 
Total volume 50μl 
 
 
                        Insert length (bp) 
Insert mass (ng) =     Vector length (bp)  x  Vector Mass (ng) x 5 (ratio) 
 
 1:5 Insert Ratio Control (No insert) Control (No ligase) 
Ligase Buffer (10x) 1.5 1.5 1.5 
Plasmid Backbone 
(60ng) 
1 1 1 
Insert DNA variable* 0 0 
Ligase Enzyme 0.5 0.5 0 
H2O to 20l to 20l to 20l 
Total Volume 20 20 20 
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The reagents were placed in thin-walled PCR tubes and positioned in a beaker of ice water 
and left for 6-10 hours or overnight in some cases. By using ice water, the reaction was 
subjected to a gradient of temperature, as opposed to a single temperature. Gradually 
overnight the temperature would increase up to room temperature (~21
o
C). This allowed a 
more efficient ligation, as only using a single temperature can often be the rate-limiting step 
of ligation. Finally, the enzyme was inactivated by incubation for 10 mins at 65°C and the 
resultant ligated mixture was then used for bacterial transformation (section 2.6.6). 
 
2.6.6: Transformation into bacterial cells 
The introduction of foreign DNA into a bacterial cell was performed to increase the copy 
number of these plasmids by using the bacteria’s rapid doubling times. The protocol was as 
follows; 
1. A vial (200μl) of competent cells (DH5, Invitrogen, cat # 18263-012) was removed 
from storage at -80°C and thawed on ice. Transformation tubes Falcon, cat # 352059) 
were also chilled on ice during this time. 
2. Once thawed 50μl of the bacteria was added to a transformation tube along with 2.5μl 
(5% total volume) of plasmid sample or ligation reaction mixture. 
3. This mixture was left on ice for 10-15 mins, heat shocked in a 42°C waterbath for 30-
40 secs then placed back on ice for a further 1-2 mins. 
4. 500μl of SOC media (Invitrogen, cat # 15544) was immediately added, and this 
mixture incubated at 37°C for 1 hour at 200rpm agitation speed. 
5. The sample was then transferred to a fresh 1.5ml tube (Costar, cat # 3620) and spun 
at 3000rpm in a bench top microfuge (Hettich Mikro 120) for 3 mins to pellet the 
bacterial cells. 
6. The majority of the supernatant was removed and the pellet resuspended in 40μl 
SOC.  
7. This was then spread on LB agar plates (10g Tryptone (Sigma, cat # T7293), 5g 
Yeast Extract (Oxoid, cat # LP0021), 10g NaCl (Sigma, cat # S7653), 20g agar select 
(Sigma, cat # A5054), to 1L with UHP water, autoclaved before use) containing 
Ampicillin or Kanamycin depending on plasmid used in ligation (100ng/ml working 
concentration) and incubated overnight at 37°C. 
 
 
2.6.7: Small scale preparation of plasmid DNA (Miniprep) 
Once transformations were completed, the next step was to generate more copies of the 
plasmids generated. Commercial kits exist for small and large scale preparation of plasmids 
from bacterial cells and the following protocol was performed as outlined in the operating 
manual; 
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1. After successful generation of transformed bacterial colonies (see 2.6.6), a single 
colony was picked and grown overnight at 37°C, 170rpm in a 5-10ml aliquot of LB 
broth (autoclaved before use) containing appropriate antibiotic. 
2. This culture was then processed using a Qiagen QIAprep Spin Miniprep kit (Cat # No. 
27106, see manufacturers protocol for details), with a final DNA elution step carried 
out using 30-50μl of TE buffer. 
3. The concentration (ng/μl) of this DNA prep was determined using a NanoDrop 1000® 
spectrophotometer. This could then be used in subsequent DNA manipulation reactions 
or stored at -20°C. Typical yields were ~200-450ng/μl. 
 
 
This miniprep sample was then used in downstream processes; typically small scale 
minipreps were suitable and used in initial tests to ensure cloning was successful and for 
sending a sample away for sequencing to Eurofins MWG™. This was followed by 
restriction digestion to cleave the insert out of the plasmid, thereby verifying that the 
correct fragment went in to the respective plasmid.  
 
 
2.6.8: Large scale preparation of plasmid DNA (Midiprep) 
For generating larger quantities of cloned plasmids, a Midiprep kit was used. This had the 
added benefit of being a more stringent purification process as the kit contained endotoxin-
free buffers and materials to ensure a cleaner (free from endotoxins) final plasmid sample.  
A larger volume of Luria broth (LB) media was used to facilitate larger scale proliferation 
of the bacterial cells. The LB recipe was: (10g Tryptone (Sigma, cat # T7293), 5g Yeast 
Extract (Oxoid, cat # LP0021), 10g NaCl (Sigma, cat # S7653), to 1L with UHP water, then 
autoclaved.  
Midipreps were used when high plasmid concentrations were required. Furthermore, the kit 
removes harmful endotoxins often from bacterial debris such as lipopolysaccharide (LPS) 
in order not to affect or be detrimental to healthy cells during transfections. The following 
protocol was performed as outlined in the operating manual; 
 
1. After successful generation of transformed bacterial colonies as before, a starter culture 
of LB and single colony, equivalent to a miniprep (5-10ml universal) was made. 
2. This starter culture was then added to a further 200ml of LB broth containing 
Ampicillin or Kanamycin and incubated overnight at 37°C, 170rpm. 
3. After incubation this culture was then spun at 6000g for 15 mins, 4°C, and the 
supernatant discarded. 
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4. The resulting cell pellet was then processed using a Qiagen Plasmid Maxi kit (Cat # No. 
12362, see manufacturers protocol for details), with a final DNA resuspension step 
carried out using 250-500μl of TE buffer. 
5. The concentration of this DNA prep was determined using a NanoDrop 1000 
spectrophotometer. This was then used in subsequent DNA manipulation reactions or 
stored at -20°C. 
 
 
2.6.9: Sequencing and Verification 
Once all the above steps were completed, the resulting samples containing the previously 
prepared DNA (plasmids + inserts), needed to be sequence verified. This was to ensure that 
the correct fragment insert was ligated into each reporter plasmid in the correct orientation 
and with no sequence mutations. Aliquots of each sample to be sequenced were sent to 
Eurofins MWG™ along with the forward and reverse primers specific to each PCR 
fragment isolated. Thus, they could sequence it base by base using the same specific 
primers. Resulting sequence information was sent back in FASTA format for analysis to 
ensure full confidence that the plasmids contained the inserted promoter sequences 
upstream of each reporter gene. 
 
2.6.10: Genomic DNA Extraction 
From actively growing CHO cell cultures, an aliquot containing approximately 1x10
6
 cells 
was removed and centrifuged at 1000rpm for 5 mins. The supernatant was aspirated and the 
cell pellet was lysed and genomic DNA extracted as per the guidelines of the Promega 
Wizard™ SV Purification kit (cat # A2360). DNA was eluted into ~150μl of RNase free 
water from the resin column into a 1.5ml eppendorf. Yields of genomic DNA were 
typically in the range of 200-450ng/μl. 
 
2.6.11: RNA Extraction  
Purification of RNA (mRNA) from biological samples was a fundamental technique used 
during this project, and in particular when studying genetics and gene expression. It can be 
done in two ways, if the total RNA was needed including microRNAs, then an isolation kit 
MirVana™ (Ambion cat # AM1561) was used, again as per kit guidelines. 
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For experiments not requiring the full complement of miRNAs, then, a Tri-Reagent® 
solution (Ambion.cat # AM9738) was used to extract RNA. This solution was used along 
with the following reagents; isopropanol (Sigma.cat # W292907), chloroform (Sigma.cat # 
C2432) and ethanol (Merck.cat # K41392783). Eluted RNA was stored in the -80
o
C 
freezers in-between experiments. RNA is easily degraded due to the abundance of 
ribonuclease enzymes in cells and tissues, so storage at -80
o
C was essential for ensuring 
RNA integrity. RNA degradation was checked by running the samples using agarose gel 
electrophoresis to visualise both ribosomal subunits (Figure 2.6.11).  
 
Note: Sometimes RNA can degrade over extended periods of time even in -80
o
C, and 
indeed when the samples are exposed to multiple freeze-thaw cycles. 
 
 
 
Figure 2.6.11: (A) An agarose gel showing gradual degradation of RNA samples from left 
(high quality) to right (degraded/poor quality). (B) An agarose gel showing the ideal quality 
of RNA samples, where the ribosomal subunits (28s and 18s) are shown. 
 
 
2.6.12: Determination of RNA purity with Bioanalyser 
The Agilent 2100 Bioanalyser® (cat # G2940CA) is a micro-fluidics based platform for the 
analysis of proteins, DNA and RNA. The supplied 12-well chip (Figure 2.6.12) contains 
interlinked channels and reservoirs allowing the analysis of samples containing minute 
amounts of starting RNA material.  
Once the wells and channels were filled, the chip becomes an integrated electrical  
circuit. The 16-pin electrodes of the cartridge are arranged so that they fit into the  
wells of the chip. The channels were first filled with a polymer gel matrix on the chip 
priming station and vortexed to fix the matrix to the chip surface. A RNA ladder (RNA 
91 
 
6000 Nano) was included for RNA size comparison and was loaded, along with the RNA 
samples to be tested, into the appropriate wells. To each well, 1μl of each sample was 
loaded with a fluorescent dye (marker) included in the Nano RNA 6000® kit (cat # G2938-
90034).  
When all samples were loaded, the chip was briefly vortexed at 2400 rpm and loaded into 
the Agilent 2100 Bioanalyser® machine. Because of a constant mass-to-charge  
ratio and the presence of a sieving polymer matrix, the molecules were separated by  
size and smaller fragments migrated faster than larger ones. The machine is fully automated 
and separates samples by injecting the individual samples into a separation chamber were 
components are electrophoretically separated and detected by their fluorescence. These 
signals are translated into gel images and electropherograms for in silico analysis. The 
software automatically compares unknown samples tested to the generated ladder 
fragments, to determine the concentration of the unknown samples and to identify the 
ribosomal RNA peaks. 
 
 
 
Figure 2.6.12: The RNA 6000 Nanochip used in the Agilent 2100 Bioanalyser®. 
 
2.6.13: DNase treatment 
After RNA extraction, it was common practice to use an enzyme called deoxyribonuclease 
(RQ1), (Promega.cat #M6101). It catalyses the hydrolytic cleavage of double and single 
stranded DNA. This was essential and beneficial for maintaining the integrity of the RNA, 
because typically after RNA extraction there may be DNA carryover and in some cases this 
could affect and hinder subsequent enzymatic experiments such as reverse transcription and 
qPCR. DNase treating the biological samples degraded any potential DNA carried over and 
thus prevent non-specific amplification.  
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Figure 2.6.13 illustrates the difference between 10 RNA purified samples at 3 different 
stages of treatment. In the original samples, we performed a PCR run on the 10 extracted 
samples which produced DNA amplicons when they shouldn’t. Then after DNase treatment 
the same PCR run yields no amplified DNA bands which were indicative of a successful 
DNase step. We performed a final PCR on the samples after a reverse transcription-cDNA 
generation step (section 2.6.14) and got clean amplified bands, indicating that the RT 
worked and qPCR can be used to calculate gene expression accurately with no DNA 
contamination present.  
 
Figure 2.6.13: The effect of DNase treatment on DNA carryover post RNA extraction to 
ensure samples could be used for future applications. 
 
2.6.14: Reverse Transcription PCR and cDNA generation 
Now that RNA material was ready to be used in downstream applications, the next step was 
to create double stranded cDNA from single stranded RNA, using the Taqman® Reverse 
Transcription kit (Applied Biosystems.cat # 4387406). This kit uses a special enzyme 
common in retroviruses called ‘reverse transcriptase’ the resulting cDNA then is amplified 
by specific PCR steps.  
By performing these steps we created a cDNA sample to be used in follow on qPCR 
experiments to measure the absolute or relative expression of gene targets between different 
samples or in comparison to an endogenous (house-keeping) gene control.  
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All reaction components were thawed on ice and if performing more than one RT reaction, 
then we scaled up as required and added 10% volume surplus extra (n+1) allowing for 
pippetting errors and volume loss of liquid when dispensing. A typical reaction can be seen 
in the table 2.6.14 and cycler conditions were as follows; 
Table: 2.6.14: Components for RT reaction. 
 
The following thermocycler conditions were programmed for this reaction; 
 
 
2.6.15: Real-Time Quantitative PCR (RT-qPCR) 
Although similar to the PCR section 2.6.2, RT-qPCR needed its own section due to its 
importance in this project and its complexity and because its follows on from the previous 
sections in the workflow. Like routine PCR, it is a technique that amplifies up a template 
portion of DNA, however, at each step a quantitative reading can be taken simultaneously 
while amplification proceeds.  
Unlike regular PCR which only allows quantification at the end point (band on a gel), 
qPCR can be used to determine whether a gene is currently over-expressed or knocked 
down in a particular sample in real-time (ex: cell line grown at a certain temperature), as 
well as comparing its relative expression between controls and other samples.  
 
Component                       Volume (μl) 
                   x1 RT reaction  
10x RT Buffer          
25x dNTPs 
10x Random Primers 
RNA inhibitor 
2 
0.8 
2 
1 
1 
3.2 
          10 (2 μg) 
RT Enzyme (MultiScribe)
 
Nuclease-free H20 
RNA sample 
Total Volume                     20 μl  
Stage Temperature Time 
1 25°C 10 mins 
2 37°C 60 mins 
3 85
o
C 5 mins 
4  4°C/ -20
o
C - 
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qRT-PCR was used to measure this expression level by using computational software on 
the Applied Biosystems® 7500 Fast thermal cycler to obtain cycle threshold (Ct) values 
(values above a cycle threshold of fluorescent detection). We subsequently calculated 
mRNA transcript copy numbers. The quantity can be either an absolute number of copies or 
a relative amount when normalised to DNA input or a house-keeping normalising gene like 
GAPDH. 
Two main ways of detection are probe-based methods (FRET) and reporter binding dyes 
(SYBR green). The probe method relies on a DNA-based probe with a fluorescent reporter 
at one end and a quencher of fluorescence at the opposite end. The proximity of both, 
determines the detection of fluorescence in a given run. Where exonuclease activity of Taq 
polymerase separates both, unquenched emission of fluorescence occurs, creating a signal 
to be detected by the software.  
Most frequently we used the dye based method involving the binding of a double stranded 
(ds) DNA and a dye which allowed detection due to increasing amounts of fluorescence 
with each cycle completed. The abundance of the SYBR green (Applied Biosystems, cat 
#4309155) signal detected dye then allowed quantification.  
One drawback is that non-specific primer dimmers (where annealing of primers to one 
another) can create small ds DNA molecules which also incorporates the dye giving false 
positive results. This was accounted for by performing dissociation/melting curve analysis 
after the initial qPCR run. The melt curve run heated the sample from 60
o
C to 95
o
C by 
increasing in increments of 1
o
C every minute till the amplicon dissociates; sharp peaks 
indicated a clean amplified product (Figure 2.6.15).  
Note: In some cases experiments needed to be run again with improved primer design. 
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Figure 2.6.15: Dissociation/Melt curve extrapolation and images. 
 
A main advantage of qPCR is the fact that it can determine the expression of a gene at a 
given point in time or under the influence of a condition such as temperature as long as it is 
a controlled. For example, you can determine the absolute expression of mRNAs or relative 
expression in comparison with endogenous control, we used either beta-actin or GAPDH 
house-keeping genes to normalise because their expression remains relatively unchanged, 
regardless of cellular state. 
A typical reaction setup was set up on ice in a Micro-Amp optical 96-well plate (Applied 
Biosystems, cat # 4346906) for qPCR, and was as follows;  
 
 
 
 
 
Component Volume x1 well (μl) 
2x SYBR/Taqman Mix 10 
Forward Primer (10nM)
 
1 
Reverse Primer (10nM)
 
1 
cDNA 1 
H2O 7 
Total Volume 20 
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Reactions were then carried out on an Applied Biosystems® 7500 Fast Real-Time PCR 
System under the following cycling conditions; 
 
 
Finally, results were analysed in excel and exported using the corresponding Applied 
Biosystems® software.  
 
 
2.6.16: Transfection of Mammalian Cells 
A common technique used by molecular scientists is transfection, where one can introduce 
foreign DNA/vectors into mammalian cells for testing and mimicking expression much like 
the in vivo environment. Transfection of cells typically means the opening of ‘pores’ on the 
cells membrane, which allow the uptake of genetic material.  
During this project we used either Lipofectamine 2000® (L2000) (Invitrogen.cat #18324-
111) or TransIT®-2020 reagent (Mirius.cat #MIR-5404) for transfection experiments.  
Transfections can be transient (short term) or stable (long term). In transient experiments, 
the DNA material is not incorporated into the cells nuclear genome and after a few cell 
cycles, is diluted by natural cell division (mitosis). However, often short term is desirable 
for what the scientist is trying to analyse.  
In stable transfections, the DNA material is integrated into the genome, due to the presence 
of a selectable marker (e.g.: G418/geneticin drug or toxin marker) routinely contained 
within a plasmid. Therefore, all subsequent progeny will have taken up the foreign DNA 
aswell. Stable clones were generated after 3-6 weeks of selective pressure and passages and 
can be used indefinitely if stored via cryopreservation in liquid nitrogen.  
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The following protocol was used for transfections in 24-well format;  
1. Approximately 18-24 hours before transfection, plates cells so that at time of transfection 
confluency is ~50-80%, I often use seeding density of 2-5x10
5
 for adherent cells and 5-
8x10
5
 for suspension cultures. 
2. Incubate overnight at 37oC in 5% CO2 incubator. 
3. Next day warm TransIT®-2020 reagent to RT and vortex gently 
4. Place 50μl serum free media per sample well in sterile tubes 
5. Add 500ng stock plasmid DNA and gently mix 
6. Add 1.5μl of TransIT®-2020 to the mixture and gently mix 
7. Incubate at RT for 15-30 mins to allow sufficient time for complexes to form 
8. Add this mix drop-wise random areas of the sample well 
9. Gently rock the plates to create a evenly distributed environment in the wells 
10. Inoculate for 24-72 hours and it is not necessary to replace with fresh media 
11. Harvest and assay as required. 
 
2.7: SEAP assays 
A functional assay was used to determine the secreted alkaline phosphatase (SEAP) 
producing capability of cells grown in culture and is called the SEAP assay. It is an 
enzymatic colorimetric detection assay and is advantageous due to it being much less 
expensive than other techniques, can be setup quickly and can be performed using a 
conventional ELISA plate spectrophotometer.  
To determine the amount of SEAP produced by CHO cells, we utilised the adapted CHO-
K1-SEAP cell line (adapted by Dr. Niraj Kumar in-house), which were grown in SFM-II 
media. Depending on the kind of experiment undertaken, sample aliquots were taken at 
appropriate time intervals (days 1-12 for our time-points) during culture growth and 
centrifuged at 13000rpm for 10 minutes and supernatant transferred for storage. Samples 
were used in the assay straight away or placed at -20
o
C storage to be used at a later date. 
For example, when all timepoints samples were collected and therefore all samples were 
ran together on the one plate.  
To perform the assay, 50μl of this supernatant media was transferred to individual wells of 
a flat-bottomed 96 well plate (Costar. cat # CLS3595). To each well, 50μl of a 2x SEAP 
buffer (10.5g diethanolamine, 50μl of 1M MgCl2 and 226 mg of L-homoarginine in a total 
volume of 50ml) was added. Plates were then incubated for 10 minutes at 37
o
C to prime the 
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reaction; during those 10 minutes SEAP substrate solution was made up (158 mg of p-
nitrophenolphosphate (Sigma, cat # P4744) in 5ml of 1x SEAP buffer in a universal 
wrapped in tinfoil (to avoid light exposure). Then just prior to placing the plate into the 
BioTek® plate reader, 10μl of the SEAP substrate solution was added to each well with a 
multi-channel pipette. The change in absorbance per minute (OD405/min) was the indicator 
of the amount of SEAP present in each sample and calculated in excel. 
 
2.8: Flow cytometry and cell imaging using Guava® Easycyte systems 
Using a microcapillary Guava® flow cytometer in-house we were able to utilise two assays 
for the project, The Viacount® Assay and the ExpressPlus® Assay. The Viacount was used 
for cell counting and to calculate the percentage viability of cells in a given culture sample.  
The Viacount assay is regarded as more accurate than using a standard haemocytometer 
coupled with higher throughput. For example, 96 samples could be multiplexed on the one 
plate. The Viacount assay distinguishes between viable and non-viable cells based on 
differential permeabilities of two DNA binding dyes in the Viacount reagent (Guava 
Technologies. Cat # 4000-0041). The nuclear dye only stains nucleated cells, while the 
viability dye brightly stains cells undergoing apoptosis (programmed cell death).  
To perform cell counts, a volume of cells in culture was processed by taking old media out 
and trypsinising the cells (no need for trypsin in suspension cultures), viacount reagent was 
allowed to equilibrate to room temperature and was aliquoted 1:1 with the sample volume 
to be tested. Samples were placed in a round-bottomed 96-well plate and incubated at RT 
for 10 minutes before reading on the Guava® flow cytometer. Cell numbers and % viability 
values were exported into excel for analysis. 
As a means to calculate promoter activity the ExpressPlus® program was used to measure 
the GFP intensity within a population of cells, and involves gating negative and positive 
GFP cells and allocating a Y-mean expression value to each sample.  
In promoter studies, transfection, as described in section 2.6.16, was carried out using the 
constructed plasmids (reporter gene and promoter fragment inserts) and attached CHO-K1 
cells grown in 24-well format. The cellular machinery then promotes protein synthesis and 
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thus GFP expression strength of our promoters of interest which were detected from their 
excitation peak at a wavelength of 395 nm when exposed to ultraviolet light in the Guava® 
flow cytometer.  
After 24-48 hours, samples were taken. Media was removed and cells were treated with 
trypsin. The sample is diluted with nuclease-free water as required depending on cell 
density and aliquoted into a round-bottomed 96-well plate and read using flow cytometry 
again. Y-mean values were indicative of GFP fluorescence intensity and values were 
exported to excel for analysis. 
Unlike the Viacount® reagent and program, the ExpressPlus® program only required cells 
to be in suspension with no additional reagent needed; therefore pippetting well after 
trypsinisation to ensure no clumping was imperative.  
 
2.9: PCR based miRNA Taqman Low Density Arrays (TLDA) 
Taqman® Low Density Arrays (Applied Biosystems.cat #4334812) are 384-well micro-
fluidic cards designed for multiplex analysis of gene expression patterns of up to 8 samples 
in parallel across a defined set of gene targets (Figure 2.9.2). TLDA arrays are highly 
sensitive and reproducible which involves PCR amplification and simultaneous 
quantification of a DNA molecule based on a similar technology to qPCR as mentioned in 
section 2.6.15.  
The arrays contain complementary probes for all known mouse miRNAs as the mouse 
genome is sequenced while the CHO genome was not fully sequenced at the time of testing. 
Homology to another rodent species was the best viable option.  
The probes are divided into two primer pool sets (A+B) with A containing the more 
common miRNAs and B having more rare, less characterised ones.  
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2.9.1: Reverse Transcription 
The RT reaction to create the full complement of cDNA prior to TLDA is described below; 
 
 
A volume of 7μl of RT mix was added to each labelled thin-walled PCR tube (as required), 
then to each tube 2μl of RNA sample (100ng) and 1μl of Multiplex RT rodent Primer Pool 
A or B were added. The sample was mixed gently and incubated on ice for 10 mins. The 
reverse transcription reaction was performed using the G-Storm thermal cycler under the 
following conditions; 
Step Type Time (mins) Temperature (
o
C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
 
 
Two separate RT reactions were performed (A+B primers), on the RNA extracted from the 
cells being tested. Analysis of miRNA expression was done in two separate experiments; 
one was based on temperature shift causing differential expression pattern shifts and thus 
identified candidate miRNAs for further study and functional validation related to 
temperature inducibility in the project.  
Another study, involved the ‘Mir-Capture’ approach (section 1.14.2), where cells 
underwent targeting by a biotinylated anti-sense oligonucleotide capture affinity technique 
(section 2.19). RNA was extracted with the MirVana™ (Ambion cat # AM1561) isolation 
kit to ensure miRNAs were kept intact. This RNA was then loaded into the micro-fluidic 
cards and loaded into the Applied Biosystems® 7900HT thermal cycler for analysis. 
Component Volume x1 RT (μl) 
100mM dNTPs 0.20 
MultiScribe™ RT enzyme (50 U/μl) 2 
10x Reverse Transcription Buffer
 
1 
RNAse Inhibitor (20 U/μl) 0.125 
Nuclease free H2O 3.675 
Total Volume 7 
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2.9.2: PCR using 2x TaqMan® Master mix 
After the RT step, the reaction tube was diluted 62.5 fold by adding 615μl of nuclease-free 
water to the 10μl RT reaction mix and each individual sample for PCR was prepared as 
follows; 
Component Volume (μl) per reservoir port 
Diluted RT reaction 50 
TaqMan 2x Universal Master mix (No 
AmpErase® UNG) 
50 
Total Volume 100 
 
This 100μl sample specific RT was then loaded into the large fill hole in the card with the 
smaller hole allowing air to escape and not cause bubbles and hinder the filling process (see 
figure 2.9.2). The card(s) are then centrifuged at 2000rpm for 1 minute to allow every well 
to be loaded equally. 
 
Figure 2.9.2: Schematic representing the loading of the Taqman® Low Density Array 
(TLDA) micro-fluidic cards to analyse miRNA expression. 
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Arrays were incubated on ice for 10 minutes and subsequently run on an Applied 
Biosystems® 7900HT real time PCR machine using the following cycle conditions; 
 
 
2.9.3: TLDA data analysis 
The resulting data from two TLDA runs generated Ct values at each cycle similar to regular 
qPCR but within the TLDA software each miRNA probe is annotated with 518 miRNAs on 
card A and 303 miRNAs on card B. Analysis was carried out using specialist software 
Statminer® from Integromics™ for the temperature-shift profiling experiment as this 
generated a huge dataset. Within each card, a set of endogenous control miRNAs are 
present, the U6 endogenous control was used for normalisation to calculate the ΔCt while a 
cycle threshold of ≤35 and p-value ≤0.05 were used as standard cut off criteria for 
identifying differential expression miRNAs.  
For the ‘MiR-Capture’ experiment, expression values were calculated using the 
comparative Ct method as previously described (User Bulletin No. 2, Applied Biosystems). 
Briefly, this technique uses the formula 2
−ΔΔCt
 to calculate the expression of target genes 
normalised to a calibrator. The threshold cycle (Ct) indicates the cycle number at which the 
amount of amplified target reaches a fixed threshold. Ct values range from 0 to 40 (the 
latter representing the default upper limit PCR cycle number that defines failure to detect a 
signal).  
ΔCt values [ΔCt = Ct (target gene) – Ct (RPLP0)], were calculated for the scrambled 
mismatch capture oligo sample and subsequently used as the calibrator. All gene expression 
values were assigned a relative value of 1.00, to determine comparative gene expression 
such that ΔΔCt = ΔCt (mismatch oligo sample) – ΔCt (XIAP capture oligo sample). PCR 
amplification efficiency was calculated by analysing the standard curves from each gene 
amplification, a slope of the line close to -3.3 was indicative of a 100% efficient 
amplification run. 
Stage Temperature Time Cycle Number 
Enzyme Activation 95°C 20 sec 1 cycle 
Denaturation 95°C 3 secs 
40 cycles 
Annealing/Elongation 60°C 30 secs 
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2.10: Functional analysis (FA) of selected gene and miRNA targets 
RNA interference (RNAi) was carried out using small interfering RNA (siRNAs) to silence 
the expression of specific genes mainly the valosin containing protein (VCP cat #4390555)) 
and X-linked inhibitor of apoptosis (XIAP cat #4390824) plus a double stranded duplex 
negative control siRNA (PM- cat #4090975). 
Other chemically synthesised small RNAs (pre-miR mimics or antagomirs) were used to 
suppress or induce the expression of selected miRNAs. We used the following pre-miR 
mimics (miR-124, miR-222 and miR-19b cat #AM17100) to validate suppression of 
endogenous XIAP in CHO-K1 and GBM SNB-19 cells. 
The siRNAs and miRNAs used in this project were purchased from Ambion/Life 
Technologies®. The siRNAs were from the Silencer® range and the miRNAs were from 
the MirVana™ range, while all were transfected into mammalian cells using NeoFX™ 
transfection reagent (Ambion.cat #AM4511). All transfections were carried out using 
sterile 1.5mL eppendorfs or filter-cap spin tubes (Sartorius) in 2ml working volumes or in 
24-well format. 
 
2.11: Bradford Assay and Protein Quantification 
In order to calculate the protein concentration of samples, a spectroscopic and colorimetric 
assay called the Bradford Assay was used and is based on the absorbance shift of 
coomassie brilliant blue dye from red to blue under acidic conditions.  
Cells were grown in culture and underwent transfection of luciferase-promoter reporter 
plasmid constructs, after 48 hours the media was removed and cells were either trypsinised 
or centrifuged if using suspension cells just centrifuged. After centrifugation cell samples 
were washed 3 times with PBS and cells pellets were lysed with an in-house lysis buffer 
cocktail (7M Urea, 2M Thiourea, 4% CHAPS, 30mM Tris and adjusted with HCL to pH 
8.5) additionally a phosphatase inhibitor (Halt™ cat#78420), RNase inhibitor (Ambion 
cat#N8080119) and a protease inhibitor (Qiagen cat#19157) were added to the lysis buffer 
cocktail to protect the lysed proteins from the cellular nucleases and proteases. 
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BSA stock (2μg/ml) was diluted to a half with nuclease-free water or the same lysis buffer 
that the samples were processed in. Then serial dilutions from this 1000x working stock 
were made to create a standard curve [1000x-750x-500x-250x-125x-0] from which the 
protein concentrations of our unknown samples can be calculated from. 
Using 96-well plates, a 5μl volume of lysed sample and a 250μl volume of BioRad® 
Quickdye reagent (cat #500-0205) was added to each sample to be read in triplicate along 
with a zero/blank sample (lysis buffer only). The samples were read using KC4 software on 
a BioTek™ Synergy HT plate reader at 595nm absorbance. The intensity of the blue dye 
increases as the samples protein concentration increases. Due to the disadvantage of a short 
linear range of the Bradford assay, samples were usually diluted (1:10) before loading to 
ensure sample results are within the standard curve range.  
 
2.12: Western Blotting 
Western blotting is a widely accepted analytical technique used to detect specific proteins 
in a given sample of tissue homogenate or extract. Proteins within a sample were first 
separated based on molecular weight (M.W) or isoelectric point (Pl) on a polyacrylamide 
gel and then transferred to a membrane where they are probed with an antibody (Ab) 
complementary to a specific protein which allowed detection of a given protein. We used 
the following 6-step protocol; 
2.12.1: Western sample preparation 
 Cell pellets were resuspended in adequate volume of cell lysis buffer (same as 
bradford lysis buffer in section 2.11) 
 Bradford assay was performed to calculate protein concentrations to ensure all 
samples contain same amount of protein 
 2x Laemmli sample buffer (Sigma. cat #S3401) was added to all samples to 
ensure lane-to-lane consistency and reproducibility; all volumes were equal on 
same gel (10μg protein) 
 For lanes of the gel that were empty; 2x Laemmli and sample buffer was used 
only to ensure no empty wells are running 
 The samples were boiled at 95oC for 5 mins, centrifuged and stored at -20oC if 
not using immediately. Note: Re-boil if re-using previously frozen samples 
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2.12.2: Preparation of gel 
 Pre-warm Invitrogen precast Bis-Tris 4-12% gels (Invitrogen.cat #EC6175BOX) at 
RT for at least 30 mins before use 
 Prepare 800mL of MOPS running buffer (NuPage 20x. cat #NP0001)) 
 Rinse wells three times and remove white label/comb 
 Load 4μl full range M.W marker (New England Biolabs. cat #P7708S) and protein 
samples into the wells 
 Add transfer buffer (BioRad. cat #161-0734) including NuPage antioxidant 
(Ambion. cat #NP0005) (inner chamber) 
 The gel was run at 200V for approx. 1 hour 
2.12.3: Transfer Preparation 
 Prepare transfer buffer (50mL per membrane) - kept on ice 
 Cut PVDF-membrane (approx same size as filter paper) 
 Equilibrate PVDF-membrane for approx 10-15 secs using methanol and rinse well 
with UHP and incubate in transfer buffer 
 Soak filter paper in transfer buffer before use  
 Cut the gel, removing the wells and thick part of gel and snip corner to keep track of 
orientation of gel 
 Equilibrate gel in transfer buffer for ~5mins on shaker platform 
2.12.4: Transfer 
 Set up semi-dry transfer as follows; 
5 sheets of Whatman 3mm filter paper (cathode plate) (Whatman. cat #1001824) 
Nitrocellulose Membrane (GE healthcare. cat #RPN3032D) 
Gel 
5 sheets of Whatman 3mm filter paper 
 Remove excess air after each layer by rolling a pipette along the surface to ensure 
no air bubbles remain 
 Transfer the proteins at 340 mA (constant), 15V max, >20mins (allow longer for 
higher MW proteins) 
2.12.5: Blocking / Antibodies 
 Stain membranes with Ponceau (Sigma. cat # P7170) to check equal loading and 
successful transfer 
 Destain with UHP water 
 Block unspecific binding for 2 hours at RT with 5% milk powder (Marvel) in 
TBS-T 
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 Add primary antibody (1o) and incubate o/n on shaker or 2 hours at RT is 
usually fine 
 Rinse membrane with TBS-T 
 Wash membrane (x3) in TBS-T, 10 mins each wash on shaker 
 Add appropriate secondary antibody (2o) and incubate for ~2hours 
 Rinse membrane again with TBS-T 
 Repeat x3 washes with TBS-T, 10 mins each on shaker 
 
2.12.6: Antibody detection 
 Prepare detection solution : ECL (Pierce®. cat #80196) 1mL solution A and 
1mL solution B (store in the dark) 
 Prepare developer (Kodak. cat #LX24) and fixer (Kodak. cat #FX-40) reagents, 
they can be reused several times, wrap bottles in tinfoil and store at RT and in 
the dark 
 Incubate membrane and detection solution for 1 min, remove excess fluid with 
tissue and cover with transparent material (poly pockets) and careful to avoid 
bubbles 
 In the dark room, using only the red light as it doesn’t damage the 
autoradiographic film (Roche. cat #11666916001) 
 Cut the film to size and place film on top of membrane (careful to mark position 
for orientation again) 
 ~2-5 mins exposure time for unknown protein samples and ~30-45 secs for 
Beta-actin and GAPDH controls 
 Careful not to over expose the film  
 After exposure, place film in developer (watch developing progress) and briefly 
immerse in water to rinse and transfer to fixer for a few minutes till film 
becomes transparent and rinse with water again  
 Air dried and observe gel image on film (scanned onto computer if necessary) 
 
2.13: Dual-Luciferase Reporter Assay (DLR) 
The dual-luciferase assay (Promega. cat #E1910 and E1960) was used for reporter studies. 
Segments of DNA (our promoter fragments of interest in this case) were placed upstream of 
a luciferase gene in promega’s pGL3-basic vector (cat #E1751) by ligation methods 
(section 2.6.5). These plasmid constructs were subsequently transfected into CHO-K1 cells 
for testing. 
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In addition to this, a pGL3-Control vector (Promega. cat # E1741) was also transfected as 
comparison control. Finally, to normalise discrepancies in transfection efficiency, a strong 
expression ‘Renilla’ luciferase pRL-CMV vector (Promega. cat #E226A) was used to co-
transfect alongside test samples.  
The DLR assay can be done from any vessel. Typically a 24-well plate format was used. 
The kit comes with all reagents necessary to complete assay and the protocol was as 
follows; 
DLR Protocol:   
Sample preparation: 
1. Cells were transfected with 0.5μg of test (Basic pGL3 + promoter fragments) vector 
and 400ng of Renilla  
2. After required time post transfection (24-48 hours typically), growth media was 
removed from wells 
3. Washed cells with cold PBS (1x) and subsequently removed 
4. 200μl of 1x PLB lysis buffer was dispensed into all wells for testing 
5. Gentle shaking of the plate for 15-20 mins on a belly dancer until all cells became 
detached and lysed 
6. Transferred to suitable vial/tubes for freezing or testing straight away on BioTek® 
Synergy™ HT multimode plate reader (prod #7091000) and performed as per 
operators manual (Bulletin #TM040) 
Dual-Luciferase Assay: 
1. The BioTek® reader has injector capabilities, so the injectors 1 and 2 were set to 
dispense 100μl of LARII and Stop & Glo® reagent respectively 
2. For measurement readings, a 1-2 second delay and 5-15 second read times were 
used 
3. Using special black flat bottomed (to avoid auto-luminescence) 96-well plates 
~20μl of each PLB lysate sample was loaded per well 
4. The software was setup and run, 100μl of LARII was dispensed and firefly-
luciferase activity was measured in kinetic reads over 10 seconds. This was 
followed by 100μl of Stop & Glo® which quenched the first firefly signal and 
triggered the Renilla-luciferase control to be measured over 10 second kinetic reads 
also 
5. All figures for firefly were normalised to Renilla values and were expressed in 
relative luciferase units (RLU) 
 
108 
 
 
Figure 2.13: Schematic representing the 3 step dual-luciferase (DLR) assay workflow 
using specific black flat-bottom coated 96-well plates. Detection signal in the KC4 
spectrophotmeter. 
 
2.14: Apoptosis/Nexin® Assay 
Proliferation and viability assays are fundamental experiments in cell culture settings while 
equally informative in cell culture techniques are apoptotic assays. As more studies and 
molecules are being shown to be involved in internal pathways such as apoptosis 
(programmed cell death), it represents another means to analyse cellular behaviour.  
Here we describe the Guava Nexin® Assay (Millipore. cat #4500-0450), during cell 
culture, as cells respond to specific induction signals they initiate intracellular processes 
that result in characteristic physiological changes. Among these are externalisation of 
phosphatidylserine (PS) to the cell surface which leads to cleavage, compaction and 
fragmentation of specific proteins leading to loss in membrane integrity. 
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Annexin-V is a calcium-dependent binding protein with a high affinity for PS, as molecules 
of PS are localized to the cell membrane where Annexin-V can readily bind them. The 
Nexin® Assay was then utilised to detect levels of PS on the external membrane of a 
population of cells in a sample and a built in dye 7-AAD give an indication of cell health 
and structural integrity and ultimately its stage of apoptosis, as three populations can be 
distinguished from the assay in tandem;  
 Non-apoptotic cells: Annexin V (-) and 7-AAD (-) 
 Early apoptotic cells: Annexin V (+) and 7-AAD (-) 
 Late stage apoptotic/Dead: Annexin V (+) and 7-AAD (+) 
 
Cells were seeded based on vessel used, frequently, 6-well plates we seeded 1x10
5
 cells per 
well and included suitable positive (sodium butyrate to induce apoptosis) and negative 
(fresh media) controls. Cells were incubated over a timecourse of usually 7-14 days. The 
Guava Nexin® reagent was equilibrated to RT prior to addition to cell samples.  
Note: Cell samples must contain at least 1% BSA or FBS for the Nexin reagent to bind to 
the cell surface. This was of no concern, as our samples were typically grown in 1-5% 
serum.  
A 100μl volume of sample was removed from each well after trypsinisation and mixed 
well. Samples were placed into round bottomed 96-well plates with 100μl of Nexin® 
reagent (1:1 ratio) and incubated at room temperature for 20 minutes in the dark before 
acquiring and running the Guava software. 
A typical output from a Nexin run is shown in figure 2.14; the software divided the plots 
into 4 quadrants: 
 Upper left: Cell debris/nuclear debris (-) (+) 
 Upper right: cells in late stage apoptosis and necrotic integrity (+) (+) 
 Lower left: Viable cells, not undergoing detectable apoptosis (-) (-) 
 Lower right: cells in early stage apoptosis (+) (-) 
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Figure 2.14: Illustration of software output file after Nexin® Assay, breakdown of 
4 quadrants post-acquisition of cell samples. 
 
2.14.1: Spent media and sodium butyrate (NaBu) treatment for apoptosis studies 
To induce apoptosis for apoptosis studies in this project, two conditions were used. One 
was the use of late culture conditional spent media (after 9 days) and based on findings 
from Druz et al, where they used spent media to induce apoptosis (Druz et al. 2011). CHO-
K1 cells grown in ATCC or SFM-II media for 9 days in culture were harvested and passed 
through 0.22 micron filters to remove cells and cellular debris. The media was then 
supplemented into healthy cell populations to trigger an apoptosis environment. 
Additionally, sodium butyrate (NaBu) was used to trigger apoptosis also. This method was 
less novel as for the last three decades, at millimolar concentrations, NaBu was added to 
cell cultures, many morphological and biochemical modifications have been reported 
(Kruh,J. 1982). However, more recently it has been used to increase monoclonal 
productivity at low concentrations (Yoon et al. 2004), but at higher concentrations it 
induces autophagy and apoptosis (Lee et al. 2012). It is the latter that we utilised NaBu for 
our work. 
A 1M stock of NaBu was made up in PBS. 1/2mM was deemed sufficient for induction of 
low level apoptosis, while 5/10mM was needed to trigger a noticeable apoptosis effect. 
Therefore from our stock we typically used 120μl in 12mLs of ATCC media to add to cells 
grown in 6 or 24-well plates.  
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2.15: EPO Assay and Quantification 
EPO (Erythropoietin) is a glycoprotein hormone and cytokine and is responsible for red 
blood cell signalling and formation. It has a predicted molecular weight of ~34kDa. 
Using a recombinant form of human EPO, a well known biopharmaceutical product, we 
cloned it into the reporter plasmid constructs.  
Extracellular and Intracellular levels of this protein were measured using western blotting 
and reverse transcriptase qPCR in order to infer that the promoters used in this thesis can be 
used to drive expression of an industrial strength important protein. EPO is secreted into the 
media aswell as having intracellular levels. 
For detection in western blotting, a primary polyclonal EPO antibody was given to our 
group by Dr. Paul Barham, and a similar anti-EPO antibody was ordered from Abcam PLC 
Cambridge (cat #Ab30545) during the later stages of the project. The EPO antibody was 
diluted to 1/1000 before use and the western protocol then was followed as described in 
section 2.12. 
Assays were performed in 24-well suspensions and adherent plate formats to keep 
concentrations of protein high and to allow for multiplexing in the same experiment.  
For extracellular detection, transfection was carried out as outlined in section 2.2.16, after 
4/5 days post-transfection, a 20μl volume of media was taken off and centrifuged to ensure 
no cellular carryover and processed as before. Note: qPCR cannot be done on extracellular 
protein.  
For intracellular detection, media was removed 4/5 days post-transfection and washed twice 
with 1x PBS, lysis buffer was added to cells and protein content measured via Bradford 
Assay. 10μg of protein was loaded onto a Bis-Tris 4-12% SDS gel as before. Additionally, 
this time replicates were left to be treated with Trizol® reagent to isolate the total RNA 
from each sample to generate cDNA for qPCR analysis and EPO mRNA transcript levels. 
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2.16: p27 Assay and Quantification 
Using an enzyme inhibitor called CDKN1B, also known as p27, was cloned into the 
promoter-plasmid constructs in order to test the promoters of interest from a more growth 
related phenotypic viewpoint. The encoded protein binds to and prevents the activation of 
cyclins A-CDK2, E-CDK2 and cyclin D-CDK4 complexes, and thus controls the cell cycle 
progression from G1 to S phases, therefore acting as a cell growth suppressor.  
This phenotypic effect was used as a proof of concept reporter while showing that the 
promoter of concern can be used in an established cell regulatory pathway scenario. 
Reduction in cell numbers were indicative of p27 expression strength and proliferation 
inhibition caused by the overexpression of p27, therefore by calculating the cell numbers 
and growth profiles in p27 positively transfected samples we could analyse the promoters 
further. 
Readings were achieved by using the Guava Flow Cytometry system and Guava Viacount® 
Assay once again to count the cell population numbers and viability as described in section 
2.8 and values exported to excel for analysis. 
 
2.17: Other Essential Techniques of Cell Culture 
2.17.1: Single Cell Cloning via Serial Dilution 
Obtaining single cell clones is an important aspect in many molecular experiments, in order 
to derive a single cell and all subsequent progeny can perform identically during a certain 
experiment. Cells can have differing rates of growth, gene expression and apoptosis for 
example therefore by performing single cell cloning we can circumvent any variability seen 
in heterogeneous mixed populations. 
In 96-well plates, we used attached cells at ~90% confluency. Cell stocks were rinsed with 
PBS and detached by incubation at 37
o
C with pre-warmed trypsin for 5-10 mins. Addition 
of fresh warm media containing serum stopped the trypsin action and samples mixed well 
to disrupt any possible cell clumping. An aliquot of these cells were then centrifuged and 
resuspended and then the following protocol from Corning Inc™ was followed;  
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1. Fill the reagent dispensing tray with 12mL of the appropriate culture medium, then 
using an 8-channel micropipettor add l00μL medium to all the wells in the 96-well 
plate except well A1 (see diagram below) which is left empty.  
 
 
 
 
2. Add 200μL of the cell suspension to well A1 (See Figure 1.) Then using a single 
channel pipettor quickly transfer a 100μL aliquot from the first well to well B1 and 
mix by gently pipetting being careful to avoid making bubbles. Using the same tip, 
we repeated these 1:2 dilutions down the entire column, discarding the original 
100μL from H1 so that it ends up with the same volume as the wells above it.  
 
3. With the 8-channel micropipettor add an additional l00μL of medium to each well 
in column 1 (giving a final volume of cells and medium of 200μL/well). Then using 
the same pipettor quickly transfer l00μL from the wells in the first column (A1 
through H1) to those in the second column (A2 through H2) and mix by gently 
pipetting. Avoiding bubbles!! 
 
4. Using the same tips, repeat these 1:2 dilutions across the entire plate, discarding 
l00μL from each of the wells in the last column (A12 through H12) so that all the 
wells end up with 100μL of cell suspension.  
 
5. Bring the final volume of all the wells to 200μL by adding 100μL medium to each 
well. Then label the plate with the date and cell type. Adding filtered conditioned 
medium (medium in which cells have been previously grown for 24 hours) to the 
wells can increase the success rate (cloning efficiency) for difficult to grow cells.  
 
6. Incubate plate undisturbed at 37°C in a humidified CO2 incubator.  
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7. Clones should be detectable by microscopy after 4/ 5 days and be ready to score 
after 7 to 10 days, depending on the growth rate of the cells. Check each well and 
mark all wells that contain just a single colony. Typically the number of single 
clonal events was around 10 clones per plate. 
 
8. After 1/2 weeks, these clones should have spread out into larger single colonies 
visible under the microscope. These colonies can then be subcultured from the wells 
into larger vessels. Usually each clone is transferred into a single well in a 12 well 
or 24-well plate for further growth.  
 
2.17.2: Cell Sorting / FACS 
A Fluorescence-activated cell sorter (FACS) can separate cells based on size and 
fluorescence intensity. Unlike the Guava flow cytometry the FACS can sort cells aswell as 
measure fluorescence. Cells transfected with a GFP gene can then be sorted by expression 
strength in real time and placed straight into a 96-well plate to proliferate from a single 
clone. Cells are directed into a stream that forms miniscule droplets after a laser is directed 
at the stream, the idea is that in one of every two or three droplets will contain a single cell. 
CHO cells were sorted based on fluorescence in the top 25% range, as detected by the FITC 
(fluorescein isothiocyanate) channel in the software and directly placed into 96-well plates. 
Pre-loaded in these plates were equal amounts of conditional and fresh ATCC media 
supplemented with 2.5% FCS. Additionally, 1x Penicillin/Streptomycin solution (to avoid 
bacterial contamination) plus 500μg/mL of G418 was also added. A stringent fluorescent 
gating cut-off was applied using untransfected/GFP negative cells (representing basal auto-
fluorescence), this facilitated the software to discriminate between positive and negative 
GFP expressing cells in the populations to be sorted.  
 
2.18: IgG ELISA Quantitation Set 
We used the Bethyl Laboratories Inc® kit (Cat#: E80-104) for the detection of human 
version of the IgG antibody in supernatant from media, plasma serum and other biological 
fluid samples in a convenient 96-well plate format (Cat#: E105).  
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Samples and control standards were diluted in suitable ELISA diluents (Blocking buffer + 
Tween 20) as required to ensure samples were all within range of a standard curve for 
concentration calculations. We used the following daily timepoints and dilutions; Day1 
1\100, Day2 1\200, Day3 1\400, Day4 1\600, Day5 1\600, Day6 1\800, Day7 1\800, Day 8 
1\1000.  
 
ELISA Procedure Overview: 
  
1. Add 100 l of standard or sample to designated wells.  
[Note: Run each standard or sample in duplicate.] 
 
2. Cover the plate and incubate at room temperature (20-25C) for 1 hour.  
  
3. Wash the plate FOUR times.  
 
4. Add 100 l of anti-human IgG Detection Antibody to each well.  
 
5. Cover the plate and incubate at room temperature for 1 hour.  
 
6. Wash the plate FOUR times.  
 
7. Add 100 l of HRP Solution A to each well.  
 
8. Cover the plate and incubate at room temperature for 30 minutes.  
 
9. Wash the plate FOUR times.  
 
10. Add 100 l of TMB Substrate Solution to each well.  
 
11. Incubate the plate in the dark at room temperature for 30 minutes.  
 
12. Stop the reaction by adding 100 l of Stop Solution to each well.  
 
13. Measure absorbance on plate reader at 450 nm ABS within 30 mins of addition of stop 
solution. 
 
See the technical sheet PDF (E80-104) supplied in the kit for all other protocol information, 
such as precautions, troubleshooting and calculation aids. 
 
 
116 
 
2.19: MicroRNA-mRNA moiety capture using biotinylated oligos 
As mentioned in the introduction, miRNAs are responsible for the regulation of gene 
expression via translational repression or messenger RNA degradation. Although numerous 
bioinformatic prediction models exist to identify miRNA-mRNA interactions, experimental 
validation of bona fide interactions from in vivo samples can be very difficult and 
laborious.  
Here we present a full microRNA ‘Mir-Capture’ affinity technique protocol which was 
used to experimentally extract cognate miRNAs that target a specific mRNA. Streptavidin 
beads were used along with an anti-sense capture oligonucleotide which was 
complementary to a specific gene of interest. In our case, the X-linker inhibitor of apoptosis 
(XIAP) gene or more specifically it’s mRNA was chosen as the target.  
 
2.19.1: Biotinylated DNA oligo design 
The secondary and tertiary structures of the CHO and Human XIAP mRNA transcript 
variants were modeled with M-Fold, which is found here; 
http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form2.3.  
The most thermodynamically stringent structures were selected in each case. Exposed 
single strand regions were identified and used as attachment points for the oligos for each 
cell line. For Human (SNB-19), two oligos were designed due to the XIAP 3’UTR being 
unusually long in order to capture full length of the transcript and not miss prospective 
bound miRNAs.  
See table 2.19.1 for a list of the capture oligos used over the project. Two control capture 
oligos were designed, one fully scrambled sequence oligo as negative control (should not 
target anything) and one oligo with a 3-base mismatch to accentuate the sensitivity of the 
miR-Capture assay compared to the affinity of the true capture oligo targeting XIAP. 
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Table 2.19.1: List of Capture oligos used for miRNA pull-down. 
 
 
Each oligo was designed with a 5’ biotin modification (5’BITEG) using canonical Watson-
Crick RNA and DNA base-pairing, by MWG Eurofins (http://www.eurofinsgenomics.eu/).  
 
2.19.2: MiR-Capture full protocol 
General Considerations: 
As it is important to isolate ‘high-quality RNA’ and reduce the chance of RNAase 
contamination, special precautions to avoid RNA degradation must be carried out. This 
included wearing gloves, routine use of nuclease-free water or DEPC-treated water, 
addition of RNasein to all buffers and use of RNase-free microcentrifuge tubes and pipette 
tips. 
1. Formaldehyde Cross-Linking 
i. Prepare three T-75 flasks of confluent cells suspended in 20 ml PBS (RT°). 
ii. Centrifuge cells at 1000g for 3 minutes and resuspend well in 10 ml cell 
medium (RT°). 
iii. Add 10 ml 2% methanol-free formaldehyde and incubate on a rocker for 10 
minutes. 
iv. Add 1.33 ml 3 M glycine for a final concentration of 0.2 M and incubate for an 
additional 5 min at room temperature.  
Note: Glycine stops the cross-linking by reacting with formaldehyde 
2. Wash cells 
i. Centrifuge cells for 4 minutes at 2000g @4°C and decant supernatant. 
ii. Wash cells twice in 50 ml ice-cold PBS by resuspending cells in a 50 ml falcon 
tube, centrifuging at 2000g for 5 minutes @4°C and decanting supernatant. 
iii. Aspirate off the remaining supernatant and resuspend in 0.6 ml ice-cold PBS. 
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iv. Transfer to screw-cap tube and wash 50 ml falcon tube with an additional 0.6 ml 
ice-cold PBS. 
v. Transfer this to the screw cap tube and centrifuge for 2000g @4°C for 5 
minutes. 
vi. Aspirate off all supernatant and flash-freeze for 1 minute in Liquid nitrogen,  -
80°C long-term storage or proceed straight to lysis step. 
 
3. Lyse cells 
i. Re-suspend cells in 0.4 ml ice cold FA lysis buffer per ~100 mg pellet.  
ii. Add 0.4 ml 0.5 mm glass beads. 
iii. In a screw-cap microtube, lyse cells by using a FastPrep cell disrupter 4 times 
for 30 sec at speed 5.5, incubating sample on ice between each treatment.  
iv. Puncture a hole in the bottom of the tube with a sterile 0.45 mm needle. 
v. Place the tube into another microtube in a 15-ml centrifuge tube. Centrifuge for 
5 minutes at 3500 g @4°C. 
vi. Add 0.6 ml FA lysis buffer to the beads and centrifuge the sample for 5 minutes 
at 3500g @4°C. 
vii. Optional Add 0.4 ml FA lysis buffer to lysate to dilute sample. 
Can store at -80
o
C.  
Can check RNA fragment size on a polyacrylamide gel. 
 
4. DNase Treatment 
i. Mix the lysate by pipetting. 
ii. On ice add the following to 1.4 ml lysate: 
25 mM MgCl2 
5 mM CaCl2 
120U Rnasein 
120 μg RNase-free DNase I. 
iii. Mix by flicking the tube, centrifuge and incubate at 37°C for 15 minutes. 
iv. Add 20 mM EDTA to stop the reaction. 
v. Centrifuge the lysate for 5 minutes at 18,000g at 4°C. 
vi. Transfer the supernatant to a new screw-cap tube. 
This is potential stopping point when the lysate is flash-frozen and stored at -
80°C. However, this is unadvisable. 
 
Magnetic Separation 
5. Bead Preparation 
i. Re-suspend beads in the original vial by rotation or vortexing. 
ii. Transfer 0.2 ml beads per sample to Eppendorf tubes. 
iii. Mix in 1 ml of 1X B&W Buffer to each tube and place on a Dynal magnet for 2 
mins. If >0.4 ml beads, pellet them first for 2 minutes on the magnet and 
remove supernatant prior to adding 1 ml 1X B&W Buffer. 
iv. Remove supernatant by aspiration with a pipette while the tube is on the 
magnet 
v. Remove the tube from the Dynal magnet and add 1 ml 1X B&W buffer. 
Consolidate samples to one tube if possible. 
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vi. Repeat steps iii-v x 2 (total washes 3 times) 
vii. Wash the beads twice in 1 ml Solution A (RT°) for 2 minutes and pellet beads 
for 2 minutes. 
viii. Wash the beads once in 1 ml Solution B (RT°), pellet beads for 2 minutes and 
remove all supernatant. 
 
6. mRNA:microRNA Capture 
i. Resuspend beads in twice the original volume of 2X B&W buffer (pH 7.5) (i.e. 
: 400 μl per 200 μl beads). 
ii. Add the same volume of oligonucleotides resuspended in 1X TE buffer at 0.8 
μmol per oligonucleotide per sample (8 μl of 100 μM oligo). 
iii. Incubate on the tube rotator for 15 minutes at RT° to allow the oligos to bind to 
the beads. 
iv. For each sample, take 800 μl bead mix, remove buffer/oligo mix and wash 
them twice in 1 ml of 1X B&W buffer (pH 7.5) @RT°. 
v. Resuspend beads in 0.7 ml Hybridisation Buffer @ 37°C. 
vi. Add 0.5 ml 1X TE (pH 7.5) @ 37°C and add 0.2 ml of the cell lysate. 
vii. Incubate, while rotating in the hybridisation oven for 1.5 hours at max speed at 
37°C. 
viii. Resuspend the beads in 1 ml Washing Buffer A @37°C and rotate in the 
hybridisation oven at 37°C at max speed for 5 minutes. During pelleting make 
sure that beads stuck to the cap of the tube are also washed down. 
ix. Repeat step viii another 3 times (total of 4 times). 
x. Resuspend the beads in 1 ml Washing Buffer B @37°C and rotate in the 
hybridisation oven at 37°C at max speed for 5 minutes.  
 
 
7. Elution of mRNA:microRNA complex 
i. Place the microfuge tube into the Dynal Magnet. Ensure that the tubes are 
properly inserted. 
ii. Allow the microfuge tube to remain in the Dynal for 2 minutes. Gently shake 
while the microfuge tubes are held in position 
iii. Remove Wash Buffer B by aspiration with a pipette while the tube remains in 
the Dynal Magnet. Avoid aspiration along the wall where the dynabeads are 
attracted by the magnet 
iv. Resuspend the beads in 200 μl 1X TE buffer (pH 7.5) @80°C by flushing the 
desired volume of medium along the side of the tube where the target material 
is attracted. Resuspend well.    
v. Heat to 80oC for 5 minutes (this will elute the sample and partially reverse 
crosslinks).  
vi. Place the tube immediately on the Dynal magnet for 10 seconds and transfer 
the eluted mRNA in the supernatant to a new RNAase free tube. Carefully 
ensure no beads have been transferred. This can be checked by centrifuging 
and observing a brown pellet. Can store at -80
o
C 
    
 8.  Reverse cross-link and Purify RNA 
i. Incubate the samples at 70°C for 45 minutes to reverse the formaldehyde 
crosslinks. 
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ii. Purify the sample using Trizol-chloroform-ethanol precipitation or column-
based purification (High pure miRNA isolation kit – Roche cat # 
05080576001). 
iii. Measure RNA yield, and proceed to Reverse Transcription qPCR (See section 
2.6.15). 
iv. Samples ready for TLDA expression analysis. TLDA (A+B) Human specific 
micro-fluidic cards were used for all processed samples and run on the Applied 
Biosystems® 7900HT fast thermal cycler (section 2.9).  
v. Enrichment analysis using the ΔΔCT method in excel was performed. 
 
 
2.20: Bioinformatic and Regulatory Web-based software 
Over the course of this project, many web-based software programs were utilised, for a 
plethora of reasons; to identify genomic data, to design primers, to check melting 
temperatures, to predict important regulatory sequences of DNA, sequence retrieval and 
searching gene nomenclature etc.  
The web resource Regulatory Sequence Analysis Tools (RSAT: http://rsat.ulb.ac.be/rsat/) 
offers a collection of these tools dedicated to processing the above enquiries. RSAT 
currently holds >100 fully sequenced genomes, and continually updated by GenBank. 
Table 2.20: List of all existing bioinformatic programs that were used during the project, 
including all hyperlinks and a brief description of the programs function. 
Web Tool: Hyperlink: Description: 
UCSC http://genome.ucsc.edu/ Genome browser for 
mammals/BLAT/In silico work 
MWG Eurofins http://www.eurofinsgenomics.eu/ Oligo and small molecule 
ordering/Sequencing checks 
Genomatix http://www.genomatix.de/ Generation of genome wide 
transcription factor data 
OligoCalc http://www.basic.northwestern.edu/biotools/oligocalc.html Oligonucleotide Properties 
Calculator/ Tm 
calculator/Hairpin loop 
formations/primer design 
M-Fold http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-
Form2.3 
2
o
/3
o
 structure folding 
pattern/Visual interpretation 
CHO consortium http://www.chogenome.org/ Expansive CHO sequence 
database/BLAST 
ClustalW/Omega http://www.ebi.ac.uk/Tools/msa/clustalw2/ Multiple sequence alignment 
program for DNA/RNA or 
proteins 
CGCDB http://www.cgcdb.org/ Transcript database for CHO 
coexpression gene patterns and 
correlation maps 
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Section 3.0  
 
 
 
 
 
 
Results 
Project 1 
Endogenous CHO promoters as tools to drive transgene 
expression. 
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3.1: Identification, Isolation and Verification of CHO gene Promoters  
3.1.1: Introduction 
The aim of this project was to identify and exploit endogenous Chinese Hamster Ovary 
(CHO) gene promoters to enhance heterologous protein expression and in turn improving 
cell lines used for biopharmaceutical production. To date ~70% of genetically engineered 
proteins for human therapy (arthritis, cancer, diabetes etc) are produced in mammalian cells 
and more specifically CHO cells. 
The cost of manufacturing biopharmaceuticals needs to be reduced in the interests of both 
patient welfare and sustaining an innovative research and development ethos. By finding 
ways to optimise the production of these drugs and minimise the costs involved, the 
research described herein may play a role in lowering the overall costs of these therapies. 
Initial profiling undertaken in the NICB collaboration with Pfizer generated an expansive 
detailed dataset with 300+ expression profiles, which have been compiled using a unique 
2
nd
 generation Wyeth proprietary (WyeHamster3a) microarray chip. In generating this 
dataset, the cell samples used covered numerous cell-lines growing in different process 
scenarios, at different temperatures, at different stages of cell culture progression, Qp, 
lactate/ammonia production, and protein products produced. These samples were then 
profiled from a transcriptomics viewpoint via the said microarray chips.  
This extensive dataset was then mined for example to identify target genes linked to cell 
lines with advantageous phenotypes [cells capable of reaching high density, high 
productivity, fast growth, tolerance to lactate or ammonia waste]. This created a sample 
matrix giving a sizable bioinformatics dataset to tackle the original aim to identify CHO 
genes with potential as cell engineering targets. 
To identify genes that are temperature responsive, the dataset was analysed based on 
differential between 37
o
C (regular culture temperature) and 31
o
C (mild hypothermic 
culture). Thus promoters from promising candidate genes could be targeted for cloning and 
analysis.  
Viral promoters have been well documented as highly active in driving transgene 
expression in different cell types and many are used commercially (SV40, CMV, RSV and 
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LTR) (Walther and Stein 1996) (Zarrin et al. 1999). As viral genomes are much smaller 
than mammalian genomes, the architecture of promoters is easier to study. Eukaryotic gene 
expression is more complex and requires precise coordination of complex regulatory 
architecture (promoters, enhancers, silencers). Recognition and binding of these promoter 
sequences by transcription factors occurs within the context of chromatin, whose dynamic 
structural characteristics play a significant role in regulating gene expression (Mellor 2005). 
A central dichotomy in industrial protein production revolves around the control between 
converting cellular metabolic energy for biomass generation versus product secretion. 
Many processes nowadays incorporate an initial growth phase quickly followed by a switch 
to production phase whereby cell growth ceases and cellular machinery resources are 
directed to protein synthesis. This is achieved most readily via temperature shift, and 
although highly useful can present logistical challenges in large bioreactors. Genes can be 
antagonistic during this biphasic setup, for example overexpression of proliferation-
enhancing genes would be advantageous earlier in the growth phase, but undesirable later 
in the production phase, it is this aspect that this project addresses.  
By undertaking this study, firstly, we aim to identify promoters capable of driving 
expression of various protein products to test their applicability and to expand the CHO 
metabolic engineering toolbox. And secondly, to assert temporal control over bioprocess-
engineering transcripts (for example; growth, viability, productivity and apoptosis related 
genes) that can be switched on or off at the appropriate times to maximise their effects in 
the production process. In doing so, we intend to investigate whether endogenous inducible 
promoters are more attractive than viral and other existing inducible systems. 
 
3.1.2: Identification of Temperature-sensitive genes in ‘Omics dataset 
3.1.2.1: Choosing target genes for study 
The original transcriptional profiling used to identify potential promoters, generated over 
300 expression profiles, covering numerous CHO cell lines grown at various stages during 
a wide series of time points.   
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This gene expression analysis, carried out on the proprietary CHO-specific WyeHamster2a 
microarray, enabled the study of ~3,500 sequences, representing approximately 10-15% of 
the CHO transcriptome (Melville et al. 2011).  
All microarray data were processed as described previously and analysis was conducted 
with the help of Dr. Colin Clarke a bioinformatician for the NICB/NIBRT (Clarke et al. 
2011). Weighted gene coexpression network analysis (WGCNA) was utilised to explore 
CHO cell transcriptome patterns associated with bioprocess relevant phenotypes. Cells 
were sampled for gene expression analysis at various stages of the culture and bioprocess-
relevant characteristics including cell density, growth rate, viability, lactate, ammonium and 
cell specific productivity (Qp) were also determined.  
A probe set is a collection of probe sequences designed to interrogate a given 
complementary sequence. The dataset used consisted of 295 microarrays from 121 
individual CHO cultures producing a range of biologics including monoclonal antibodies, 
fusion proteins and therapeutic factors. Non-producing cell lines were also included in the 
study consisting of CHO-K1 and CHO-DUX cell types (Clarke et al. 2011). The complete 
sampleset can be found online at (ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3032). 
We wanted to identify genes from the dataset whose expression changed from high to low 
or vice versa in response to a temperature shift to 31
o
C. We then analysed the fluorescent 
expression readings to discern values most positively or negatively correlated with culture 
temperature – in this case either 37oC or 31oC (Table 3.1.2.1). 
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Table 3.1.2.1: List of genes most highly correlated or anti-correlated with culture 
temperature. The list represents the resulting directory of genes up-regulated at 31
o
C (blue) 
and genes down-regulated at 31
o
C (red) temperature shift, the closer the correlation is to -1 
or 1 the more differentiated it is. Additionally, logarithmic and linear fluorescence 
expression (Exp) units and Fold change (FC) were shown for each temperature. 
 
 
Table 3.1.2.1 showed the correlation values and expression fold-change (FC) plus the 
fluorescence units from the probe sets, while the p-values indicated how significant the 
result was. As expected Cirbp (a well known cold-shock protein (CSP) and discussed 
further in section 1.9.2) is top of the dataset as it was upregulated at 31
o
C. Interestingly 
PPID showed slightly higher correlation but in the opposite direction, i.e: down-regulated 
at 31
o
C. Full gene nomenclature can be found in table 3.1.4. 
Figure 3.1.2.2, illustrates a theoretical correlation between gene expression and 
temperature. The closer the (PCC) Pearson correlation coefficient (a measure of the 
strength and direction of the linear relationship between two variables that is defined as the 
sample covariance of the variables divided by the product of their standard deviations) is to 
-1 or 1, the better differentiated it is between 37
o
C and 29-31
o
C and thus indicative of 
potential induciblity strength. 
 
Fluorescence Exp Units from Probes
Probeset ID Gene ID Correlation p value log2 37C log2 31C Lin 37 Lin 31 FC
AF022942_at Cirbp -0.8300 2.84E-76 5.0580 6.4685 33.3 88.6 2.66
WAN013I2Q_at SSU72 -0.8156 1.41E-71 6.3503 7.4743 81.6 177.8 2.18
WAN013I96_at MDM2 -0.7859 4.10E-63 5.8465 6.8534 57.5 115.6 2.01
WAN008E3Q_at Zfp180 -0.7835 1.69E-62 5.0642 5.5602 33.5 47.2 1.41
WAN008CFZ_at HSBP1 -0.7772 6.73E-61 6.8876 7.5605 118.4 188.8 1.59
WAN0088WY_at RBBP9 -0.7614 4.20E-57 5.0998 5.3787 34.3 41.6 1.21
WAN008E1S_at PPID 0.8826 4.57E-98 6.0474 4.9556 66.1 31.0 2.13
WAN013HVE_at NARS 0.8363 1.85E-78 6.9074 6.0437 120.0 66.0 1.82
WAN013I1P_at HNRPA2B1 0.7923 7.66E-65 8.1388 7.0289 281.9 130.6 2.16
WAN008CX4_at MCM5 0.7690 6.96E-59 6.1437 5.0653 70.7 33.5 2.11
WAN008DZY_at MCM7 0.7511 8.94E-55 6.9750 6.0094 125.8 64.4 1.95
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Figure 3.1.2.2: Graphical representation of the theory behind the correlation analysis. Two 
genes were chosen for illustration purposes. 1 and -1 represent perfect correlation or anti-
correlation between gene expression and temperature.  
 
This approach was based on the hypothesis that genes whose mRNA levels closely 
correlate to temperature changes, are likely to be under the transcriptional control of 
temperature-sensitive promoters. These promoters, in turn, could be utilised for driving 
expression of choice transgenes, to engineer particular CHO phenotypes in a process 
parameter-dependant manner, temperature in this case. 
 
3.1.2.2: Identification of constitutive genes 
In addition to temperature sensitive genes, we also looked for constitutively highly 
expressed genes within the dataset whereby the expression level stayed constant (ideally at 
a high level) regardless of process stage (Exponential, Lag), temperature and irrespective of 
cell line.  
The premise being that, strong endogenous promoters might be useful alternatives to viral 
promoters for transgene expression. Constitutive expression ideally should be independent 
of any exogenous stimulus or response, compared to inducible expression which can be 
controlled by exogenous signals (Williams, Christensen and Helin 2011).  
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Figure 3.1.2.2.1: Graphical representation depicting the expression level between 
temperature change samples across the entire dataset. Some genes can have higher 
expression values but large variability; PPIA and UBA52 have the highest mean expression 
across the sampleset value while maintaining relatively low variance.  
 
All genes below the expression threshold of 100 fluorescent units were discounted from 
subsequent study as they would not be expected to drive transgene expression to an 
adequate level and were identified as having high mean fluorescent expression detected by 
the microarray probes while those highly expressed with the lowest variance (cut-off of 
0.06 was applied) were deemed most suitable for further study and cloning (Figure 
3.1.2.2.1).
128 
 
Table 3.1.2.3 (A): List showing the least variable genes across the entire dataset at 37
o
C. Fluorescence mean denotes the log2 mean 
intensity of the fluorescent probe for a particular gene. Variance accounts for the standard deviation of the genes mean intensity across 
all probes. 
 
 
 
  
 
 
37oC Gene Fluorescence
Probeset ID Symbol Gene Name: MEAN Variance
WAN013I1V_at NA POSSIBLE UNIGENE 11.6565 0.0477
WAN013I9I_at PPIA Peptidylprolyl isomerase A (cyclophilin A) 11.3494 0.0598
WAN008DXW_at RPLP1 Ribosomal protein, large, P1 11.1367 0.0579
WAN0088IV_x_at Mm.393149 Transcribed locus, moderately similar to XP_223768.3 PREDICTED: similar to OTTHUMP00000060196 10.7009 0.0533
WAN013HXJ_at NA Cluster includes WAN008D0Z 10604B-D01 10.6103 0.0600
AF081142_at UBA52 Ubiquitin A-52 residue ribosomal protein fusion product 1 10.5659 0.0569
WAN013I40_at Mm.309697 PREDICTED: Mus musculus similar to ribosomal protein S14, transcript variant 2 (LOC545121), mRNA 10.5620 0.0474
WAN013I1R_at CHCHD2 Coiled-coil-helix-coiled-coil-helix domain containing 2 10.1004 0.0459
WAN008COL_at RPL29 Ribosomal protein L29 9.7244 0.0580
WAN013I0F_at RPL4 Ribosomal protein L4 9.6603 0.0577
WAN008EDB_at COX4I1 Cytochrome c oxidase subunit IV isoform 1 8.9102 0.0482
WAN008D39_x_at AUP1 Ancient ubiquitous protein 1 8.6597 0.0175
X13175_f_at NA X13175 Hamster KG4 mRNA related to cellular proliferation 8.5803 0.0400
WAN00OGTM_x_at NKX6-1 NK6 transcription factor related, locus 1 (Drosophila) 8.5116 0.0546
U62588_x_at SDC1 Syndecan 1 8.4345 0.0532
WAN008D42_at HSPB8 Heat shock 22kDa protein 8 8.4132 0.0587
WAN008EXK_x_at Uqcrc1 Ubiquinol-cytochrome c reductase core protein 1 8.3798 0.0419
WAN013I9C_at SDHC Succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa 8.3225 0.0531
L00366_x_at TK1 Thymidine kinase 1, soluble 8.2619 0.0438
WAN008E36_at PSMB5 Proteasome (prosome, macropain) subunit, beta type, 5 8.2396 0.0455
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Table 3.1.2.3 (B): List showing the least variable genes across the entire dataset at 31
o
C. Fluorescence mean denotes the log2 mean 
intensity of the fluorescent probe for a particular gene. Variance accounts for the standard deviation of the genes mean intensity across 
all probes. 
 
 
31oC Gene Fluorescence
Probeset ID Symbol Gene Name: MEAN Variance
WAN014IYJ_at NA WAN014IYJ Internal ribosomal entry site (IRES) from AR135605 Sequence 1 from Wyeth patent US 6136536. 12.8454 0.0521
WAN013I14_at NA POSSIBLE UNIGENE 12.2278 0.0531
WAN013I1V_at NA POSSIBLE UNIGENE 11.5927 0.0206
WAN014IYS_f_at DHFR Dihydrofolate reductase 11.4824 0.0436
WAN013I9I_at PPIA Peptidylprolyl isomerase A (cyclophilin A) 11.3603 0.0523
WAN013HV1_at RPS8 Ribosomal protein S8 11.1138 0.0583
AF081143_at Rps18 Ribosomal protein S18 11.0390 0.0515
WAN0088IV_x_at Mm.393149 Transcribed locus, moderately similar to XP_223768.3 PREDICTED: similar to OTTHUMP00000060196 [Rat] 10.7042 0.0509
WAN013I40_at Mm.309697 PREDICTED: Mus musculus similar to ribosomal protein S14, transcript variant 2 (LOC545121), mRNA 10.6191 0.0487
AF081142_at UBA52 Ubiquitin A-52 residue ribosomal protein fusion product 1 10.5677 0.0547
WAN013I06_at NA Cluster includes WAN008E0Q 11229C-H06 10.3438 0.0504
WAN013I1E_at 1810064F22Rik RIKEN cDNA 1810064F22 gene 10.1183 0.0499
WAN013I1R_at CHCHD2 Coiled-coil-helix-coiled-coil-helix domain containing 2 10.0775 0.0430
WAN013HXA_at Gnb2l1 Guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 10.0269 0.0480
WAN013I3Q_at RPS19 Ribosomal protein S19 9.8787 0.0441
WAN008COL_at RPL29 Ribosomal protein L29 9.7988 0.0447
WAN013I1Y_at EIF3S2 Eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa 9.6027 0.0589
WAN008EDB_at COX4I1 Cytochrome c oxidase subunit IV isoform 1 9.0282 0.0434
WAN008ENW_at TKT Transketolase (Wernicke-Korsakoff syndrome) 8.8994 0.0573
WAN013HZU_at Sdhc Succinate dehydrogenase complex, subunit D, integral membrane protein 8.7338 0.0468
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The four genes highlighted in blue table 3.1.2.3(A+B), were prioritised for isolation of their 
respective promoter sequences; PPIA, UBA52, COX4l1 and Sdhc. As can be seen from the 
fluorescence values for these four genes, there was very little fluctuation between their 
expression at 37
o
C and 31
o
C.  
In contrast, DHFR was highly expressed with low variance seen across all samples cultured 
at 31
o
C (Figure 3.1.2.3 B), however it was not found amongst the list of most highly 
expressed genes at 37
o
C (Figure 3.1.2.3 A). DHFR was a transgene from a plasmid cloned 
into CHO cells and driven by a viral promoter, so high expression levels were expected as 
viral promoters generally drive high expression levels of genes they precede.  
In addition to the mRNA expression profiling dataset mentioned, we also had access to a 
microRNA profiling dataset generated in the lab previously. This dataset contained 
expression data on approx 350 miRNAs across 30 CHO samples with varying growth rates. 
Upon similar analysis, as performed on the mRNA dataset, the miR-17-92 cluster was 
found to be highly expressed and constitutive across samples. Therefore, we also prioritised 
isolating the promoter of this miRNA cluster to investigate its potential to drive constitutive 
transgene expression. Independent of this profiling, the cluster has been shown to be 
involved in highly proliferative cell types such as; Neuroblastoma and lung epithelial 
progenitor cells reported by (Mestdagh et al. 2010) (Lu et al. 2007) respectively. 
 
3.1.3: Target gene summary 
Now that priority gene targets were identified, the next step with our investigation was to 
validate these CHO-specific target genes from tables 3.1.2.2 and 3.1.2.3 above.  
Figure 3.1.3, shows all gene targets extrapolated from expression profiling regarding 
inducible and constitutive expression. In 2011, Xu et al released a draft CHO-K1 genome 
assembly comprising of 2.45 Gb of genomic sequence, with 24,383 predicted genes 
arranged in scaffolds after whole genome shotgun sequencing. The availability of this 
genomic sequence facilitated us in identifying the CHO-specific target gene sequences 
which were arranged on assembly scaffolds (Xu et al. 2011). 
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Table 3.1.3: Full Cricetulus griseus (CHO) Gene names, NCBI/GenBank scaffold ID and 
common functions they are involved in. 
Gene Full Name Scaffold ID Function 
Cirbp Cold inducible RNA 
binding protein 
Scaffold 881_79 
 
 SSU rRNA binding 
 mRNA 3'-UTR binding 
 nucleotide binding 
 poly(A) RNA binding 
 Translation repressor activity 
SSu72 RNA Polymerase II 
CTD Phosphatase 
Homolog 
Scaffold 2657_20 
 
 CTD phosphatase activity 
 Protein binding 
 
MDM2 Mouse 3T3 double 
minute 2 homolog 
Scaffold 
414_104+414_105 
 Enzyme binding 
 Identical protein binding 
 Ligase activity 
 Metal ion binding 
 p53 binding 
PPID Peptidylprolyl 
isomerase D 
Scaffold 1479_109  Estrogen receptor binding 
 Heat shock protein binding 
 Peptidyl-prolyl cis-trans 
isomerase activity 
 Protein binding 
 Transcription factor binding 
 
Nars asparaginyl-tRNA 
synthetase 
Scaffold 1555_74 
 
 ATP binding 
 asparagine-tRNA ligase activity 
 Nucleic acid binding 
HNRPa2b1 Heterogeneous nuclear 
ribonucleoprotein 
A2/B1 
Scaffold 291_30 
 
 RNA binding 
 Nucleotide binding 
 poly(A) RNA binding 
 pre-mRNA intronic binding 
 
PPIA peptidylprolyl 
isomerase A 
(cyclophilin A) 
Scaffold 750_45  Peptidyl-prolyl cis-trans 
isomerase activity 
 Poly(A) RNA binding 
 Protein binding  
 Unfolded protein binding 
 Cyclosporin A-mediated 
immunosuppression 
 Virion binding 
UBA52 ubiquitin A-52 residue 
ribosomal protein 
fusion product 1 
Scaffold 1845_23  Targeting cellular proteins for 
degradation by the 26S 
proteasome 
 Maintenance of chromatin 
structure 
 Regulation of gene expression 
 Regulation of stress response 
 
miR-17-92 
cluster 
[miR-17, miR-
18a, miR-19a, 
miR-20a, miR-
19b, and miR-
92a] 
miRNA polycistron 
consisting of also 
known as oncomir-1 or 
host gene [MIR17HG] 
Scaffold 3425_6  Found in several human B-cell 
lymphomas (non-Hodgkin's) 
 Regulates cell proliferation and 
collagen synthesis 
 Over expressed in Lung cancers 
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In light of the dogma regarding promoters being located adjacent/upstream to the genes 
they control, in order to isolate sequence, the location of each promoter and the ATG start 
codon was determined. The CHO sequence was identified using cross-species alignments 
from mouse, human, and rat sequence conservation. We implemented an arbitrary range of 
~5000bp upstream of this determined ATG start site (+1) in order to optimistically capture 
all putative regulatory sequence. First we will present the validation of these genes as 
suitable targets, the workflow and isolation of putative promoters will be expanded further 
in sections 3.1.7 and 3.1.8. 
 
3.1.4: Real Time-qPCR validation of target genes 
The first objective was to differentiate between target genes that exhibit temperature shift 
dependant expression versus mRNAs that are simply more stable and thus remain in the 
cells cytoplasm for longer. High mRNA transcriptional turnover rather than increased 
mRNA stability should be indicative of a more active/responsive promoter. 
First RT-qPCR was performed on these genes in the original RNA samples from the 
previous profiling experiment (Table 3.1.4.1), to verify the array-detected levels of the 
priority genes and provide further evidence for choosing them as targets.  
 
Table 3.1.4.1: RNA sampleset tested via qRT-PCR for the expression levels of all 
identified target genes. Note: miR-17-92 was determined in a separate sample set profile 
including small RNAs. 
 
Sample 
ID Cell Type
Time 
Point
Culture 
Temp oC
Cell Density 
(x10
6 
cells/ml)
Culture 
vessel type
Culture 
volume
135 CHO DG44 3 Days 37 1.19 Shake Flask 50 mls
244 CHO DUX 3 Days 37 2.54 Shake Flask 50 mls
294 CHO DUX 3 Days 29.5 10.4 Bioreactor 1 liter
204 CHO DUX 4 Days 37 2.37 Shake Flask 30 mls
336 CHO DUX 5 Days 31 9.23 Shake Flask 50 mls
309 CHO DUX 7 Days 37 2 Bioreactor 1.6 liters
209 CHO DUX 8 Days 31 3.27 Shake Flask 30 mls
20 CHO K1 3 Days 37 3.19 Bioreactor 1 liter
265 CHO K1 5 Days 31 7.57 Shake Flask 200 mls
99 CHO K1 7 Days 37 2.64 Shake Flask 60 mls
175 CHO K1 9 Days 31 8 Bioreactor 1.8 liters
442 CHO K1 10 Days 31 9.93 Bioreactor 2 liters
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By choosing a diverse RNA sampleset for validation, including wide variation in culture 
growth timepoints, different CHO cell types and of course different culture temperatures, 
the aim was to have as wide a scope as possible.  
The first step was to order specific qPCR primers (see appendices) for the same targets. 
Some considerations were needed here. These qPCR-specific primers differed from cloning 
primers seen in section 3.1.6. All qPCR primers were designed as stringently as possible to 
each other with respect to melting temperature (~56-61
o
C), nucleotide size and GC content, 
to allow analysis of more than one gene set per 96-well reaction plate. Also by ensuring the 
primers spanned intron-exon boundaries, provided assurance that the mRNA target only is 
detected after reverse transcription. Additionally, by designing the primers to produce small 
amplicons (~100-250bp) this promotes efficient amplification to ensure they are accurately 
quantified.  
In order to perform absolute qPCR analysis to calculate the mRNA copy number for each 
gene target, first we needed to generate material for a standard curve. In parallel, the 
sampleset RNA quality was verified on an agarose gel to ensure the samples were of 
suitable quality (Figure 3.1.4.1).  
 
 
Figure 3.1.4.1: Agarose gel electrophoresis to perform a RNA quality check on the CHO 
sampleset extrapolated from Table 3.1.4.1. Sample ID labels are shown on the gel image 
(Black). Both large and small ribosomal subunits (28S and 18S) were shown to be intact 
across sampleset and the 28S subunit was approximately double the intensity of the 18S. 
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Traditionally, the intensity of these rRNA bands on denaturing agarose gels have been used 
to calculate a ratio that served as an indication of RNA integrity. A 28S/18S gradient of two 
is considered to be indicative of good quality RNA. The RNA samples were all deemed to 
be sufficient quality for proceeding to qPCR validation, with very little smearing, which is 
often an indication of RNA quality (Figure 3.1.4.1). 
Next the RNA samples from Table 3.1.4.1 were reverse transcribed to convert RNA to 
cDNA; 1μg in total was used in a 20μl reaction with a DNase treatment step beforehand to 
ensure no DNA carryover into the qPCR reaction. 
Separately, standard PCR and agarose gel extraction were performed to isolate and purify 
all gene amplicons for the standard curve generation. Absolute quantification relates the 
PCR signal to input copy number using a calibration curve.  
To generate material/transcript copies of each gene for this standard curve, we generated 
the amplicons using regular PCR and subsequently analysed them using Agilent 
technologies Bionalyzer 2100® to ensure a single amplicons that were contamination free 
and of good quality (Figure 3.1.4.2). 
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Figure 3.1.4.2: Agilent 2100® Bioanalyzer results on extracted DNA amplicons prior to 
RT-qPCR. 9 genes were tested plus ‘Beta-actin’ and ‘GAPDH’ house-keeping genes in 
order to have a choice of reference genes for qPCR. (A) ‘Single peaks’ in between both 
upper and lower markers are indicative of a pure amplicon. (B) Artificial gel image 
generated by the software to visualise any contaminating bands and size calculation. 
Additional table containing amplicon details such as sizing, concentration and migration 
time in the gel also shown. Note: HNRPa2b1 repeated (label: HNRP pcr) twice. 
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For creation of the standard curve we calculated the copy number for each gene amplicon, 
to generate a stock DNA concentration in [ng/μl]. These stocks were used to generate a 
standard curve via serial dilution for each gene after using a dsDNA copy number 
calculator found here http://cels.uri.edu/gsc/cndna.html.  
 
 
This calculation is based on the assumption that the typical weight of a base pair (bp) is 
650Da. This means that one mole of a bp weighs ~650g and that the molecular weight of 
any double stranded DNA template can be estimated by taking the product of  its length 
(in bp) and 650 and by using Avogadro's number, 6.022x10
23
 molecules/mole, the number 
of molecules of the template per gram can be calculated.  
Next serial dilutions were performed to represent the exponential dilutions based on each 
order of magnitude (10^). Ideally, having ~3.3 PCR cycle difference between each genes 
10-fold dilution is indicative of efficient amplification cycles. By pre-calculating all copy 
numbers of the stock gene amplicons as shown in table 3.1.4.4, the CTs calculated from 
each run can be cross referenced to the standard curve for each gene to establish the copy 
number. In this way we can evaluate if there is a difference in mRNA copy number across 
the sampleset in response to temperature change. 
Note: Only three genes were prioritised from here onwards, Cirbp, MDM2 and SSu72 and 
are representative of the analysis done on the entire gene target list (Table 3.1.3). Post-
validation, these 3 genes were highlighted as the best candidates (based on initial GFP 
screen performance) and became the main focus of this project and encouraged us to avoid 
displaying repetitive results. 
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Table 3.1.4.4: Total copy number per 20μl stock for Cirbp, MDM2 and SSu72 genes with 
exponential dilution concentration and their respective copy numbers per 20μl calculated 
from a standard curve. Figure representative of all genes tested, however, only three genes 
with the highest priority for the next phase of analysis were shown.  
 
 
Gene
Total Copy (per 
20μl) Sample dil Conc [ng/ μl]
Copy No per 
20μl:
Cirbp 10 -1 17 9.55E+10
Stock Conc: 170ng/ul 9.55E+11 10 -2 1.7 9.55E+09
Amplicon size: 165bp 10 -3 0.17 9.55E+08
10 -4 0.017 9.55E+07
10 -5 0.0017 9.55E+06
10 -6 0.00017 9.55E+05
10 -7 0.000017 9.55E+04
10 -8 0.0000017 9.55E+03
10 -9 0.00000017 9.55E+02
10 -10 0.000000017 9.55E+01
Gene
Total Copy (per 
20μl) Sample dil Conc [ng/ μl]
Copy No per 
20μl:
MDM2 10 -1 1.6 1.6E+10
Stock Conc: 31ng/ul 1.60E+11 10 -2 0.16 1.6E+09
Amplicon size: 180bp 10 -3 0.016 1.6E+08
10 -4 0.0016 1.6E+07
10 -5 0.00016 1.6E+06
10 -6 0.000016 1.6E+05
10 -7 0.0000016 1.6E+04
10 -8 0.00000016 1.6E+03
10 -9 0.000000016 1.6E+02
10 -10 0.0000000016 1.6E+01
Gene
Total Copy (per 
20μl) Sample dil Conc [ng/ μl]
Copy No per 
20μl:
SSu72 10 -1 6.6 6.1E+10
Stock Conc: 66ng/ul 6.11E+11 10 -2 0.66 6.1E+09
Amplicon size: 100bp 10 -3 0.066 6.1E+08
10 -4 0.0066 6.1E+07
10 -5 0.00066 6.1E+06
10 -6 0.000066 6.1E+05
10 -7 0.0000066 6.1E+04
10 -8 0.00000067 6.1E+03
10 -9 0.000000067 6.1E+02
10 -10 0.0000000067 6.1E+01
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Figure 3.1.4.5: Standard curve values and plot for absolute copy number calculation for 
three genes [Cirbp, SSu72 and MDM2] out of the nine tested. Triplicates of each 10
5
 to 
10
10
 serial standard dilution used. A slope of -3.3 indicates a PCR efficiency = 100%. 
Generally 3.3 ±0.15 is considered acceptable for quantification purposes. 
 
Standard curves were generated by including triplicate standards (10
5
 to 10
10
) onto the 
same qPCR reaction plate as the sampleset RNAs which had been reverse transcribed 
previously (Figure 3.1.4.5).  
All 3 standard curve slopes in this case are within acceptable limits and the R
2
 values are 
relatively linear for all 3 across the concentration range also (all above 0.99). The standard 
triplicates used only ranged from 10
5
 to 10
10
, this was optimised to this range as lower than 
a 10
5
 dilution was shown to be too concentrated and led to inaccurate cycle threshold (Ct) 
readings of less than 12. 
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Next we wanted to investigate the copy number per 20ng of RNA per sample for each of 
the three priority genes between 37
o
C and 31
o
C samples from the RNA sampleset, denoted 
by the sample IDs. We performed qRT-PCR to get Ct values for each sample tested. The 
samples were grouped together based on original culture temperature from table 3.1.4.1.  
In all 3 cases the 31
o
C samples all have substantially more mRNA transcript copy numbers 
(Figure 3.1.4.6). MDM2 had much higher Ct values overall and therefore a much lower 
copy number range, all under 250 copies, than Cirbp and SSu72. However, the 37
o
C 
sample copy numbers were all calculated to be comparable being between 50 and 150 
copies for each gene. 
No obvious trend was seen from the analysis; however some interesting results were 
observed, for example; for all 3 genes, the 336 (5 days in culture) and 442 (10 days in 
culture) samples both being cultured at 31
o
C, showed that 442 samples had lower copy 
numbers overall compared to 336 samples.  
Furthermore, the 294 samples (also at 31
o
C) had more copy numbers than both 336 and 442 
samples, the only difference being that the 294 samples were only in culture for 3 days 
(Figure 3.1.4.6). This would indicate that as time in culture progressed, each genes mRNA 
levels decreased at 31
o
C; perhaps indicating that mRNA was degraded to some extent. This 
was encouraging because generally it is accepted that at 31
o
C transcripts can become more 
stable, and if this was the case here, then these target genes and their putative promoters 
would not be suitable for use as inducible transgene expression tools.  
This was further addressed in section 3.1.5. 
 
140 
 
 
Figure 3.1.4.6: Absolute copy number values for 3 priority genes measured by qRT-PCR 
per 20ng of RNA, across the sampleset panel. Sample ID labels represent the IDs from 
Table 3.1.4.1 and were grouped into 37
o
C and 31
o
C. Copy numbers were calculated from 
the triplicate average CT values.  
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3.1.5: Investigation of promoter activity versus transcript stability 
Having verified the microarray data for our genes of interest by qPCR, we wished to 
establish whether the change in the quantities of mRNA observed in each case was due to 
high transcriptional turnover of the mRNA (desirable) or if the mRNA of that particular 
gene was just highly stable (undesirable).  
In order to test this, cells were cultured at 37
o
C and 31
o
C in the presence or absence of 
actinomycin D (a transcriptional inhibitor) and total RNA was extracted at various 
timepoints. Transcripts exhibiting greater stability (half-life) would be expected to be 
detectable at higher levels by qPCR than more labile mRNAs post-actinomycin D 
treatment. 
Table 3.1.5.1: CHO-K1 cells cultured at 37
o
C and 31
o
C were treated with a 5mM 
concentration of actinomycin D. RNA was extracted after time (T) 0, 12 and 24 hours, 
reverse transcribed and the average CT results for the 3 respective genes were calculated by 
qRT-PCR. The copy number for each gene was calculated from the logarithmic (ln) 
standard curve. The % copy number values relative to the T0 values were also shown. 
 
Time Gene Avg CT Ln Copy No Copy No % of T0
37 T0 Cirbp 22.6 9.6031 14811 1.0
T12 Cirbp 24.3 8.2930 3996 27.0
T24 Cirbp 29.6 4.2221 68 0.5
31 T0 Cirbp 23.3 9.0821 8796 1.0
T12 Cirbp 23.4 9.0438 8466 96.2
T24 Cirbp 28.8 4.8478 127 1.4
Time Gene Avg CT Ln Copy No Copy No % of T0
37 T0 MDM2 29.8 3.1309 23 1.0
T12 MDM2 31.7 1.7731 6 25.7
T24 MDM2 32.7 1.0747 3 49.7
31 T0 MDM2 30.2 2.8452 17 1.0
T12 MDM2 32.4 1.2750 4 20.8
T24 MDM2 32.6 1.1260 3 86.2
Time Gene Avg CT Ln Copy No Copy No % of T0
37 T0 SSu72 22.1 10.6926 44031 1.0
T12 SSu72 24.0 9.2266 10164 23.1
T24 SSu72 30.9 3.8922 49 0.5
31 T0 SSu72 24.8 8.6273 5582 1.0
T12 SSu72 24.8 8.6016 5440 97.5
T24 SSu72 29.0 5.3814 217 4.0
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Figure 3.1.5.1: Absolute mRNA transcript copy numbers calculated for the 3 genes in 
CHO-K1 cells grown at 37
o
C (A) and 31
o
C (B). Copy numbers after ActD treatment (T24) 
versus no treatment control (T0) as determined from a standard curve. Copy number 
calculated as per 100ng of RNA, reverse transcribed to cDNA. Also shown is the fold 
change [x] between pre and post-ActD treatment. (C) Dissociation/melt curves for each 
gene qPCR amplicon is under its corresponding bar graph.  
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SSu72 was found to be the most abundant transcript at 37
o
C and Cirbp the most abundant 
at 31
o
C, while MDM2 was the least for both temperatures (Figure 3.1.5.1 A+B).  The fact 
that Cirbp was the most abundant transcript detected at 31
o
C was not surprising based on it 
being a well characterised cold-shock protein (CSP) and becomes up-regulated at lower 
culture temperatures. 
The cycle thresholds increase over time in the presence of ActD for each gene, so fewer 
transcripts are detected indicating that treatment was effective (Table 3.1.5.1A+B). 
Additionally, to optimise the concentration of actinomycin D to use, we assessed 3 
concentrations. We added [0-2-5mg/ml] ActD after 0, 12 and 24 hours in comparison to 
PBS/DMSO control samples (No treatment) also after 0, 12 and 24 hours. It was deduced 
that 2mg/ml of ActD was less inhibitory than the 5mg/ml concentration; therefore 5mg/ml 
was used in this experiment (data not shown).  
After calculating the copy number, the biggest differential was seen in the SSu72 samples. 
This would suggest that the SSu72 transcripts were less stable than Cirbp and that MDM2 
transcripts were the most stable. Finally the dissociation curves demonstrated specific 
amplification of the target; a single peak was indicative of a single product and thus no 
contamination during amplification steps (Figure 3.1.5.1 C).  
Note: The absolute mRNA copy number values shown in figure 3.1.5.1 were markedly 
more abundant than mRNA values seen in figure 3.1.4.1. We were unsure as to why this 
was observed, one possible reason is the fact that the RNA samples were archival from >6 
years and although we showed them to be relatively undegraded maybe less RNA was 
subjected to qRT-PCR analysis. In addition, we used a higher concentration of starting 
RNA (100ng) per sample compared to 20ng in the initial qRT-PCR validation. 
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Another point to consider was the ½ life of each transcript. Regulation of mRNA turnover 
in the cytoplasm is important for controlling the abundance of cellular transcripts and, in 
turn, the levels of protein expression (Ross 1995) (Parker and Song 2004) (Wilusz, 
Wormington and Peltz 2001). In mammalian cells, the first major step that triggers mRNA 
decay is deadenylation (i.e. removal of the 3′-poly(A) tail) (Chen et al. 2008).  
So by estimating the mRNA decay (Figure 3.1.5.2), for the purpose of further assurance 
that my gene promoters have a prominent decay rate, signifying that they are 
transcriptionally active rather than transcriptionally stable (Harrold et al. 1991). 
To determine the decay rate (–k) in hour-1 and subsequent half-life (t1/2) of the transcripts 
between no treatment controls and actinomycin D treatment at each timepoint the following 
formulas were used as described by (Chen, Ezzeddine and Shyu 2008);  
 
 
 
The turnover rate or stability of mRNA in vivo is usually reported as the time required to 
degrade by 50% of the original amount of mRNA molecules (i.e., the half-life of mRNAs). 
Additionally, it is important to note that the half-life of an mRNA (t1/2) is inversely 
proportional to its decay rate constant (kdecay), while the minus symbol indicates that the 
mRNA is being degraded rather than synthesized. 
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Figure 3.1.5.2: Copy numbers of each gene in order to compare decay (red lines) between 
times 0 (T0) and 24 hours later (T24) for 37
o
C (◊) and 31oC (◊). The 12 hour timepoint was 
disregarded for decay and half-life determination.  
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Figure 3.1.5.2 showed that there was a more appreciable change in copy number after 24 
hours than 12 hours after treatment with ActD. For this reason, we calculated decay rates 
based on differences between copy numbers at time zero (T0) and 24 hours (T24) for both 
temperatures (Table 3.1.5.2). 
 
Table 3.1.5.2: Decay rates and half-life (T1/2) of gene transcripts between 2 timepoints; 
Time 0 and Time 24, post-actinomycin D treatment of CHO-K1 cells. Values calculated 
from Figure 3.1.5.2 results.  
 
 
The decay rate was lower and mRNA half-life was higher at 31
o
C in all cases (Table 
3.5.1.2). Cirbp decay and stability appeared to be relative constant with only a marginal 
decrease in decay rate and as a result a marginal increase in mRNA half-life. Al-Fageeh and 
Smales also reported similar results for various Cirbp 5’ UTR leader sequences from NIH-
3T3 mouse cells. They showed that although Cirbp mRNA stability was increased at 31
o
C, 
half-life of 13.9 hr at 37
o
C versus 15 hr at 31
o
C, it was marginal compared to a beta-actin 
control which had a more substantial difference between 37
o
C (10.4 hr) and 31
o
C (15.8 hr) 
(Al-Fageeh and Smales 2009).  
MDM2 mirrored this observation; however the mRNA levels were much lower overall, 
based on higher CTs and it doesn’t appear to be as highly expressed in CHO-K1 cells at 
37
o
C or 31
o
C, unlike Cirbp and SSu72. SSu72 was a little over twice as stable at 31
o
C as at 
37
o
C, based on the decay rate being 2.44 hr
-1
 at 37
o
C and 5.12 hr
-1
 at 31
o
C. This could 
perhaps contribute partly to higher SSu72 mRNA detection from the original microarray 
profiling, but as it is known that at lower culture temperature mRNA transcripts do become 
more stable so this was not unexpected. 
 
37 31
Time (kdecay) h -1 t 1/2 Time (kdecay) h -1 t 1/2
Cirbp 24h-0h -0.2243 3.09 hr Cirbp 24h-0h -0.1761 3.97 hr
MdM2 24h-0h -0.0846 8.19 hr MdM2 24h-0h -0.0722 9.60 hr
SSu72 24h-0h -0.2833 2.44 hr SSu72 24h-0h -0.1353 5.12 hr
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In conclusion, the gene promoter targets identified and prioritised in this project are indeed 
promising candidates to drive temperature dependant gene expression. The most 
transcriptionally active gene appears to be SSu72, with post-actinomycin D treatment 
indicating high turnover rate and least stability. By calculating the copy number at the 
mRNA level, it would appear that the promoters of these genes were highly active. 
 
3.1.6: In silico identification of promoter sequences 
At the beginning of my project, the Chinese Hamster genome was not fully sequenced so 
laborious cross-species alignments between mouse, human and rat were used, until (Xu et 
al. 2011) published a draft of the genome in 2011 and generously uploaded it onto the 
GenBank public database. 
Having established that the higher mRNA levels of the target genes seen at 31
o
C were not 
due to excessive RNA stability, we progressed them for promoter cloning to test their 
utility. Before the CHO genomic sequence became publicly available in 2011, it was 
difficult to identify the putative promoter sequences upstream of the gene targets. Therefore 
the initial part of this project involved designing primers based on conserved regions 
between human/mouse and rat genomic sequence (Figure 3.1.8.1). 
The first step was to extract the correct CHO gene-coding sequence from the database at 
http://www.chogenome.org/. By first obtaining the mouse/rat ortholog coding sequence 
(CDS) for each gene in the list, then by using ‘BLAST’ (Basic Local Alignment Search 
Tool) as an algorithm for comparing primary biological sequence information, the 
sequences could be extrapolated from the CHO sequence information stored in assembly 
scaffolds and contigs within the database based on evolutionary conservation between these 
species. 
Using multiple sequence alignment software tools (Tcoffee and ClustalW) we were able to 
pinpoint the ATG start site, and from this point upstream obtain the putative CHO promoter 
regions for each target gene. Furthermore, although invaluable for this project to progress, 
the CHO draft sequences published by Xu et al had only arranged the sequences in 
scaffolds and contigs in FASTA format and were poorly annotated making extracting 
sequences difficult.  
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Because of this, even when the start codon (ATG) for each gene was located within a 
scaffold, sometimes the scaffold only contained a couple of hundred bases upstream before 
encountering the end of the scaffold. Both the MDM2 and miR-17-92 promoter cloning 
were affected in this way, making it challenging to design appropriate primers to amplify 
longer stretches of putative promoter sequence. 
 
3.1.7: Workflow of Isolation and Cloning of Gene Promoters 
The schematic in figure 3.1.7.1 represents a step by step workflow of how these promoter 
constructs were isolated and cloned into vectors to test their activity.  
To make this undertaking more manageable, the top three temperature sensitive genes from 
table 3.1.2.1 were chosen for further study. We focused on Cirbp, SSu72, MDM2 due to 
being up-regulated at 31
o
C and PPID, Nars and HNRPa2b1 for being down-regulated at 
31
o
C and finally *AUP1, PPIA, UBA52 and miR-17-92 cluster for showing constitutive 
expression across the array data.  
Note: *AUP1 was identified in the early part of this project as a target for constitutive 
expression based on least variance across the dataset. However after re-analysis of the mean 
expression values, where the mean fluorescence signal was found to be very low across the 
probe set when checked against the list generated in table 3.1.2.3 and was deemed not to be 
strong enough to drive transgene expression and excluded from this point on. 
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Figure 3.1.7.1: Experimental workflow for promoter cloning and functional assessment. [A] Performing BLAST on input sequence (ATG+ 
sequence for given gene) on whole genome shotgun (WGS) database from www.chogenome.org. [B] Cross-species alignments of CHO, 
mouse and rat using ClustalW® software suite to delineate the ATG start site. [C] Design of multiple forward primers and generally one 
reverse primer for cloning (with res sites) based on sequences analysis and conservation between rat, human and mouse. [D] Post-
transfection we conducted reporter assays to test activity of promoter fragments to drive transgene expression (for example; GFP and 
Luciferase). 
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3.1.8: Primer Design 
Having obtained the CHO specific sequence, next primers were designed to extract the 
putative promoter upstream of these genes by identifying regions of sequence conservation 
across mouse, rat and human orthologues.  
Note: Before the CHO sequence became available the project began with designing and 
screening mouse-specific primers against CHO genomic DNA. This proved futile for 
amplifying CHO promoter sequence; however by isolating the mouse sequences we 
obtained promoters capable of driving transgene expression as a back-up to the CHO 
promoters. This was based on the assumption that promoter sequences from another rodent 
species would be active in CHO cells if the endogenous CHO sequences were too difficult 
to obtain. Primer design across species was reliant on sequence conservation like the 
example shown in figure 3.1.8.1.  
The reverse primer was designed to bind upstream of the gene start codon [ATG] and a 
series of forward primers were designed to create a panel of progressive truncated promoter 
fragments for each prioritised gene. However, not all gene primers were shown in figure 
3.1.8.2, owing to cloning issues explained in later sections. 
 
 
Figure 3.1.8.1: Cross-species alignments between mouse, rat, and human to design CHO-
specific primer sequences for the target genes (forward and revere primers for the Cirbp 
gene shown for illustration purposes). The principle being, that if the primers were 
designed in highly conserved regions, then there was a high chance the primer would 
facilitate PCR amplification and extraction from CHO and mouse gDNA templates. 
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Figure 3.1.8.2: Primer maps designed for isolation of a panel of varying lengths of 
promoter regions upstream of each prioritised CHO gene. Also shown were the sizing and 
nucleotide positions. MDM2, SSu72 and Cirbp were categorised into inducible and the 
miR-17-92 cluster was categorised as constitutive. (Cirbp m) denotes the mouse version 
while (Cirbp C) denotes the CHO version.   
 
The 3 most promising gene promoters regarding temperature inducible differential 
expression (MDM2, SSu72 and Cirbp) can be seen here along with the truncated promoter 
primers for the Cirbp mouse orthologue control gene. The miR-17-92 mouse and CHO 
constructs were included with these prioritised gene promoters for further study as a 
comparison while the CHO-promoter sequence of this cluster is more novel.  
Mouse primers for all genes from the list were also designed as a backup if isolating the 
CHO sequences proved problematic (Appendices section 6.2.1), but were not included in 
figure 3.1.8.1, as they ultimately were not cloned due to the CHO isolation being 
successful. 
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3.1.9: Promoter amplification and isolation 
Having now generated a panel of primers for cloning, the next step was isolating the 
sequences upstream of each genes ATG start site from genomic DNA extracted from 
mouse and CHO cells. For the PCR template, total genomic DNA was extracted from 
CHO-K1 and mouse (min-6) cell pellets using the Promega Wizard® extraction kit. 
Post-extraction we wanted to check this DNA template to see if it was suitable and not 
degraded in order to proceed to PCR. Agarose gel electrophoresis using a low percentage 
gel (0.6%) was performed to visualise the quality of the high molecular weight gDNA 
(Figure 3.1.9.1) and the gDNA band was estimated to be approximately 23kb. This was 
followed by NanoDrop™ results to check DNA integrity, a 260/280 ratio = 1.8 – 2.0 was 
indicative of high-quality DNA. Genomic DNA that would be considered unusable would 
be indicated by a large smear in the gel lanes, and if it was sheared then bands less than 
12kb would be apparent. 
 
Figure 3.1.9.1: Quality checks of the different extracted mammalian genomic DNA used 
over the project. L = Ladder. Human SNB-19 gDNA (wells 1, 2), CHO-K1 gDNA (wells 3, 
4), CHO-K1-SEAP (well 5), min-6/murine gDNA (wells 6, 7).  
 
Having identified suitable template for mouse and CHO, next we wanted to isolate the 
various sizes of each genes promoter sequence by using the primers designed from figure 
3.1.8.2 and polymerase chain reaction (PCR). 0.8-1.2% agarose gels were run to identify 
the various sizes of fragment generated from PCR. As a representative example, MDM2-
specific primers were used to amplify products so they could be extracted using gel 
extraction kit and purified for downstream cloning (Figure 3.1.9.2). 
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Figure 3.1.9.2: Amplification and isolation of MDM2 promoter fragments via PCR using 
the designed primer sets. Band sizes were 4562bp, 3000bp, 2708bp, 1400bp and 370bp and 
matched primer maps and sizing shown in figure 3.1.8.1. 
 
 
Upon completion, several upstream promoter fragments were successfully amplified from 
CHO and mouse gDNA templates (Table 3.1.9.3). Ideally ~300-5000bp upstream was 
considered a good starting point to test regulatory regions. 
 
Table 3.1.9.3: Library of isolated putative promoter fragments specific to mouse and CHO 
amplified by PCR with amplicon size in base pairs. N/A denotes no achievable promoter 
fragments isolated for that target gene.  
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As mentioned briefly, halfway through the project our focus switched from mouse 
extraction to CHO once it was possible to obtain the CHO draft sequence from Genbank. 
As a result mouse experiments were sidelined to concentrate on extracting the CHO 
specific fragments (Table 3.1.9.3) and hence why there were numerically more CHO 
fragments isolated.  
Having now created a library of various promoter fragments, we decided to screen them 
initially using a GFP-reporter to see if they could drive detectable GFP expression (Table 
3.1.11). 
 
3.1.10: Cloning into Expression Vectors Design/Manipulation 
The promoter fragments isolated from table 3.9.1.3 were cloned using a pEGFP-C1 plasmid 
from Clontech Laboratories, Inc (USA) and a pGL3 Luciferase plasmid from Promega 
(USA) (Figure 3.1.10.1).  The CMV promoter was first removed from pEGFP-C1 to allow 
insertion of a synthetic linker (Figure 3.1.10.2), which in turn allowed cloning of the 
isolated promoter fragments (containing restriction sites from the primer design) upstream 
of the GFP-reporter gene. 
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Figure 3.1.10.1: Illustrated are the two reporter vectors used to test the activity of the 
isolated promoters (by driving a reporter gene). An enhanced GFP (pEGFP-C1) was altered 
to generate (pEGFP-altAL) containing a linker (synthetic MCS) and was placed upstream 
of a GFP gene. Additionally, a polyA tail termination sequence was included upstream of 
the promoter. Also shown was the commercially available Luciferase (pGL3-Basic) which 
did not undergo any alterations. 
 
 
Figure 3.1.10.2: Illustration of synthetic ‘linker’ sequence containing multiple cloning sites 
was designed based on the MCS from pGL3-basic vector to complement the design of the 
cloning primers. Contained within the linker, was a Nhe1 restriction site. It was altered so 
as not to have two sites that might impede cloning, as a Nhe1 was already present upstream 
of the GFP gene. AseI and NheI (pink) sites flank the linker which allowed an insertion 
point for the linker into the pEGFP-C1 vector. 
 
156 
 
Some restriction sites existed twice as a result of linker insertion, so further digestion by 
BamHI and BspEI restriction enzymes removed the downstream multiple cloning site 
(MCS) and klenow treatment was used to blunt and re-ligate the plasmid backbone.  
Additionally, to finalise the pEGFP vector for reporter work, a poly-A termination 
sequence was inserted upstream of the linker site to ensure background expression was 
quenched. First the poly-A sequence from the pGL3-basic was amplified by PCR and 
isolated. Then it was cloned with the following primers containing AseI and Acc65i 
restriction sites; 
5’- ggccattaatAAGGTACGGGAGGTACTTGG – 3’ Forward (Ase1 @ +4629bp from ATG) 
5’ – atatggtaccTTACCAACAGTACCGGAATGC – 3’ Reverse (Acc65i @ -55bp from ATG)       
 
 
Figure 3.1.10.3:  (A) Poly-A PCR gel electrophoresis result using the above primers at 
55
o
C and 60
o
C annealing temperatures, followed by ligation into pEGFP with digestion 
verification using Ase1 + Acc65i restriction enzymes. (B) Sequencing result aligned 
against original pEGFP-C1 vector backbone sequence using ClustalW software, 
highlighting the inserted poly-A, denoted in red.  
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In addition to these two reporter vectors, we wanted to construct two more vectors to 
compliment the promoter findings with GFP and Luciferase. Erythropoietin/EPO (34kDa) 
is a glycoprotein hormone that controls erythropoiesis and it is a well established 
recombinant protein that is commercially produced. 
We also chose to test a cyclin-dependent kinase inhibitor 1B (p27) a cell cycle inhibitor 
protein. In humans it is encoded by the CDKN1B gene. The encoded protein binds to and 
prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls 
cell cycle progression at G1. It is often referred to as a cell cycle inhibitor protein because 
its major function is to stop or slow down cell division.  
p27 and EPO coding sequences were amplified and isolated from in-house vectors and 
cloned into the pEGFP-altAL vector, to replace the GFP sequence previously cloned. 
Primers were designed using the following primer sets detailing the melting temperature 
(Tm), GC % content and nucleotide length (nt);  
 
p27 [597bp] 
  
Tm % GC nt 
For aatagctagcATGTCAAACGTACGAGTATCTAAC 60.3 38 24 
Rev aataggatccTTACGTCTGGTGTCTTCGGAG 61.2 52 21 
       EPO [585bp] 
  
Tm % GC nt 
For aatagctagcATGGGGGTGCACGAATGTC  59.5 58 19 
Rev aataggatccTCATCTGTCCCCTGTCCTG 59.5 60 19 
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Figure 3.1.10.4: Vector map detailing the creation of p27 and EPO vectors. The GFP gene 
was removed from pEGFP-altAL using NheI and BamHI and replaced by either the EPO or 
p27 CDS. In parallel, EPO and p27 primers were designed to clone out the EPO and p27 
CDS (585bp + 597bp respectively) from in-house vectors containing each gene. 
 
In summary, we successfully constructed a GFP and reporter vector (pEGFP-altAL) with a 
MCS and poly-A termination sequence to be utilised in promoter studies. EPO is an 
example of a protein product, while p27 is an example of an engineering target, both of 
which may benefit under temporal expression control from potential promoter sequences, 
which was next to be examined.  
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3.1.11: Promoter fragments - Initial expression screen 
The next step was to examine these promoter fragments by cloning into the pEGFP-altAL 
vector in order to test GFP transgene expression. Rather than progressing with ligations for 
all promoter fragments generated from the previous section into all four vectors, we used 
the pEGFP-altAL reporter vector to initially screen the fragments from table 3.1.9.3. This 
initial screen was used to identify gene promoter fragments which would be suitable 
candidates for further testing and cloning into the other reporter vectors. 
CHO-K1 cells were transfected in triplicate in 24-well format and GFP fluorescence 
measured 24-hours later, quantitatively on the Guava™ flow cytometry system and 
qualitatively using the Leica® fluorescent microscope. Four promoters, Cirbp, MDM2, 
SSu72 and miR-17-92, exhibited moderate to strong GFP expression when tested and 
followed the expected expression trend (Table 3.1.11). 
This large panel screen gave us an insight to the initial expression behavior of the various 
isolated gene promoters and was a good starting point for further study. Additionally, it 
may also serve as a guide in future promoter studies, as to progress with all fragments was 
not a viable option. Full GFP expression quantification is reported in section 3.2.2. 
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Table 3.1.11: Initial mouse and CHO promoter fragment panel screen. Summary of GFP expression (exp) reporter results, expected and 
observed effects, and fragment sizing ligated into pEGFP-altAL designed vector. N/A denotes not applicable due to no cloning. (+) denotes 
GFP strength with (+++) being strongest, (-) denotes no detectable expression.  
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After screening all gene promoters of various sizes, efforts became focused on 6 promoter 
fragments of interest from 4 gene sources [MDM2, SSu72, Cirbp, miR-17-92]. These were 
categorised into 4 inducible promoters, three being novel to CHO (MDM2, SSu72 and 
Cirbp) while a Cirbp-promoter from mouse was used as a control sequence as it was shown 
to be temperature inducible in previous studies. Additionally, 2 constitutive promoter 
fragments from the miR-17-92 cluster were included (one for CHO and one for mouse).  
We were disappointed that initial GFP reporter results showed no detectable expression 
from the other constitutive promoters investigated, namely UBA52 and PPIA which 
showed substantial expression from the array data (Table 3.1.2.3). We hypothesised that 
perhaps essential promoter and indeed any temperature sensitive sequence was located 
further upstream and thus not contained within the isolated fragments.  
Note: For these reasons, the fragment mapping seen in figure 3.1.8.2 contains all 6 of these 
promoters as representative of entire screen. 
There were no similar promoter studies found in the literature based on these four 
promoters in CHO, while only Cirbp has been explored in murine models (Al-Fageeh and 
Smales 2009). The miR-17-92 cluster was explored in various human models (Hayashita et 
al. 2005) (Lu et al. 2007) (Ji et al. 2011), however, the promoter was not. 
In conclusion, 6 promoter fragments from 3 different target genes plus one miRNA cluster 
were successfully identified and cloned. These promoter fragments were subsequently 
chosen for progression to further promoter studies using the 3 additional vectors described 
previously. The mouse equivalent promoter fragments were not pursued, only the Cirbp and 
miR-17-92 cluster mouse promoter fragments were progressed in tandem with their CHO 
orthologues. Furthermore, the miR-17-92 promoter fragments were included due to their 
novelty in CHO. 
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3.2: Driving reporter-gene expression in a temperature-dependant manner 
3.2.1: Introduction 
All promoter constructs were cloned into the respective vectors as described in section 
3.1.10. Some larger fragments were problematic to clone and coupled with the shorter 
sequences portraying good expression characteristics, shorter fragments were prioritised as 
being more attractive as regulatory tools. For this reason, the decision to halt further 
analysis of the larger variants was taken. 
As a result the following promoter fragments were utilised from this point onward; 828bp 
CHO Cirbp, 370bp MDM2 and 654bp SSu72 fragment sizes were chosen based on having 
a favourable size as well as being capable of high GFP expression. Additionally, an 889bp 
mouse promoter fragment from Cirbp was included in all experiments, this fragment can be 
viewed as a temperature-sensitive control based on previous reports and being the most 
correlated between 37
o
C and 31
o
C from microarray profiling. In addition, it was used as a 
comparison for the Cirbp-CHO fragment which has not been investigated for temperature 
induciblity before and holds novelty compared to mouse Cirbp, which have been reported 
(Al-Fageeh and Smales 2009) (Sumitomo et al. 2012).  
Furthermore, by including the mouse and CHO versions of Cirbp in all reporter 
experiments served two purposes, firstly it provided a control comparison for temperature 
induciblity for all other promoters and secondly to examine any potential differences 
between mouse and CHO, for which no reports currently exist for the latter in the literature.  
In conclusion, promoter choice influences the efficacy of specific gene expression, as does 
the cell type (Spenger et al. 2004). So ultimately the aim was to provide a complete 
representation of expression levels of these putative promoter fragments across all 4 
reporter vector platforms to investigate the candidate promoters’ utility in driving transgene 
expression. 
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3.2.2: GFP-reporter expression results 
Firstly, we wanted to investigate these constructs both qualitatively and quantitatively. 
Using a combination of microscopy and flow cytometry to detect GFP expression resulting 
from a GFP reporter vector driven by these isolated promoter sequences. CHO-K1 cells 
were transiently transfected with the 8 GFP-promoter constructs and cells grown at 37
o
C or 
31
o
C in parallel. GFP mean expression was typically measured 24-48 hours post-
transfection using the Guava™ flow cytometry modus operandi. For qualitative analysis, 
GFP fluorescence images were also taken using the Leica® Fluorescent microscope at 37
o
C 
and 31
o
C for comparison (Figure 3.2.2.1).  
The GFP expression results (pEGFP-altAL + 8 promoter fragments), included the inducible 
promoter constructs (Cirbp-mouse and CHO, SSu72 and MDM2) along with the miR-17-92 
promoter constructs from mouse and CHO. A positive control (CMV) vector, a 
promoterless negative control (pTATA (-)) plus the endogenous comparison control (Cirbp-
mouse) were also included (Figure 3.2.2.1). 
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Figure 3.2.2.1: GFP fluorescence of CHO-K1 cells transfected with 8 GFP-promoter 
[pEGFP-altAL+ promoter] constructs. Cells were grown in 6-well plate format and 
incubated at 37
o
C and 31
o
C. Images were taken using the Leica® Fluorescent microscope 
36 hours post-transfection.  
 
All novel CHO promoters (MDM2, SSu72 and Cirbp) gave an indication of being 
temperature sensitive promoters. Post-transfection into CHO cells, all 3 CHO promoters’ 
showed increased GFP expression based on fluorescence intensity upon temp shift to 31
o
C 
from 37
o
C. The p-TATA (-) promoterless control showed basal level GFP intensity 
compared to all other constructs as expected. 
The Cirbp-mouse promoter appeared to have noticeably increased GFP fluorescence at 
31
o
C compared to 37
o
C, indicating an increase in GFP expression owing to reduced culture 
temperature as expected of this comparison control construct.  
Interestingly, the CMV promoter control also exhibited an increase upon temperature shift, 
which was unexpected and this observation will be discussed further in section 3.2.4. 
MDM2 showed much lower GFP expression at 37
o
C which complies with the native 
expression levels seen from the qPCR validation (Figure 3.1.4.6), however, expression 
noticeably increases at 31
o
C.  
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Cells transfected with the SSu72 promoter construct showed a moderate GFP expression 
increase upon 31
o
C temperature shift and also had higher GFP intensity than MDM2 at 
37
o
C, and SSu72 seemed to drive GFP expression strongly at both temperatures. Cells 
transfected with the Cirbp-CHO promoter performed as expected relative to Cirbp-mouse 
control, displaying increased GFP expression at 31
o
C.  
Cells transfected with the miR-17-92 constitutive promoter constructs displayed lower GFP 
expression than expected considering it is acknowledged as a highly expressed cluster. In 
fact, increased saturation gain on the images for miR-17-92 samples was required to 
visualise positive GFP expressing cells (Figure 3.2.2.1). 
Next the cells were analysed by flow cytometry in order to more accurately quantify the 
levels of fluorescence from each promoter construct transfected into CHO-K1 cells and 
tested at 37
o
C and 31
o
C again (Figure 3.2.2.2).  
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Figure 3.2.2.2: Average GFP mean fluorescence values of cell populations’ transfected 
with promoter-pEGFP-altAL constructs. After transfection in 24-well plates, cells were 
incubated at 37 and 31
o
C (shifted after 6-8 hours) and measured for GFP activity 24-48 
hours later. Error bars represent standard deviation (± SD) between biological triplicates of 
samples taken at both temperatures. The fold changes (x) represent 37v31 values to show 
relative expression change for each promoter. * represents statistical significance p-value 
<0.05, ** p-value<0.01, *** p-value<0.001, determined by a 2 tailed students T-Test 
between both sets of triplicate samples for both temperatures. (n = 9). 
 
Figure 3.2.2.2 illustrates the strength of each promoter construct at each temperature plus 
the fold change between those temperatures - indicative of temperature induciblity. MDM2 
had the biggest fold change (3.77x) followed by CMV (3.25x). With the expectancy that 
the inducible promoter constructs tested should portray a high fold change between 
temperatures, it was unexpected that the CMV-promoter displayed such temperature 
responsive expression also. Although the GFP expression of the Cirbp constructs for mouse 
and CHO mirrored each other, the CHO version showed higher GFP expression at both 
temperatures; however a slightly lower fold change of 2.79x was calculated.  
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The SSu72 construct, despite having the lowest fold change of 2.46x, drove higher GFP 
expression at both temperatures than MDM2, but lower than both Cirbp constructs and the 
CMV control. The CMV promoter drove strong GFP expression as expected and was 
marginally the best performing construct and had a mean fluorescence of ~350. The 
pTATA (-) control had very low GFP expression as expected with a fold change of 1.13x 
representing the basal/background level of GFP expression by the promoterless vector 
backbone. 
The miR-17-92 cluster promoters did not drive strong GFP expression, but was detectable 
nevertheless and resulted in higher GFP expression than the basal control pTATA (-). The 
CHO version did however show slightly higher GFP expression at 31
o
C; perhaps indicating 
it may not be constitutive regulatory sequence as expected, while the mouse version 
expression was unchanged based on an insignificant p-value. The low levels of GFP 
expression resulting from these 2 promoter fragments would suggest that crucial parts of 
the regulatory sequence may be missing. 
 
Figure 3.2.2.3: Relative GFP mean fluorescence values for all promoter constructs as a 
percentage compared to CMV-promoter control at each temperature. CMV activity was set 
to 100%. 
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Figure 3.2.2.3 illustrates the GFP expression differential between temperatures for all 
promoter constructs tested. Only the Cirbp–CHO construct had stronger expression strength 
relative to the CMV at 37
o
C, whereas the MDM2 construct has the lowest GFP expression 
at both temperatures but was very promising from a fold change viewpoint, while the 
activity relative to CMV was ~50% and ~48% for each temperature.  
The SSu72 promoter showed higher expression at both temperatures than MDM2 and had 
~75% activity relative to CMV at 37
o
C and ~45% at 31
o
C. The Cirbp-CHO promoter 
activity was ~103% and ~89% for 37
o
C and 31
o
C respectively and marginally out-
performed the Cirbp-mouse control which correlated with the observations from the 
microscope images (Figure 3.2.2.1). 
The miR-17-92 cluster promoters overall activity was much less than the 3 inducible 
promoters with activities between 20% and 10% relative to the CMV promoter. 
Nonetheless, these promoters could still have utility regarding control of lower transgene 
expression, as high constitutive expression is not always desirable and smaller incremental 
expression is needed depending on the transgene being expressed in a bioprocess. 
Finally, we repeated the same protocol but alternatively measured promoter activity using a 
second flow cytometer platform – a FACSAria™ from BD Biosciences (Figure 3.2.2.4). 
We used a second flow cytometry platform in order to compare GFP expression results 
between two separate technologies.  
The FACS is capable of detecting a much greater range of fluorescence intensity – several 
orders of magnitude greater than than the Guava. This analysis was performed to ensure we 
were not missing a population of cells with expression levels outside the range detectable 
on the Guava.  
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Figure 3.2.2.4: FACS results 36 hours post-transfection of 8 promoter constructs into attached 
CHO-K1 cells in 24-well format. Dotplots are shown in the left images below the label for 
each promoter construct with GFP+ cells gated using the software. This gate was further sub-
divided into mid to high FITC ranges as shown. On the X-axis is the GFP-FITC fluorescence 
and on the Y-axis is side-scatter (SSC) which is proportional to the granularity and overall 
size of the cells. Plots show the cell populations at both temperatures (37
o
C - top and 31
o
C - 
bottom). The left sector (black) indicates the non-florescent cell population. The far right 
sector displays the cells with highest GFP intensity (dark green). Cells transfected with the 
pTATA (-) and a cells only control were included as controls. 
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Once again, CHO-K1 cells were transfected with the 8 promoter constructs, cultured at 
either 37
o
C or 31
o
C and GFP fluorescence measured 36 hours later. In all cases, the GFP 
positive populations of cells were shifted to the right (more cells showing higher GFP 
fluorescence) upon temperature shift to 31
o
C (Figure 3.2.2.4).  
GFP intensity in all three low, mid and high sub-gate ranges increased at 31
o
C especially in 
the highest GFP intensity range (far right sector). The sector breakdown for medium and 
high GFP intensity plus the number of cells (#Events) in each of the gated populations can 
be seen in appendices 6.2.2.  
The CMV control GFP intensity increased at 31
o
C in each gate compared to 37
o
C, and also 
was the strongest promoter once again. Interestingly, the miR-17-92-mouse promoter 
showed markedly more GFP expression and there was an obvious increase in expression at 
31
o
C compared to 37
o
C. This would indicate that it is acting contrary to its expected 
constitutive nature. The miR-17-92-CHO counterpart showed expression levels equivalent 
to the pTATA (-) negative control.  
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Figure 3.2.2.5: FACS results for the GFP-promoter constructs transfected into CHO-K1 
cells showing mean fluorescence of GFP+ gated populations (from figure 3.2.2.4) assayed 
36 hours later. Shown as bar headers were the temperature shift fold change (x) values 
between 37
o
C and 31
o
C. Error bars represent standard deviation (± SD) between biological 
triplicates of samples taken at both temperatures. * represents statistical significance p-
value <0.05, ** p-value<0.01, *** p-value<0.001, determined by a 2 tailed students T-Test 
between both sets of triplicate samples for both temperatures.  
 
The CMV promoter once again drove the highest GFP expression (~72000) and a 5.44x 
fold increase upon temperature shift to 31
o
C. The mouse miR-17-92 promoter had stronger 
expression at both temperatures than the CHO version, however, unlike the analysis 
performed using the Guava®, in this case, the promoter resulted in >2-fold increased GFP 
expression at 31
o
C compared to 37
o
C. This is not dissimilar to the changes seen in the 
Cirbp promoters.  
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Figure 3.2.2.6: Median GFP expression values in transiently transfected CHO-K1 cells. 
Error bars represent standard deviation (± SD) between biological triplicates of samples 
taken at both temperatures. In the bar headers showed the temperature shift fold change (x) 
values between 37
o
C and 31
o
C. * represents statistical significance p-value <0.05, ** p-
value<0.01, *** p-value<0.001, determined by a 2 tailed students T-Test between both sets 
of triplicate samples for both temperatures. 
 
The median figures were calculated by measuring the GFP intensity of the highest 
expressing cells within the gated population and here it demonstrated a very similar pattern 
to the mean values reported in figure 3.2.2.5. However, discrete differences were seen 
between data sets, especially at a fold change level. MDM2, for example, was double 
[8.38x] that of SSu72 [4.34x], while Cirbp-mouse had a higher median than the Cirbp-CHO 
ortholog, meaning that although the average FITC signal might be high, the median showed 
that some cells were of a higher GFP intensity range. 
One of the most striking observations was the impact of temperature reduction on the 
activity of the CMV viral promoter. This will be addressed later in the section. 
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In conclusion, using GFP as a reporter gene, all of our novel isolated promoters can drive 
GFP expression albeit at various degrees of strength. MDM2, SSu72, miR-17-92-mouse, 
miR-17-92-CHO and Cirbp-CHO constructs all showed markedly increased fold changes 
due to temperature downshift (31
o
C) when compared to the strong CMV control and also 
compared favourably to the endogenous Cirbp-mouse control. Additionally, it was 
interesting to observe that the CHO version of Cirbp had marginally better expression than 
its mouse orthologue.  
 
3.2.3: Luciferase reporter expression results 
Having tested the various promoter fragments for their ability to drive GFP at 37
o
C and 
31
o
C we then switched vectors to investigate their activity in another reporter gene, 
Luciferase. 
The GFP assays didn’t account for variations in transfection efficiency between the various 
promoter constructs. Therefore, by incorporating a second vector and reporter gene, in this 
case, a Renilla Luciferase from the sea pansy ‘Renilla reniformis’ we now had a vector 
which could be included in every experiment as a normalisation control. This second vector 
was under the control of a CMV promoter and the resulting Luciferase signal from Renilla 
can then be used to account for small differences in transfection efficiency. 
It became apparent that the Renilla vector was also temperature sensitive, presumably 
owing to the fact that Renilla expression was under a similar CMV promoter control. 
Therefore, this observation highlighted that the vector would not be a suitable control for 
normalisation between samples. To rectify this we reverted to using a Bradford protein 
assay to calculate total protein concentrations per sample in order to normalise across all 
samples. The Luciferase results of transfections normalised in this manner are shown in 
figure 3.2.3.1.  
The positive control in this assay was a viral SV40 driven Luciferase (pGL3-Control), not a 
CMV as used in the GFP assays; finally a basic promoterless control (pGL3-basic) vector 
was used as a negative control. 
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Figure 3.2.3.1: Luciferase results for CHO-K1 cells grown in 24-well plates. Cells were 
transfected with pGL3-plasmids containing promoters of interest driving expression of 
Luciferase gene and relative Luciferase units were measured on a BioTek® Plate reader 48 
hours later. Included controls were a strong positive promoter (SV40) and a minimal-
TATA negative promoter (pGL3-basic). The bar headers represent the temperature shift 
fold change (x) values between 37
o
C and 31
o
C. Error bars represent standard deviation (± 
SD) between biological triplicates of samples taken at both temperatures. * represents 
statistical significance p-value <0.05, ** p-value<0.01, *** p-value<0.001, determined by a 
2 tailed students T-Test between both sets of triplicate samples for both temperatures. 
Luminescence (RLU) values were normalised to protein concentration measured using the 
Bradford assay.  
 
The first point to note is that, unlike the GFP experiments, the positive control construct 
using another viral promoter (SV40) was much less responsive to a temperature downshift. 
However, there was a significant increase (~1.5x) in expression, but it was much more 
modest than the CMV-driven control in the GFP assays seen previous. 
Interestingly, the miR-17-92-mouse promoter had the highest Luciferase expression at 
37
o
C, while the Cirbp-mouse control promoter drove the strongest expression at 31
o
C, out-
performing the CHO version in contrast to the GFP expression results. MDM2 had a 
markedly higher fold change of 41.62x in comparison to all other promoter constructs.  
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This large fold change was in contrast to the GFP results where it was only 3.77x higher at 
31
o
C (Figure 3.2.2.2). 
SSu72 had a more modest FC of 1.67x, however the promoter drove higher expression of 
Luciferase at both temperatures, similar to the SV40 control. The miR-17-92-CHO 
promoter displayed very low Luciferase expression, only slightly higher than the 
promoterless pGL3-basic control. 
 
Figure 3.2.3.2: Relative promoter activity results measured by the Luciferase reporter 
assay. Data represented as a relative % of SV40 viral promoter control for both 37
o
C and 
31
o
C temperatures. SV40 activity was set to 100%.  
 
Interestingly, the miR-17-92-mouse promoter out-performed all other constructs at 37
o
C 
being ~42% stronger than SV40, while the CHO version was relatively lower at ~23%. In 
comparisons to the SV40 control at each temperature, MDM2 and SSu72 showed 5% and 
99% activity at 37
o
C, but upon temperature shift this activity rose to 145% and 118% 
respectively. The MDM2 promoter demonstrated a large differential between 37
o
C and 
31
o
C, indicating the strongest temperature responsiveness which was quite striking. 
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In this assay the Cirbp-mouse promoter outperformed the CHO equivalent by 11.9% at 
37
o
C and 35.7% at 31
o
C, while both were more expressive than SV40 at 31
o
C by 113% and 
77% respectively which was very promising. MDM2 and SSu72 promoters although less 
active than the Cirbp-promoters, also seemed to be interesting candidates for future study as 
their expression results were on par with SV40. 
Furthermore, the SV40 control promoter did not illicit the same expression strength at 
either temperature compared to the CMV promoter used in the GFP experiments. In fact, 
the different results achieved using the two different reporter platforms highlight the 
importance of testing the activity of promoter sequences of interest in more than one 
experimental circumstance, in order to gain a complete picture of their transcriptional 
properties. 
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3.2.4: CMV and SV40: Poor viral controls  
Upon completion of the above two reporter platforms for target promoters, one concern was 
continuously raised over the results. Why do the CMV and SV40 promoters display 
inducible expression when it is commonly accepted that they are constitutive promoters? 
Having appropriate controls is important when conducting promoter studies; our results so 
far have demonstrated that these viral promoters were in fact not suitable controls in 
temperature shift promoter studies. CMV (also contained in commercial Renilla vector) and 
to a lesser extent SV40 promoters were all shown to be responsive to a low temperature 
culture shift.  
In fact, Bruening et al demonstrated that CMV promoters were upregulated in response to 
stress, and was induced from reduction in available nutrients, accumulation of metabolic 
by-products and of course reductions in culture temperature. They showed that reduced 
temperature culture of mouse NIH-3T3 cells caused up-regulation of the early CMV 
promoter (pCMV-lacZ) after transfection, and appeared to result in activation of the MAP 
kinase cascade pathway. They concluded that if the CMV promoter (or any viral promoter 
control) can be up-regulated by cellular stresses like cold shock, inadvertent activation of 
the stress kinase pathways may complicate, if not invalidate, the interpretation of a wide 
range of experiments (Bruening et al. 1998). 
More commonly, it is believed to be an innate immune response to combat pathogenicity, 
although the exact mechanism is unclear, by viral DNA in order to survive and remain 
quiescent within a host until conditions become more favourable, in this case lower 
environment temperature (Bruggeman et al. 1995).  
To test whether the CMV promoter was behaving as a temperature inducible promoter an 
experiment was designed to observe if the CMV-driven reporter gene expression increase at 
31
o
C was occurring due to the mRNA being more stable or more transcriptionally active at 
this temperature.  
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CHO-K1 cells were transfected with the CMV-GFP vector and either treated with 
actinomycin D or fresh culture media only, coupled with a temperature shift to 31
o
C to 
investigate the effects of 31
o
C on the mRNA transcript level. Cells were harvested 4, 14 
and 24 hours later and RNA was reverse transcribed and GFP mRNA levels quantified by 
qPCR. 
The copy number in a given sample was calculated from a standard curve (see appendices 
table 6.2.2.1) as described previously in section 3.1.4.  
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Figure 3.2.4.1: Calculation of the mRNA stability of a GFP reporter gene driven by the 
CMV-promoter. GFP transcript copy numbers were calculated after using RT-qPCR. A 
pEGFP vector driven by the CMV-promoter was transfected into CHO-K1 cells in 6-well 
plate format and grown over 24 hours with no treatment (A) or actinomycin D treatment 
(B) at 37
o
C or 31
o
C. Samples were taken at 4, 14 and 24 hours (h).   
 
Figure 3.2.4.1 A, illustrates the copy number of GFP transcripts over 24 hours at 37
o
C and 
31
o
C. A no treatment control was included as a guide to the performance of the CMV 
promoter to drive GFP expression over 3 timepoints at both temperatures.  
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More critically, we wanted to examine the drop in GFP transcript number post-actinomycin 
D treatment over the same time points and at both temperatures (Figure 3.2.4.1 B). 
In the untreated samples at 37
o
C, transcript copy numbers increased from 8.61x10
5
 at 4 
hours to 9.24x10
6
 after 24 hours while at 31
o
C copy numbers increased from 1.52x10
6
 at 4 
hours to 1.19x10
7
 after 24 hours (Figure 3.2.6.1 A). Interestingly, there was more GFP 
transcript measured at 14 hours compared to 24 hours at 31
o
C, which was unexpected. This 
could indicate that there is interplay between stability and transcript turnover yet to be fully 
understood between 14 and 24 hours at mild hypothermia and may be cell cycle related.   
There was some fluctuation in copy number over the 3 timepoints which was unexpected; 
however, Al-Fageeh and Smales also reported such anomalies between timepoints. They 
observed that between 2, 6 and 12 hours the transcript levels of mouse Cirbp mRNA 
transcripts varied significantly upon 31
o
C cold-shock with copy number being lower at 12 
hours compared to the copy number 6 hours previous (Al-Fageeh and Smales 2009).  
During the first 4 hours at 31
o
C, GFP transcript numbers were 2-fold higher than the 
numbers at 37
o
C, owing to more GFP expression being driven under the CMV under 
normal (no treatment) conditions (Figure 3.2.4.1 A). The expected transcriptional increase 
at 31
o
C by CMV in the untreated samples only becomes substantial from 4 hours onwards. 
The difference in copy number between temperatures after 4 hours was 2.97x10
5
 compared 
to the difference after 14 and 24 hours, which were 8.68x10
6
 and 7.72x10
6
 copies 
respectively, thus showing a strong increase in transcription upon temperature shift after the 
initial 4 hours (Figure 3.2.4.1 A). 
The absolute copy number of GFP transcripts dropped as early as 4 hours in the 
actinomycin D treated samples and more so after 24 hours, where the transcript level had 
dropped by approximately 21-fold at 37
o
C and 110-fold at 31
o
C. Transcripts also decayed 
more quickly during the first 10 hours at 31
o
C than the same time period at 37
o
C (Figure 
3.2.4.1 B).  
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Overall, the GFP mRNA under control of the CMV promoter appeared to be less stable at 
31
o
C than at 37
o
C based on higher decay rates and lower half-life of GFP mRNA between 
24 hours and 4 hours. The half-life at 37
o
C was calculated to be 4.51hr
-1
 compared to 
2.45hr
-1
 at 31
o
C over the 20 hours in culture (Table 3.2.4.2).  
We assume this accounted for the increased GFP expression caused by temperature 
downshift shown in the reporter assays previous. The complete decay rate and half-life 
values between each time-point were shown in table 3.2.4.2.  
 
Table 3.2.4.2: Decay rate (k in h
-1
) and half-life (t1/2) for actinomycin D treatment at both 
temperatures representative of figure 3.2.4.1 results.  
 
 
We conclude that the change in mRNA abundance can be attributed to a transcriptional rate 
change, and not increased transcript stability caused by the CMV promoter within the cells. 
It was also observed that in the untreated control samples at 37
o
C and 31
o
C, the transcript 
copy numbers increased over time at 31
o
C while with the addition of actinomycin D the 
reverse was seen. In other words, we saw reduced stability at 31
o
C versus 37
o
C and 
comparatively increased transcriptional activity at 31
o
C after 24 hours. Finally, the CMV 
promoter used in these studies appears to be more transcriptionally active at 31
o
C and 
therefore will no longer be referred to as a reporter control. 
 
 
 
ActD @ Time (kdecay) h
-1 t 1/2
37oC 24h-4h -0.1535 4.51
24h-14h -0.1843 3.76
14h-4h -0.1227 5.64
31oC 24h-4h -0.2824 2.45
24h-14h -0.1881 3.68
14h-4h -0.235 2.94
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3.2.5: Driving expression of a bioprocess product (EPO) 
Erythropoietin was the first recombinant protein from mammalian cells to achieve 
blockbuster status, with sales over $1 billion annually (Wurm F. 2004).  
We chose it to investigate whether its synthesis could be controlled according to culture 
temperature and, as a result, whether yield of the protein was better or worse than in 
isothermic culture. The hypothesis being that reduced expression at 37
o
C early in the 
bioprocess may allow cells reach higher density, followed by a switch to 31
o
C which slows 
growth and directs cellular energy to produce more EPO in parallel with these temperature 
inducible promoters to increase productivity. It also would showcase the promoter’s 
potential in driving expression of an important biopharma product. 
As in the case of Luciferase and GFP, the promoter sequences were cloned into an EPO 
vector and transfected into CHO-K1 cells to investigate EPO transgene expression. Two 
out of the three novel endogenous CHO promoters were shown to drive EPO expression 
(Cirbp-CHO and SSu72) in a temperature dependent manner, with a definite expression 
gradient between 37
o
C and 31
o
C. The Cirbp-mouse promoter control EPO vector also 
functioned well by exhibiting strong EPO expression at both temperatures (Figure 3.2.5.1).  
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Figure 3.2.5.1: EPO mRNA transcript copy number calculated after RT-qPCR. The 8 
promoter-EPO constructs were transfected into CHO-K1 cells and cultivated at 37
o
C and 
31
o
C over 36 hours. Total RNA was extracted and 1μg was DNase treated and reverse-
transcribed to generate cDNA. Fold change between 37
o
C and 31
o
C was denoted by [x] 
under each sample. 
 
At the transcriptional level the CMV promoter drove the highest level of EPO at both 
temperatures, with copy numbers reaching ~5.23x10
5
 at 37
o
C and ~1.40x10
6
 at 31
o
C. 
However, the effect of temperature shift on transcript copy number was not as apparent as 
with GFP and Luciferase assays with a smaller fold change of 2.7x observed between 
temperatures. This is more in-line with an expected result from a constitutive promoter but 
this was not seen at a protein level where there was quite an obvious shift in protein 
expression for the CMV samples between 37
o
C and 31
o
C (Figure 3.2.5.2). 
Out of the novel CHO promoters, MDM2 only expressed 444 copies at 37
o
C and 7416 
copies at 31
o
C, however, the fold change between temperatures was much larger being 
16.7x which was comparable to the Cirbp-promoters.  
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The SSu72 promoter performed the best of all the promoters tested (excluding CMV) 
regarding transcript abundance at both temperatures and indeed at the protein level at both 
temperatures (Figure 3.2.5.2).  
The basal pTATA (-) control produced low levels of EPO transcript as would be expected 
of a minimal promoter. The miR-17-92-mouse promoter expressed marginally more 
transcripts than the CHO version, while both promoters drove transcription slightly better at 
31
o
C. The abundance of EPO transcripts varied greatly from the Luciferase values 
produced by the miR-17-92 promoters. The miR-17-92 mouse promoter only produced 785 
copies at 31
o
C while the CHO ortholog produced 295 copies at 31
o
C.  
For the Cirbp-promoters, the effect of temperature shift to 31
o
C was shown to increase EPO 
transcript copy numbers in both orthologs tested. Although the CHO sequence generated 
more transcripts at each temperature, the temperature induciblity was less pronounced with 
the fold change being marginally less (24.4x) than the Cirbp-mouse promoter, with itself 
been the most temperature responsive among all promoters and had a 26.3-fold difference 
between 37
o
C and 31
o
C. 
 
Figure 3.2.5.2: Western blots for the 8 promoter-EPO constructs plus a cells only control. 
CHO-K1 cells were transfected with the promoter constructs and cultured in 24-well plates 
at 37
o
C and 31
o
C. Supernatant from each sample well was harvested 48-hours later. 
Supernatant was subsequently loaded onto a 4-12% SDS/Bis-Tris gel and probed with anti-
EPO antibody from Abcam®. As extracellular EPO was secreted into the growth media; no 
loading control for EPO was available.  
 
Figure 3.2.5.2 shows that no EPO protein was detected for pTATA (-), MDM2 or either 
miR-17-92 promoter; this was unexpected in lieu of previous results in Luciferase and GFP 
assays. Surprisingly, the MDM2 promoter resulted in very low EPO mRNA levels, and 
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consequently no protein was detectable by western blot. This result was evidently different 
to what was observed for the two reporter proteins previously.  
Chen et al see such anomalies aswell, using only two reporter protein platforms for analysis 
of transgene expression (GFP and Luciferase). They tested two putative promoter CHO 
fragment sequences derived from a promoter-trap method that underwent hygromycin 
selection. They showed that clone #2 was strong enough to drive GFP expression but not 
Luciferase. Furthermore, clone #2 only exhibited ~20% GFP expression strength for 
compared to the SV40 viral promoters used in the study (Chen et al. 2013). Our promoters, 
although varying in strength across reporter platforms, performed to relatively higher levels 
than the 20% of the CMV and SV40 promoters. As a result, we conclude that MDM2 might 
not be suitable for EPO production but could still hold value in other protein production 
settings. 
Both Cirbp promoters drove expression of EPO as evidenced by qPCR and western blotting 
data (Figure 3.2.5.1 and 3.2.5.2). At a transcriptional level the Cirbp-CHO promoter 
expressed more copies of EPO than the Cirbp-mouse version at both temperatures. This was 
encouraging as a novel finding because so far, only Cirbp promoters from mouse had been 
reported in the literature (Al-Fageeh and Smales 2006).  
Furthermore, the lack of EPO expression from the miR-17-92-CHO promoter was not 
surprising due to its low level GFP and Luciferase expression compared to the other 
promoters in previous sections. Moreover, the miR-17-92-mouse promoter had an extra 
259bp which may contain addition regulatory sequence. However, to recount, this was not 
apparent after cloning in a 1.1kb fragment of the miR-17-92-CHO during the initial 
promoter fragment GFP screen (Table 3.1.11), but the landscape of both promoters may be 
different. Regardless, in theory, the miR-17-92 CHO promoter could still be utilised to 
drive expression of genes that are not required at high levels, such as toxic proteins or dose-
dependent engineering targets that do not require strong expression. 
In conclusion, three of the novel isolated promoters [SSu72, Cirbp-CHO, and Cirbp-mouse] 
have shown their utility from a bioprocess product viewpoint. They drove expression of a 
well-known and important therapeutic glycoprotein [EPO] at both 37
o
C and 31
o
C, with 
markedly increased expression seen at 31
o
C.  
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3.2.6: Driving expression of an cellular engineering transgene (p27) 
In the previous section, we investigated the use of several promoters on the production of 
EPO at different temperatures. Realistically the product gene is unlikely to be expressed in 
an inducible manner such as this, although there have been examples reported (eg: 
Regenerons’ ciliary neurotrophic factor (CNTF)/Axokine and interleukin-1) (Preti 2003) 
(Gabay 2003).  
Inducible promoters are more likely to be useful for controlling the temporal expression of 
a cell engineering transgene. Therefore, our next experiment was to consider their use in 
this manner. We chose to use cyclin-dependant kinase inhibitor 1B (p27) to investigate 
whether they could drive expression of an engineering target to influence a phenotype in 
culture. Successful induction of p27 should result in reduced cellular growth via cell cycle 
inhibition in the G1 phase. 
Controlling p27 expression by inducible promoters could be utilised in a CHO cell line 
bioprocess to arrest cell growth and to quickly transition cells into a productive phase to 
increase protein production for example. 
Here the effect of p27 expression was reported after transfecting the promoter constructs 
into attached parental CHO-K1 cells as well as a specially adapted in-house suspension 
CHO-K1-SEAP cell line.  
We chose a second cell line for two reasons. Firstly to see if p27 could be induced in more 
than one cell type in order to impact proliferation and secondly we also wanted to measure 
the SEAP productivity of the cells at different cell densities by the varying p27 expression 
resulting from the different promoters. 
Finally, including a suspension culture will provide data on the utility of these promoters in 
a format more relevant to industrial bioprocesses.  
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3.2.6.1: Temperature responsive p27 expression in ‘attached’ culture 
CHO-K1 parental cells were seeded and grown at 37
o
C in 24-well plates for 12 hours prior 
to transfection of promoter constructs driving p27. Six hours after transfection, half the 
cultures were switched to a 31
o
C incubator and 66 hours later all cultures were trypsinised 
and subsequently stained for viability and analyised by flow cytometry (Figure 3.2.6.1). In 
addition, we calculated relative cell density normalised to the pTATA (-) control for all 
samples at each temperature (Figure 3.2.6.2).  
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Figure 3.2.6.1: (A) Cell densities were measured 72 hours post-transfection with p27-
promoter constructs. Guava™ flow cytometry was used to calculate cell numbers for 
attached CHO-K1 cells grown in 24-well plate format. Error bars represent standard 
deviation (± SD) between biological triplicates at both temperatures. * represents statistical 
significance p-value <0.05, ** p-value<0.01, determined by a 2 tailed students T-Test 
between the pTATA (-) control and all other constructs over 3 replicate experiments. (n = 
3). (B) Percentage viability values were also measured by flow cytometry 72 hours later at 
37
o
C and 31
o
C.  
 
Post-transfection, all promoter constructs caused a reduction in cell number at 37
o
C 
compared to the pTATA (-) control (Figure 3.2.6.1 A). Interestingly, both MDM2 and 
SSu72 constructs caused greater growth suppression than CMV at 37
o
C, plus SSu72 caused 
greater suppression at 31
o
C also. The Cirbp promoters had a similar effect as CMV, 
whereas the miR-17-92 promoters only caused slightly reduced cell densities compared to 
pTATA (-) control at 37
o
C. Switching the cells to a 31
o
C incubator resulted in 6x10
4
 less 
cells per well in the pTATA (-) control samples, representing approximately a 18% drop 
compared to cells maintained at 37
o
C and this was taken to be in response to temperature 
shift alone, on cell growth. All promoter constructs tested had a higher cell density 
differential when compared to this value from the pTATA (-) control.  
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In contrast, the CMV promoter transfected cells had ~60% reduction in cell numbers at 
31
o
C compared to 37
o
C, presumably due to the added effect of transgenic p27 expression 
and its subsequent added suppression on proliferation. MDM2 and SSu72 both displayed a 
45% and 53% reduced cell density upon temperature shift. However, the greatest impact 
caused by temperature shift on relative cell density, between 37
o
C and 31
o
C, was in 
cultures transfected with the Cirbp promoters, as highlighted by significant P-values across 
3 similar experiments (Figure 3.2.6.2).  
Cirbp-CHO had the biggest differential between temperatures being 2.51x10
5
 cells/well; 
this represented a reduction of 74% of 37
o
C cell numbers. The Cirbp-mouse promoter had 
the next highest cell number differential of 2.26x10
5
 cells/well; this represented a reduction 
of 70% of 37
o
C cell numbers. By taking into account the pTATA (-) control at 18%, we 
calculated the more accurate cell number reduction percentages of 55% (Cirbp-CHO) and 
51% (Cirbp-mouse) as a result of normalising to the pTATA (-) control. For the full figures 
and % cell number reductions for each p27 construct see tables 6.3.1 and 6.3.2 in the 
appendices. 
The CMV cell number differential between temperatures was 1.97x10
5
 cells/well compared 
to MDM2 and SSu72 being 1.23x10
5
 and 9.20x10
4
 cells/well respectively. This resulted in 
a larger fold change seen in the CMV promoter samples than MDM2 and SSu72 samples 
and appeared to be more inducible upon temperature shift providing further evidence that 
CMV was not a good control. 
Interestingly, the viability values measured at 31
o
C were marginally lower overall than the 
viability values at 37
o
C (Figure 3.2.6.1 B). This was unexpected, as lower cultivation 
temperature in usually reported to increase viability. There are potentially two reasons why 
this may have been observed. One is that maybe the cells were still only adjusting to cold 
shock after 3 days and secondly, perhaps the transfection procedure was more impactful at 
31
o
C. Indeed as the viability was lower in all samples that underwent transfection, whereas 
the cells only samples had slightly higher viability at 31
o
C being 97.8% compared to 96.8% 
at 37
o
C.  
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The miR-17-92 promoters had minimal impact on cell density at 37
o
C but showed reduced 
cell numbers at 31
o
C compared to the pTATA (-) control. However, their impact was not 
comparable to the other promoters at either temperature and had the least relative cell 
density reduction compared to the pTATA (-) control (Figure 3.2.6.2). This correlated to 
the RT-qPCR validation which showed much less p27 mRNA transcripts (Figure 3.2.6.3).  
Additionally, they showed a significant response to temperature shift (p<0.05) at an mRNA 
transcript level which again is not what one would expect of constitutively active 
promoters. 
 
Figure 3.2.6.2: Relative CHO-K1 cell density fold-change (fc) in attached culture. Cell 
densities were normalised to the promoterless (pTATA-) negative control sample (Set to 
1.0) of its respective 37
o
C versus 31
o
C values. 
 
Overall, there was a correlation between increased copy number and the effect on growth 
due to overexpression of p27 (Figure 3.2.6.1 A). For example; MDM2 and SSu72 had the 
biggest effect on the cell growth and this correlated with greater p27 mRNA transcript 
abundance (Figure 3.2.6.3). 
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Figure 3.2.6.3: Quantification of p27 transcript expression in CHO-K1 cells transfected 
with 8 promoter-p27 constructs and cultured at 37
o
C and 31
o
C. Absolute transcript copy 
number was measured by RT-qPCR and calculated using a standard curve for p27. Total 
RNA was extracted 72 hours after transfection and 1μg was DNase treated and reverse-
transcribed to generate cDNA. Bar headers showed the absolute values for p27 transcript 
copy numbers for each sample. 
 
The Cirbp-CHO promoter was shown to be the most transcriptionally active promoter, 
reaching 6.23x10
3
 transcripts at 37
o
C and 1.96x10
4
 transcripts at 31
o
C after 72 hours. The 
Cirbp-mouse promoter was marginally less active at driving p27, than its CHO counterpart, 
however Cirbp-mouse had a larger transcript fold change between temperatures at 3.7-fold 
whereas Cirbp-CHO was 3.1-fold. The CMV construct produced the highest transcript fold 
change between temperatures, at 5.8-fold.  
The MDM2 and SSu72 promoters appeared to be less active, with less transcripts detected 
at both temperatures compared to the Cirbp promoters, however they both had large 
transcript fold changes between temperatures.  
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The fold change between 37
o
C and 31
o
C for MDM2 and SSu72 copy numbers were 
calculated to be 3.4-fold and 5.4-fold respectively, indicating that they were the most 
temperature responsive at a transcriptional level when driving p27. 
The observed correlation between growth arrest and p27 transcript abundance encouraged 
us to investigate the levels of p27 protein present in the cells using western blot analysis 
(Figure 3.2.6.4).  
There was an obvious increase in p27 protein (band intensity) expression in the 31
o
C 
samples compared to the 37
o
C samples overall. The pTATA (-) control detected low levels 
of p27 protein at 37
o
C and slightly more at 31
o
C; this was also seen at a transcriptional 
level (Figure 3.2.6.3). There was no endogenous level of p27 detected in the cells only 
sample at either temperature. 
The CMV promoter appeared to drive the most amount of p27 protein at 31
o
C. MDM2 and 
SSu72 also produced strong detection at 31
o
C and interestingly, SSu72 had similar 
detection at 37
o
C (Figure 3.2.6.4). The Cirbp-promoters had dissimilar results compared to 
each other. The Cirbp-mouse promoter had a bigger differential between temperatures than 
the Cirbp-CHO and the CHO version as more p27 was detected at 37
o
C; however less p27 
was detected than in the CMV samples. The miR-17-92 mouse promoter appeared to drive 
reasonable p27 protein expression based on the protein detected with no apparent intensity 
difference between temperatures.  
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Figure 3.2.6.4: Western blots for the 8 promoter-p27 constructs plus a cells only control. CHO-K1 cells were transfected with the p27 
promoter constructs and cultured at 37
o
C and 31
o
C. 1x10
6
 cells were trypsinised and then lysed 72 hours post-transfection with an in-house 
lysis buffer cocktail. A Bradford assay was performed to calculate protein concentration for all samples. 10µg of protein was subsequently 
loaded onto a 4-12% SDS/Bis-Tris gel and probed with anti-p27 antibody from Abcam® and a house-keeping gene GAPDH as a loading 
control. [p27 = ~27kDa and GAPDH = ~40kDa]. 
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3.2.6.2: Temperature responsive p27 expression in ‘suspension’ culture 
Our early experiments had illustrated the transcript-dependent nature of the 
activity/induciblity of these promoters. Having observed such interesting and encouraging 
results with p27 – under the transcriptional control of the Cirbp promoters in particular – 
we wanted to assess whether this effect was maintained in cells grown in a different culture 
format i.e.: suspension culture.  
This is important, as ultimately the aim was to develop tools for use in commercial 
bioprocesses in bioreactors and oftentimes the dynamics of different culture formats can 
have adverse effects on gene expression. Feng et al examined differential expression of two 
viral promoters (SV40 and CMV) and one mammalian (beta-actin) and they found that 
beta-actin and SV40 promoters exhibited suppressed gene expression of 70 and 56%, 
respectively, in suspension cells. They conclude that regardless of mammalian or viral 
vectors, one cannot assume that all expression vectors behave similarly in both suspension 
and adherent state. (Feng, Hicks and Chang 2003).  
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Figure 3.2.6.2.1: (A) Guava™ flow cytometry was used to calculate cell numbers for 
suspension CHO-K1-SEAP cells grown in 24-well suspension plate format. Cell densities 
were measured 72 hours post-transfection with p27-promoter constructs. Error bars 
represent standard deviation (± SD) between biological triplicates at both temperatures. * 
represents statistical significance p-value <0.05, ** p-value<0.01, determined by a 2 tailed 
students T-Test between the change in cell numbers at 37
o
C and 31
o
C between pTATA (-) 
control and all other constructs over 3 replicate experiments (n = 3). (B) Percentage 
viability values were also measured by flow cytometry 72 hours later at 37
o
C and 31
o
C. 
 
All constructs displayed reductions in cell numbers for both temperatures compared to the 
pTATA (-) control (Figure 3.2.6.2.1). Switching the cells to a 31
o
C incubator resulted in 
6x10
4
 less cells per well in the pTATA (-) control samples, representing a 23.6% drop 
compared to cells maintained at 37
o
C and this impact on cell growth was taken to be in 
response to temperature shift alone. All promoter constructs tested had more substantial 
reductions at 31
o
C compared to their 37
o
C counterpart samples.  
Cirbp-CHO had the largest drop at 48.2% followed closely by the MDM2 and SSu72 
constructs which showed 45.2% and 39% reductions in cells at 31
o
C compared to cells 
maintained at 37
o
C when normalised to the pTATA (-) control. The MDM2 and SSu72 
promoter cell densities between temperatures showed differentials of 1.84x10
6
 cell/mL and 
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1.51x10
6
 cells/mL respectively, and both caused substantial growth suppression at both 
temperatures. However, only MDM2 was shown to be statistically significant over 3 
similar experiments. For the full figures and % cell number reductions for each p27 
construct see tables 6.3.1 and 6.3.2 in the appendices. 
The transfected CMV promoter resulted in the fewest cell numbers at both temperatures 
presumably due to strongly driving p27 expression. Surprisingly, this was the opposite of 
the attached culture results (Figure 3.2.6.1.1 A), whereby the MDM2 and SSu72 promoters 
caused a bigger reduction in cell numbers than the CMV promoter. However, the cell 
number differential between 37
o
C and 31
o
C for CMV was only 5.18x10
5
 cells/mL and was 
less than the differential between 37
o
C and 31
o
C for pTATA (-) control which was 
8.31x10
5
 cells/mL. This perhaps indicated that CMV was the least temperature responsive 
promoter in suspension CHO-K1-SEAP culture, however, CMV did show a 16% reduction 
after normalisation to the pTATA (-) control. 
The Cirbp-CHO promoter had the largest cell density differential at 1.91x10
6
 cells/mL 
while the Cirbp-mouse ortholog promoter had a difference of 1.80x10
6
 cells/mL between 
temperatures. Both Cirbp promoters, like the attached culture results, showed significant P-
values from 3 replicate experiments when compared to the pTATA (-) control. 
The miR-17-92 constructs had a similar impact on suspension CHO cells compared to the 
attached cells but once again the impact on cell numbers was modest but not 
overwhelming. Again the mouse version outperformed the CHO version, when normalised 
to the pTATA (-) control, miR-17-92-mouse promoter resulted in a 20.4% reduction in cell 
numbers compared to a 13.5% reduction from the miR-17-92-CHO promoter. 
Overall, the viability % in the suspension cultures was lower compared to attached culture 
(Figure 3.2.6.2.1 B). This could be attributed to suspension cells being more sensitive to the 
transfection process and hypothermic environment. The reduced viability seen previously 
in attached culture was evident again, with all 31
o
C samples having been less viable 
following flow cytometry analysis. However, we also see that the cells only control 
samples which did not undergo transfection showed marginally (1.6% increase) higher 
viability at 31
o
C was more in-line with what we expected.  
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Figure 3.2.6.2.2: Relative CHO-K1-SEAP cell population density as a fold-change (fc) in 
suspension culture. Cell densities were normalised to the promoterless (pTATA-) negative 
control sample (Set to 1.0) of its respective 37
o
C versus 31
o
C values. 
 
All promoter constructs showed decreased cell density relative to the pTATA (-) basal 
control, suggesting that all constructs drove p27 expression sufficiently to inhibit growth at 
varying strengths. Once again, the miR-17-92 promoters had the least impact on growth – 
having between ~5-14% lower growth than pTATA (-) across both temperatures. The CMV 
had the biggest impact and indeed similar reduction of ~60% at both temperatures after 
normalisation to the pTATA (-) control values for both 37
o
C and 31
o
C (Figure 3.2.6.2.2).  
The Cirbp-CHO promoter showed the strongest effect at 31
o
C compared to all other 
promoters with a 62% reduction in cell density, marginally more than the CMV promoter. 
It also had the largest response to temperature with a 2.12-fold reduction in cell density. 
MDM2 and SSu72 promoter constructs had moderate effects on cell growth at both 
temperatures with 52% and 55% reductions when normalised to the pTATA (-) control 
values at both temperatures. Furthermore, both had cell density differentials between 37
o
C 
and 31
o
C of 1.85-fold and 1.93-fold respectively.  
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Finally, the CMV promoter did cause cell growth to be reduced significantly but there was 
a very small difference between temperatures. This indicated that the CMV promoter was 
less temperature responsive in this experiment also. We hypothesised that this was maybe 
due to the growth repressive effect of p27 expression reaching saturation within the cells,  
whereby the natural growth of the suspension cells could simply not be reduced any lower 
than ~7.82x10
5 
cells/mL (Figure 3.2.6.2.1 A).  
 
 
Figure 3.2.6.2.3: Absolute transcript copy number results from RT-qPCR analysis. 
Suspension culture CHO-K1-SEAP cells were transfected with all eight p27-promoter 
constructs. RNA was extracted from the cells after 72 hours in culture at 37
o
C and 31
o
C. 
RNA was then reverse transcribed to generate cDNA for qPCR and analyised using a 
HT7900 applied Biosystems™ PCR thermal cycler.  
 
The activity of the CMV promoter resulted in more p27 transcript expression compared to 
all other promoter constructs. Cells only and pTATA (-) controls showed very low levels of 
p27 as expected. The miR-17-92 constructs did not seem to drive p27 at as high a level as 
the four temperature sensitive promoters (Figure 3.2.6.2.3).  
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However, the mouse version did perform better than the CHO version, having 8.3-fold and 
9.9-fold more transcripts at 37
o
C and 31
o
C respectively.  
Interestingly, MDM2 and SSu72 showed lower amounts of transcripts at both temperatures 
compared to the CMV contrary to the attached culture result (Figure 3.2.6.3). MDM2 and 
SSu72 promoters along with the Cirbp-promoters showed quiet varying amounts of p27 
transcripts than what was expected, based on the cell growth numbers being reported as 
consistently reduced among all four promoters (Figure 3.2.6.2.1 A). The Cirbp-CHO 
promoter was the only construct that expressed p27 transcripts to a similar level as the 
CMV promoter after temperature shift to 31
o
C.  
Because qPCR only measured mRNA expression and not total protein synthesis, it is 
important to be aware that disparities can exist between qPCR (transcript) and western blot 
(protein) results (Figure 3.2.6.2.4). 
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Figure 3.2.6.2.4: Western blots for the 8 promoter-p27 constructs plus a cells only control. CHO-K1-SEAP cells were transfected with the 
p27 promoter constructs and cultured at 37
o
C and 31
o
C. 2x10
6
 cells were lysed 72 hours post-transfection with an in-house lysis buffer 
cocktail. A Bradford assay was performed to calculate protein concentration for all samples. 10µg of protein was subsequently loaded onto a 
4-12% SDS/Bis-Tris gel and probed with anti-p27 antibody from Abcam® and a house-keeping gene GAPDH as a loading control. [p27 = 
~27kDa and GAPDH = ~40kDa]. 
202 
 
Similar to the attached culture transfections, all constructs showed increased p27 protein 
expression at 31
o
C (Figure 3.2.6.2.4). Cells only and pTATA (-) controls did not drive p27 
to a detectable level. The 3 CHO promoters, MDM2, SSu72 and Cirbp all had similar p27 
detection based on band intensity (Figure 3.2.6.2.4), however the Cirbp-mouse promoter 
appeared to have less p27 detected an indeed not as an obvious increase at 31
o
C. 
Surprisingly, both miR-17-92 promoters appeared to drive p27 protein at 31
o
C only, with 
the mouse version having a marginally bigger band. 
 
3.2.6.3: p27 effect on SEAP activity in CHO-K1-SEAP  
Additionally, as we used a suspension CHO-K1-SEAP adapted cell line created in-house by 
Dr. Niraj Kumar a secreted alkaline phosphatase (SEAP) assay was performed having taken 
the cell supernatants 72 hours post-transfection with the p27 plasmid constructs. This 
exercise was to see if SEAP productivity was affected by using temperature-inducible 
expression of a growth-associated gene i.e: p27. 
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Figure 3.2.6.3: Secreted Alkaline phosphatase (SEAP) production (units/mL) by SEAP-
secreting CHO-K1 cells 3 days post-transfection with p27 constructs. Error bars represent ± 
SD. A cells only control was included as an indicator of the intrinsic SEAP productivity at 
each temperature.  
 
SEAP yield seemed to be proportional to the amount of cells present (see figure 3.2.6.2.1 
A) and SEAP production wasn’t affected by inducing p27 expression with a temperature 
shift to 31
o
C. The hypothesis was that the more active a promoter was in driving p27, the 
less SEAP that should accumulate in the supernatant as a result of less cells being present. 
For example, there was more SEAP protein present as expected in the basal pTATA (-) 
control at both temperatures (~414 and 323 SEAP units per mL respectively) than all other 
transfected constructs. All transfected promoter constructs [MDM2, SSu72 and both Cirbp 
orthologs] had an indirect effect on SEAP productivity, we saw lower SEAP detected at 
31
o
C and all had similar levels of SEAP, with Cirbp-CHO having the lowest at 92 SEAP 
units per mL (Figure 3.2.6.3).  
All transfected promoters had a larger SEAP differential between 37
o
C and 31
o
C, in 
comparison to the cells only and pTATA (-) controls. Assuming the 37
o
C samples were 
100% we found that the % drop in SEAP was lowest in the CMV promoter samples (~11%) 
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while the largest drop was seen in the MDM2 promoter samples (~43%) followed by 
Cirbp-CHO (~40%). MDM2 showed the largest differential in SEAP and was represented 
with a fold change of 2.86-fold drop in SEAP units between 37
o
C and 31
o
C samples.  
The cells transfected with the miR-17-92 promoters showed the highest SEAP 
concentrations, directly linked to the growth numbers (Figure 3.2.6.2.1 A), and presumably 
indirectly linked to their modest ability to drive p27 expression. They did show a reduction 
in SEAP at 31
o
C compared to 37
o
C, albeit much less of a reduction than the other 
endogenous promoters but interestingly showed a higher reduction than the CMV (11%), 
with a 19% reduction for the mouse and a 16% reduction for the CHO version.  
Cells transfected with the CMV constructs showed the lowest SEAP concentration at both 
temperatures but had a lower fold change of 1.49-fold and the response to temperature shift 
was not as impactful on SEAP productivity as the inducible endogenous promoters.  
As hypothesised from the attached culture results seen previous, this may be attributed to a 
saturation of p27 overexpression by the CMV promoter, whereby the cells were not going 
to be growth inhibited any further at 31
o
C as there is already a strong inhibitory effect on 
growth in the 37
o
C sample. Additional growth inhibition by p27 overexpression caused by 
the temperature downshift by the CMV promoter samples may have experienced an 
expression overloading on the cells, preventing a further reduction in growth. 
Cells transfected with the Cirbp promoters showed marginally lower SEAP overall 
compared to cells transfected with the MDM2 and SSu72 promoters, this was more than 
likely due to Cirbp being marginally more active at driving p27 expression leading to a 
reduced cell growth and therefore lower SEAP concentration.  
In conclusion, our data demonstrated that placing novel CHO and mouse promoter 
sequences upstream of a cytostatic growth gene (p27), can cause a phenotypic and 
metabolic effect on two CHO cell lines especially MDM2 and SSu72 promoters. Variation 
was seen between attached and suspension culture probably due to different growth 
dynamics. One cannot assume that all expression vectors behave similarly in both 
suspension and adherent state as shown by (Feng, Hicks and Chang 2003). The miR-17-92 
cluster promoters performed the poorest in driving p27 and like the EPO section, the 
promoters seem limited in their functionality, with the mouse performing marginally better.  
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Furthermore, all transfected promoters resulted in quite variable levels of transcripts and 
protein levels, highlighting one of our main findings; that it if these inducible promoters are 
to be used as tools in gene expression/regulation, then it is important to match the most 
suitable promoter to the right gene of interest GOI (Table 3.2.7). 
 
3.2.7: Promoter – Ranking to GOI 
To summarise the performance of our promoters over all four reporter platforms used in 
this project, table 3.2.7 was devised to establish a somewhat subjective promoter ranking 
catalogue. The ranking was based on total expression strength based on protein levels (A) 
and temperature induciblity (B) depending on the promoter’s purpose. We believe this 
catalog can be expanded as future work contributes further to the promoter toolkit for use in 
fine-tuning gene regulation.  
From analysing the performance of all promoters across all 4 reporter systems, there was no 
obvious behavioral trend apparent by any promoter post-ranking. MDM2, SSu72 promoters 
and both orthologs of Cirbp vary from one reporter assay to the next.  
For example, the MDM2 promoter was ranked 4
th
 compared to Cirbp-CHO in 1
st
 for GFP 
expression and ranked 3
rd
 compared to Cirbp-mouse in 1
st
 in driving Luciferase expression 
(Table 3.2.7 A). However, regarding induciblity at 31
o
C as indicated by the fold changes 
measured between both temperature expression values, MDM2 was ranked higher within 
the GFP and Luciferase assays than all other promoters. The miR-17-92 cluster promoters 
were consistently the weakest performing promoters within the study but represent very 
novel sequences capable of driving transgene expression nonetheless. 
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Table 3.2.7: Ranking of gene promoters [#1-6] from this study, excluding CMV and SV40 
promoters, based on reporter gene expression. (1 = best). (A) Represents an indication of 
promoter strength. Ranking based on accumulative total expression from both temperatures. 
(B) Represents an indication of the strength of promoter temperature induciblity. Ranking 
was based on the fold change between 37
o
C and 31
o
C in each reporter case. (-) denotes an 
equal rank value. 
 
 
 
 
 
 
 
 
 
 
Expression level [37+31]
Rank #
GFP Luciferase EPO p27
MDM2 4 3 4 2
SSu72 3 4 1 1
Cirbp-CHO 1 2 2 3
Cirbp-mouse 2 1 3 4
mir17-92-CHO 5 6 5 5
mir17-92-mouse 6 5 6 6
Temp shift FC [31/37]
Rank #
GFP Luciferase EPO p27
MDM2 1 1 3 3
SSu72 3 4 4 2
Cirbp-CHO 2 3 2 1
Cirbp-mouse 4 2 1 4
mir17-92-CHO 6 6 5- 5
mir17-92-mouse 5 5 5- 6
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3.3: Bioinformatics / In-silico analysis of promoter sequences 
3.3.1: Introduction 
As a general rule, promoter regions tend to be located 1500-50bp (but could be thousands 
of base pairs further away) from the transcriptional start site (TSS). Enhancer elements and 
trans-acting molecules can be located several thousand base pairs away and even on 
different chromosomes for example, making analysis as well as isolation difficult 
(Khambata-Ford et al. 2003). Several open source promoter prediction programs are 
available for public use and can be used to evaluate prospective DNA sequences.  
Several online tools (Genomatix, UCSC) were used throughout to provide a comprehensive 
analysis of the isolated promoter sequences. Transcription factor binding sites (TFBS) and 
polymerase-II binding sites can be located within a promoter sequence to build a 
framework of each promoter.  
One of the important goals in the post-genomic era is to predict gene expression regulation 
on the basis of presence of TFBS in promoter regions (Ding et al. 2013). Genome wide 
comprehension of TFBS would be useful to build a transcriptional regulatory network in 
CHO biology however understanding of Transcription Factors (TF’s) and TFBS remains 
relatively poorly understood, especially in CHO cells. 
 
3.3.2: Promoter mapping 
3.3.2.1: Cross-species alignments and TFBS location 
There is a plethora of software tools and algorithms at present but for this project we 
concentrated on four resources, Genomatix ElDorado™ (MatInspector/FrameWorker 
applications), the web resource Regulatory Sequence Analysis Tools (RSAT), ‘Cpgplot’ 
and the UCSC genome browser. The specificity of a transcription factor can be described 
by a sequence pattern. Two alternative formats are currently used to identify these 
regulatory patterns: strings (including the IUPAC alphabet for ambiguous nucleotides) or 
position-specific scoring matrices (PSSM) (van Helden 2003) 
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Figure 3.3.2.1 illustrates a multi-alignment conservation snapshot of each promoter 
sequence; the ATG start codons and predicted transcriptional start sites (TSS) were also 
shown. Various transcription factors were identified as a result of highlighting conserved 
sequence across evolutionary related organisms and which is often indicative of regulatory 
sequence. 
This comparative cross species alignment of all 4 promoter sequences [MDM2, SSu72, 
Cirbp and miR-17-92] from Rat, Mouse and CHO was done to try and provide detailed 
representative maps for identifying the promoter framework encompasing TFBS, core 
promoter and possible temperature sensitive regions (Figure 3.3.2.2).  
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Figure 3.3.2.1: Cross-species alignments using ‘ClustalW’ multiple alignment software by inputting the respective promoter sequences in 
FASTA format. TF’s were identified using the PROMO:ALGEN™ transcription factor analysis tool which utilises the TRANSFAC™ 
database. Shown are the predicted TFBS loci and sequence conservation between species for the 4 novel promoters used in this study. 
Mouse orthologs for miR-17-92 and Cirbp are included. The predicted TSS’s are denoted by (\\). [ denotes the ATG start site. 
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The predicted TSS positions from the translational start site ‘ATG’ were as follows; 
MDM2 -218, SSu72 -192, miR-17-92 -361 and Cirbp at -387. Additionally, a second TSS 
was found in the Cirbp sequence at -1170. This was interesting, in light of Cirbp being 
reported by Al-Fageeh and Smales, as being modulated by alternative mRNA leader 
sequences and exhibits internal ribosome entry segment (IRES)-like activity (Al-Fageeh 
and Smales 2009).  
 
 
Figure 3.3.2.2: Representative promoter mapping of the predicted TSS and TFBS loci and 
annotation for all 4 promoter sequences. Transcription factors across evolutionary related 
organisms (mouse, rat and CHO) between sequences were highlighted and mapped for each 
promoter. (+1) denotes the transcription start sites. 
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Table 3.3.2.1: Identity matrix showing the sequence homology %. Analysis performed 
across all four promoter sequences against promoter sequences from two other rodent 
species sequences. Analysis was performed by the ClustalW Omega™ software. 
 
 
 
Interestingly, the CHO sequence tested in all cases was shown to be more homologous to 
rat than mouse when an identity matrix calculation was used to examine the sequence 
conservation of all three species. For example; the CHO Cirbp sequence shared 66% 
homology with mouse and 70% with rat (Table 3.3.2.1). 
It is generally known that miRNAs themselves are well conserved across species and 
evolution but tend to have indistinct promoter regions. Interestingly however, the promoter 
sequence alignment across species did reveal a relatively high conservation based on a high 
identity matrix percentage. The CHO miR-17-92 sequence was shown to be 61% 
homologous to mouse and 63% to rat. 
In fact, the CHO SSu72 promoter showed the least conservation with only 51.37% and 
51.42% compared to mouse and rat respectively. The highest conservation was seen in 
MDM2 with the CHO promoter being 67% and 74% respectively.  
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Finally, we noticed that in all cases, at a gene aswell as promoter conservation level, rat 
was always more analogous to CHO, which was interesting as the general consensus is that 
mouse is the nearest neighbour in evolution (since its genome was sequenced). 
 
3.3.2.2: Genomatix™ analysis 
Additionally, we used the reputable Genomatix™ website to investigate transcription factor 
binding sites further. MatInspector™ is a software tool contained in the website that utilizes 
a large library of matrix descriptions for TFBS in order to locate matches in DNA 
sequences. MatInspector has been shown to not be as fast as searching for ‘IUPAC’ strings 
but has been shown to produce superior results. It assigns a quality rating to matches and 
thus allows quality-based filtering and selection of matches (Quandt,K. 1995). 
The FrameWorker™ software uses a genome annotation system called ‘ElDorado’; it 
stores biological data consisting of annotation and gene network data plus all transcription 
factor information that is contained in MatBase. This lets researchers analyse and interpret 
their experimental results in an in silico biological context for more than 30 different 
species. 
Figure 3.3.2.2.1 illustrates the FrameWorker™ output for each of the four CHO promoters 
used in this study. Mouse sequences were automatically tested for TFBS homology in 
parallel for Cirbp and miR-17-92 promoters. It was shown that the amount of TFBS was 
proportional to the size of the promoter sequence examined. For example, there were 6 
TFBS identified in MDM2 and 15 TFBS identified in miR-17-92 sequences, with the miR-
17-92 sequence being ~620bp longer. There were 11 TFBS identified within the SSu72 
promoter sequences and 14 TFBS identified in the Cirbp promoter sequences. 
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Figure 3.3.2.2.1 A: MatInspector™ / FrameWorker ™ analysis on MDM2 and SSu72 promoter sequences across CHO (1), rat (2) and 
mouse (3) using the software suite with ElDorado annotation for the species within the database. The TFBS shown were generated by using 
a high core and matrix similarity cutoff (>0.90) where >0.80 is considered a good match. The matrix families were denoted by V = 
Vertebrate and O = Other functional elements. Black bars indicate the relative size of the input sequence. Above the line represents the sense 
strand directionality, and below the line represents the anti-sense strand. 
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Figure 3.3.2.2.1 B: MatInspector™ / FrameWorker ™ analysis on Cirbp and miR-17-92 promoter sequences across CHO (1), rat (2) and 
mouse (3) using the software suite with ElDorado annotation for the species within the database. The TFBS shown were generated by using 
a high core and matrix similarity cutoff (>0.90) where >0.80 is considered a good match. The matrix families were denoted by V = 
Vertebrate and O = Other functional elements. Black bars indicate the relative size of the input sequence. Above the line represents the sense 
strand directionality, and below the line represents the anti-sense strand. 
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3.3.2.3: ‘Cpgplot’ results 
CpG islands are typically located near transcription start sites and are commonly associated 
with promoter regions for most genes. Promoters can often be broadly classed into either 
TATA-based or CpG island-based promoters (Carninci et al. 2006).  
The European Molecular Biology Open Software Suite (EMBOSS) is a high quality, well 
documented package of open source software tools for molecular biology (Rice et al. 
2000).  
CpG islands scoring (The CpG score is the number of CG dinucleotides in the putative 
island sequence). CpG islands are associated with genes, particularly housekeeping genes, 
in vertebrates. Getting a relative CpG island score for each promoter will aid in their 
characterisation.  
The EMBOSS suite is found at http://www.sanger.ac.uk/Software/EMBOSS/. 
The CHO sequence for all four promoters was put into the EMBOSS Cpgplot software. The 
ratio of observed to expected number of GC dinucleotides patterns is calculated over a 
window of user-specified size (-window parameter). The window moved along the input 
sequence and the ratio was recalculated until the end of the sequence was reached.  
By default, Cpgplot defines a CpG island as a region where the calculated (%G + %C) 
content was over 50% and the calculated Observed/Expected ratio was over 0.6. The 
calculated ratios were then plotted graphically, together with the regions which match the 
program's definition of a putative "CpG island" (a window containing a CG dinucleotide 
rich area). 
Both the SSu72 and Cirbp CHO promoters were identified as having putative islands 
present in their input sequences, while MDM2 and miR-17-92 promoters did not (Figure 
3.3.2.3.1). For the SSu72 promoter sequence, a CpG rich region was located between the 
340 and 684 nucleotides, while the Cirbp sequence contained a CpG rich region between 
nucleotides 583 and 816.  
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Figure 3.3.2.3.1: (A) Emboss® output results for CpG island analysis of MDM2 and 
SSu72. (B) Emboss® output results for CpG island analysis of Cirbp and miR-17-92. The 
grey boxes indicate the putative CpG islands, while analysis was performed using default 
settings. 
 
Furthermore, CpG based promoters can also be sub-divided into high CpG (HCG) content 
or low CpG (LCG) content as a further classification step. Saxonov et al adopted a direct 
and comprehensive survey to identify the locations of all CpGs in the human genome and 
found that promoters segregate naturally into two classes by CpG content.  
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Overall they found that 72% of promoters belong to the class with high CpG content 
(HCG), and 28% were in the class whose CpG content is characteristic of the overall 
genome (LCG) (Saxonov et al. 2006). Finally, new methods are being explored to genome 
sequence exploration, Chuang et al proposed a specific CpG islands prediction analysis 
platform (CpGPAP). The platform's supported algorithms (CPSO and CGA) provide a 
higher sensitivity and a higher correlation coefficient when compared to Cpgplot, however 
we did not compare results (Chuang et al. 2012). 
 
3.4: Co-expression pattern analysis (PCA) 
Next we performed co-expression pattern analysis on Cirbp, SSu72 and MDM2 (Figure 
3.4.1); unfortunately this cannot be done for the miR-17-92 miRNA cluster, due to its lack 
of a clearly defined open reading frame (ORF) and software input limitation. 
This co-expression analysis was based on the hypothesis that groups of genes that display 
similar expression patterns are likely to be; 1) involved in similar pathways/processes and 
more importantly for our study, 2) under the same regulatory control sequences.  
In other words, if one takes a large scale profiling dataset (such as the one used to identify 
our target promoters originally) and look for subsets of genes whose expression behaviour 
over time (or treatment) is very highly correlated, many of these will contain common 
regulatory elements within their promoter sequences. The hypothesis was that by aligning 
and comparing the promoter regions of these co-expressed genes, it should be possible to 
identify common elements. 
To perform this co-expression analysis we took all the expression information contained in 
the profiling dataset and correlated the expression of every gene in each sample with the 
expression of; MDM2, SSu72 and Cirbp. Only genes with a Pearson correlation coefficient 
(PCC) value of >0.7 were chosen for further analysis (Figure 3.4.1). 
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Figure 3.4.1: Graph representing co-expression theory of genes following a similar 
expression profile. We used the Pearson correlation coefficient (PCC) to identify genes that 
followed the same expression pattern from the in-house microarray dataset. The PCC cutoff 
was set to 0.7 and ranges from [0-1]. This range represented how close genes were in 
comparison to each other.  
 
The co-expressed gene maps were then grouped by the software and showed genes with 
similar expression pattern coefficients based on strength of the relationship between genes, 
with 1 or -1 being the highest and lowest similarity (Figure 3.4.2).  
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Figure 3.4.2: Co-expression result for the 3 genes used during this project. Analysis was done using the software at www.cgcdb.org, genes 
joined by red lines were indicated as having a positive correlation and green lines indicated an anti-correlation. SSu72 had 9 co-expressed 
genes based on the stringent 0.7 PCC cut-off, while Cirbp and MDM2 had 2 and 7 genes co-expressed respectively. Full gene annotation is 
described in the appendix. 
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Having now identified these 16 co-expressed CHO genes using the software at 
www.cgcdb.org, all respective promoter sequences from ~800bp upstream of the start 
codon (ATG) for each gene was extracted from the Genbank database. These 16 putative 
promoter sequences were compiled and formatted for further analysis (see supplementary 
data). 
We used the Genomatix™ conserved TF families suite, using the most stringent cutoffs, 3 
novel transcription factors were identified in all 16 gene promoter sequences tested. These 
were the Ecotropic viral integration site-1 (EVI1), the testis-determining factor (TDF), also 
known as Sex-determining region Y (SRY) protein and the Forkhead (FKHD) transcription 
factor which consists of many family members.  
All three transcription factor binding sights were found in all 16 sequences but interestingly 
they had no previous association with CHO or any promoter related studies based on a 
comprehensive literature search.  
Additionally, a single consensus motif ‘CCCCAGC’ was identified, using the motif finder 
from Genomatix™, in all 16 co-expressed gene upstream promoter sequences, including all 
4 novel CHO promoters from this study (Table 3.4.3).  This motif may be essential for the 
temperature sensitive nature of these said sequences.  
 
 
221 
 
Table 3.4.3: Determination of consensus sequence ‘CCCCAGC’ which was present in all 16 co-expressed temperature sensitive gene 
promoter sequences. Gene name, stepwise alignment, nucleotide position and matrix similarity values were shown. A matrix similarity of 1 
was only assigned if only if the candidate sequence corresponded to the most conserved nucleotide at each position of the matrix. A score 
above 0.8 was indicative of a good match. 
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3.5: Viral versus Endogenous stability 
To establish if there was a difference between viral and endogenous promoter sequences we 
wanted to investigate the stability between the CMV promoter and two of the novel CHO 
promoters, miR-17-92 and SSu72. Viral sequences can become silenced over time leading 
to cell line instability (Williams et al. 2005). Investigating endogenous promoter sequences 
may provide a means of overcoming this.  
We transfected the pEGFP-altAL reporter plasmid into CHO-K1 cells, the GFP reporter 
containing these three test promoters to measure GFP transgene expression over time in 
stable mixed and stable single cell populations. By transfecting the CMV, CHO SSu72 
(654bp) and miR-17-92 (992bp) promoter constructs we wished to examine and compare 
GFP reporter expression and therefore stability over an extended culture timecourse.  
 
3.5.1: GFP-stability - Mixed population results 
Post-transfection, G418 (Gentamycin) was used to select a stable mixed population over 3-
4 weeks, for each of the 3 constructs. This provided us with a viral promoter (CMV) versus 
two endogenous promoters (one strong inducible and one weak constitutive) chosen based 
on previous reporter results, for a 3 month transgene stability experiment. 
In addition to measuring GFP over an extended period in the mixed populations (Figure 
3.5.1), we also performed FACS sorting on these populations in order to separate high, 
medium and low GFP positive cells into single cell colonies for further stability analysis. 
This allowed comparison of stability in mixed stable populations as well as single cell 
clones. 
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Figure 3.5.1: Guava™ flow cytometry GFP stability sampling results from 3 promoter 
variants (CMV, SSu72 and miR-17-92) stably transfected into CHO-K1 cells. Graph 
illustrated the progression of the 3 stable mixed populations during twice weekly passages 
by measuring GFP mean expression. 
 
Figure 3.5.1 illustrates the progression of the mixed population over sampling points; the 
cells stably expressing GFP under CMV control resulted in much higher GFP expression 
overall (~1000) but varied considerably over the first 5 timepoints. The SSu72 promoter 
driven stable GFP cells showed lower GFP expression in comparison (~200) but seemed 
more consistent and did not appear to fluctuate over the timecourse. Finally, the cells stably 
expressing GFP under control of the miR-17-92 promoter resulted in very faint GFP 
expression (~90), in keeping with previous GFP reporter results. 
The most striking feature of the data was the collapse in GFP expression in the CMV stably 
transfected cells after passage 9, dropping to 5.9% (a decrease of 94.1%), of the original 
expression. Conversely the SSu72 and miR-17-92 transfected cells remained consistent in 
their levels of GFP intensity. 
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Furthermore, the SSu72 promoter seemed to marginally enhance GFP expression over time 
(Figure 3.5.1). This was verified as the average expression figures indicated a rise from ~90 
mean GFP to ~170 mean GFP over the time period. Finally, cells transfected with the miR-
17-92 promoter, showed a reduction to 94% (decrease of 6%) of the original value which 
was not as severe as the CMV promoter effect.  
 
3.5.2: GFP-stability - Single cell populations 
Next we examined the clonal cell lines that were generated from FACS sorting (see 
Appendices 6.3.3) at weekly intervals for 14 weeks. Clones were sorted based on high, 
medium and low GFP expression this was done in order to eliminate high CMV expression 
levels seen in the mixed population results, as the cause of instability.  
After sorting, cells were maintained under selective pressure with intermittent G418 
addition to the ATCC media every 3 weeks. Cells were passaged twice weekly and GFP 
fluorescence was measured using the Guava™ flow cytometry system during one of these 
passages (Figure 3.5.2). 
We observed that all CMV driven GFP stable single cell clones show markedly reduced 
GFP expression over the 14 week timecourse in comparison to our two novel endogenous 
SSu72 and miR-17-92 driven GFP stable clones which stayed remarkably consistent. The 
drop-off in expression in single cell clones was not as obvious as was seen in the mixed 
population experiment; CMV (clone 11) was the only clone that did not yield lower GFP 
expression by the end of the experiment (GFP mean of 155 at beginning and 161 at the end 
of the timecourse) (Figure 3.5.2 A).  
Although GFP expression in the stable SSu72 clones fluctuated over the timecourse, 
whereby during weeks 3-7 we saw 6 out of 12 clones increase their GFP expression but 
ultimately returned to the original expression level by weeks 9 and 10 (Figure 3.5.2 B). 
GFP expression exhibited by the miR-17-92 clones was again relatively lower compared to 
the CMV and SSu72 clones but was noticeably consistent over the timecourse with the 
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majority of clones having higher GFP expression, albeit marginally by the last timepoint 
(Figure 3.5.2 C). 
In addition, we calculated the overall trend of the 12 clones for each gene promoter. The 
slope (m) of the trendline for each clones set of data points was calculated in Excel 
(Supplementary data). Then the average slope value across all 12 trendlines was calculated 
and imposed onto each graph to represent the overall trend of GFP expression for the entire 
12 clonal populations (Figure 3.5.2).  
CMV driven single cell clones had the largest slope of -40.2 which was indicative of the 
largest decrease in GFP expression, the minus representing a decrease. Interestingly, SSu72 
clones showed an increased trend in GFP expression levels with a slope of +8.9. Finally, 
miR-17-92 clones showed a decrease in GFP expression, but this was minute compared to 
the CMV with a slope of -0.73.  
In conclusion, this demonstrated that both endogenous promoter sequences tested can 
maintain GFP expression strength compared to a viral counterpart. Furthermore, they 
appeared to be exempt from promoter silencing over extended culture time, thus 
showcasing their potential for use in driving transgene expression in bioprocessing, by 
offering an alternative to commonly used viral promoter sequences. 
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Figure 3.5.2: FACS sorted stable single cell clonal plots for each promoter sampled over 
the same time period. Guava™ flow cytometry was used to take samples over the 
timecourse. Red line denotes overall average slope of all 12 populations for each gene 
promoter (CMV, SSu72 and miR-17-92). 
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Section 4.0  
 
 
 
 
 
 
Results 
Project 2 
XIAP as an anti-apoptotic genetic engineering target in CHO 
and a subsequent ‘MiR-Capture’ affinity pulldown technique 
to identify miRNAs targeting XIAP mRNA. 
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4.1: XIAP as a novel target for engineering in CHO 
4.1.1: IAPs and their origin 
The Inhibitor of Apoptosis protein (IAP) family are characterised by a novel domain of 
∼70 amino acids termed the baculoviral IAP repeat (BIR) one of the 3 domains defining 
the family, the name of which derives from the original discovery of these apoptosis 
suppressors in the genomes of baculoviruses by Lois Miller and her colleagues (Crook, 
Clem and Miller 1993) (Birnbaum, Clem and Miller 1994). 
First discovered in baculoviruses, IAPs were shown to be involved in suppressing the host 
cell death retort to viral infection. Interestingly, ectopic expression of some baculoviral 
IAPs blocks apoptosis in mammalian cells, suggesting conservation of the cell death 
program among diverse species and commonalities in the mechanism used by the IAPs to 
stall apoptosis in very complex mechanisms and thus be suitable targets for gene therapy 
(Smolewski and Robak 2011). 
More recently, a second group of BIR-domain-containing proteins (BIRPs) have been 
identified that includes the mammalian proteins Bruce and Survivin as well as BIR-
containing proteins in yeasts and Caenorhabditis elegans (Verhagen et al. 2001). 
 
4.1.2: XIAP in Glioblastoma 
We became interested in the possibility of using one of these IAPs, more specifically XIAP, 
as an engineering target in CHO cells after having contributed to a project entitled “MiR-
23b targets the X-Linked Inhibitor of Apoptosis (XIAP) gene in Glioblastoma”. 
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant 
primary brain tumor in humans.  
It was established that XIAP expression correlated with faster growing more invasive 
Glioma cell lines. It was concluded that by increasing the expression of miR-23b in the 
established Glioma cell line SNB-19, a 30% decrease in proliferation was achieved. 
Furthermore, from qRT-PCR analysis a 65.3% knockdown of XIAP was seen; western blot 
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analysis of the XIAP protein confirmed the expression was strongly inhibited and that there 
was a correlation between miR-23b and XIAP and both could be potential candidates for 
targeted treatment options in cancer. It is possible that a decrease of miR-23b expression in 
Glioblastomas, and subsequent unregulated expression of XIAP, has contributed to the 
ability of glioblastoma cells to evade apoptosis. 
 
4.1.3: XIAP – from human to CHO engineering 
This previous work on XIAP in the SNB-19 GBM cell line encouraged us to consider the 
use of XIAP as an engineering target in CHO cells.  
We settled on an approach to combine and apply both miRNA - XIAP anti-apoptotic theory 
and practice to the CHO environment. The first step was to see if XIAP was detectable in 
various CHO cell lines using the human SNB-19 Glioma cell line (Figure 4.1.4.1) as a 
comparison control. 
In parallel, a human XIAP overexpression vector (Origene – TruCloneTM) was transfected 
into CHO-K1 cells for the following reasons. 1) To have positive controls for the initial 
XIAP western, to make sure XIAP antibody detects XIAP expression in CHO cell lines and 
also to see difference between stable and transient transfection of the XIAP vector in CHO.  
2) To investigate whether overexpression of XIAP in CHO-K1 cells displays an anti-
apoptotic phenotype/survival compared to control cultures. We planned to measure this in 
extended time-course experiments in conjunction with using spent medium (Day 9) and 
sodium butyrate (NaBu) addition to mimic an apoptotic culture environment. 
Questions to be answered in this part of the project include; is XIAP expressed in CHO? 
Does over expression of XIAP in CHO stable clones inhibit the onset of apoptosis? Can 
XIAP specific miRNAs be identified through an in vivo capture method? Is XIAP a useful 
target in CHO engineering?  
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4.1.3.1: XIAP sequence comparison – Human and CHO 
Before progressing further, as we were investigating XIAP between both species a 
comparison between XIAP sequences from CHO and human was performed. Until recently 
the UCSC genome browser  (https://genome.ucsc.edu/) did not have a CHO sequence 
interface for searching CHO-specific sequence until Xu et al released the first draft of the 
CHO-K1 genome in 2011, but now the sequence information has been integrated into the 
UCSC website (Xu et al. 2011). 
After initial inspection, the human XIAP full genomic sequence size appeared to span 
54.1kb compared to 21.5kb in CHO (Figure 4.1.3.1). In addition, the full mRNA  transcript 
size was 8.4kb compared to 1.5kb in CHO. The 3’UTR was found to be 6791bp long in 
human XIAP whereas it was found to be 28bp in CHO.  
 
Figure 4.1.3.1: UCSC genome browser BLAT output illustrating the incomplete mapping 
of 54.1kb of human XIAP total sequence as a comparison across other species. [1] denotes 
the chromosomal location (chrx = x chromosome). [2] denotes the 3 transcript variants of 
human XIAP. [3] Mouse, Rat and CHO homolog’s highlighted as Refseq versions of 
XIAP. [4] denotes the species conservation comparisons for the mRNA coding sequences. 
[5] denotes the overall species conservation across 8 additional species for comparison in 
that region. 
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Mouse (Mus) and Rat (Rattus) homologs share similarity with the 3 human transcript 
variants shown, both span the same sequence distance, while the CHO (Cricetulus) 
homolog was markedly shorter (Figure 4.1.3.1). A comparison between the human XIAP 
mRNA sequence and CHO mRNA sequence revealed that in the human mRNA there was 
6879 more nucleotide bases, nevertheless, the sequences were found to be 88.76% 
homologous using ClustalW®.  
However, we believed this discrepancy in transcript length was highly unlikely and 
proposed that the end of the CHO XIAP 3’UTR was poorly annotated and ill-defined 
owing to the draft-nature of sequence annotation (Figure 4.1.3.1). Therefore, we 
downloaded the CHO XIAP sequence from www.CHOgenome.org, where the Cricetulus 
griseus/CHO sequences are publicly available, to establish the boundary for the CHO XIAP 
3’UTR using manual annotation.  
The scaffold containing the XIAP gene was identified as NW_003615119 from GenBank. 
By mapping the human XIAP 3’UTR to this CHO scaffold we were able to align conserved 
putative 3’UTR sequence for CHO. This allowed us to search for CHO-specific expressed 
sequence tags (ESTs) which provide further evidence of the true extent of the 3’UTR 
sequence. When tested in BLAT on the UCSC genome browser, the chromosomal location 
in the UCSC browser was found to be annotated as KE376346, not chromosome-X as 
expected. However, using Ref-Seq and expressed sequence tag (EST) comparisons, the 
location was established.  
The CHO 3’UTR sequence length cut-off was estimated based on a BLAT search of human 
XIAP 3’UTR against available C.griseus/CHO sequences using the most 3’ EST 
(JP055852). Thus we identified the transcript with the most 3’ EST sequence homology 
(TSA: Cricetulus griseus Contig13990.Crgrv2 mRNA sequence)(Figure 4.1.3.2). 
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Figure 4.1.3.2: BLAT output mapping the CHO-specific XIAP mRNA using the UCSC 
genome browser software. [1] denotes the chromosomal location. [2] denotes the input 
CHO XIAP mRNA sequence from GenBank with exons in solid blocks and introns as 
arrowed lines (arrows show direction of expression). [3] denotes the species conservation 
comparisons. [4] denotes the 3’ outermost EST reads JP055852 (long) and JI871897 
(short). Note: The orientation is 3’-5’ as XIAP in CHO is on the anti-sense strand. 
 
 
The next step was to use the multi-sequence alignment tool ClustalW® to align the XIAP 
mRNA transcript (CDS and 3’UTR only) from both species to investigate the conservation 
(see Appendices 6.2.3.1). It was found that the CHO total sequence size was 6300bp with a 
4782bp 3’UTR while the human total sequence size was 8413bp, 6791bp being the 3’UTR. 
The full transcripts had 81.01% similarity after alignment whereas the alignment for both 
3’UTR regions alone revealed 64.22% similarity.  
Figure 4.1.3.2 [3], shows that the rat 5’UTR is longer than the human and CHO homologs 
but is similar to mouse and extends outside the cropped image. Furthermore, the rat XIAP 
3’UTR is a shorter sequence compared to CHO, mouse and human. The human has 2113 
nucleotides more than the CHO transcript. One implication of this is that it may potentially 
contain more miRNA binding sites compared to rodent species.  
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Finally, the human XIAP codes on the + strand while the CHO XIAP codes on the –strand. 
In summary, using manual annotation and in silico mapping, we performed a comparison 
between both the CHO and Human XIAP gene sequence. The coding sequence was found 
to be 99% homologous (result not shown), however the 3’UTRs were less so at 64.22%, 
and the sequence similarity was interspersed even though it spans the same chromosomal 
distance (Figure 4.1.3.3). Furthermore, the CHO XIAP 3’UTR was deduced to be 2113bp 
shorter in size compared to the human version although the CHO does span the same 
chromosomal distance. It remains to be seen if this interspersed additional sequence will 
impact the amount of miRNAs detected with the expectation that miRNAs are likely to find 
binding sites on longer 3’UTR sequences.  
 
Figure 4.1.3.3: BLAT sequence of XIAP 3’UTR from CHO compared to human. Also 
shown are the transcript variants for mouse (Mus XIAP), wild boar (Sus XIAP) and rat 
(rattus XIAP) as a general comparison to the difference in conservation across species. 
 
4.1.4: XIAP expression in various cell lines 
If we were to implement XIAP as an engineering target it was important to first establish 
the levels of endogenous expression in CHO cells. Using an antibody specific to XIAP, we 
performed a western blot (Figure 4.1.4) on the following cell lines (Table 4.1.4): CHO-K1 
parental and CHO-K1-SEAP cells to test for endogenous XIAP expression, CHO cells 
transiently and stably transfected with the human XIAP plasmid as positive control and to 
examine the level of XIAP protein in a stable population. Two Glioblastoma (GBM) cell 
lines (DK-MG and SNB-19) and a normal human astrocyte (NHA) cell line were also 
included as controls.  
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Table 4.1.4: Various human and CHO cell lines (Wells 1-10) for western blot analysis, 
covering different clonal populations denoted as (1) or (2), and CHO transient and stable 
lines overexpressing XIAP. 
 
 
 
Figure 4.1.4.1: Western result for XIAP protein expression on a 4-12% SDS-Bis/Tris gel 
using protein lysates from the ten cell lines (Table 4.1.4.1). XIAP expression was detected 
at ~55 kDa along with beta-actin expression (~40 kDa) using a beta-actin house-keeping 
antibody as a loading control. XIAP was not detected in the NHA cell line (lane 5). 
 
Figure 4.1.4.1 showed that all cell lines except the ISPB-18 cell line in well 5, possessed 
detectable levels of XIAP. The CHO cells in wells 1, 4 and 10 displayed moderate 
endogenous XIAP expression. Wells 6 and 7 contained cell lysates from a transient and 
stable (mixed population) CHO-K1 parental cell line transfected with the XIAP 
overexpression vector (Origene – TruCloneTM cat. #SC119404).  
Note: In the SNB-19 cells the XIAP protein had a double-band, which has been reported 
before (Spee et al. 2006). 
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4.1.5: Single cell cloning/Isolation of XIAP high producers 
Stable XIAP-overexpressing CHO cells were generated by co-transfection of the XIAP 
vector with another vector encoding red-fluorescent protein and neomycin 
phosphotransferase (RFP-Neo). Following transfection, selection media containing G418/ 
Geneticin was used to generate mixed pools from which to derive single cell clones from, 
using the single cell cloning method (see section 2.17.1). 
After 4 weeks, 13 XIAP-positive single cell clones were isolated. A western blot was 
subsequently performed on all 13 clones. The highest XIAP expressers were identified 
from this panel to perform further functional studies (Figure 4.1.5). 
 
Figure 4.1.5: Western blot of stable XIAP clones isolated from single cell cloning. (A) 
Stable XIAP overexpression clones and GAPDH loading controls [1-3]. (B) XIAP clones 
[4-13] plus CHO-K1 parent transiently transfected with XIAP overexpression vector as a 
positive control (XIAP ~55 kDa) (GAPDH ~ 40 kDa). 
 
From figure 4.1.5, it was evident that clone 12 was the highest XIAP expresser. This was 
based on the signal strength of XIAP detected, plus the fact that it displayed a slightly 
lower signal of GAPDH protein in the loading control. This indicated there was slightly 
less protein loaded. Clones 5, 10 and 11 were also chosen for the next series of functional 
studies. The stable clones were transferred into T25 flasks and expanded while frozen 
stocks were also generated for future work.  
In parallel, the RFP-Neo vector only, was stably transfected into CHO-K1 cells and a stable 
mixed population was used as a comparative control for apoptosis studies as it represents 
the same composition apart from the XIAP cDNA. This RFP-Neo therefore represented a 
non-functional transgene control. 
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4.2: Apoptosis functional validation on cells over expressing XIAP 
Now that these XIAP stable cell cultures were derived, a series of experiments was 
performed to examine if XIAP overexpression had a beneficial phenotypic effect such as; 
increased growth, extended viability, or resistance to apoptosis.  
A study by Druz et al, used day 9 spent media to induce/trigger apoptosis in early stage 
culture settings to test apoptosis regulation by miRNAs (Druz et al. 2011). We took a 
similar approach by cultivating CHO-K1 cells for 9 days and extracting the spent media to 
use in this manner. 
We also utilised Sodium Butyrate (NaBu) which is well documented to increase cellular 
productivity, but can also induce apoptosis at higher concentrations in culture. Sodium 
butyrate is an inhibitor of histone deacetylation, and possibly, increases gene transcription 
by enhancing gene accessibility to transcription factors (Jiang and Sharfstein 2008). On the 
contrary, combinational strategies using NaBu and RNAi to both induce and curtail 
apoptosis have been shown to lead to increased production of a range of foreign proteins 
such as; EPO, iL-2, β-interferon etc (Yoon, Hong and Lee 2004) (Kim and Lee 2000) 
(Hong et al. 2011) (Sung et al. 2007).  
Subsequently, addition of NaBu was found to inhibit cell growth and decrease cell viability 
in a dose-dependent manner after optimisation (results not shown), and was chosen as a 
positive control/trigger during functional validation.  
 
4.2.1: Preliminary testing – cell behaviour in apoptosis-inducing conditions 
To begin, we tested the effect of NaBu and spent media treatment on XIAP clone 12 and 
RFP-Control stable populations. Cells were seeded at 2x10
5
/well using 6-well plate format 
which allowed 4-5 days of growth before reaching 100% confluency. The impact on cell 
morphology over time can be seen in figures 4.2.1(1, 2 & 3). We also had an untreated 
control plate seeded in parallel to monitor the progression of growth and morphology over 
time with no apoptosis inducing treatment. 
 
 
240 
 
 
Figure 4.2.1.1: Growth and cell morphology was monitored over 28 days in 6-well plate 
format. The comparison was between XIAP clone 12 and RFP-Control (Cont) stable cell 
lines cultured in ATCC media only. Images were taken by the Leica™ microscope imaging 
suite on various days in culture (3 of which were shown).  
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RFP-Control cells reached confluency by day 4, while XIAP clone 12 reached it 
approximately 24-36 hours earlier. By day 14, both populations appeared to be highly 
condensed on the plate surface, while the XIAP clone 12 populations had a more elongated 
morphology compared to the RFP-Control populations. At this early stage it seemed that 
XIAP not only conferred faster growth but seemed to result in notably less death/apoptosis. 
Furthermore, by day 28, clone 12 cells appeared healthier morphologically and RFP-
Control cells looked unhealthier, i.e: more detached and much grainier. 
Next an independent test was performed to examine if the day 9 spent media (section 
2.14.1) could be used to trigger growth arrest/apoptosis. Two types of spent media were 
used; ATCC supplemented with fetal calf serum (FCS) and ATCC without FCS, sourced 
from two populations of cells grown over 9 days. Cells were seeded at 5x10
4
/well in 24-
well plates and allowed attach for 24 hours before addition of spent media and incubated 
for 5 days at 37
o
C (Figure 4.2.1.2). 
 
 
Figure 4.2.1.2: Effect of ATCC day 9 spent media on XIAP clone 12 after 5 days in culture 
in 24-well plate format. Comparison was done between No treatment (fresh ATCC media) 
versus ATCC spent media without FCS (-) versus ATCC spent media with FCS (+). Images 
were taken by the Leica™ microscope imaging suite using default settings. 
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The absence of FCS caused more death and detachment of cells and led to an unhealthier 
cell state in both cell lines. However, the spent media containing FCS still had a 
morphological effect (spiral and elongated cell structure) on the XIAP clone 12 compared 
to the non-treated control cells (Figure 4.2.1.2).  
This morphology shown may be a defensive mechanism for cell survival or in response to 
harsh culture conditions and allowed stronger attachment/adhesion to the substratum. There 
is no evidence of this after a literature search, however, many publications have explored 
bacteria and cell morphology over extended culture. One publication showed that long term 
survival was dependant on the cell wall integrity and that S. aureus cells decreased their 
cell size significantly when starved of fresh medium (Watson et al. 1998).  
Interestingly, CHO cells elongated and seemed to get larger in harsh culture conditions. 
Future experimentation would be required involving isolating cells when they are in this 
state and testing for cell adhesion molecules (CAMs) such as integrins, selectins, CD44 and 
N-cadherin under flow/shear conditions.  
Having observed this abnormal morphological effect we repeated the experiment in 6-well 
plates to test over longer time period, owing to increased surface area. We used spent media 
once again, but this time included an ATCC media control with no FCS (-) and NaBu 
treatment (10mM) on XIAP clone 12 and RFP-Control cultures (Figure 4.2.1.3). 
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Figure 4.2.1.3: Growth and morphology of XIAP clone 12 and RFP-Control cells exposed 
to three treatments; ATCC (-) growth media without FCS, ATCC media supplemented with 
NaBu at a 10mM concentration and finally spent day 9 media also without FCS (-). Cells 
were seeded at 5x10
5
/well and allowed cells to attach in 6-well format for 12 hours before 
each treatment step. Cells were cultured over 6 days and images taken at day 2 and day 6 
time points. 
 
Observations suggested that in ATCC media, the XIAP clone 12 grew to higher densities 
with the well becoming overcrowded, however without any obvious sign of death. The 
RFP-Control also grew well albeit not to the same high densities and cells tended to 
become detached more easily, i.e: more floating cells (circular morphology) in the media 
observed (Figure 4.2.1.3). 
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The NaBu treatment resulted in the biggest difference in cell numbers and cell morphology 
between the RFP-Control and clone 12 populations. After 2 days, growth was visibly 
reduced based on comparison to ATCC (-) fresh media samples, but the XIAP clone 12 had 
more cells (ie: less affected by NaBu treatment presumably owing to the stable XIAP 
overexpression) than the RFP-Control samples.  
This was even more evident at day 6, where the RFP-Control sample wells showed  very 
low viable cell numbers and although the XIAP clone 12 samples had less cell growth in 
the NaBu treated wells than the ATCC (-) treated wells, clone 12 wells had markedly more 
growth than the corresponding RFP-Control wells regardless of condition. This would 
suggest greater resilience to death/apoptosis due to overexpression of XIAP. 
The spent media samples gave contrasting results, at day 2 there seemed to be more cells in 
the RFP-Control, however by day 6, XIAP clone 12 samples exhibited a change in 
morphology (cells became more elongated and spiral patterns were seen). Clone 12 also 
seemed to be more confluent than the RFP-Control samples beyond day 4-5.  
The NaBu treatment method appeared to be more consistent and is more routinely used in 
the literature than spent media to induce apoptosis (often there can be gross differences 
between spent media collection batches); however spent media is more representative of 
late-stage conditions in a industrial bioprocesses. 
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4.2.2: Growth and viability in adherent culture 
By performing batch timecourse experiments over 9 days, we wanted to see if differences 
in cell numbers existed between the XIAP clone 12 stable cell line and the control vector 
(RFP-Control) stable cell line. To achieve this we measured cell density, viability and 
prolonged culture survival cultured in fresh ATCC media, ATCC media supplemented with 
sodium butyrate or day 9 spent media as mentioned previously (Figure 4.2.2.1).  
The non-treated samples were indicative of a natural timecourse progression, giving an 
insight into the behaviour between clone 12 stably expressing XIAP and the RFP-Control 
population. In addition, we tested the effect on cell numbers after the induction of two 
previously reported apoptosis triggers (NaBu and day 9 spent media). 
Note: A NaBu concentration of 10mM was found to be optimal by titration experiments to 
check the effect of NaBu on healthy CHO-K1 cells, indicated by a substantial decrease in 
viability, prior to commencement of the timecourse experiment (results not shown). 
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Figure 4.2.2.1: (A) A 6-well batch culture testing growth characteristics via Guava™ flow 
cytometry Viacount®. Cell numbers calculated for stable clones expressing RFP-Neo (RFP 
cont) in comparison with XIAP (clone 12) over three treatment conditions. (No 
treatment/ATCC (-), 10mM NaBu treatment and day 9 spent media added on day 1). Cells 
seeded on day 0 at 5x10
4
 in 6-well plates and counted 6 hours later to allow attachment for 
day 0 time point. * represents statistical significance p-value <0.05, ** p-value<0.01, 
determined by a 2 tailed students T-Test between both sets of triplicate samples for RFP-
Control and XIAP populations. Error bars represent standard deviation between triplicate 
biological samples. (B) Percentage viability averages over the timecourse experiment. 
Standard deviation was so minute that it was not included. (n = 4).  
 
Interestingly, NaBu showed a growth promoting effect on Clone 12 over the first 6 days 
(4.2.2.1 A) when compared to no treatment (-) control whereas in the RFP-Control samples 
treated with NaBu, growth was arrested if not reduced markedly. Perhaps the treatment 
with NaBu increased the expression of XIAP from the CMV promoter (NaBu is a 
deacetylase inhibitor)  in clone 12, hence improving cell growth early in culture. Further 
analysis of transcript levels would be required to establish whether this was the case. It was 
also concluded that XIAP clone 12 out-performed the RFP-Control (RFP cont) regarding 
growth in the no treatment/ATCC and NaBu samples, with more significant difference seen 
at later culture time points. For example; in the no treatment samples at day 9, RFP-Control 
cell numbers reached 7.20x10
5
 cells/well whereas clone 12 cell numbers reached 1.55x10
6
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cell/well. In NaBu containing media samples, clone 12 reached 1.48x10
6
 cells/well at day 9 
compared to 4.33x10
5
 cells/well for RFP-Control.  
NaBu treatment appeared to trigger growth arrest and even decline based on counts from 
day 4 onwards compared to no treatment (-) populations. As early as day 2 the XIAP clone 
12 not only seemed to be less affected by treatment and recovered faster but rather 
continued to exhibit strong growth up to day 9.   
Although the spent media addition did trigger growth arrest in early culture, contradictorily 
the RFP-Control had infact higher growth on days 6 and 9 compared to clone 12 while the 
XIAP clone 12 counts were only higher [1.8x] than the RFP-Control on day 4, being 
2.46x10
5
 and 4.54x10
5
 cells/well respectively. 
Figure 4.2.2.1 (B) illustrates the cellular viability over the timecourse; viability for four of 
the six sample populations remained relatively high and constant whereas the two spent 
media treated populations showed reduced viability. Interestingly, the RFP-Control spent 
population seemed less affected by spent media addition than the XIAP clone 12 population 
in day 2, 4 timepoints. However, XIAP clone 12 did recover back up to ~96% in the two 
later timepoints while the RFP samples remained the same at ~76-78%. There was variation 
seen in both spent media samples (RFP-control and clone 12 populations) on day 0. This 
may possibly have been because we took the day 0 sample a few hours after seeding – 
hence the spent media had already been detrimental to the culture and thus the viability of 
the cells. 
Next we wanted to test this same approach in smaller scale 24-well plate adherent format 
(Figure 4.2.2.2). This was to observe cell behaviour in two scale formats as at different 
scales, cellular dynamics can often be varied (Feng et al. 2003). Even when seeded at a low 
density, 24-well scale only allowed for 5-6 days of culture due to confluency on the wells 
surface. Once CHO cells become confluent, growth rates typically decrease and true 
differences between cell growth counts can become less accurate. Therefore, cells were 
seeded at a lower density of 2x10
4
 cells/well to extend the culture timecourse, and although 
cells became confluent ~day 6/7, a day 9 time point was included nevertheless. 
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Figure 4.2.2.2: (A) A 24-well batch culture testing growth characteristics via Guava™ 
flow cytometry Viacount®. Cell numbers calculated for stable clones expressing RFP-Neo 
(RFP cont) in comparison with XIAP (clone 12) over three treatment conditions.  (No 
treatment (-), 10mM NaBu treatment and day 9 spent CHO-SFM-II media added on day 1 
cells have attached o/n). RFP-Control and XIAP clone 12 stable cells seeded on day 0 at 
2x10
4
 /well in 24-well plates and were allowed attach for 24 hours before treatment step. * 
represents statistical significance p-value <0.05, ** p-value<0.01, *** p-value<0.001 
determined by a 2 tailed students T-Test between both sets of triplicate samples. Error bars 
represent standard deviation between triplicate biological samples.  (B) Percentage viability 
averages over the timecourse experiment. Viability of day 0 cells was set to 99%. Standard 
deviation was so minute that it was not included. (n = 3).  
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Figure 4.2.2.2 shows the comparisons between RFP-Control and XIAP clone 12 over 9 
days in culture. In all cases the XIAP overexpressing clone 12 outperformed the RFP-
Control regarding growth and reduced onset of death and presumably apoptosis. The cell 
numbers correlate positively with preliminary observations seen in section 4.2.1 suggesting 
increased XIAP expression can benefit the longevity of adherent CHO cell culture.  
Both NaBu addition and spent media treatment appeared to trigger growth arrest thus 
allowing observations of apoptosis in CHO cells to test the effects of XIAP stable 
overexpression in apoptosis-inducing culture.  
However, contradictorily, NaBu addition onto clone 12 cells appeared to cause an 
additional growth increase compared to untreated (-) clone 12 cells. NaBu is a known 
inhibitor of histone deacetylase – perhaps treatment of Clone 12 increased acetylation of 
the viral promoter thus enhancing XIAP expression and inproving the growth/survival of 
those cells. However, this would require further investigation.   
The viability percentages can be misleading in some cases where the population densities 
of the samples are not taken into account. In other words, the viability for clone 12 samples 
were not significantly better than the RFP-Control based on the Viacount assay, however 
this does not take into consideration that there was a large disparity between population 
numbers.   
Visually we observed that XIAP clone 12 underwent a change to its cellular morphology 
(spiral/elongated) when treated with spent media in all cases. The presence of FCS in the 
spent media also prolonged and protected the cells from death for up to 4 weeks compared 
to no FCS spent media; Clone 12 seemed to enter a state of arrest/senescence while RFP-
Control cells consistently died off. 
Cell counts indicated that clone 12 had extended growth and longevity but whether this was 
a result of a direct anti-apoptotic effect was unclear at this point until we measured 
apoptosis directly via Nexin® assay (See section 4.2.5).  
Clone 12 also seemed to display extended survival in culture when compared to the RFP-
Control in most instances, early day 2 spent treatments being the only exception. The cells 
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morphology seemed to respond to spent media in XIAP clone 12, while the NaBu treatment 
seemed to trigger growth arrest and death in both stable cell lines tested. But the XIAP 
clone 12 appeared to be more resilient overall and thus seemed to be a promising 
engineering target in CHO at this early stage. 
Overall there was a difference between culture formats regarding spent media addition. The 
6-well experiment showed that spent media had a positive impact on growth but a negative 
impact was seen on growth in the 24- well plates. This may have been due to the fact that 
we used different spent media batches, even though both batches were extracted in a similar 
fashion. However, subtle variations in composition from batch to batch may have occured. 
They may have contributed to the conflicting observations on growth. 
 
4.2.3: Growth and viability in suspension culture 
Commercial bioprocessing is customarily performed in suspension culture, so we wanted to 
observe cellular behaviour in a suspension setting by first adapting both stable cell lines 
[XIAP clone 12 and RFP-Control] to suspension growth.  
Once populations were adapted after 3-4 weeks under G418 selection (Geneticin), selection 
and growth was monitored in suspension tubes in 1mL media and sub-cultered twice a 
week. After 4 weeks it was deemed that cell viability of both clone 12 and RFP-control 
cells had reached ~90% after each subsequent passage. However, when RFP-control cells 
were grown in 50mL tubes in 5mL volume, RFP-control cells had anemic growth which 
may have been a result of incomplete adaption to larger volumes and thus may not have 
been a suitable control. 
Dedicated suspension culture 24-well plates (Cellstar®) were used to cultivate the adapted 
lines (Figure 4.2.3.1). Additionally we used 50mL spin tubes (5mL working volume) 
formats in order to assess two different scales of suspension culture (Figure 4.2.3.2).  
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Figure 4.2.3.1: (A) Impact of XIAP overexpression on cell growth. Cell numbers for RFP-
Control and XIAP clone 12 in 24-well suspension plate format. Cells were seeded at 
2x10
5
/well in CHO-SFM-II serum free media and measured via Guava™ flow cytometry. 
Error bars represent standard deviation between triplicate biological samples. (B) Cellular 
% viability over the 12 day timecourse. Error bars represent standard deviation between 
triplicate biological samples. * represents statistical significance p-value <0.05, ** p-
value<0.01, *** p-value<0.001 determined by a 2 tailed students T-Test between both sets 
of triplicate samples. (n = 3). 
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Figure 4.2.3.2: (A) Impact of XIAP overexpression on cell growth. Cell numbers for RFP-
Control and XIAP clone 12 in 5mL suspension tubes. Cells were seeded at 2.5x10
5
/mL in 
CHO-SFM-II serum free media and measured via Guava™ flow cytometry. Error bars 
represent standard deviation between triplicate biological samples. (B) Cellular % viability 
over the 15 day timecourse. Error bars represent standard deviation between triplicate 
biological samples. * represents statistical significance p-value <0.05, ** p-value<0.01, *** 
p-value<0.001 determined by a 2 tailed students T-Test between both sets of triplicate 
samples. (n = 3). 
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Figures 4.2.3.1 and 4.2.3.2, illustrate the difference in growth and viability between XIAP 
clone 12 compared to the RFP-Control stable cell lines in two separate culture formats. The 
larger 5mL volume format allowed extension of culture up to day 15 compared to day 12 
for 24-well plates. Interestingly, the behavior for XIAP clone 12 is similar in both formats, 
with day 9 showing the largest cell density differential between cell lines. At each time-
point, the differences in cell numbers were significantly higher in the clone 12 samples.  
In the 24-well results, RFP-Control day 9 cell numbers reached 6x10
4
 cells/mL compared 
to ~7x10
5
 cells/mL for clone 12 - whether the low seeding density suited clone 12 more 
than the RFP-Control remains to be seen. Other seeding densities were tested but due to cell 
clumping in the RFP-Control early in culture, higher seeding densities were not pursued. 
Day 9 cell numbers in 5mL culture reached over 3x10
6
 cells/mL compared to RFP-Control 
cell samples reaching less than half that at ~1.40x10
6
 cells/mL. 
However, there were differences in viabilities seen between formats. In 24-well plates the 
cellular viability for clone 12 was relatively high considering the late stage of culture, being 
~53% compared to ~23% in RFP samples on day 12. From the 2mL results on days 3 and 
6, RFP samples actually had higher viability, RFP being ~89% after day 3 and ~66% after 
day 6, compared to clone 12 being ~74% after day 3 and ~61% after day 6.  
However, cell numbers on these two days were double in the clone 12 samples compared to 
RFP, so we attributed some of this viability difference to a faster growth phenotype 
displayed by clone 12. Regardless, it appears clone 12 exerted its superior resistance to 
death/apoptosis and a switch was seen between days 6 and 9 (Figure 4.2.3.2 B), 
culminating in clone 12 having a viabilities of 39% compared to 18% for RFP-Control after 
15 days in culture.  
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4.2.3.1: XIAP clonal variation – Growth in suspension culture 
In order to discount the possibility of simple clonal effects as the source of the beneficial 
phenotypes we wanted to adapt and test the other XIAP clones [5, 10 and 11] previously 
isolated to see if they follow the same phenotype as clone 12. This was conducted using the 
same experimental design but with CHO-SFM-II serum free media as the no treatment 
control instead of ATCC used previously and again NaBu addition was used to induce 
apoptosis to see if clonal differences were apparent.  
From the western (Figure 4.1.5) we saw that after FACS sorting of XIAP clones (1-13) had 
slightly varying levels of XIAP expression and all lower than clone 12 (hence why it was 
chosen originally), clones 5, 10 and 11 were chosen along with clone 12 to test further. To 
recap, the RFP-Control is a mixed population of CHO cells transfected with the RFP-Neo 
vector, which was co-transfected with the XIAP overexpression vector originally to 
facilitate cloning selection. 
These three XIAP overexpressing clones were first adapted to serum-free suspension 
culture. This was achieved by growing the cells in T25 flasks for 4 weeks while 
continuously titrating to lower % FCS and a blend of CHO-SFM-II and ATCC media. 
Finally, as the cells no longer needed FCS they were cultured in CHO-SFM-II serum free 
media specially formulated for suspension growth. 
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Figure 4.2.3.1.1: (A) Cell numbers for RFP-Control stable CHO-K1 cell line and XIAP clones 5, 10 and 11 grown in 24-well plate 
suspension culture format. Cells were seeded at 2.5x10
4
/well in 1mL CHO-SFM-II serum free media and or NaBu treatment 12 hours post 
seeding. Cell were measured via Guava™ flow Cytometry and viacount® reagent. * represents statistical significance p-value <0.05, ** p-
value<0.01, *** p-value<0.001 determined by a 2 tailed students T-Test between both sets of triplicate samples with the asterisk placed on 
the XIAP clone sample bars representing its corresponding RFP-Control bars. Error bars represent standard deviation between triplicate 
biological samples. (n = 3). 
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Figure 4.2.3.1.1: (B) Cell percentage viability of samples seen in figure 4.2.3.1.1. Cells 
measured via Guava™ flow Cytometry and Viacount® reagent over a 15 day timecourse. 
Error bars represent standard deviation between biological triplicates. (n = 3). 
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Overall the same trend was observed, regardless of scale between 24-well and 5mL in 
suspension, where XIAP clone 12 surpassed the RFP-Control in growth and extended viability 
in culture. Whether this was due to a direct anti-apoptotic effect to mitigate death/apoptosis 
will be investigated with the Nexin® assay in section 4.2.5.  
These results suggested our previous observations for clone 12 were not a clonal anomaly as 
we provide evidence using three other XIAP clones (5-10-11) that perform in a similar 
fashion, albeit with clone 10 to a lesser extent in control CHO-SFM-II and NaBu treatment 
samples from figure 4.2.3.1.1 (A). Although higher counts were seen in XIAP clone 10 at all 
timepoints irrespective of treatment, clone 10 cell counts were only significantly different at 
day 9 for SFM samples being 4.29x10
5
 cells/mL in RFP-Control versus 4.57x10
5
 cells/mL in 
clone 10. While in the NaBu samples, the same trend was observed with the XIAP clone 10 
having higher cell counts but the differential between RFP-Control and clone 10 were only 
significant on days 3 and 12.  
This observation correlates well with the initial western blot clonal screening where clone 10 
had a lower XIAP expression (and thus perhaps less anti-apoptotic influence) compared to 
clones 5, 11 and clone 12 which displayed the highest XIAP expression although this was not 
quantified directly but based on visual interpretation of the western blot (Figure 4.1.5).  
The viability of clones 5, 10 and 11, grown in the control serum-free media in all cases was 
highest over the batch timecourse, with the only exception on day 15 for clone 5, whereby 
viability dropped below both NaBu treated samples. There was also a noticeable drop in 
viability at day 6 in all NaBu treated samples, presumably due to the effect of the NaBu 
influencing the cells more strongly. Interestingly, both the RFP-Control and all 3 clones 
appeared to recover at similar rates, however, the XIAP overexpression does seem to allow 
recovery to higher viability percentages (Figure 4.2.3.1.1 B). 
 
 
 
 
 
 
258 
 
4.2.4: Fed-batch culture – Growth and viability in suspension culture 
This positive impact in a batch culture setting led us to consider whether it would be equally 
beneficial in a fed-batch setting.  Having previously adapted all stable clones [RFP-Control 
and XIAP clones 5-10-11-12] to suspension growth, clones were monitored in 5mL volumes 
in 50mL suspension culture tubes over the same timecourse with batch feeding (CHO CD 
Efficientfeed™ A) - every second day to replace 10% of media volume. 
The question of whether the advantageous phenotypes carry over into a fed-batch setting was 
investigated and the growth and viability results were shown in figures 4.2.4.1 (A, B). The 
reasons for this experiment were two-fold. Firstly, to investigate XIAP overexpressing clones 
in a small-scale fed-batch setting and secondly, to confirm clonal variance wasn’t seen in fed-
batch culture. 
Factors impacting on density can be attributed to non-optimal feeding, coupled with the much 
smaller seeding density of 5x10
4
 cells/mL compared to 2x10
5
 cells/mL, more commonly used 
for timecourse experiments. Since the aim was to capture as much of the cell behaviour over 
the longest possible time range, cell seeding needed to be this low. 
Cells proliferated exponentially over the first 2 days based on seeding of 5x10
4
 cells/mL 
reaching ≥2x105 cells/mL by day 2, but growth appeared to slow after the first supplement of 
Efficientfeed™. The feeding was perhaps not optimal for exponential growth past day 4, 
however it did allow enough time for the cells to be observed up to day 10.  
Osmolality, substrate inhibition and nutrient turnover may be limiting parameters here also; 
but without the same resources to investigate these more complex factors of a fed-batch 
culture the interplay between these factors remains unclear.  
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Figure 4.2.4.1: (A) Cell numbers for RFP-Control stable cell line and XIAP clones 5, 10, 11 
and 12 cell lines in 50mL tube suspension fed-batch format (5mL working volume). Cells 
were seeded at 5x10
4
 cells/well in CHO-SFM-II serum free media and measured via Guava™ 
flow Cytometry viacount® over 10 days. * represents statistical significance p-value <0.05, ** 
p-value<0.01, *** p-value<0.001 determined by a 2 tailed students T-Test between both sets 
of triplicate samples with the asterisk placed on the XIAP clone sample bars representing the 
difference between the corresponding RFP-Control bars on left of blue line. Error bars 
represent standard deviation between triplicate biological samples. 0.5mL of culture was 
removed and supplemented with 0.5mL Efficientfeed™ every 2 days (10%). (B) Cell 
percentage viability of samples seen in (A) over 10 days. Error bars represent standard 
deviation between triplicate biological samples. (n = 3). 
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Two observations were reported. All 4 stable XIAP clones tested against the RFP-Control 
exhibited greater propensity for higher growth densities at each timepoint, for example, clones 
5 and 12 had 5-6-fold greater cell numbers than RFP at day 10 (Figure 4.2.4.1 A). 
Interestingly, the RFP-Control viability was higher than all clones apart from on day 10 
(Figure 4.2.4.1 B), again this observation may be attributed to higher cell densities in all XIAP 
clones overall. Clone 10 again appeared to exhibit less of a growth effect than the other XIAP 
clones regarding growth rate and survival compared to the RFP-Control, mirroring results seen 
in figure 4.2.3.1.1. Viability of the RFP-Control dropped 7% on day 10 while all XIAP clones 
were markedly higher with clone 12 having the most viable cells at 47%. XIAP clones 5 and 
11 had larger decreases in viability between days 8 and 10, being 48% and 56% respectively 
(Figure 4.2.4.1 B). 
These results demonstrate that stable expression of anti-apoptotic gene XIAP can increase the 
growth and survival in a CHO cell line over a range of culture formats and scale. As 
mentioned clumping was an issue for the RFP-Control, where the population began clumping 
after day 4; this was circumvented to some extent with the supplementation of polyvinyl 
alcohol (PVA) in the media. PVA is a water soluble non-toxic synthetic polymer which 
prevented clumping in all XIAP clones after day 6, but was less effective in RFP-Control 
samples, maybe highlighting further the utility of XIAP overexpression in suspension culture.  
However, the experiment appeared to suffer from some constraints compared to batch culture, 
such as; the RFP-Control cells did not grow well in larger suspension volume and exhibited 
cell clumping after day 4 in culture, likewise none of the populations seem to fulfill their 
potential for high viable cell density (AIVCD) as seen in other fed-batch experiments, with 
cells normally reaching 5x10
6
 cells/mL in 5mL total volumes as reported by (Hewitt and 
Nienow 2007)( Yang et al. 2014)(Lee et al. 1999). 
Finally, although XIAP would be expected to mediate its effect on cell density via inhibition 
of apoptosis, this only appeared to be the case later in culture. At earlier timepoints, if 
anything, the viability seemed to be routinely higher in the RFP-Control cell line; this was 
confirmed later in the Nexin® assay. 
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4.2.5: Apoptosis - Nexin® Assay on adherent and suspension culture 
In the early stages of apoptosis, changes occur at the cell surface which can be difficult to 
recognise and differentiate between the stages of death. The Nexin® /Annexin V assay, offers 
the possibility of detecting early phases of apoptosis before the loss of cell membrane integrity 
and permits measurements of the kinetics of apoptotic death (Vermes et al. 1995).  
The assay uses the Annexin V protein to tag apoptotic and dead cells within a culture, the 
numbers are then counted by Guava® flow cytometry. The mix-and-read Guava Nexin Assay 
relies on a two-dye strategy. The assay utilises Annexin V-PE to detect the translocation of 
phosphatidylserine (PS) to the external surface of the membrane of apoptotic cells, an early 
indication of commitment to apoptosis. The Guava Nexin Assay incorporates this PS-Annexin 
V-PE binding as an indicator of early stage apoptotic cells. The cell impermeant dye 7-AAD is 
included in the Guava Nexin Reagent as an indicator of membrane structural integrity. 7-AAD 
is excluded from live healthy cells and early apoptotic cells, but permeates late stage apoptotic 
and dead cells.  
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Figure 4.2.5.1:  Measuring Apoptosis via Nexin® Assay apoptotic index for RFP-Control and 
XIAP clone 12 cell lines. Cells were evaluated using the Guava™ flow cytometry over a 12 
day timecourse in 24-well adherent culture. Error bars represent standard deviation between 
triplicate biological samples. * represents statistical significance p-value <0.05, ** p-
value<0.01, *** p-value<0.001 determined by a 2 tailed students T-Test between both sets of 
triplicate samples with the asterisk placed on the XIAP clone sample bars representing the 
difference between its corresponding RFP-Control bars.  
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In keeping with the earlier viability measurements, XIAP clone 12 was found to have higher 
levels of apoptotic cells on days 3 and 6 compared to the RFP-Control. However on day 9 a 
shift occurred where XIAP clone 12 still maintained a higher percentage of cells in early 
apoptosis but actually had fewer cells progressing to late apoptosis unlike the RFP samples 
(Figure 4.2.5.1). For example; out of 2500 events measured by flow cytometry on day 12, 
RFP-Control samples had on average 703 cells in early apoptotic state and 328 cells in late 
apoptosis, compared to clone 12 which had 734 cells in early apoptosis but only 58 cells in 
late apoptosis.  
It is important to note that total cell numbers for XIAP clone 12 samples were double 
compared to RFP-Control samples on days 3, 6 and 9 due to higher growth rate as seen in 
section 4.2. For example on day 3, the average cell density for RFP-Control was 5x10
5
 
cells/mL while in clone 12 samples the cell density was 1.49x10
6 
cells/mL. On day 12, RFP 
average cell densities were 4.73x10
5
 cells/mL while clone 12 average the cell density was 
9.92x10
5
 cells/mL.  
In conclusion, the extended culture survival phenotype of XIAP clone 12 can be attributed to 
an anti-apoptotic effect at later stages of culture for both attached and suspension experiments. 
Therefore, it is unlikely that entire clonal behavior was down to apoptosis-resistance solely.  
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4.2.6: Functional Validation using RNAi - XIAP effect on growth 
Stable XIAP overexpression appeared to increase cell growth and reduce apoptosis in the 
previous section. In order to further confirm the role of XIAP in this observation, the aim of 
this experimental section was to specifically knockdown XIAP in two cell lines using RNAi. 
To examine whether this increased growth/reduced apoptosis was specifically a result of XIAP 
overexpression, we wanted to see whether these phenotypes could be reversed by specifically 
knocking down XIAP using RNAi.  
XIAP clones and CHO-K1 cells (not to be confused with the stable RFP-control CHO cells) 
were grown in two formats, 24-well suspension plates and 2mL suspension tubes. We 
measured the cell counts and viability post- transfection to see the impact various siRNAs had 
on both cell lines. Additionally a comparison using two different CHO cell lines, the CHO-K1 
parental cell line and the XIAP stable clone 12 (CHO-K1 also had detectable endogenous 
XIAP expression as shown in figure 4.1.3.1) in 24-well suspension culture over a 6 day 
timecourse. 
The XIAP siRNA was pre-designed by Ambion® from the Silencer® select range to target the 
human XIAP transcript (NM_001167U32974.1) which the stable XIAP clone 12 was 
transfected with. A control VCP siRNA was also chosen, and targets the Valosin-containing 
protein which is an ubiquitin segregase that remodels multimeric protein complexes by 
extracting polyubiquitinated proteins for recycling or degradation by the proteasome. It is 
responsible for proper functionality of CHO cells and when knocked down, reduces viability 
and growth radically. It has been used as an in-house siRNA knockdown positive control since 
it was identified and functionally validated by Doolan et al, in a large scale microarray CHO 
specific profiling study (Doolan et al. 2010). The negative siRNA control (siNeg) was a 
scrambled sequence that should not target any coding sequence within CHO cells and served 
to control for non-specific effects of the transfection. 
Figure 4.2.6 depicts the sequence comparison between the siRNA and the CHO mRNA target. 
Despite the 2 base mismatches, we predicted that it might also target the endogenous hamster 
XIAP transcript the main purpose was to reverse the overexpression of human XIAP – not 
necessarily deplete endogenous version. 
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Figure 4.2.6: Sequence alignment between Silencer® XIAP siRNA and the CHO mRNA 
sequence target. A 2 base mismatch is shown at base numbers 11 and 16. 
 
After transfection, we analysied the cells via flow cytometry to see the effects of the various 
siRNAs. Figure 4.2.6.2 illustrates the cell counts and viability results for XIAP clone 12 in 
2mL suspension tubes over 6 days post-transfection with XIAP, VCP and scramble negative 
siRNAs. 
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Figure 4.2.6.1: Functional validation using siRNAs targeting XIAP, VCP and a scrambled negative control (siNeg) of cells grown in 
24-well suspension over 6 day culture. CHO-K1 and XIAP clone 12 cells used for functional comparison and the cells were seeded at 
2x10
5
/mL. * represents a p-value <0.05, ** p-value<0.01, *** p-value<0.001 as determined by a 2 tailed students T-Test between 
triplicate samples and placed on the siNeg data points to represent the statistical significance between siXIAP and siNeg values. 
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Figure 4.2.6.2: Functional validation using siRNAs targeting XIAP, VCP and a scramble 
siRNA negative (siNeg) control for XIAP stable clone 12 cells grown in 2mL tube 
suspension over 6 day culture. Cells were seeded at 2x10
5
/mL. Error bars represent 
standard deviation between triplicate biological samples. * represents a p-value <0.05, ** 
p-value<0.01, *** p-value<0.001 as determined by a 2 tailed students T-Test between 
triplicate samples and placed on the siNeg data points to represent the statistical 
significance between siXIAP and siNeg values.  
 
The cell counts and viability measured from the 24-well format culture showed that over 6 
days the XIAP-specific siRNA (siXIAP) did significantly impact on cell growth and 
viability in Clone 12 and CHO-K1 cells in comparison to the negative control (siNeg) 
siRNA. The siVCP positive control displayed the expected phenotype (suppressed growth 
and decreased viability) demonstrating that the transfection was successful (Figure 4.2.6.1).  
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By knocking down XIAP there was a significant reduction in cell numbers at days 4 and 6, 
while a reduction in cell counts was seen at day 2 for both cell types, though not significant.  
Clone 12 cell numbers were the highest on day 4, with the siNeg samples reaching 
1.30x10
6
 cells/mL; this indicated the natural cell density of the stable XIAP clone 12 cells, 
whereas after knocking down XIAP, cell counts decreased to 8.2x10
5
 cells/mL. 
Interestingly, the highest cell numbers seen in the CHO-K1 siNeg samples were on day 6 
and reached 9.65x10
5
 cells/mL compared to 5.75x10
5
 cells/mL in the siXIAP treated 
samples, again indicating that knocking down XIAP does appear to impact on the growth 
characteristics of both clone 12 and CHO-K1 cell lines. 
Furthermore, the results showed that viability was significantly reduced in siXIAP 
transfected samples in comparison to the siNeg control transfected samples on days 2, 4 
and 6 for both clone 12 and CHO-K1. Interestingly, the percentage viability seen in siXIAP 
transfected samples on day 6 in the CHO-K1 cells dropped to 30%, 8% below the siVCP 
transfected samples.  
The biggest differential between cell counts after siRNA transfection of clone 12 was seen 
on day 4 in 24-well culture whereby siXIAP samples were 8x10
5
 cells/mL and the siNeg 
control counts were 1.30x10
6 
cells/mL. The biggest viability differential was seen on day 6 
in the 24-well culture, where clone 12 had 71% viability in the siNeg and 39% in the 
siXIAP. In contrast the CHO-K1 cell line had 50% viability in siNeg samples while in the 
siXIAP samples had 32% viability at day 6.  
XIAP knockdown had a more marginal functional effect on cell growth and viability after 
day 6 compared to clone 12 in 24-well culture at day 6, but was statistically significant 
(Figure 4.2.6.2). The biggest differential was seen on day 6 in cell count with siNeg 
transfected cells being 4x10
5
 cells/mL and siXIAP transfected cells being reduced to 
2.8x10
5
 cells/mL, while the viability was 32% in siNeg samples and reduced to 19% in 
siXIAP samples. 
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Additionally, a western blot was performed to show XIAP expression at the protein level 
(Figure 4.2.6.3). This was performed to see the functional efficacy of the XIAP siRNA 
post-transfection into CHO-K1 and XIAP clone 12 cells. It was observed that the XIAP 
was knocked down on day 3 in both cell lines with CHO-K1 showing less XIAP protein 
compared to XIAP clone 12 (Figure 4.2.6.3).  
 
 
Figure 4.2.6.3: Western blot to validate XIAP siRNA knockdown in CHO-K1 and XIAP 
clone 12 cell lines in 24-well suspension culture post-transfection. A positive XIAP protein 
control sample from a transient transfection sample seen in figure 4.1.3.1 plus a GAPDH 
loading control were also included. (XIAP ~55-57kDa) (GAPDH ~ 40kDa).  
 
Figure 4.2.6.3 illustrates that by day 6 the XIAP knockdown was more obvious in the 
CHO-K1 cell line which may simply be due to the higher levels initially present in clone 
12. In the clone 12 samples, the XIAP protein was reduced, but was still present on day 3; 
and detection of the protein was shown to be similarly decreased at day 6.  
Additionally, Gapdh appeared to be marginally lower in the siNeg XIAP clone 12 samples 
compared to siXIAP – this would, in theory, mean endogenous XIAP levels were higher 
than they appear on the western gel image. 
Taken together, from these results we concluded that the XIAP siRNA (siXIAP) caused a 
reverse in functional phenotype in the XIAP clone 12 and indeed parental CHO-K1 growth 
densities compared to a scramble siRNA negative control (siNeg). Late culture exhibited 
the most significant cell count changes, with the most significant differences seen at day 6. 
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The siXIAP samples were evidently reduced compared to the scramble siNeg control in all 
cases (Figure 4.2.6.1), thus confirming the functional role of XIAP, at least partially in 
impacting cell growth and survival.  
 
4.2.7: XIAP clone 12 productivity results 
In light of of previous results showing increased growth and survival by the XIAP clones 
and clone 12 in particular, the next step was to see if XIAP engineering could be used to 
impact on productivity. SEAP, and two industrially relevant proteins, EPO and IgG were 
transfected into clone 12 to investigate whether this phenotype could increase overall 
protein production compared to the RFP-Control. 
 
4.2.7.1: SEAP productivity 
A vector containing SEAP driven by the CMV promoter was transfected into XIAP clone 
12 and RFP-Control cell lines to test SEAP productivity over 12 days. Cells were seeded at 
1.5x10
4 
cells/well into 24-well plates on day 0 and allowed attach for 12 hours before 
transfection of SEAP-vector (a sample was taken here as day 0).  
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Figure 4.2.7.1.1: (A) Volumetric SEAP productivity assay over a 12 day timecourse post-
transient transfection of the SEAP vector into XIAP clone 12 and RFP-Control cell lines. 
SEAP was measured per 50μl of supernatant from cells grown in 24-well suspension plates. 
Cells were seeded at 1.5x10
4
 cells/well in ATCC+5% FCS on day 0. SEAP units were 
normalised by calculating the mean V (slope) of the SEAP activity using the BioTek™ 
KC4 plate reader. * represents statistical significance p-value <0.05, ** p-value<0.01, *** 
p-value<0.001 determined by a 2 tailed students T-Test between both sample sets of 
triplicate samples. (B) Normalised SEAP productivity calculated per cell by dividing total 
SEAP by the cell counts for each sample. All error bars represent standard deviation 
between triplicate biological samples.  
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Volumetric SEAP activity was more than twice as much in clone 12 samples compared to 
RFP-Control samples at all time points. For example on day 9 SEAP was ~125 SEAP units 
in RFP-Control samples compared to ~320 SEAP units in clone 12 samples (Figure 
4.2.7.1.1 A). 
We also wanted to investigate a normalised SEAP productivity per cell, from our analysis 
there was no significant difference between both cell lines in terms of specific 
productivities. However, on each day, productivity per cell tended to be higher in clone 12. 
For example; on day 9 normalised SEAP activity per cell was 0.00501 in RFP-Control 
compared to 0.00732 SEAP detected in clone 12 (Figure 4.2.7.1.1 B).  
In addition, the large increase in SEAP activity per cell seen at day 12 can perhaps be 
attributed to a substantial drop in cell viability for both cell lines, therefore less viable cells 
were subsequently counted on day 12, causing the per cell productivity to appear increased. 
 
4.2.7.2: EPO productivity 
Next we wanted to investigate the productivity of another protein in clone 12 compared to 
the RFP-Control. Cells were seeded at the same density of 1.5x10
4
/well and grown in 
ATCC+5% FCS for 12 hours prior to transfection of an EPO-vector driven by a CMV 
promoter into both cell lines. Erythropoietin (EPO) is an example of a therapeutic protein 
manufactured in CHO cells and many studies have been conducted to increase its 
production (Trummer et al. 2006) (Hong et al. 2007) (Park et al. 2012). 
A western blot was performed to measure the levels of EPO protein post-transfection, 
samples were taken at days 2, 4, 7, 10 and 12 with days 4, 7 and 10 results shown (Figure 
4.2.7.2). 
We observed an increase in EPO protein yield over the timecourse for both cell lines, with 
an obvious increase in the XIAP clone 12 samples at each time-point compared to the RFP-
Control.  
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Figure 4.2.7.2: Western blot of extracellular EPO secreted by RFP-Control and XIAP 
clone 12 cell lines over 12 days in 24-well suspension culture. Cells were seeded at 
1.5x10
4
/well. (XIAP ~55-57kDa). Equal volumes of supernatant were loaded per lane. No 
GAPDH loading control used as extracellular protein taken from culture supernatant. 
 
4.2.7.2.1: Densitometry - EPO 
Additionally, we converted all EPO band intensities from the western result into 
quantitative numerical values using densitometry to quantify the difference in EPO 
production between RFP-Control and XIAP clone 12. Using Total-Lab Quant™ software 
we analysed the optical density of the pixels on the photographic film (Figure 4.2.7.2.2). 
From this, we were able to calculate a percentage and fold-change increase relative to the 
RFP-Control samples at each time-point. 
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Figure 4.2.7.2.1: Densitometry using Total-Lab Quant™ on the western blot for EPO 
productivity. Comparison of RFP-Control (set to 1) and XIAP clone 12 cell lines over days 
4, 7 and 12. Percentage increase between RFP-Control and clone 12 on each day placed on 
the XIAP bar headers. 
 
Densitometry results provided further evidence that XIAP clone 12 did indeed produce 
more EPO than the RFP-Control. On day 4 the largest increase of 1.42-fold was seen in 
XIAP clone 12, while on day 7, the increase was much less but still higher at 1.08-fold. 
Five days later, presumably owing to increased cell numbers at the early stages of culture 
and resistance to apoptosis at later stages (after day 6 based on Nexin results seen 
previously), the XIAP clone 12 produced 1.28-fold more EPO than the RFP-Control.  
Ideally, for a future experiment we would like to extend this culture even longer and 
examine EPO productivity beyond 12 days, however, we are aware that product quality 
may deteriorate over time in harsh culture conditions. 
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4.2.7.3: IgG productivity  
Finally, we wanted to determine whether cells stably overexpressing IgG (in-house CHO 
1.14 cell line) yielded more monoclonal antibody (mAb), compared to control cells. Both a 
XIAP overexpression vector and a RFP-Neo vector (as before) were co-transfected with an 
in-house hygromycin resistance (HYG) vector into CHO 1.14 cells and was used to select 
stable mixed populations after 4 weeks.  
Note: Having previously experimented with transient transfection of both vectors into CHO 
1.14, no significant effect was seen (results not shown).  
To ensure that the increased growth and survival phenotypes, seen previously in stable 
transfected CHO-K1 cells, repeated in another CHO cell line – we first measured the cell 
numbers and viability of the 1.14 cell line stably expressing RFP and XIAP (Figure 
4.2.7.3.1). Due to clumping, day 9 was the maximum longevity of the timecourse.  
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Figure 4.2.7.3.1: CHO 1.14 cell numbers and viability percentage measured over 9 days to 
investigate the RFP-Neo control stable population compared to the XIAP stable population. 
Cells were seeded at 2x10
4
/well in 24-well plates and measured via Guava™ flow 
cytometry. * represents statistical significance p-value <0.05, ** p-value<0.01, *** p-
value<0.001 determined by a 2 tailed students T-Test between both sample sets of triplicate 
samples for cell counts and cell viability. Asterisks were placed on viability error bars of 
XIAP 1.14 data points and denote the statistical significance between the respective RFP 
1.14 data points. 
 
It was shown that stable XIAP transfected CHO-1.14 cells grew faster and had prolonged 
viability compared to RFP stably transfected CHO 1.14 cells (Figure 4.2.7.3.1). Cell 
numbers at each time point were significantly higher overall in the XIAP expressing cells 
than the respective RFP expressing cells. After 2 days in culture XIAP stable cell densities 
reached 5.05x10
4
 cells/well which was 1.56-fold higher than the RFP stable control average 
density of 3.3x10
4
 cells/well.  
More strikingly, on day 9, XIAP expressing cell numbers reached 1.98x10
5
 cells/well 
compared to only 7.33x10
4
 cells/well for the RFP expressing cells, making the differential 
between cell numbers 2.7-fold higher in the stable XIAP samples.  
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Furthermore, viability was also shown to be significantly higher overall in XIAP stable 
cells, for example; viability for XIAP 1.14 cells was comparatively higher ~51% than the 
RFP 1.14 cells which dropped to ~25% on day 9. Taken together, once again this 
highlighted that the stable overexpression of XIAP increased growth and reduced death 
phenotypes, this time in a variation of another CHO cell line. 
In parallel, we took supernatant aliquots from all assayed cell samples at each timepoint in 
order to examine the IgG productivity using an ELISA assay (Figure 4.2.7.3.2).   
 
 
Figure 4.2.7.3.2: ELISA assay to test IgG concentration of stable CHO 1.14 cells 
transfected with XIAP and RFP-Neo vectors grown in 2mL suspension tubes over a 9 day 
timecourse. Error bars represent standard deviation between triplicate biological samples. 
Fold change between cells represented by [x]. * represents statistical significance p-value 
<0.05, ** p-value<0.01, *** p-value<0.001 determined by a 2 tailed students T-Test 
between both sets of triplicate samples.  
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It was found that at each timepoint, IgG concentration was higher in the XIAP stable cell 
line in comparison to the RFP control, with the fold change between RFP and XIAP clone 
12 reaching a maximum of 2.98-fold on day 6. On day 9, the IgG concentration in the 
XIAP expressing 1.14 samples had reached ~370 ng/mL compared to ~162 ng/mL in the 
RFP expressing control samples (Figure 4.2.7.3.2).  
This increase in IgG could be attributed to more cells being present in the XIAP samples, 
whereby it out-performed the RFP control, owing to the increased growth and survival 
phenotypes shown previously.  
Therefore, we wanted to examine the average specific productivity (Qp) for each sample. 
The specific productivity was calculated and revealed that on days 2, 4 and 6, the stable 
XIAP 1.14 cells had a significantly higher Qp than the stable RFP cells (Table 4.2.7.3). 
However, the day 9 values were not statistically significantly different between RFP and 
XIAP cell lines. 
 
Table 4.2.7.3: Specific IgG per cell productivity (pg/cell/day) of RFP stable 1.14 CHO 
cells compared to XIAP stable 1.14 CHO cells over 9 days in culture. Specific productivity 
(Qp) was calculated as the IgG titre divided by the accumulated integral viable cell density 
(AIVCD). * represents statistical a significance p-value of <0.05, ** p-value<0.01, 
determined by a 3 tailed students T-Test between both sets of triplicate samples. 
 
In conclusion, these productivity results, further support findings that XIAP overexpression 
in two separate cell lines can be beneficial in increasing IgG productivity, with a more 
modest impact on SEAP and EPO productivity.  
 
Specific (Qp)  IgG
RFP  Qp ± SD XIAP Qp ± SD
Day 2 0.175 0.009 0.238* 0.024
Day 4 0.201 0.010 0.267* 0.025
Day 6 0.167 0.007 0.276** 0.022
Day 9 0.155 0.009 0.174 0.012
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4.3: Identification and Validation of miRNAs using a novel Capture technique 
4.3.1: XIAP is a direct and functional target of miRNAs 
As mentioned in sections 4.1.2 and 4.1.3, we referred to previous work in Glioma which 
had identified an anti-correlation between XIAP and miR-23b expression in SNB-19 cells. 
In this section we aim to use a novel method to identify other miRNAs that target XIAP. 
Having shown XIAP to be an attractive gene target for engineering in CHO cells, we 
wanted to establish which miRNAs regulate its expression.  
Since miRNAs regulate gene expression usually via controlled targeting of a mRNA, a 
rational step was to identify miRNAs involved in XIAP expression with a view to using 
them as a means to manipulate XIAP expression in CHO cells in a bioreactor setting for 
example. Furthermore, this study provided an opportunity to perform a direct comparison 
between human (SNB-19) and CHO (CHO-K1) XIAP transcripts in terms of the milieu of 
miRNAs that bind to each orthologue. 
Upon bioinformatic analysis it was shown that the human XIAP 3’UTR was much longer 
(2113bp) in sequence than its CHO orthologue (Figure 4.1.3.3). From the outset, this would 
imply that many more miRNAs have the potential to interact and bind with human XIAP. 
Investigating the difference between a longer XIAP sequence and a shorter one in two 
different organisms to see what miRNAs are common or unique would be interesting.  
Through in silico analysis, the XIAP sequence was screened using prediction tools; 
TargetScan™ (www. Targetscan.org) miRanda® (www.microRNA.org) and mirBase® 
(www.mirbase.org) - together these databases predicted many miRNAs including three 
putative binding sites for miR-23b (Figure 4.3.1.1).  
In a parallel study in human Glioblastoma cell lines, we used standard miRNA 
methodologies to determine whether XIAP mRNA was a molecular target of miR-23b. By 
using an miR-23b pre-miR mimic to increase the abundance of miRNA-23b in SNB-19 
GBM cells, we wanted to examine the effect on XIAP expression. This was achieved by 
analyising GFP-reporter gene expression combined with the presence of the XIAP 3’UTR.  
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Figure 4.3.1.1: (A) The three predicted binding sites of miR-23b within the 6791bp XIAP 
3’UTR sequence. Shown are the base pair positions of the 3 predicted binding sites +999, 
+3102 and +4634 from the start (+1) of the XIAP 3’UTR after the TAA stop codon of the 
XIAP gene. (B) The miR-23b mimics mature sequence with nomenclature and order 
number. 
 
We also investigated the effect overexpression of miR-23b had on the mRNA (qPCR) and 
protein level (Western blot) of XIAP after transfection into SNB-19 cells (Figure 4.3.1.2). 
XIAP expression was suppressed following transient transfection of SNB-19 cells with 
miR-23b mimics. The cellular levels of a genuine biological target of a miRNA would be 
expected to anti-correlate with the levels of the miRNA in question. The levels of the XIAP 
mRNA post-transient transfection with miR-23b were found to be significantly repressed 
(~65 %) in comparison to the control cells and premiR-scramble negative (PMN) (Figure 
4.3.1.2 A).  
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This was further confirmed by a western blot, whereby XIAP protein levels were also 
considerably lower in miR-23b treated cells, demonstrating that miR-23b played a role in 
regulation of the cellular levels of XIAP in these cells. A decrease in protein expression 
was seen after miR-23b mimics transfections (Figure 4.3.1.2.B), this could have been direct 
or indirect; to refine this further the next step was to functionally test this XIAP-miR-23b 
interaction.  
 
 
Figure 4.3.1.2: (A) Relative expression of XIAP in SNB-19 cells measured by qRT-PCR 
post transfection with pre-miR-23b. A negative pre-miR (PM-Neg) was used as a control; 
each sample was measured in technical triplicate (n = 3). (B) Western blot of XIAP protein 
expression in SNB-19, samples for cells only with no miR-treatment plus cells post 
transient transfection with negative-pre-miR (PM- control) and the premiR mimics of miR-
23b. 
 
We used 3 reporter plasmids designed to contain a destabilized GFP reporter gene coupled 
with the isolated XIAP 3’UTR sequence extracted by PCR (containing one, two or all three 
in silico predicted target sites for miR-23b shown in figure 4.3.1.1) downstream of this 
GFP. The reporter plasmids were subsequently co-transfected with premiR-23b into SNB-
19 cells and the effect on GFP was measured post-transfection.  
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Figure 4.3.1.3: XIAP 3’UTR map and results of co-transfection of the SNB-19 cell line. 
Measurements were taken 24 hour post-transfection for Guava™ flow cytometry analysis 
using the ExpressPlus® software. Plasmids containing a GFP reporter plus one, two or 
three XIAP 3’UTR binding sites for miR-23b along with a plasmid with no UTR sequence 
as a control. 3µl Lipofectamine 2000® used with 100 nM concentrations of pre-miR-23b 
and a pre-miR-Negative (PMN). ** represents a statistical significance p-value of <0.01, 
and was determined by a 2 tailed students T-Test between both sets of triplicate samples.(n 
= 3). 
 
Only the longest XIAP 3’UTR sequence containing all 3 predicted binding sites (XIAP3) 
showed a significantly decreased GFP signal of 36.1 % (Figure 4.3.1.3). This would 
suggest that the 3
rd
 (most 3’) site is the only biologically active miR-23b binding site in the 
transcript. Or, that the full 3’UTR must be present, for structural reasons perhaps, for miR-
23b to mediate its effect. 
 
 
 
 
 
 
 
283 
 
4.3.2: MiR-Capture as a tool to identify mRNA:miRNA interactions 
As mentioned in section 4.3.1, we investigated the miR-23b role in targeting human XIAP 
in SNB-19 GBM cells using a more conventional approach. This led us to ask whether we 
could identify miRNAs that regulate XIAP in CHO cells and indeed if they are any 
different than the miRNAs identified in human. 
One of the challenges with identifying miRNAs that bind a particular gene is that each 
miRNA is believed to regulate multiple transcripts and many transcripts are thought to be 
regulated by multiple miRNAs (Hafner et al. 2012)(Treiber, Treiber and Meister 2012). . 
This is due to imperfect base pairing as miRNAs bind to their target mRNAs by partial 
complementarity over a short sequence of usually 2-7 bases termed the ‘seed region’, 
however, these seed matches are not always sufficient for repression, indicating that other 
determinants may be needed to help specify targeting of miRNA secondary to this seed 
pairing. Grimson et al presented a model which can extend beyond this limited seed pairing 
prediction. Their model predicts site efficacy without recourse to evolutionary 
conservation, and it also identifies effective non-conserved sites and siRNA off-targets 
(Grimson et al. 2007).  
Furthermore, many computational programs exist to predict miRNA targets, and though 
considerable efforts have been made by research groups to recognise miRNAs associated 
with a certain binding site on a 3’UTR of a target gene, this can be difficult and computer-
based in silico prediction can only go so far. Using TargetScan™, miRANDA™ and other 
such prediction tools can lead to high false positive rates due to the short ‘seed’ region 
sequence  and temporal/spatial differences of miRNA:mRNA interactions (Sethupathy et 
al. 2006) (Megraw and Hatzigeorgiou 2006). 
Here we have used a recent novel experimental technique first described in (Orom and 
Lund 2010) (Hassan et al. 2013), to search for miRNAs targeting a given mRNA based on a 
capture affinity assay. The assay utilises a biotinylated DNA anti-sense oligonucleotide, 
which is designed to bind to an exposed loop section within the secondary structure of an 
mRNA transcript. Few methods can comprehensively identify miRNAs that target a single 
mRNA, see table 1.13.1 for a list of various competitive methods. 
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We proposed to use this method to ‘pulldown’ miRNAs which bind to CHO and human 
XIAP mRNAs thus allowing a bone fide validation of miRNA:mRNA interactions. Another 
advantage to this method compared with those seen in table 1.13.1, is that it has been 
shown that miRNAs can unexpectedly target the mRNA coding region and even the 5’UTR 
in some cases (Nonne et al. 2010) (Hsu and Tsai 2011). 
As a result, some methods used can miss important interactions based on 3’UTR focused 
localisation only, whereas this approach captures all miRNAs bound to the full length 
mRNA transcript.  
The success of the capture can be dependent on many variables, most importantly the 
capture oligonucleotide design. A 5’-Biotin modification incorporates a biotin moiety at the 
5' terminus of the oligonucleotide (Figure 4.3.2.1). Biotin binds to avidin or streptavidin 
conjugates (beads) which are used as a ‘hook’ to pulldown miRNA:mRNA interaction 
molecules. 
 
Figure 4.3.2.1: 5’ Biotin moiety modification to the capture oligo in order to facilitate 
pulldown using streptavidin affinity beads.  
 
Using Basic Local Alignment Search Tool (BLAST) to check if the oligo only binds to the 
chosen target mRNA and that it doesn’t bind anywhere else within the genome is a crucial 
step. However one drawback can be that, the in vivo environment can often vary greatly 
compared to what can be discerned from in silico prediction.  
As this technique was never performed in CHO cell lines, alterations to the method were 
used to optimise the experiment which will be discussed.  
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In summary, by identifying miRNAs that bind to XIAP in CHO, it may provide a route to 
regulate CHO XIAP expression (ie: by targeting CHO-specific miRNAs). It would also 
provide an opportunity to compare in vivo miRNA-XIAP interactions to those predicted by 
in silico approaches such as miR-Walk™ (http://mirwalk.uni-hd.de/). Finally, by 
performing the same capture method in human and CHO cells in parallel, we aimed to 
identify species/cell line specific differences in the milieu of miRNAs binding XIAP.  
 
4.3.3: Designing the capture oligo-hook for human and CHO XIAP mRNAs 
In order to study miRNA interaction with XIAP, the affinity capture technique was 
designed to capture or hook the XIAP mRNA complete with bound miRNAs in a way 
amenable to downstream rigor i.e: streptavidin bead capture consisting of extensive 
washing, eluting and extraction. Two steps are necessary for this, secondary structure 
modelling to design a capture ‘hook’ oligo and formaldehyde treatment to cross-link the 
miR-Ago-RISC complexes to their mRNA targets. 
The complex rules for multi-branch loops were predicted using the M-fold server which 
organises the structures and orders them by their initial free energies (ΔG) (Mathews et al. 
1999). Using M-fold, the first step was to determine the most thermodynamically stringent 
single-stranded regions (ss) within the total XIAP mRNA. The oligos were designed to 
target single-stranded regions in the XIAP secondary structure, for CHO (CHO-K1 cell 
line) (Figure 4.3.3.1) and human (SNB-19 cell line) (Figure 4.3.3.2).  
Due to the XIAP 3’UTR being a longer sequence in human than its CHO counterpart, 
making the overall mRNA target sequence more difficult to pulldown, two capture oligos 
were designed (one in the CDS and one in the 3’UTR) to ensure such a long transcript was 
pulled down.  
Initially, a ‘naked’ unfixed capture was performed with all the capture oligos excluding the 
formaldehyde step, to bind the mRNA only before completing the full capture protocol (see 
section 2.19). This was to test and optimise the oligos for binding specificity to the mRNA 
target without undertaking the entire protocol. 
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Figure 4.3.3.1: (A) M-fold snapshot of the predicted secondary structure of the CHO XIAP mRNA transcript. (B) An exposed single-
stranded (ss) region located between bases 116-140. (C) Oligo nomenclature and details including the capture sequence location. 
(N.B: T = U). The blue dots indicate the hydrogen bonding between the adjacent bases.  
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Figure 4.3.2.2: (A) M-fold snapshot of the predicted secondary structure of the human (SNB-19) XIAP mRNA transcript. (B) An 
exposed single-stranded (ss) region located between bases 116-140. (C) Oligo nomenclature and details including the capture 
sequence location. (N.B: T = U). The blue/red dots indicate the strength of the hydrogen bonding between the adjacent bases. Blue 
being less tightly bound. 
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Analysis with the Basic Local Alignment Search Tool (BLAST) showed the oligo 
sequences to have 100% homology and to be specific to XIAP transcripts.  
Figure 4.3.3.2 (C), illustrates human oligos 3 and 4 nomenclature, make note of 5 ds bases 
and 3 ds bases respectively following the oligos name and bp. This indicated that each oligo 
overlaps with a region that is single stranded with the exception of 5 and 3 bases which are 
double stranded at their respective loci. The colour of the dots indicates the type of double 
stranded bond: red G-C (strong), blue A-U (weaker), green G-U (very weak). 
 
4.3.4: Validation of XIAP mRNA:miRNA specific isolation 
To validate the oligos designed for ‘capture’, qRT-PCR was performed with primers 
specific to XIAP, GAPDH, and RPLOP genes to measure levels of mRNA post-capture. If 
the oligo design was competent then we expected to see an enrichment of XIAP mRNA 
after bead affinity purification compared to total RNA cell lysates for both human and 
CHO cell lines.  
An initial ‘unfixed’ capture was carried out minus formaldehyde step in order to optimise 
the efficiency of the capture oligos at binding and ‘pulling down’ the XIAP target mRNA 
based on mRNA enrichment compared to total RNA isolated in parallel (Figure 4.3.4.1). 
The levels of XIAP mRNA in the ‘captured’ sample were normalised against GAPDH 
mRNA levels in both captured and total RNA samples.  
Total RNA samples were exposed to the beads only (without capture oligo) to identify 
background noise caused by highly abundant mRNAs that might bind non-specifically to 
the streptavidin-coated beads. 
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Figure 4.3.4.1: Validation of XIAP mRNA specific isolation technique. qRT-PCR was 
used to measure XIAP target enrichment in the ‘unfixed’ capture on both SNB-19 and CHO 
cell lysates post-affinity capture using 3 different oligos for each cell line (the most 
efficient oligo shown for each). Relative mRNA enrichment to total lysate was calculated 
using the 2
- ∆∆Ct method and normalised using the abundant house-keeping gene GAPDH 
(set @ 1).  
 
Enrichment of XIAP mRNA was calculated to be 160-fold for SNB-19 and 141-fold for 
CHO samples post-capture compared to XIAP mRNAs in the total lysates. Additionally, 
dissociation curve analysis was performed to ensure single qPCR XIAP and GAPDH 
amplicons were detected (see appendices 6.2.3.3.1).  
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In addition to incubating cell lysates with the capture oligos, we extracted cell lysates in 
parallel using a non-specific oligonucleotide (NSO) as a negative control (to control for 
non-specific binding of the oligos) and a total cell lysate (without a capture oligo) to be 
tested alongside the two XIAP targeting oligos. The non-specific mismatched sequence 
controls were designed not to bind or be specific for any mRNA within either genome 
(Human or CHO), based on a BLAST alignment and subsequently qPCR validation (Figure 
4.3.4.2). 
Once satisfied with the capture technique and efficiency of the oligos, cell lysates 
underwent a ‘full’ capture protocol, this included formaldehyde crosslinking and proteinase 
K treatment steps. Formaldehyde causes covalent DNA-protein and protein-protein 
crosslinks that stabilise complexes during stringent downstream washing steps while it can 
be easily reversed at >70
o
C and has been widely used in a range of molecular biology 
procedures such as ChIP (Sutherland, Toews and Kast 2008). Proteinase K was used to 
clean up the final captured sample by digesting and denaturing protein bound complexes 
including RBPs and DNase remaining post-elution and to release the mRNAs and the 
miRNAs from the beads.  
Post-capture there was substantial enrichment of the XIAP mRNA (188 and 96-fold) for 
SNB-19 human and CHO cell lines respectively. The mismatch/NSO oligo capture lysates 
had less XIAP enrichment at 101-fold for SNB-19 and 50-fold for CHO when compared to 
total RNA lysate for each cell line (Figure 4.3.4.2). The NSO enrichment values obtained 
are consistent with other published studies (Hassan et al, 2013) and it can be expected that 
an oligo with only a 3-base mismatch would yield relativily higher enrichment background 
than a totally non-specific oligo based on sequence complimentarity. However, as this was 
a control oligo which consistently resulted in less enrichment than the true XIAP capture 
oligo, we belived this was a suitably stringent control to ensure that XIAP mRNA:miRNA 
specific isolation was occurring. 
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Figure 4.3.4.2: ‘Full’ capture run using QRT-PCR validation to measure XIAP mRNA 
enrichment fold-change from both SNB-19 and CHO cell lines post affinity bead capture 
with additional steps; formaldehyde crosslinking and proteinase K. A non-specific capture 
oligo experimental control (NSO) was also included. Relative mRNA enrichment was 
calculated using the 2
- ∆∆Ct method using the house-keeping gene RPLOP to normalise (set 
@ 1). (n = 3). 
 
Figure 4.3.4.2 illustrates the results for the complete pulldown of XIAP mRNA using two 
capture oligos ‘hooks’, one specific for XIAP and one for a non-specific negative control. 
The human SNB-19 capture results showed more XIAP mRNA enrichment (188.7-fold) 
compared to the CHO capture (96.1-fold) when normalised relative to total lysate sample. 
Enrichment comparing the non-specific oligo (NSO) and the capture oligo was higher in 
the SNB-19 human capture overall.  
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4.3.5: TLDA analysis – miRNA expression profiling on captured eluate 
The next step was to use the captured RNA samples that were isolated from the pull-down 
to test the samples for presence of miRNAs bound and subsequently eluted from the beads. 
These miRNAs were detected by qPCR using Taqman™ low density arrays (TLDA). 
By running the capture samples on the TLDA cards, we wanted to achieve two things; to 
examine if the pulled down mRNA contained bound miRNAs and to quantify and compare 
the expression profiles for any miRNAs that were present in these captured samples 
between human and CHO. 
In the pre-processing of the data, one crucial analysis step was normalisation, in order to 
reduce measurement errors and technical variability among arrays that might have arisen 
during the execution of the experiments. Furthermore, a cycle threshold below 40 was 
considered to indicate a miRNA being expressed, while this cut-off would usually be 
considered high; it was set to 40 owing to the minute amounts of RNA expected in the 
captured eluate.  
Prior to miRNA detection, we performed a pre-amplification step on the pulled down 
samples. As it was expected that the RNA would be minute in amount, this step was to 
boost the starting amount of cDNA before conducting TLDA profiling. However, after 
comparing capture samples that were pre-amplified (preamp +) and non-amplified (preamp 
-) in parallel using the SNB-19 full capture sample, it was observed that captured samples 
with no preamp treatment subsequently yielded better detection results than capture 
samples with preamp. This was based on lower endogenous U6 miRNA control Ct values in 
the preamp (-) sample (Cts of ~24 compared to Cts of ~33 in preamp (+)).  
In addition, more miRNAs were detected overall in the preamp (-) sample with 15 miRNAs 
being detected compared to only 3 miRNAs detected in the preamp (+) sample, and these 
were the 3 endogenous miRNA controls (two U6 and one RNU44) (Figure 4.3.5.1).  
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Figure 4.3.5.1: TLDA-qPCR output for 384 (top left grid) miRNA probes. The SDS output file illustrates the comparison between pre-
amplification (PreAmp +) and no pre-amplification (PreAmp -) steps. By not performing the pre-amplification step, many more miRNAs 
were detected below the 40 cycle threshold cutoff. In the PreAmp – run, only 3 endogenous control miRNAs (two U6 and one RNU44) were 
detected in the SNB-19 full capture sample when loaded into a human-specific TLDA A card. Flat line amplification curves denote 
undetected miRNA probes. 
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Proceeding without pre-amplification, the output from the Applied Biosystems® 7900HT 
PCR instrument, showed detection of the endogenous controls and was indicative of a 
successful experimental run using captured samples. MammU6, RNU43, RNU6B and Let-
7 endogenous controls were all detected in the 18-39 Ct range. Cts were calculated for total 
RNA samples, the mismatch/scramble oligo captured eluate and the full XIAP oligo 
captured eluate.  
To normalise the data on each card, the Cts values from the detected endogenous control 
mammU6 were subtracted from the Ct for each miRNA on that TLDA card. Anything 
above 40 cycles was considered absent. The relative quantity (RQ) of each detected 
miRNA was calculated relative to the NSO samples. An RQ >1 indicated miRNA 
differential expression (enrichment) between the scramble/NSO and full captured samples. 
The total RNA samples were included as a measure of the endogenous levels of expressed 
miRNAs.  
For example, miR-124 was detected in all 3 samples for human SNB-19 (Total, NSO 
capture and XIAP capture) and the RQ of the XIAP capture showed ~1.5-fold enrichment 
for miR-124 in comparison to the NSO capture in the SNB-19 pulldown. In the CHO 
pulldown, the RQ of the XIAP capture oligo was ~65-fold higher than the NSO; however 
the total RNA sample also had a high RQ (Table 4.3.5.1).  
 
Table 4.3.5.1: Analysis study snapshot of miR-124 results from SNB-19 and CHO 
captured samples post-TLDA run using the ΔΔCt method and relative quantity (RQ) was 
calculated using 2^-( ΔΔCt) normalised to the NSO capture samples.  
 
SNB-19 sample miRNA ID CT Avg Endo CT Avg (U6) Δ CT ΔΔ CT RQ
Total RNA miR-124 34.7 21.7 13.0 9.4 0.001
NSO Capture miR-124 36.0 32.4 3.6 0.0 1.000
XIAP Capture miR-124 35.1 32.1 3.0 -0.6 1.499
CHO sample miRNA ID CT Avg Endo CT Avg (U6) Δ CT ΔΔ CT RQ
Total RNA miR-124 28.2 25.0 3.1 -5.9 59.958
NSO Capture miR-124 40.0 31.0 9.0 0.0 1.000
XIAP Capture miR-124 35.1 32.1 3.0 -6.0 65.960
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In cases of a miRNA not being detected in the total sample but detected in capture samples, 
this was maybe due to strong enrichment of that miRNA in the capture step, despite being 
expressed at low (undetectable) levels in the cell. We will discuss this in more detail in 
later sections. 
The low numbers of miRNAs detected led us to believe that the formaldehyde and perhaps 
the proteinase K steps may have damaged/denatured some of the miRNAs during the 
pulldown technique. This was based on an independent TLDA run conducted whereby we 
used the SNB-19 total RNA captured samples, one unfixed and one fixed, and compared 
both to see the effect of formaldehyde treatment.  
It was found that in the ‘unfixed’ capture there was 102 miRNAs detected compared to 60 
miRNAs detected in the ‘fixed/full’ total RNA SNB-19 human captured samples from 
TLDA analysis  (Figure 4.3.5.2).  
TLDA analysis revealed that, in total, 40 miRNAs across both cell lines were detected and 
4 miRNAs were common to both cell lines (miR-124, miR-526b*, miR-760 and miR-877) 
for a detailed list of these miRNAs and nomenclature analysis see table 4.3.5.2. 
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Figure 4.3.5.2: TLDA-qPCR output for 384 (top left grid) miRNA probes. An independent test illustrating the difference between an 
unfixed capture compared to formaldehyde fixed capture of SNB-19 human cells. More miRNAs were detected in the ‘unfixed’ capture 
sample as illustrated by more amplification curves being present. A 384-well human-specific TLDA A card was used. Flat line amplification 
curves denote undetected miRNAs. 
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Table 4.3.5.2: Profiling of miRNAs using TaqMan Low-Density Array™ based on an Applied Biosystems® 7900HT micro fluidic cards 
consisting of two cards with 667 individual miRNA probes to test simultaneously over two cards (A and B). The sequence detection system 
(SDS v2.2.2) software was used to operate the 7900HT. Additionally, results from mirWalk® (http://mirwalk.uni-hd.de/) showed if the 
detected miRNA targets were predicted to bind XIAP full length mRNA in silico. (Y = predicted, N = not predicted). * denotes passenger 
strand of the miRNA. 
 
  
Predicted Predicted Predicted Predicted Predicted
in silico A cards B Cards in silico in silico A cards B Cards in silico in silico
Y miR-124 miR-135a* N Y miR-124 miR-125b-2* Y miR-124 Y
Y miR-197 miR-135b* Y Y miR-125b miR-30a* Y miR-526b* Y
Y miR-204 miR-149* Y Y miR-17 miR-30e Y miR-877 Y
Y miR-222 miR-188-5p Y Y miR-19b miR-526b* Y miR-760 Y
Y miR-323-3p miR-516a-3p Y N miR-20a miR-572 N
Y miR-494 miR-520c-3p Y Y miR-30b miR-610 Y
miR-526b* Y miR-760 Y
miR-567 Y miR-877 Y
miR-623 Y
miR-625* Y
miR-626 Y
miR-629* Y
miR-630 Y
miR-632 Y
miR-760 Y
miR-768-3p N
miR-801 N
miR-877 Y
miR-923 N
miR-99b* Y
Human SNB-19 CHO-K1 Common to both
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It was also evident that the human SNB-19 miR-Capture resulted in more bound miRNAs 
than CHO. This was somewhat expected owing to the previous mapping of the XIAP 
transcript which showed that the human XIAP transcript was 2113bp longer than CHO, 
meaning it could potentially contain many more miRNA binding domains. There were 26 
miRNAs detected in the human capture, whereas there were 14 miRNAs detected in the 
CHO capture (Table 4.3.5.2). 
There were 10 miRNA passenger (star) strands detected on the B cards, 7 were detected in 
SNB-19 capture and 3 in the CHO capture with miR-526* being common to both cell lines. 
Interestingly, in the CHO capture, the miR-125b guide strand was detected on the A card, 
while the passenger strand miR-125b* was also detected on the B card (Table 4.3.5.2).   
Next we wanted to identify miRNAs bound to XIAP that existed in clusters or families. We 
hypothesised that miRNAs identified by miR-Capture, that exist in clusters (same genomic 
location) or families (same seed sequence) may be indicative of co-functional relationships 
via co-regulating or co-ordinately regulating cellular XIAP.  
From the CHO capture, miR-30b was detected on the A card while miR-30a* and miR-30e, 
which are all from the same family, were detected on the B card (Figure 4.3.5.2). miR-30 
members are generally highly expressed in human cardiovascular and muscle cells (Chen et 
al. 2014). Noticeably, no miR-30 family members were detected in the human SNB-19 
capture, while there has been only one CHO-specific publication related to miR-30 
expression. Fischer et al suggested that the entire miR-30 family substantially improves 
bioprocess performance of CHO cells. It was shown that stable miR-30 over-expressing 
cells outperformed parental cells by increasing SEAP productivity or maximum cell density 
of approximately twofold (Fischer et al. 2014). 
Other notable miRNA families identified were; the miR-154 family on chromosome 14 
containing miR-323-3p and miR-494 were detected from the SNB-19 capture. In addition, 
the miR-10 family containing miR-125b was detected from the CHO capture. Finally, the 
miR-515 family on chromosome 19 which contains miR-516a-3p, miR-520c and miR-
526b* was identified from the SNB-19 capture. 
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The miR-17-92 cluster members (miR-17, miR-19b and miR-20a) were all detected in the 
CHO capture. MiR-222 was detected in the SNB-19 capture and is often co-expressed with 
miR-221; however miR-221 was not present in SNB-19 or indeed CHO pulldowns (Table 
4.3.5.2).  
None of the 4 miRNAs detected in both cell lines [miR-124, miR-526*, miR-877, miR-
760] have previously been associated with XIAP or CHO in the literature but all are 
predicted to bind to XIAP in silico. In some cases a miRNA may not be predicted in silico 
but was still detected in the capture. For example, while the TLDA analysis showed that 
miR-20a in the CHO miR-Capture samples was pulled down, it was not predicted in silico 
(Table 4.3.5.2). Furthermore, out of the 40 identified miRNAs, only 6 were not predicted in 
silico by using the MirWalk™ database (miR-135, miR-768-3p, miR-801, miR-923, miR-
572 and miR-20a). There was 209 miRNAs predicted to bind to XIAP across 5’UTR, CDS 
and 3’UTR sequence in total (Full table in supplementary data). 
Similarly, Hassan et al reported that miR-19b was captured in human cell lines but was not 
predicted to bind to the mRNA target they were testing, alpha-1 antitrypsin (AAT). 
Nevertheless, from our miR-Capture, miR-19b showed functional effects irrespective of 
prediction (Figure 4.3.6.1).  A potential recommendation we have is that extra biochemical 
assays should be performed to independently confirm such anomalies (Hassan et al. 2013). 
In summary, we have presented a readily accessible method for identifying miRNAs that 
target a specific mRNA transcript. This method was obtained by combining methodology 
from the publication by Hassan et al, and additional steps divised in association with Dr. 
Sebastian Vecken (RCSI) . An advantage includes the capture of a full length mRNA and 
not just the 3’UTR region. It is also a useful tool to compare mRNA:miRNA interactions 
across cell lines via parallel miR-Captures. For example; as we have shown, only 4 
miRNAs were common to XIAP transcripts between hamster and CHO cell lines. 
Additionally, as it is a relatively novel technique, there is scope for improvement; an 
example would be to optimise the formaldehyde crosslinking step to try to isolate bound 
miRNAs more efficiently.  
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4.3.6: Functional effects of XIAP mRNA-specific miRNAs 
To further validate target miRNA enrichment, Taqman™ single-plex assays were 
performed by reverse transcribing the same captured lysate and normalising to the 
endogenous U6 highly expressed control miRNA.   
For single-plex Taqman™ PCR, miR-124 was chosen as it is a common XIAP target from 
TLDA detection in both cell types (Table 4.3.5.2). Two more miRNAs were chosen to 
validate, miR-19b (which is part of the miR17-92 cluster mentioned previously) and miR-
222 were selected for validation in CHO and SNB-19 respectively.  
Interestingly, as mentioned miR-222 is usually co-expressed with miR-221, however miR-
221 wasn’t detected from the TLDA profiling. By investigating or targeting miR-222, it 
could lead to a better understanding between both cluster members and compare it to XIAP 
regulation in GBM and CHO cells. Recently, it has been shown that targeting miR-221-222 
could serve as potential therapeutic targets for increasing radio-sensitivity of glioblastoma 
cells due to modulating the DNA damage response (DDR) (Li et al. 2014a). 
To investigate individual miRNA levels in capture eluate from each cell line, first RNA 
from the same pulldown capture samples were reverse transcribed with specific RT primers 
for the chosen miRNAs plus the specific RT primers for the U6 endogenous house-keeping 
control for normalisation. Next Taqman® PCR was performed on the Applied BioSystems 
7900HT to measure the relative quantity (RQ) of these miRNAs using more specific single-
plex Taqman™ assays (Figure 4.3.6.1). 
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Figure 4.3.6.1: Single-plex miRNA specific Taqman™ qPCR assays. RQ quantified by 
using the 2
-ΔΔCT
 method and normalised to the scramble/NSO sample (set @ 1). MiR-124-
222-19b levels were normalised to endogenous levels of U6 snRNA for correction of RNA 
input. (A) Relative expression RQ results for CHO full captured lysate samples versus 
CHO scramble captured lysates from the same capture run previous. (B) Relative 
expression RQ results for SNB-19 full captured lysate samples versus SNB-19 scramble 
captured lysates from the same capture run previous.  
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The RQ of all four chosen miRNAs was increased within the XIAP oligo samples 
compared to the non-specific oligo samples (Figure 4.3.6.1), thereby validating the TLDA 
data, via single-plex miRNA enrichment. 
The next step was to determine whether these XIAP-specific miRNAs have a specific 
impact on XIAP expression in both cell lines.  
Pre-miR mimics were transfected in SNB-19 and CHO-K1 cells to observe if they impact 
on XIAP mRNA levels via qRT-PCR (Figure 4.3.6.3) and protein level via western blotting 
(Figure 4.3.6.4).  
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Figure 4.3.6.3: Impact of various mimics on XIAP expression. Calculation of decrease in 
XIAP mRNA using qPCR post-transfection with mimics in human SNB-19 cell line (A) 
and CHO-K1 (B). RQ of each miRNA was calculated relative to the pre-miR (-)/ (PM-) 
which was set @ 1. Also included was the XIAP siRNA (siXIAP) as a positive control for 
XIAP downregulation. * represents p-value <0.05, ** p-value<0.01, determined by a 2 
tailed students T-Test between both sets of triplicate sample CTs using endogenous U6 for 
normalisation.  
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In CHO cells, miR-222 was included as an experimental control as it should not cause a 
change in XIAP expression based on it not being captured, and indeed it showed no 
significant effect. The two other miRNA mimics tested (miR-124 and miR-19b) caused 
decreases in XIAP mRNA levels compared to the pre-miR (PM-) control, further 
suggesting that they directly interact with XIAP to down-regulate its expression (Figure 
4.3.6.3 A). 
In SNB-19 cells, miR-124 and miR-222 transfections both resulted in decreased XIAP 
mRNA levels of 13% and 55% respectively compared to PM-. Interestingly, miR-222 
treatment had the most notable effect on XIAP expression levels, compared to the PM- 
treated sample (Figure 4.3.6.3 B).  
In addition, the XIAP control siRNA had a modest effect on XIAP mRNA levels, resulting 
in a 38% decrease compared to PM-. The siXIAP treatment showed less impact than miR-
222 which was unexpected, as a specific XIAP-siRNA would be expected to induce a more 
effective knockdown effect based on previous knockdown results seen in figure 4.2.6.3. 
Next we wanted to investigate the impact on the protein level and to see if they correlated 
with the qPCR results. Figure 4.3.6.4, illustrates the results from the transfection of mimics 
into two cell lines on their XIAP protein levels. 
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Figure 4.3.6.4: Impact of various miRNA mimics on XIAP protein expression. CHO-K1 
(A) or SNB-19 (B) cells were transiently transfected with individual miRNA mimics (miR-
124, miR-222, miR-19b) or combinations (Combi) and lysates were analysed for XIAP 
expression 60hrs later by western blot (~55-57 kDa). PM- is the scrambled control. The 
house-keeping gene GAPDH is the loading control (~40 kDa). The siXIAP control was 
included as a positive control.  
 
Both miR-124 and miR-19b overexpression in CHO cells appeared to reduce XIAP protein 
expression (Figure 4.3.6.4 A), while the combination sample showed a more modest 
decrease compared to the PM- treated cells. This was interesting considering the impact 
was greater individually on XIAP expression.  
There was no significant decrease in XIAP expression compared to the PM- sample; in 
SNB-19 cells, however there did appear to be a modest decrease in the combination 
transfection (miR-124-222) sample (Figure 4.3.6.4 B). The siXIAP-treated SNB-19 cells 
displayed nearly complete knockdown of XIAP expression compared to miR-222, PM- and 
Cells only samples. However, this was not seen at the mRNA transcriptional level (Figure 
4.3.6.3 B), and is most likely attributed to miRNAs blocking translation only. 
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4.3.6.1: XIAP 3’UTR targeting by miRNA- in silico 
RNAhybrid™, an open source and flexible online prediction tool was used to identify all 4 
miRNAs binding positions (pos) within the XIAP 3’UTR, loop structures and minimum 
free energy (mfe). The miRNA-mRNA forms an RNA duplex, while the structure with the 
lowest mfe is predicted to have the most stable structure (Figure 4.3.6.1.1).  
RNAhybrid™ is available at http://bibiserv.techfak.uni-bielefeld.de/rnahybrid.  
 
 
Figure 4.3.6.1.1: RNAhybrid™ result for each miRNA targeting the XIAP 3’UTR 
sequence in CHO and Human. The green strand represents the miRNA and the red strand 
is the mRNA. (A) miR-124 and miR-19b secondary structure duplex, minimum free energy 
and nucleotide position in the CHO XIAP 3’UTR (4782bp) sequence. (B) miR-124 and 
miR-222 secondary structure duplex, minimum free energy and nucleotide position in the 
SNB-19-human XIAP 3’UTR (6791bp) sequence. 
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It was predicted that these miRNAs have binding sites in both human and CHO XIAP 
3’UTR sequence. After RNAhybrid™ analysis of the full XIAP transcript, we identified 
predicted sites for miR-124 in CHO and miR-222 in human sequences respectively.  
These binding sites had much lower affinity for each miRNA based on weaker seed regions 
(more Uracil present) and lower free energy calculations and perhaps may not be true 
binding sites. However, other potential binding sites may exist in the XIAP CDS and 
5’UTR, but for the purposes of 3’UTR targeting, this analysis was sufficient. 
 
4.3.6.2: XIAP 3’UTR targeting by miRNA- in vivo 
Next we performed another functional assay to see if there was an interaction between 
these miRNAs and the XIAP 3’UTR. We used a specifically designed GFP plasmid 
containing a cloned 3.7kb 3’UTR XIAP human sequence [NM_001167.2] (Figure 4.3.3.2) - 
downstream of the GFP, to test if the XIAP 3’UTR was a target of these same 4 miRNAs. 
We co-transfected into SNB-19 and CHO-K1 cells once again, to examine the effects of 
these miRNAs on GFP-reporter expression.  
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Figure 4.3.6.1.2: Functional pre-miR XIAP 3’UTR-GFP reporter assay. The pGFP (xiap3) 
denotes the GFP-reporter vector containing 3.7kb of XIAP 3’UTR sequence. PM- denotes 
the pre-miR-negative mimic (50nM concentration). The Y-mean GFP figures when the 
pGFP constructs are co-transfected with 50nM mimics into CHO-K1 (A) and SNB-19 cells 
(B) Error bars represent standard deviation between triplicate biological samples. * 
represents statistical significance p-value <0.05, ** p-value<0.01, *** p-value<0.001 
determined by a 2 tailed students T-Test between both sets of triplicate samples.  
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In CHO cells, the GFP mean florescence showed a significant decrease when the XIAP 
3’UTR sequence was present (Figure 4.3.6.1.1 A). The difference in GFP expression 
between pGFP (with xiap3 sequence) and miR-124/miR-19b versus pGFP + miR-124/miR-
19b (with no xiap3 sequence) showed that miR-124 mimics reduced GFP expression by 
38.7% while miR-19b reduced GFP expression by 33.9%. A significant decrease in GFP 
expression was observed for miR-124 (37.1%) and miR-19b (9.2%). 
A reduction in GFP florescence was also seen upon transfection of miRNA mimics 
[miR124/222] in SNB-19 human cells (Figure 4.3.6.1.1 B). By comparing pGFP (xiap3) + 
PM- to pGFP (xiap3) + miR-124/miR-222, we see that miR-124 reduced GFP expression 
by 11.2% but was not statistically significant whereas miR-222 reduced GFP expression by 
28.9%. Furthermore, the SNB-19 cell line was harder to transfect, hence lower GFP 
expression range overall.   
The pGFP (xiap3)-only transfected sample showed a reduction in GFP expression 
compared to the three pGFP + (mir124/222/PM-) samples, and would perhaps indicate the 
endogenous levels of miRNAs targeting the 3.7kb 3’UTR, irrespective of additional 
miRNA mimics. However, the long 3.7kb 3’UTR sequence might reduce transfection 
efficiency compared to the pGFP vector on its own, due to its larger size - larger constructs 
often being more difficult to transfect. In addition, we cannot compare across cell types as 
there is potentially different levels of endogenous miRNA present in each cell line.  
In summary, here we present an alternative validated method to identify multiple miRNAs 
targeting a predetermined mRNA. Our data showed 40 miRNAs in total, that may be cell 
specific, plus 4 common and that co-elute with XIAP mRNA transcript in two cell types. 
From this target list (Table 4.3.5.2), two miRNAs were chosen for each cell line (miR-124, 
miR-19b for CHO and miR124, miR-222 for SNB-19) to test the impact of their 
overexpression using premiR mimics in vivo. All four miRNAs subsequently showed a 
functional impact on XIAP expression at varying degrees when measured using qRT-PCR, 
single-plex Taqman assays, western blotting and GFP-reporter 3’UTR knockdown analysis. 
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5.1: Project 1 Discussion – Endogenous promoters as gene engineering tools 
5.1.1: Project overview 
The most frequently used promoters in expression vectors were derived from the simian 
virus 40 (SV40), Rous sarcoma virus (RSV), cytomegalovirus (CMV), and mouse 
mammary tumor virus (MMTV). On one hand viral promoters allow high expression rates, 
but on the other hand, they can lead to instability and silencing via promoter methylation in 
response to foreign sequence being continuously overexpressed (Brooks et al. 2004) 
(Mariati et al. 2014). 
Consequently, the aim of this study was to identify endogenous promoter that could be used 
as tools to improve recombinant protein production in CHO cells. We wanted to investigate 
if promoters derived from CHO cells were more beneficial than viral or other exogenous 
sequences. Two possible applications of these promoters are, firstly to drive ‘product’ gene 
expression in a process-dependant manner and secondly, to drive an engineering gene 
designed to impact on CHO cell behaviour in a process dependent manner. The process-
dependent parameter that we focused on in this work was culture temperature. 
Initial profiling undertaken in the NICB, generated an expansive CHO transcriptome 
dataset, which facilitated differential gene expression analysis. This dataset was mined for 
genes which changed expression in response to temperature and more specifically, genes 
that increased or decreased expression at lower temperature (Table 3.1.2.1). Additionally, 
we identified genes displaying constitutive expression which had the least variance across 
the entire dataset (Table 3.1.2.3), however, none of these gene promoters were successful in 
driving reporter gene expression effectively when tested. 
It should be noted that none of the genes identified in this analysis demonstrated complete 
temperature-dependant induciblity. In other words, none were completely repressed (off) at 
one temperature and strongly expressed (on) at the lower or higher temperature. Therefore, 
the promoters would unlikely behave like ‘classic’ inducible systems such as the TetOn/off 
system. However, this doesn’t negate their potential value and utility as the field of CHO 
cell engineering matures.  
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As we strive to gain greater control over the CHO ‘platform’ there is every reason to 
believe that in some cases simply switching from on to off or vice versa may not be 
desirable for optimal control.  
By having a range of inducible tools available with different expression characteristics, we 
will ensure that a suitable choice can always be made based on the gene whose expression 
is being controlled, in addition, to how that control is mediated – e.g.: by changing culture 
temperature, rather than adding or subtracting inducer molecules (IMs).  
Fussenegger and co-workers have shown a plethora of exogenous IMs and synthetic 
inducible systems to increase expression or indeed tightly control inducible expression, 
examples include; gas acetaldehyde, biotin, drug-sensing hydrogels, exocytic SNAREs, 
siRNA toggle switch and pTRIDENT (Fux et al. 2004)(Werner et al. 2007, Weber et al. 
2009) (Ehrbar et al. 2008) (Peng, Abellan and Fussenegger 2010). 
However, most of these are not industrially viable as the use of artificial/exogenous 
molecules is not feasible from a regulatory point of view (Weber et al. 2009) (Wieland and 
Fussenegger 2012). Therefore, more natural/endogenous inducible mechanisms are being 
sought. 
The mouse (Cirbp and miR-17-92) and CHO-derived promoters studied in this project 
(MDM2, SSu72, miR17-92 and Cirbp) could not only drive expression of product genes to 
a similar and often better level than viral ones frequently used in bioprocessing settings, but 
additionally were shown to be inducible upon a temperature shift to 31
o
C. 
This property could be advantageous in a biphasic bioprocess (Figure 1.11.1), whereby 
adjusting a culture to a lower culture, we could arrest growth and simultaneously boost 
expression of a particular gene by using a temperature sensitive promoter. When cells are 
not growing/dividing they can concentrate cellular energy on protein synthesis (Kaufmann 
et al. 1999) (Clark, Chaplin and Harcum 2004) (Yoon et al. 2004) (Kim and Lee 2007). 
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5.1.2: Promoter isolation 
As a result of sparse genomic sequence available publically for Chinese hamster in the 
early part of this project, we took a different approach to isolating the promoters of these 
genes, than reported in studies of analogous nature; (Thaisuchat et al. 2011) (Pontiller et al. 
2008) (Chen et al. 2013) (Running Deer and Allison 2004).  
For example, Running-Deer and Allison used an approach whereby they screened the 
flanking regions of a CHO-K1 lambda phage library after highly expressed genes were 
identified. They extracted and cloned a large 12kb region (including the 5’UTR) flanking 
the CHEF-1α gene to test it for promoter activity. Ideally, shorter more concise regulatory 
sequences would be more attractive in transgene expression vectors; therefore, they tried to 
shorten it considerably. They managed to reduce the size from 12kb to 4.1kb without loss 
of expression levels; however, once they shortened the fragment to 3.3kb, this reduced 
expression by half. Ultimately, 3.3kb was acknowledged as perhaps still too large to be 
utilised in a biopharma vector construct (Running Deer and Allison 2004). 
Another method is to use restriction enzymes fragment the genomic DNA of the chosen 
cells followed by random recombination to re-ligate into reporter plasmids. These are then 
screened to identify ‘active’ fragments that drive expression of a reporter gene (Pontiller et 
al. 2008). A promoter trap method can also be used whereby a promoterless plasmid 
containing GFP and selectable marker is transfected and integrated into cells. Drug-
resistant, GFP positive cells are isolated and the sequences upstream of the integrated 
plasmid are identified by sequencing.  
Although the name of the method suggests that regulation automatically assumes it is 
promoter region specific, however here the isolated regulatory sequences were not 
necessarily derived from gene promoter regions (Chen et al. 2013). This study showed that 
some strong regulatory elements can be located at unexpected locations in the CHO 
genome and this would imply more scope to find potential regulatory sequences/tools as 
opposed to focusing on promoter regions only.  
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Our approach was to first identify target genes based on microarray transcriptome data. As 
mentioned, we identified genes capable of increased or decreased expression at 31
o
C (Table 
3.1.2.1). Furthermore, we identified genes capable of constitutive expression across a wide 
range of parameters including culture stage, temperature and cell type (Table 3.1.2.3). 
This was a similar to the approach taken by Le et al to isolate the Thioredoxin-interacting 
protein (Txnip) promoter (Le et al. 2013). Then we used cross-species alignments (Figure 
3.1.8.1) to identify conserved locations for primer design (Figure 3.1.8.2) to PCR amplify 
and extract the promoter regions. This way we could be more certain that putative 
promoters were being isolated and not just random segments of DNA which may or not be 
clearly defined. Ideally ~300-5000bp upstream sequence was considered a good starting 
point to test putative promoter regions.  
 
5.1.3: Screening target genes and transcript validation  
5.1.3.1: Initial promoter fragment screen 
Various promoter fragments were amplified from gDNA by PCR (Table 3.1.9.3). These 
were cloned into a GFP-reporter plasmid and screened (Table 3.1.11.1) for GFP expression 
initially to identify suitable fragments for further study in plasmids containing other 
transgenes.  
There were some interesting observations from the screen. None of the promoters chosen 
based on constitutive activity (UBA52, PPIA and AUP1) from either mouse or CHO, were 
successful in driving detectable expression except for the miR-17-92 cluster promoter. For 
example; despite PPIA topping the list of constitutively highly expressed genes in the array 
analysis, reporter plasmids containing either of two putative promoter fragments 1424bp 
and 750bp upstream of the PPIA ATG start site failed to drive expression of GFP.  
The most obvious reason for this would be that these fragments didn’t contain the necessary 
promoter elements needed for the apparent strong transcriptional activity in vivo. This is 
and has been one of the greatest challenges in promoter analysis in higher eukaryotes – the 
fact that very distal elements and epigenetic/chromatin context can play a major role in 
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promoter activity. Indeed, the classical promoter analysis approach is to start with a large 
(2-5kb) of sequence from 5’ of the translational start site, cloned into a reporter vector and 
systematically delete ‘chunks’ of sequence while monitoring the effect on reporter output 
(Pontiller et al. 2010) (Thaisuchat et al. 2011). Although it would have been interesting to 
study some of the non-functional sequences cloned in this project more closely, we opted to 
focus on the shorter, more active sequences, keeping in mind our goal of generating 
engineering tools for use in vectors to drive transgene expression. 
In summary, the mouse miR-17-92 cluster fragments were more effective than the CHO 
orthologues. For genes that were identified as being upregulated at 31
o
C (Cirbp, MDM2 
and SSu72) the observed effect correlated with the expected effect from the profiling 
dataset with all performing similarly. For genes that were identified as being downregulated 
at 31
o
C, only mouse fragments of HNRPa2b1 and Nars (1326bp and 2466bp) and CHO 
fragments of PPID (560bp and 1025bp) were successful in driving GFP expression and 
may be candidates for future work regarding using temperature shift in the opposite 
manner.  
Finally, another consideration before we progressed the promoters to other reporter assays 
was that we chose promoter fragments based on size and how easy the fragment could be 
cloned into other vectors. All viral promoter sequences used in commercial vectors are 
small concise sequences capable of driving strong expression levels and do not impinge on 
transfection efficiency like larger sequences would.  
 
5.1.3.2: RT-qPCR analysis and half-life determination 
The transcript abundance for Cirbp, MDM2 and SSu72 genes was confirmed to be much 
lower in the 37
o
C samples compared to the 31
o
C cultured samples over the entire sampleset 
(Figure 3.1.4.6). Unexpectedly, MDM2 transcript copy numbers were much lower overall 
compared to SSu72 and Cirbp in contrast to the high fluorescence signals observed in the 
initial array data. Despite this, we decided to continue with MDM2 as a candidate 
promoter. 
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Transcript levels for miR-17-92 were not measured in this particular instance as small 
RNAs were not present due to the extraction method used, but data from a separate study 
in-house as well as published reports (Hayashita et al. 2005) (Hernandez Bort et al. 2012), 
showed members of this cluster to be most abundantly expressed in various CHO cell lines. 
Furthermore, we were interested to see whether a promoter sequence derived from a 
miRNA cluster could be used to drive expression of a protein-encoding gene. 
Of course, a strong signal on an array or high copy numbers as measured by qPCR could be 
as a result of two separate phenomena, high transcriptional turnover of the mRNA 
(desirable) or if the mRNA of that particular gene was just highly stable (undesirable) and 
subsequently had a slower decay rate within the cells, it may give the impression of 
increased expression upon temperature shift. 
Stability analysis revealed that the decay rates were quite varied between all 3 genes at both 
37
o
C and 31
o
C, however, the decay rate was consistently lower (and thus mRNA half-life 
was higher) at 31
o
C for each individual gene (Table 3.1.5.2). Similarly Cirbp and MDM2 
showed a marginal decrease in decay rate and as a result a marginal increase in mRNA 
half-life at 31
o
C with MDM2 shown to be more stable overall at both temperatures. Al-
Fageeh and Smales reported similar results for various Cirbp 5’ UTR leader sequences 
from NIH-3T3 mouse cells. They showed that although Cirbp mRNA stability was 
increased at 31
o
C, half-life of 13.9 hr at 37
o
C versus 15 hr at 31
o
C, it was marginal 
compared to a beta-actin control which had a more substantial difference between 37
o
C 
(10.4 hr) and 31
o
C (15.8 hr) (Al-Fageeh and Smales 2009).  
Conversely, SSu72 was a little over twice as stable at 31
o
C as at 37
o
C, based on a decay 
rate of 2.44 hr
-1
 at 37
o
C and 5.12 hr
-1
 at 31
o
C. This could perhaps contribute partly to the 
higher SSu72 signal the original microarray profiling, but as it is known that at lower 
temperature mRNA transcripts tend to be more stable, this was not unexpected. Finally, 
although we can partially attribute the increased transcript levels detected from the original 
profiling to this increase in stability, it is clearly not responsible for the 6/7-fold increase 
observed in the 31
o
C samples (Figure 3.1.4.6). 
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As a point of reference, Thaisuchat et al also conducted mRNA stability on the S100a6 
gene promoter using actinomycin D treatment and a luciferase reporter. It was difficult to 
compare results as they analysed mRNA stability over only 6 hours compared to 24 hours 
for our analysis but nevertheless they found the transcript decayed by 33% at 37
o
C, 
whereas in parallel the transcript only decayed by 5% in 33
o
C culture (Thaisuchat et al. 
2011). This observation indicates that mRNA stability is enhanced by lowering culture 
temperature (only after 4 hours was this apparent) which must contribute to higher mRNA 
levels. It was also shown that after 4 hours there was no significant change in stability and 
indeed at 37
o
C transcripts were more stable. Translation presumably has its own set of 
limitations at lower temperature and the level with which it influences overall protein 
expression in this instance remains unclear. 
 
5.1.4: Prioritising useful promoters 
Promoter fragments from Cirbp, SSu72, MDM2 and miR-17-92 cluster were prioritised as 
the most suitable candidates for progression as a result of an initial GFP expression reporter 
screen (Table 3.1.11.1). As mentioned, there was difficulty in cloning some of the larger 
fragments so we focused on the following for the remainder of the project: 828bp CHO 
Cirbp, 370bp MDM2 and 654bp SSu72. Not only did this set appear capable of high GFP 
expression but smaller fragments would be more suitable in a vector designed for routine 
transfection. 
Cirbp was one of the most highly ranked genes on our list and although less novel than 
some of the other genes, it was included as a recognised temperature sensitive positive 
control with which to compare induciblity of the more novel promoters identified (Al-
Fageeh and Smales 2009) (Nishiyama et al. 1998) (Sumitomo et al. 2012). Additionally, an 
889bp promoter fragment from mouse Cirbp was included in all experiments as a further 
control. 
Cold-inducible RNA-binding protein (Cirbp) is a cold-shock protein (CSP), and is well 
characterised in human and mouse and is believed to function as a chaperone protein 
(Nishiyama et al. 1997) (De Leeuw et al. 2007) (Kaneko and Kibayashi 2012). It assists in 
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assembly, transport, preventing transcription termination and folding of other 
macromolecules during various critical cellular responses caused by stimuli such as; 
hypoxia and hypothermia (Mihailovich et al. 2010). It has also been reported to be involved 
in interleukin IL-1β regulation (Brochu et al. 2013).  
Recent results by Liu et al suggest that CSPs (Cirbp and Rbm3) regulate temperature 
specific circadian gene expression by controlling alternative polyadenylation (APA) and the 
depletion of Cirbp or Rbm3 significantly reduced the amplitudes of core circadian genes. 
Having performed PAR-CLIP analysis, they showed that the 3'UTR of a range of circadian 
genes were significantly enriched for Cirbp and Rbm3 near the polyadenylation sites 
(PASs) (Liu et al. 2013b).  
First discovered in yeast, RNA polymerase II CTD phosphatase (SSu72) is an essential 
phylogenetically conserved transcription factor phosphatase and is a component of the 
cleavage/polyadenylation factor (CPF). It interacts with the general transcription initiation 
factor (TFIIB) and termination complexes, promoting RNA polymerase pausing and release 
(Krishnamurthy et al. 2004) (Ganem et al. 2003). Pappas and Hampsey, identified a 
recessive ssu72-1 allele and showed that it was a synthetic enhancer of a TFIIB (sua7-1) 
defect, resulting in a heat-sensitive (Ts(-)) phenotype and a dramatic downstream shift in 
transcription start site selection (Pappas and Hampsey 2000). He et al, demonstrated that 
SSu72 is required for 3' end cleavage of pre-mRNA but is dispensable for poly(A) addition 
and RNAP II termination and interacts with Sub1 and Pta1 genes (He et al. 2003).  
Mouse double minute 2 homolog (MDM2), plays a key role in processes like cell growth, 
senescence and apoptosis. It is an important negative regulator of the p53 tumor suppressor 
and has been identified as a proto-oncogene. MDM2 functions both as an E3 ubiquitin 
ligase that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor 
suppressor and as an inhibitor of p53 transcriptional activation (Iwakuma and Lozano 2003) 
(Uhrinova et al. 2005). 
Lalonde et al identified two promoters for MDM2 in humans which influence its 
expression; an internal promoter (P2), which is located near the end of intron 1 and is p53-
responsive, and an upstream constitutive promoter (P1), which is p53-independent.  
 
 
317 
 
They postulated that sequence variation in the promoter region of MDM2 could lead to 
disregulated expression and variation in gene dosage. Their data suggests that part of the 
variability in the MDM2 expression levels could be explained by allelic p53-independent 
P1 promoter activity (Lalonde et al. 2012).  
In a follow up study, a human MDM2 promoter polymorphism (SNP309T>G) was found to 
be associated with enhanced Sp1 transcription factor binding and elevated MDM2 
transcription while 309G has been found to be associated with elevated cancer risk 
(Knappskog and Lonning 2011). 
In addition to the protein-encoding gene promoters used in this study, a highly abundant 
miRNA cluster (see section 1.12.1) was identified from miRNA expression profiling in-
house. The main focus of this project was to identify temperature-inducible promoter 
sequences capable of driving transgene expression; however, it was acknowledged that 
investigating a promoter from the miR-17-92 cluster might be an interesting and novel 
endogenous tool in CHO cell culture. This cluster was identified as being highly abundant 
and it has been shown to be highly expressed in various cell lines in the literature, so it 
seemed worthwhile to examine if its promoter could drive transgene expression also. 
None of these gene promoters had previously been reported in driving transgene expression 
either inducibly or constitutively in any species.  
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5.2: Reporter-gene expression   
5.2.1: GFP and Luciferase transgenes 
Qualitative analysis using the fluorescent microscope showed that there was an obvious 
increase in GFP expression between populations of cells grown at 37
o
C and 31
o
C using 
MDM2, SSu72 and both Cirbp promoters (Figure 3.2.2.1). This was evidenced further by 
flow cytometry to give quantitative values to each promoter’s strength in driving GFP.  
The fact that CMV drove strong GFP expression was not unexpected, however the Cirbp-
CHO promoter activity was encouraging compared to the mouse orthologue and was a 
novel finding. All promoters showed temperature sensitivity including the CMV promoter 
which showed higher GFP expression at 31
o
C. This was unexpected and called into 
question its suitability as an appropriate control in temperature-shift experiments. 
Nonetheless, this led us to examine more than one reporter gene when investigating 
promoter behaviour. Only the MDM2 promoter had a larger fold change between 
temperatures (Figure 3.2.2.2). This was encouraging that the MDM2 promoter was so 
active despite the contrasting results from the qPCR and microarray analyses where we saw 
very low transcript numbers from the qPCR validation (Figure 3.1.4.6) and high 
fluorescence from the microarray profiling (Figure 3.1.2.1). This gave us confidence in 
MDM2 as a potentially useful promoter. Perhaps one reason for this discrepancy is that the 
reverse transcription step was not efficient for this gene, as low transcript numbers were 
frequently seen in RT-qPCR results throughout the project. The Cirbp-CHO promoter was 
the only promoter to drive better GFP expression at both temperatures relative to CMV 
(Figure 3.2.2.3).  
As most commercial systems utilise viral promoters to drive product gene expression it is 
unusual that there are no reports in the literature of viral promoters displaying this 
temperature responsiveness. However, it is well known that reducing temperature during 
recombinant protein production can improve yield (Wulhfard et al. 2008). Although this is 
often related to an improvement in cell viability or culture duration, improved gene 
expression could also contribute – Wulhford et al showed it was feasible to use large-scale 
(up to 100L) transient gene expression (TGE) in CHO cells and as a result they increased 
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transient recombinant antibody expression by more than 3-fold at 31
o
C as compared to 
expression at 37
o
C. 
The miR-17-92 cluster promoter was disappointing in terms of its ability to consistently 
drive high expression of GFP. Although studies on miRNA promoters specifically are 
scarce, especially those of mammalian miRNAs, there is reason to believe that they could 
be useful as engineering tools due to the dynamic nature of miRNA expression (Jadhav et 
al. 2013). Analogous to this reasoning, Lee et al developed a dual-luciferase reporter 
system to monitor expression and posttranscriptional regulation of miR-23a in cells in vitro 
and in vivo. They used a plasmid encoding firefly luciferase under the control of a 5′ 
regulatory sequence from the human miR23a∼27a∼24-2 gene cluster to determine whether 
the degree of miR-23a transcription is cell-type dependent or differentiation-stage specific. 
This demonstrated a functional use for a miRNA promoter sequence in driving a protein-
encoding gene (Lee et al. 2008).  
The regulation of intragenic miRNAs by their own intronic promoters is one of the open 
questions relating to the understanding of miRNA biogenesis. It is still poorly understood 
how miRNAs are regulated and their respective promoters are not well characterised. This 
is partly due to the difficulty of predicting promoters from short conserved sequence 
features without producing a high number of false positives (Megraw and Hatzigeorgiou 
2010) (Schanen and Li 2011). Thus, methods to identify miRNA promoter regions are 
being sought. Marsico et al described a model called PROmiRNA, it is a new approach for 
miRNA promoter annotation based on a semi-supervised statistical model trained on 
deepCAGE data and sequence features. In addition to the model identifying more miRNA 
promoters than other methods (miRBase v18 and Ensembl v66), PROmiRNA also returns 
all possible alternative promoters for a particular miRNA, including intronic promoters 
(Marsico et al. 2013). 
Another way to identify miRNA promoters is using chromatin analysis. Ozsolak et al 
identified the proximal promoters of 175 human miRNAs by combining nucleosome 
mapping with chromatin signatures (Ozsolak et al. 2008). In addition, Long et al analysed 
the 5' flanking regions of intergenic miRNAs and intronic miRNAs. They used luciferase 
reporter assays also and showed that 22 of the 30 promoters drove gene expression in HEK-
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293 cells, indicating a high accuracy of the TSSG promoter prediction. Further analysis 
showed that approximately 60% of the miRNA promoters tested had a TATA-like box 
contained in their sequence (Long et al. 2011). In summary, the high-throughput 
identification of miRNA promoter and enhancer regulatory elements can shed light on the 
control of miRNA transcription and using a combination of these analysis tools may permit 
rapid identification of transcriptional networks of miRNAs. 
Another routinely used reporter is the luciferase gene. In order to facilitate normalisation 
for transfection efficiency owing to different promoter and plasmid size configurations, we 
used the luciferase reporter in conjunction with Bradford assays to quantify the amount of 
protein present. Although a constructive assay, there was no normalisation for the GFP 
assay in this regard therefore this led to utilising the luciferase reporter gene and Bradford 
assay. 
The most interesting initial observation was that the SV40 promoter did not appear to be as 
responsive to temperature as CMV. Our data showed Cirbp-mouse and Cirbp-CHO both 
had the most striking expression change between 37
o
C and 31
o
C (Figure 3.2.3.1). MDM2, 
SSu72, Cirbp-CHO and Cirbp-mouse all showed higher expression at 31
o
C relative to the 
SV40 promoter, while only miR-17-92-mouse and SSu72 promoters drove luciferase 
expression to a higher level than SV40 at 37
o
C (Figure 3.2.3.2). This was both interesting 
and encouraging as the miR-17-92-mouse promoter performed so poorly in the GFP assay. 
Broadly speaking though, the patterns of expression and induciblity were similar to that 
observed using GFP as a reporter. 
Thaisuchat et al reported on an endogenous CHO promoter (S100a6) which was compared 
to SV40 viral promoter using a luciferase reporter, however, it was unclear how they 
performed subsequent normalisation post-transfection. They used the Dual-luciferase assay 
co-transfecting a plasmid encoding the Renilla luciferase (under the control of a CMV 
promoter), however, when we tried to utilise the same plasmid as a normalising control, we 
found its expression to be temperature sensitive. For this reason we adopted the Bradford 
assay as a means of normalisation. In their study, the SV40 luciferase expression units were 
set to 100 % activity for each temperature and all other samples were measured relative to 
them.  
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At most, increases of 2/3-fold in luciferase expression were observed using the various 
truncated promoter fragments after adjusting the culture to 31
o
C, with the majority showing 
between 1.5/2-fold (Thaisuchat et al. 2011). Conversely, our data showed that upon 
temperature shift, the MDM2 and Cirbp-CHO promoters were capable of increasing 
luciferase expression levels to ~41-fold and ~3.8-fold respectively, higher than SV40. In 
short, it was difficult to compare the absolute activities we observed to their data. 
 
5.2.2: Driving inducible expression of a ‘product gene’ using temperature  
Having observed encouraging results using these promoters in both GFP and luciferase 
reporter assays, the next step was to test them with more industrially relevant proteins. We 
examined the expression of EPO under the control of our various promoters by western blot 
and qPCR. At this point, the issue of promoter specificity was raised. In other words, the 
ability of individual promoter sequences to drive transcription (at either temperature) 
seemed to vary depending upon the gene being transcribed. MDM2 and both miR-17-92 
promoters, for example, appeared to be incapable of driving EPO expression (Figure 
3.2.5.2). This was surprising considering the substantial expression of GFP and luciferase 
for all 3 promoters. In contrast, the SSu72 promoter generated high levels of EPO and was 
significantly more active at 31
o
C. The difference appears to be transcription-specific, as 
opposed to a problem with translation, as very little EPO mRNA was detected using these 
promoters (Figure 3.2.5.1). 
The CMV promoter drove higher EPO expression at 31
o
C compared to 37
o
C, than all other 
tested promoters. This highlighted once again, that viral promoters are temperature 
sensitive and that they are perhaps poor controls for promoter studies relating to 
temperature.  
So is inducible expression of a product gene in mammalian culture the way to go? In other 
words, is controlling expression using CHO-specific regulatory sequences an attractive 
alternative to existing technologies? Although there are commercially available inducible 
systems from companies like Clontech and Life Technologies e.g.: GeneSwitch™, there 
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has not been any approved CHO-related regulatory sequence used in large scale 
manufacture of protein to date.  
Controlled gene expression represents an unmatched potential for biopharmaceutical 
manufacturing of unstable, growth-impairing and cytotoxic proteins as well as conditional 
metabolic engineering to improve desired cell phenotypes (Werner,N.S et al. 2007). In an 
field where inducible systems are difficult to implement technologically, the TetOn/Off 
inducible system is the most widely publicised and has shown tight regulation of gene 
expression with fold changes of product genes reaching up to many hundred folds 
(Sprengel and Hasan 2007) (Nishijima et al. 2009). Other antibiotics and hormones have 
also been designed to utilise transgene transcription control systems such as; streptogramin, 
macrolide, coumermycin, rapamycin and progesterone (Hartenbach and Fussenegger 2005), 
but some of these drugs may elicit side effects following long-term administration at 
regulation-effective concentrations (Sartor and Cutler 1996) (Lautermann et al. 2004).  
Additionally, drug-based inducers are less suited for transgene modulation of 
biotechnologically relevant production cell lines since preparation of inducer-free product 
formulations remains a costly downstream processing challenge and requires additional 
cross-talk with regulatory authorities. 
Although it is interesting to test product gene expression under control of some sort of 
inducible system, a more permissible approach would involve the generation of stable cell 
lines expressing the product gene. For example, if we take the temperature shift results out 
of the equation, at the more normal culture temperature of 37
o
C our SSu72 promoter was 
capable of driving equal or higher expression than the strong CMV promoter and Cirbp-
mouse control of EPO at a protein level (Figure 3.2.5.2).  
Recently, alternate ways to trigger product gene expression have been sought; one method 
involves gaseous acetaldehyde, which is physiologically inert and approved as a food 
additive by the FDA. Weber et al pioneered an acetaldehyde-inducible regulation (AIR) 
technology which takes advantage of gaseous acetaldehyde to modulate product gene 
expression levels. They showed that human IFN-beta production was fully reversible while 
maintaining 95% cell viability during the entire batch process and they suggest it will foster 
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novel opportunities large-scale manufacturing of difficult-to-produce protein 
pharmaceuticals (Weber and Fussenegger 2004b) (Weber and Fussenegger 2004a) (Weber 
et al. 2005) (Werner et al. 2007). 
In contrast to our temperature inducible expression results, the AIR system was shown to 
be tightly regulated via autoregulated, bidirectional and multicistronic mammalian and 
lentiviral expression vectors that exhibit strict 1:1 transcription stoichiometry. They show 
all 3 to be robust and versatile expression platforms for the gas-inducible transgene control 
system which they expect to foster future advances in gene therapy and tissue engineering 
as well as biopharmaceutical manufacturing (Hartenbach and Fussenegger 2005). Although 
this tight control AIR system has potential, it still requires the addition of external 
component i.e: gas whereas our temperature responsive promoters do not. 
 
5.2.3: Driving inducible expression of an ‘engineering gene’ using temperature  
In the previous section, we discussed the induction of product gene (EPO) expression at 
different temperatures. Realistically the majority of product genes are unlikely to be 
expressed in an inducible manner such as this. The promoters identified in this project are 
more likely to be useful for controlling the temporal expression of a cell engineering 
transgene. Therefore, our next focus was to consider their use in this manner. We chose to 
use cyclin-dependant kinase inhibitor 1B (p27) to investigate whether they could drive 
expression of an engineering target to influence a phenotype in culture. Successful 
induction of p27 should result in reduced cellular growth via cell cycle inhibition in the G1 
phase. 
Overall, there was a correlation between increased transcript copy number of p27 and the 
effect on cell number (Figure 3.2.6.1 A). For example, MDM2 and SSu72 promoters had 
the biggest effect on the cell growth and this correlated with greater p27 mRNA transcript 
abundance (Figure 3.2.6.3). This demonstrates that cell growth can be influenced by using 
temperature as a switch mechanism to induce these endogenous CHO promoters. This 
mechanism could be valuable in bioprocesses where control over cell density is required. 
These promoters could potentially be used to achieve dynamic control of other cellular 
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behaviours for enhanced process characteristics during a bioprocess. For example, 
mammalian cell culture metabolism is characterised by glucoglutaminolysis, that is, high 
glucose and glutamine uptake combined with a high rate of lactate and non-essential amino 
acid secretion (Quek et al. 2010). Thus to circumvent the onset of glucoglutaminolysis, 
gaining control over cell density by using a systematic p27 inducible construct, may be a 
suitable way to extend culture longevity for example.  
Gene expression is a dynamic process by nature, which is constantly adjusting to cope with 
various environmental perturbations and other signals. Consequently, endogenous 
promoters with intrinsic dynamic activities represent attractive tools to control the 
expression dynamics of transgenes. In a study relating to dynamic metabolic engineering 
using CHO-specific promoters, Le et al isolated an 800bp promoter fragment containing 
part of the putative 5′ UTR and the upstream region of the Thioredoxin-interacting protein 
and showed that it could drive expression in concert with cell growth. They further 
employed this promoter to control dynamic expression of the mouse GLUT5 fructose 
transporter in CHO cells, enabling them to utilize sugar according to the cells needs rather 
than in having excess as typically seen in culture (Le et al. 2013).  
Alternative dynamic engineering methods such as engineering of metabolic, secretory, and 
growth control pathways in producing cells to enhance their growth and product secretion 
traits have all been attempted to control expression in CHO cells (Datta et al., 2013) (Kim 
et al., 2012) (Kaufmann and Fussenegger, 2003) (Seth et al. 2006). It is reasonable to 
assume that in the future, further advancements in protein production will be a reality as a 
result of combinatorial approaches utilising many areas of engineering including the use of 
endogenous promoter tools. 
Additionally, our data from CHO-K1-SEAP cells demonstrated that using the isolated 
promoter sequences upstream of a cytostatic gene had a direct effect on cell growth and an 
equal but indirect effect on SEAP productivity after 3 days (Figure 3.2.6.2.5).  
Furthermore, as the assay was transient by nature, it would be interesting to see the impact 
over a longer period generating cell lines with stably integrated temperature-responsive p27 
and subsequently measure SEAP secretion over time in various batch or fed-batch settings.  
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Ultimately, the goal of any engineering intervention is to improve the final yield and/or 
quality of recombinant protein from a particular process. While, inducible p27 expression 
clearly impacted on cell density in response to temperature as planned, this had a knock-on 
negative impact on SEAP yield. Therefore, while p27 provided us with a useful model cell 
engineering gene, clearly its implementation in a bioprocess in terms of productivity is 
impractical. However, it does provide a good demonstration of the applicability of this 
approach. It may well be that temperature shift is enough in its own right to reduced cell 
growth and that temperature-responsive promoters could be implemented to switch 
expression of other genes involved in processes related to recombinant protein production 
(rather than cell growth). 
In summary, the promoters investigated in this project resulted in quite variable levels of 
transcript and protein depending on the reporter gene, highlighting one of our main 
findings; that if these inducible promoters are to be used as tools in gene 
expression/regulation, then it is important to match each individual transgene of interest to 
the most suitable promoter (Table 3.2.6.3.1). 
 
5.3: In silico promoter analysis 
The focus of the project was to identify promoter sequences that could be used as tools to 
drive transgene expression in a temperature sensitive manner. However, we also had 
opportunity to investigate which, if any, promoter elements (such as transcription factor 
bind sites (TFBS)) or other features might be responsible for this induciblity. In silico 
promoter analysis of the 3 gene promoters used in the reporter studies would be insufficient 
for this type of analysis as unlike coding sequence, for example, regulatory sequences are 
under different constraints in terms of evolutionary conservation. Even a single base change 
in coding sequence may be unacceptable due to the negative impact it may have on the 
function or expression of the resulting protein.  
On the other hand, promoter modules (2-3 TFBS in tandem that combine to control 
initiation of transcription) may tolerate considerable variations in intervening sequence, 
without changing the functionality of the regulatory module. Indeed, even TFBS can be 
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quite promiscuous in terms of their exact sequence motif – often allowing interchangeable 
use of different nucleotides without impacting TF binding/recruitment.  
For these reasons, alignment algorithms used to identify conserved patterns of promoter 
elements use different ‘rules’ to those used to align coding sequence and furthermore, 
require greater numbers of input promoter sequences in order to perform or predict real 
promoter modules effectively.  
In order to explore this concept further, we identified a cohort of genes whose expression 
patterns across a large transcriptional dataset mimicked that of the 3 temperature-inducible 
genes. This ‘guilt-by-association’ approach assumes that genes that are co-expressed are 
controlled by the same regulatory elements. In this manner, upstream sequences of 16 co-
expressed genes from the cohort (Figure 3.4.2), were extracted in silico. We used the 
‘Conserved TF-family suite’ from Genomatix™ with the highest stringency for analysis 
and as a result, we identified binding sites for 3 TFs; EVI1, SRY and FKHD/FOX. None of 
these TFs have had previous links to any specific inducible promoter studies in CHO, but a 
literature search showed examples in mouse and human disease models.  
A gene associated with both murine and human myeloid leukemia is ecotropic viral 
integration 1 (EVI1). It is a nuclear TF involved in many signaling pathways for both 
coexpression and coactivation of cell cycle genes. EVI1 is a proto-oncogene conserved 
across humans, mice, and rats, sharing 91% homology in nucleotide sequence and 94% 
homology in amino acid sequence between humans and mice (Buonamici et al. 2003). The 
EVI1 gene codes for a zinc finger transcription factor with important roles both in normal 
development and in leukemogenesis. The exact mechanism by which EVI1 induces 
leukemogenesis is not clear but a study by Fuchs, has shown that EVI1 upregulates cell 
proliferation, impairs cell differentiation, and induces cell transformation (Fuchs 2006). 
A review by Wieser highlighted that experimental overexpression of EVI1 by itself was 
insufficient to cause leukemia in animal model systems, but it did interact with other genes 
(Wieser 2007). For example, it was shown that putative interference of EVI1 with the DNA 
binding activity of the transforming growth factor-beta (TGF-β) responsive Smad3/Smad4 
in causing leukemogenesis (Kurokawa et al. 1998). In summary, EVI1 is able to interfere 
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with the actions of TGF-β in a variety of biological systems and appears to be cell line 
specific. 
The sex-determining region Y (SRY) or testis-determining factor (TDF) is a member of the 
SOX (SRY-like box) gene family of DNA-binding proteins. When complexed with the SF1 
protein, SRY acts as a transcription factor that can upregulate other transcription factors, 
most importantly SOX9 (Haqq et al. 1993). More recently it has been dubbed the 
masterswitch in sex-determination by Kashimada et al. They discuss the cascade of events 
triggered by SRY and the mechanisms that reinforce the differentiation of the testes in 
males while actively inhibiting ovarian development (Kashimada and Koopman 2010). 
Finally, Hiramatsu et al, highlight a more time-specific window on the importance of SRY 
action in the initial 6-hour phase for the female-to-male switching of FGF9/WNT4 
signaling patterns (Hiramatsu et al. 2009).  
FOX (Forkhead box) proteins are a family of transcription factors that play important roles 
in regulating the expression of genes involved in cell growth, proliferation, differentiation, 
and longevity. Many FOX proteins are important in embryonic development (Tuteja and 
Kaestner 2007). There are many members of the FOX family, many annotated by a suffix, 
for example, FOXO. Members of the class O regulate metabolism, cellular proliferation, 
stress tolerance and possibly lifespan. The activity of FOXO is controlled by post-
translational modifications, including phosphorylation, acetylation and ubiquitination (van 
der Horst and Burgering 2007). 
Chromatin can be visualised as a string of nucleosome beads linked by ribbons of DNA. 
Much of the DNA in the eukaryotic cell is wrapped around nucleosomes and thereby 
occluded by histones. This raises the question of, how can a transcription factor find its 
binding site, given that an enhancer or other element might be condensed in the 
nucleosomes? Recent work has revealed certain transcription factors like Pbx that can 
penetrate repressed chromatin and bind to sites in DNA sequences with high affinity, acting 
much like a homing beacon for other TFs and their associated co-factors (Berkes et al. 
2004). These have been termed ‘pioneering transcription factors’ which appear to be 
critical in establishing certain cell lineages. Interestingly, FOX proteins have also shown 
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pioneering transcription activity by being able to bind condensed chromatin during cell 
differentiation processes (Zaret and Carroll 2011). 
A review by Fukunaga, Shioda and co-workers showed instances of gerbil and mouse brain 
ischemia connections to the Akt pathway with the Forkhead box transcription factor, class 0 
(FOXO) (Fukunaga and Shioda 2009) (Shioda et al. 2007). Interestingly, after in silico 
analysis of the Txnip promoter discussed previously, Le et al identified a FOXO binding 
site flanked by two CAAT-box sites in the 800bp promoter sequence. This is intriguing that 
both our promoters and the Txnip promoter sequences possess this TFBS. The presence of 
this pioneering TF may be related to dynamic induciblity and/or expression strength 
reported. In other words, scenarios in vivo in which the binding of a series of TFs to their 
binding sites is improbable owing to sites being located at densely packed chromatin 
locations and thus not initially cooperative for any interactions, then these special pioneer 
transcription factors can be at hand to engage target sites in this dense chromatin location  
(Zaret and Carroll 2011). 
The CREB TF was located in 15 of the sequences. CREB was first described in 1987 as a 
cAMP-responsive transcription factor regulating the somatostatin gene. CREB binds to 
certain DNA sequences called cAMP response elements (CRE), thereby increasing or 
decreasing the transcription of the downstream genes (Montminy and Bilezikjian 1987). 
More recently, its downregulation has been linked to disease progression in disease states 
like Alzheimer’s when the expression of CREB in the hippocampal neurons of mice was 
examined (Pugazhenthi et al. 2011). 
More commonly studied transcription factors such as; TBP, STAT and E2FF had TFBS 
located in 13 out of the 16 sequences tested. TATA-bind protein (TBP) and the Signal 
Transducer and Activator of Transcription (STAT) especially, are well studied TFs that 
play crucial roles in initiating or enhancing transcription with STAT proteins also being 
involved in immune tolerance and tumour surveillance (Darnell 1997). In addition, E-box 
and CAAT-box motifs were identified in 12 out of 16 sequences, and are regarded as vital 
drivers of transcription and regulation with the CAAT-box being frequently regarded as 
part of the core promoter architecture (Bi et al. 1997). Furthermore, C2H2 Zinc Finger 
Transcription Factors 2 (ZF02) and CCCTC-Binding factor or 11-zinc finger protein 
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(CTCF) sites were also found in 12 of the sequences. CCCTC-Binding factor or CTCF was 
initially discovered as a negative regulator of the chicken c-myc gene. This protein was 
found to bind to three regularly spaced repeats of the core sequence CCCTC and thus was 
named CCCTC binding factor (Lobanenkov et al. 1990). It requires additional sequences 
outside the three recognition motifs for tight binding, like many TFs its mode of action is 
synchronous with other factors/elements for transcriptional functionality. All of these 
identified transcription factors and their respective binding sites could perhaps be, at least 
partially, responsible for the promoter functionality shown throughout this project, but this 
has yet to be fully elucidated.  
Additionally, a single consensus motif ‘CCCCAGC’ was identified by examining across all 
these 16 input sequences (including a 1kb upstream portion of the putative miR-17-92 
promoter sequence). We used the motif-finder software tool from Genomatix™ choosing 
the most stringent cut-off parameters for analysis. This sequence was identified in all 16 co-
expressed gene promoter sequences, including all 4 novel CHO promoters from this study 
(Table 3.4.3). While interesting, this sequence has not been identified as a TFBS in the past, 
and would require closer investigation using site-directed mutagenesis or similar 
experimental verification to draw any further conclusions. 
 
5.4: The most appropriate promoter for each GOI - Promoter specificity 
One of the main findings of this project was that the isolated promoters all drove transgene 
expression at varying levels, showing utility across 4 reporter gene platforms. For example: 
the Cirbp-CHO promoter was more efficient at driving GFP than luciferase but the opposite 
was seen for the Cirbp-mouse promoter. Equally, the EPO protein could only be detected 
with SSu72, CMV and both Cirbp promoters while MDM2 and both miR-17-92 promoters 
could not, even though the latter 3 all drove luciferase to moderate or high expression. 
It is important to note that the efficiency of an inducible or indeed any exogenous promoter, 
in driving transcription, is dependent on the nature of the gene it regulates, for example it’s 
toxicity, and the host cell it is being produced in. This promoter specificity was observed 
throughout the project, although we didn’t expose the promoters to such experimental rigor 
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as driving toxic proteins or transfection into a wide-range of cell types, we did observe 
mixed levels of promoter activity across the 4 reporter genes.  
Promoter usage can be dependent on which location or tissue the sequence resides and 
indeed the species and cell type (Carninci et al. 2006) (Spenger et al. 2004) (Lim et al. 
2010) and how the diverse mechanisms regulating transcription of different promoter’s 
work, still remains unclear for the majority of promoters, especially CHO-specific ones. 
Additionally, Strid et al reported on the use of a promoter derived from a key enzyme in 
leukotriene biosynthesis called Leukotriene C4 synthase. They used this promoter to drive 
expression of enhanced GFP (EGFP). Specific GFP expression was observed in human 
monocytic leukemia (THP-1) and rat basophilic leukemia (RBL-1) myeloid cells but not in 
human embryonic kidney (HEK293/T) demonstrating cell specificity (Strid et al. 2008). 
Similarly, Haverkamp et al showed the cell line specificity was the restrictive reason for 
different observed levels of GFP expression. They performed in vivo studies using 4 
transgenic mouse cell lines that expressed EGFP under the control of 3 cell-specific 
promoters from calretinin, choline-acetyltransferase and parvalbumin genes (Haverkamp et 
al. 2009). 
Conversely in an older study, Hollenhorst et al, as a promoter specificity determinant, 
tested the mRNA levels of the ETS family of TFs. The mRNA levels of the 27 paralogous 
human ETS genes were measured in 23 tissues and various cell lines, with the premise 
being that ETS factors display highly conserved DNA binding properties and would not be 
expected to retain promoter selectivity across tissues (Hollenhorst et al. 2004). Tissues and 
complementary cell lines showed similar expression patterns perhaps indicating that tissue 
complexity was not always a limitation to specificity.  
Either way, it seems apparent that promoter specificity results from the promoter only being 
a ‘sum of its parts’, the diverse TFs and combination of elements present in a promoter 
sequence all work in concert or if elements are missing or modified through 
phosphorylation for example, then the sequences will inadvertently exhibit different 
transcriptional rates and promoter selectivity. A recent publication by Authier et al, 
revealed that IKK - IκB kinase α (IKKα) and IκB kinase β (IKKβ) – interacts and 
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phosphorylates oncogene related B (RelB) to modulate its promoter specificity and leads to 
increased fibroblast migration (Authier et al. 2014). Through phosphorylation, promoter 
activity and its transcriptional rate can be altered. Therefore, it is reasonable to assume that 
all elements of a promoter sequence can succumb to various levels of activity as a result of 
modifications and diverse combinations of TF interactions. 
In conclusion, it would appear essential to map the most suitable promoter to an individual 
transgene and that using more than one reporter gene assay to test transgene expression 
would be good practice for promoter studies overall. 
 
5.5: Viral versus endogenous stability in extended culture 
The cytomegalovirus (CMV) major immediate-early promoter/enhancer is used in many 
cell culture systems and is considered to be one of the strongest promoters in vitro. 
However, when this promoter was used in in vivo approaches for gene therapy, it was 
silenced within a few weeks in several organs including the liver (Loser et al. 1998).  CMV 
silencing was also reported by Teschendorf et al, they showed that >97% of stable HT-29 
clones homogeneously expressing GFP, under control of the CMV promoter gave rise to a 
scattered patterns of high and low GFP expression (Teschendorf et al. 2002). 
The human cytomegalovirus promoter (hCMV) has also been shown to be susceptible to 
gene silencing in CHO cells, most likely due to epigenetic events, such as DNA 
methylation and histone modifications (Mariati et al. 2014b). Therefore, we assumed that 
over time, a CMV viral sequence would become unstable due to promoter silencing in 
comparison to endogenous sequence. We examined the performance of two endogenous 
promoters (SSu72 and miR17-92) versus a CMV, by stably transfecting each promoter-
GFP construct into CHO-K1 cells to test GFP expression over extended culture time.  
Figure 3.5.1, illustrates the 3 GFP stable clonal mixed populations and their mean GFP 
fluorescence over three months. Decreases in GFP expression were seen in the clones 
transfected with the CMV promoter compared to the two endogenous SSu72 and miR17-92 
driven clones over time. This drop in GFP expression was more acute in the CMV stable 
mixed population, where GFP expression fell by ~95%.   
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In addition, we sorted these 3 stable GFP heterogeneous populations into single clones 
expressing high, medium or low GFP levels to examine this silencing effect further using 
homogeneous populations. Over 14 weeks, clones carrying the CMV promoter, once again 
showed decreased GFP expression/stability over time, whereas more consistent GFP levels 
were seen over the same time period by both SSu72 and mir17-92 clones (Figure 3.5.2).  
This underlines once again, the importance of the choice of promoter, in this case, for the 
generation of stable cell lines in bioprocessing. Even though our findings showed that viral 
promoters were marginally better at driving high level expression (luciferase exempt), 
using the endogenous promoters, not only do we get moderate to high expression but we 
also get added stability over time in culture, which could be advantageous in a bioprocess 
setting. 
In parallel to using endogenous CHO promoters to improve stability and expression in 
CHO cells, however, alternate ways to circumvent the transcriptional silencing commonly 
seen by the CMV viral promoter have been explored. For example; methylation-free CpG 
island sequences derived from TBP and HNRPa2b1 genes were inserted into vectors 
containing the human hCMV promoter, conferred more stable GFP transgene expression, 
aswell as, improved resistance to heterochromatin-mediated silencing (Antoniou et al. 
2003) (Williams et al. 2005).. 
Similarly, to combat silencing over extended culture, Mariati et al successfully inserted a 
core CpG island element (IE) from the hamster adenine phosphoribosyltransferase gene 
into a human CMV promoter. It was found to be effective in preventing DNA methylation 
and silencing. They also showed that the insertion of IE into a chimeric murine CMV 
(mCMV) enhancer and human elongation factor-1α core (hEF) promoter in reverse 
orientation did not enhance expression stability, indicating that the effect of IE on 
expression stability was possibly promoter specific (Mariati et al. 2014b) (Mariati et al. 
2014a). 
This experiment demonstrated two things: first, it validated what is generally accepted 
regarding viral promoters, i.e: they are susceptible to promoter silencing over long exposure 
in culture. Secondly, that endogenously sourced regulatory/promoter sequences maintain 
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strong expression characteristics compared to viral sequences over extended time in culture. 
Future work would be to include a repeat of this experiment using various other reporter 
proteins to assess whether the stable expression is independent of the transgene downstream 
of the promoter. 
 
5.6: Comparisons to analogous promoter studies 
In cell line and bioprocess optimisation, dynamic expression using inducible promoters 
represents an attractive tool to control the expression of transgenes. Existing inducers such 
as tetracycline, hormones and IPTG are undesirable at a manufacturing scale. 
Consequently, groups including us have acknowledged that utilising endogenous sequences 
from CHO may have more beneficial effects than those involving exogenous sequences 
reported in similar studies.  
Chen et al isolated 17 stable clones containing CHO sequence using a promoter trap 
approach. They generated a collection of transgenic lines with random insertions of a 
promoter-less reporter gene and screened for clones expressing the highest levels of 
reporter activity. They used GFP to evaluate expression for all clones. Only two clones 
showed high quality BLAST matches to the CHO genome and subsequent experimentation 
focused on these two clones. Clone 2 showed stronger GFP expression than the basal empty 
vector control (~20% of the SV40 viral promoter activity), while clone 11 did not. A clone 
2 fragment of 864bp was truncated and placed upstream of a luciferase gene and expression 
was reported to be highest in a 156bp fragment (~63% of SV40 control). In comparison, 2 
of our promoter constructs displayed higher luciferase expression than SV40 at 37
o
C and 3 
promoters displayed luciferase expression higher than SV40 at 31
o
C. Finally, only clone 2 
was capable of expression in both reporter systems (Chen et al. 2013), similar to what we 
observed across reporter assays. 
Another group isolated novel CHO sequences using inverse PCR methodology and tested 
their utility using the luciferase reporter assay. When constructs C1 – C5 were transfected 
into CHO cells, luciferase expression of ~25% and ~40% as a % of the SV40 control were 
reported for constructs C1 and C4 and were deemed the most promising. They performed 
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minimal mapping and in silico transcription factor binding site prediction. Only two 
predicted TATA-boxes were detected (Pontiller et al. 2010). Both of these studies reveal 
sequences that were successful in driving transgenes, however, further characterisation of 
the regulatory sequences is needed, and neither relate to dynamic or inducible expression.  
Thaisuchat et al did however identify a temperature sensitive promoter - S100a6 
(Calcyclin), which wasn’t identified on our initial microarray data. They examined the 
promoter activity using the luciferase assay only, but screened an extensive panel (~19) of 
truncated S100a6 constructs. From these, 12 displayed activities above the SV40 positive 
control. 
Although, our promoters do infact drive expression of an industrially applicable protein of 
interest, the reporter results were not without their inconsistencies. For example, MDM2 
did not produce EPO protein (Figure 3.2.5.2) even though it had shown promise in the 
other reporter assays. Perhaps this is highlighting that it should be standard practice to use 
more than one reporter assay as a true measurement of a regulatory sequences’ utility. A 
typical example is seen at a transcriptional level, where the Cirbp-CHO promoter expressed 
more EPO than the Cirbp-mouse version at both 37
o
C and 31
o
C (Figure 3.2.5.1), however, 
in the luciferase assay the Cirbp-mouse drives luciferase to higher levels than the CHO 
version.  
Furthermore, both promoters drove similar moderate to high EPO expression based on 
qPCR and western blotting (Figure 3.2.5.1 and 3.2.52), and very little difference in activity 
was seen. Nevertheless, regardless of varying promoter activities across reporter platforms 
this was encouraging, as to date only Cirbp from mouse is reported in the literature and as a 
result of this project, the CHO equivalent can now be further analyised and comparisons 
can be made between both promoters, based on having prior knowledge of the mouse 
version.  
Additionally, with reporter assay comparisons between CHO and mouse species, as in the 
case for miR-17-92 and Cirbp promoters, distal regulatory sequences and their location 
relative to the ATG start site may differ between species. Alternative promoters may also 
exist as well as with different TSS’, as was the case for mouse Cirbp (Al-Fageeh and 
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Smales 2009). In other words, even though the ATG start site was located in two species, 
and fragments of similar size were extracted relative to this ATG, then it is likely that they 
won’t necessarily have the same framework and elements arranged in the same locations, 
meaning they could, and often will as our results show, have different activities. This may 
go some way towards explaining why we observed different levels of reporter gene 
expression between promoter orthologues, irrespective of the promoter specificity for the 
transgene it controls.  
Other factors may also come into play demonstrating that functionality of a promoter is not 
solely dependent on the reporter gene. For example; we found that transgene expression can 
be influenced by culture format. Feng et al fused three different promoters (viral CMV and 
SV40 and human beta-actin) to luciferase and beta-galactosidase reporter genes and tested 
their expression in adherent and suspension formats. They found that beta-actin and SV40 
exhibited suppressed gene expression when transfected into mouse epidermal cells 
suspended over-agar compared with cells attached on culture plates. In contrast to the SV40 
promoter, CMV promoter activity was not decreased in cells suspended in an over-agar 
assay when compared with adherent cells. These studies show that regardless of 
mammalian or viral promoters, one cannot assume that all promoter-reporter gene 
constructs behave similarly in all conditions (Feng, Hicks and Chang 2003).  
The miR-17-92 promoters displayed lower GFP activity than expected, considering the 
cluster being highly expressed in many CHO cell lines (Hernandez Bort et al. 2012) and it 
being prevalently expressed in lung cancers (Jin et al. 2014) (Hayashita et al. 2005). 
However, after examining both using the luciferase reporter, the mouse version was found 
to be capable of driving higher luciferase expression than all other promoters tested 
including the SV40 control at 37
o
C (Figure 3.2.3.1). The CHO version did drive luciferase 
but not strongly, hinting that there may be crucial regulatory elements missing in the CHO 
sequence.  
This was interesting as both the mouse and CHO sequences had high sequence homology. 
As with the other gene promoter sequences investigated the truncated nature of the 
sequences compared to the endogenous locus may be responsible for the observed results. 
The reasonably novel nature of using a miRNA-derived promoter sequence also meant that 
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there were sparse published studies, at the time of analysis, to compare our observations 
with. 
More recently, miR-17-92 transcription was shown to be partly controlled by an E2F-
regulated host gene promoter. An intronic A/T-rich region exists directly upstream of the 
miRNA coding region and has shown to be a contributor to the clusters expression. 
Deletion analysis of the A/T-rich region revealed a strong dependence on c-Myc binding to 
the functional E3 site. Yet, constructs lacking the 5'-proximal ~1.3 kb or 3'-distal ~0.1 kb of 
the 1.5 kb A/T-rich region still retained residual promoter activity, suggesting multiple 
transcription start sites (TSS) in this region (Thomas et al. 2013). In light of this study, we 
investigated the sequence of human, rat, mouse and CHO approximately 1.5kb upstream of 
the miR-17-92 coding sequences.  
Although subjective, we believe that these A/T rich regions are present in all 4 species, 
however, interestingly the mouse promoter, being a larger fragment (more 5’ upstream 
sequence), was shown to contain a conserved E-Box site ‘CACGTG’ - this site was not 
located in the CHO orthologue and may be a reason for poor expression in 3 of the 4 
reporter assays but further work is required for validation. This is in line with the finding 
that cluster expression is activated by c-myc binding to a conserved E-box element (E3) 
~1.5 kb upstream of the miRNA coding sequence (Ji et al. 2011) (Thomas et al. 2013). 
 
5.7: Inducible mechanisms for improving bioprocess behaviour 
Although adjusting culture temperature is routinely used to increase productivity through 
extended viability and stationary culture phase, it serves a slightly different function in this 
study. Here we present the reoccurring theme of using temperature shift as a control 
mechanism. It is an attractive inducible switch because it requires no external molecules or 
further engineering (Yoon, Song and Lee 2003) (Fogolin et al. 2004). All promoters used in 
this study showed temperature induciblity, which in turn we hope to utilise as 
bioproduction tools. 
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Many inducible systems and inducer molecules (IMs) have been pioneered by Fussenegger, 
Weber and colleagues over the last ten years. They visualise the cellular environment like 
an electronic circuit capable of fully integrated tuneable expression allowing control via 
response to distinct input signals/triggers.  
These synthetic biology approaches will expand the biological toolbox for manipulation of 
cells for use in bioprocessing. Our endogenously sourced promoters and indeed any 
regulatory sequences may have added benefits when sourced from a host cell (CHO in our 
case), based on stability and greater ease of regulatory approval. 
The use of an appropriately chosen native promoter can also have the benefit of providing 
more refined control over transgenes with regard to timing and dosage. Le et al, showed 
such control by employing a pTixnip-driven mGLUT5 (a mouse fructose transporter under 
the pTixnip promoter) to demonstrate the concept of dynamic expression based around a 
metabolic engineering approach, to control fructose consumption in sync with culture 
growth stage (Le et al. 2013).. As a result, the GLUT5 fructose transporter under control of 
the Txnip promoter enabled CHO cells to utilise sugar according to cellular needs rather 
than in excess as typically seen in culture. Thus, less lactate was produced, resulting in a 
better growth rate, prolonged culture duration, and higher product titer. 
Recently it was shown that more dynamic expression that is in sync with the cells natural 
circadian rhythm or clock genes is the holy grail of precise inducible regulation (Le et al. 
2013) (Lopez et al. 2014). Clock genes are transcriptional regulators engaged in the 
generation of circadian rhythms. Cirbp guarantees high amplitude expression of the 
circadian clock genes and drives the rhythmic expression of a broad array of genes that 
orchestrate metabolism such as; sleep/wake behaviour, and the immune response. Their 
results represent a new mechanism of cytokine-regulated expression of clock genes namely 
Cirbp by modulating expression based on various concentrations of cytokines TNF and 
TGF-beta. This was supported by the finding that overexpression of Cirbp protects cells 
from the inhibitory effects of TNF and TGF-beta (Lopez et al. 2014).  
If Cirbp expression can be responsive to multiple factors i.e: temperature (as we have 
shown) and these two cytokines then its reasonable to assume that a useful molecular 
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circuit could be generated which incorporates sequences responsible for the responsiveness, 
and apply it to CHO protein production. This more natural circuit based around Cirbp 
which so obviously has a fundamental impact on cell behaviour, based on the amount of 
processes it is involved in , would be more appealing than the exogenous or IM circuits 
discussed previously. 
Although inducible systems and newer dynamic systems as mentioned have inherent 
benefits regarding more ‘real’ control of cells via their genes, in some instances the use of 
an inducible type system may not be desirable in large-scale manufacturing. This could be 
attributed to manufacturing costs and where a bioreactor design isn’t suitable. Another 
drawback seen is through lowering temperature is that it decreases specific growth rate (μ) 
and thus volumetric productivity often does not increase even though specific productivity 
(q) does (Hong et al. 2007). 
 In conclusion, progress is being made to bridge theory and application between fine tuning 
gene expression via synthetic biology or exploring control in sync with the cells natural 
rhythm in order to improve bioprocess outcomes. 
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5.8: Conclusions – Project 1 
Here we have described a study on CHO-specific promoters with particular emphasis on 
temperature induciblity. From the study we make the following conclusions; 
 Promoter activity was shown to be cell line specific and dependent on the nature of 
the transgene it controls. 
 Having isolated 6 functional promoter fragments of a certain size, there was a 
possibility that there is some regulatory sequence missing, potentially preventing 
the promoters from performing even better.  
 It was shown that MDM2 and Cirbp genes both had similar mRNA half-life and 
decay rates at both temperatures, suggesting that they were transcriptionally equally 
active at both temperatures.  
 The SSu72 gene on the other hand was shown to be twice as stable at 31oC and had 
a lower decay rate which may contribute to the increased expression seen when 
driving reporter genes upon temperature shift to 31
o
C.  
 The Cirbp-CHO promoter out-performed the Cirbp-mouse promoter in the GFP, 
EPO and p27 reporter results regarding expression strength and temperature 
induciblity.  
 The SSu72 and both Cirbp promoters appeared to be less temperature sensitive in 
luciferase reporter results than in GFP assays, especially compared to the MDM2 
promoter which had a very large differential of ~41-fold between 37
o
C and 31
o
C, 
which was very encouraging from an inducible viewpoint.  
 The MDM2 promoter was not effective in driving an EPO product, whereas SSu72 
and Cirbp-CHO promoters were. 
 All promoters successfully drove p27 expression, directly causing an impact on cell 
growth; however, this did not improve SEAP productivity. 
 It was shown that some results in the GFP and Luciferase reporter formats did not 
necessarily transmit similar results using more complex proteins like EPO and p27.  
 It was shown that two typical viral promoter sequences (CMV and SV40) did not 
exhibit constitutive expression at different culture temperatures and were 
temperature responsive in all four reporter assays. 
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 Therefore, CMV and SV40 to a lesser extent are unsuitable controls to use in 
temperature shift experiments.  
 The CMV promoter was shown to more transcriptionally active at 31oC than 37oC 
when transfected into CHO-K1 cells. 
 Three TFs were identified as having binding sites in all 16 co-expressed genes; 
EV1I, SRY and FKHD/FOXO. Further elucidation is needed to see whether they 
contribute to the promoter activities seen and the interactions they may have with 
one another. 
 A consensus sequence ‘CCCCAGC’ was also identified across all 16 temperature 
sensitive co-expressed genes. Whether this sequence was essential for promoter 
functionality remains to be seen and further work is required. 
 It was shown that viral promoter sequence stability was more susceptible to gene 
silencing and unstable at driving GFP expression over an extended culture period 
than two of the endogenous promoters used in this study.  
 It should be a prerequisite to identify the best promoter sequence to drive a gene of 
interest before beginning a bioprocess due to different promoter efficacies across 
the different reporter platforms.  
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5.9: Future work – Project 1 
5.9.1: Promoters from other CHO cell types 
The promoters isolated in this study were from the parental CHO-K1 cell line and showed 
varying levels of expression, some with great potential. However, it would be interesting to 
extract all equivalent promoter fragments from other choice CHO cell types, for example, 
CHO-DG44 cell line. Owing to the diversity of different cell lines, coupled with mutations 
like SNPs, indels, chromosome or copy number variations, this may provide us with 
analogous versions of the promoters from these other cell lines. These analogous promoters 
could be better or indeed worse than the promoters from the CHO-K1 cell line. 
 
5.9.2: Clone longer promoter fragments 
Although we were restricted by ligations involving larger fragments over ~1.5kb, and the 
lack of CHO sequence information at the beginning of the project, as time progressed, the 
CHO sequence became easier to navigate using bioinformatics approaches. As a result, it is 
now possible to PCR amplify any chosen sequence size upstream of our target genes (Table 
3.1.2.1) and re-test for improved activity using the reporter plasmids. Even though our 
promoter fragments showed the ability to drive moderate to high expression of various 
reporter genes, it may well be that more sequence would illicit more reporter gene activity, 
perhaps due to the presence of enhancer elements and other trans-factors. On the contrary, 
cloning more sequence may show reduced activity, as extra sequence may contain silencer 
regions for example, so a comprehensive study to test various larger constructs is 
recommended. 
 
5.9.3: Create stable CHO lines to test activity in fed-batch culture 
It would be interesting to generate CHO cells stably expressing an anti-apoptotic or 
proliferation gene under the control of the promoters identified in this study and 
subsequently test these cells in a fed-batch reactor setting. By controlling the cells using 
these promoters, we could aim to increase protein production by controlling advantageous 
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bioprocess genes. We could utilise a biphasic culture by dropping the temperature during 
the culture run to potentially boost expression as our promoters have shown increased 
expression levels at 31
o
C, this would in turn also slow cellular growth and direct cell 
metabolism towards increased protein output.   
 
5.9.4: Analyse the degree of inducibility of promoters over various temperatures 
In the aftermath of identifying CHO and mouse temperature inducible promoters by 
reducing the culture temperature to 31
o
C, we recommend to analyse these promoters in 
driving expression of reporter genes at other low culture temperatures. It would be 
interesting to observe the level of inducibility of these promoters and see if they can be 
‘tuned’ to exhibit varying levels of gene expression. In other words, would we see varying 
levels of reporter gene activity by altering the culture temperature at say 33
o
C or 29
o
C 
(other noted temperatures for low temperature culture) to see how gene expression responds 
to various temperatures. This may facilitate the promoters’ ability for more tunable control 
based on adjusting the temperature of the culture at various points of a batch run for 
instance.  
 
5.9.5: Viral controls in temperature shift experiments 
The use of viral promoters as a comparative control against unknown promoter sequences 
is maybe not the best gauge to use in temperature shift experiments owing to their inducible 
expression under mild hypothermia conditions of 31
o
C. In each case the CMV and SV40 
viral show increased expression at 31
o
C compared to 37
o
C.  
So these promoters contain discrete sequence information discerning cold-inducible 
expression, infact many enhancer and other functional sequences making up a typical 
vector construct have viral-origin sequences, even the polyA termination sequence in the 
luciferase pGL3-control vector could play a role in temperature shift.  
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It would be interesting to observe the behaviour of a range of virus-derived sequences and 
their response to temperature shift. 
 
5.9.6: Transcription factors further work 
We identified some unusual transcription factors especially the 3 TF’s common to all 16 
temperature sensitive promoter sequences; SRY, FKHD and EVl1. If they are indeed 
responsible for the promoter functionality we see throughout the project, then all 3 are 
attractive for future genetic engineering. We propose that modulating transcription factor 
amplification through vector transfections, could be used in conjunction with our 
promoters, as shown by Mangalampalli et al, where they co-transfected the Mouse 
Mammary Tumor Virus Promoter system with another vector expressing its specific 
transcription factor (glucocorticoid receptor). Increased production of SEAP resulted from 
CHO cells grown in increased concentrations of methotrexate supplemented into the 
growth media (Mangalampalli et al. 2002).  
Ideally mutational studies, for example; the GeneTailor™ kit from Invitrogen should be 
used in conjunction with the 3 TFBS, to alter the binding sites within the CHO promoters to 
test if this has a knock on effect to the expression levels. Additionally, we could use the 
‘Electrophoretic mobility shift assay’ (EMSA) approach to confirm transcription factor 
binding. This procedure can determine if a protein or mixture of proteins is capable of 
binding to a given DNA or RNA sequence sequences which have bound to the TF for 
example will migrate slower due to increased mass (Moxley and Jarrett 2005) (Smith and 
Humphries 2009) (Nagore et al. 2013). 
Finally, a notable consensus sequence ‘CCCCAGC’ was found in all 16 co-expressed gene 
promoters (Figure 3.4.3), while a temperature responsive MCRE element was seen in the 
mouse Cirbp promoter sequence, also reported by (Sumitomo et al. 2012) (Higashitsuji et 
al. 2012). They showed that the MCRE binds to SP1 and contributes to expression 
induction at 32
o
C. The group further duplicated the sequence (MCRExx48), when placed 
upstream of luciferase reporter it promoted >2-fold increases in luciferase expression. If the 
consensus sequence we identified was shown to be crucial to induciblity or responsible for 
 
 
344 
 
the moderate to high expression of reporter genes, then similarly duplication of this 
sequence would be a possible future endeavour to increase expression further.  
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6.1: XIAP – potential as an anti-apoptotic bioprocess target in CHO cells 
Over the last decade, there has been a steady increase in the volume of studies exploring the 
use of gene engineering strategies in order to improve various aspects of CHO cell 
performance in a bioreactor (Figueroa et al. 2007) (Lee et al. 2009) (Doolan et al. 2012) 
(Mariati et al. 2014b). 
Recently, a member of the inhibitor of apoptosis (IAP) proteins family has attracted more 
interest (Eckelman, Salvesen and Scott 2006). XIAP was shown to inhibit activation of 
members of the caspase family of cell-death proteases, namely caspase-3, caspase-7 and 
caspase-9 (Smolewski and Robak 2011). As a result, apoptosis can now be regulated by 
targeting anti-apoptosis genes such as XIAP and Bcl-2 (Lee et al. 2012). Furthermore, due 
to their prominent ability to control cell death and elevated expression in a variety of cancer 
cell types, IAP proteins are attractive gene targets for the development of novel anti-cancer 
treatments (Hunter, LaCasse and Korneluk 2007) (de Almagro and Vucic 2012). However, 
we aimed to address this from a more bioprocessing perspective, in particular improving 
biologic production by CHO cells. 
XIAP was identified as a potentially interesting engineering target based on data generated 
in a cancer project that was ongoing in the NICB labs. That work established that XIAP 
expression correlated with faster growth and a more invasive phenotype in Glioblastoma 
(GBM) cells, therefore we hypothesized that XIAP manipulation via overexpression could 
affect CHO cell culture behaviour, maybe beneficially.  
 
6.2: Stable overexpression of XIAP in CHO exhibit beneficial phenotypes 
When XIAP was stably overexpressed in CHO cells, the general propensity was for cells to 
reach higher growth densities and have longer viability in culture while maintaining cellular 
homeostasis. Such phenotypes are actively being sought for bioprocessing engineering to 
increase batch productivity and yield (Wong et al. 2006)(Dorai et al. 2010)(Wei et al. 
2011). These effects were observed to a greater or lesser extent depending on various 
factors, including the amount or degree of XIAP overexpression in a particular clone 
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(covered in later sections), the culture environment (media type/additives) and the culture 
format. We observed the effect of XIAP overexpression on CHO cell behaviour under 
apoptosis-inducing conditions (day 9 spent media and NaBu addition) and in adherent 
(Figure 4.2.2.1) and suspension (Figure 4.2.3.1) culture further validating these phenotypes.  
In previous studies, XIAP overexpression was shown to inhibit activities of caspase 3, 7 
and 9 in CHO-K1 cells and offered protection against etoposide (a cytotoxic anticancer 
drug), spent media-induced apoptosis and Sindbis virus infection and subsequently showed 
improved cell viabilities by 9-12% 48 hours post-infection (Sauerwald, Betenbaugh and 
Oyler 2002) (Sauerwald et al. 2006). Kim et al followed up this inquiry by researching the 
impact of XIAP overexpression in recombinant CHO (rCHO) cells producing EPO and 
treated with sodium butyrate (NaBu) to induce apoptosis. This was similar to our method of 
inducing apoptosis, however, unlike our results which showed XIAP overexpression 
circumventing NaBu-induced apoptosis to some degree, Kim et al showed that XIAP 
overexpression could inhibit Sindbis virus-induced apoptosis but not inhibit NaBu-induced 
apoptosis, as evidenced by DNA fragmentation. They concluded that XIAP overexpression 
did not affect cellular growth nor EPO production significantly, suggesting that the release 
of mitochondrial proteins might induce caspase-independent apoptosis, which may explain 
the specificity of apoptosis inhibition within the cells (Kim and Lee 2009). 
In addition, NaBu has also previously been shown to increase the specific productivity and 
mRNA transcription in CHO cells (Jeon and Lee 2007) (Jiang and Sharfstein 2008) (Hong, 
Lee and Yoon 2011). There is a fine line between adding too much NaBu and not enough, 
as too much induces apoptosis (>10mM) while the optimal butyrate concentration for 
productivity was observed to be ~2/3 mM. Mimura et al showed 2-4 fold increase in 
productivity of chimeric recombinant IgG when using 2mM NaBu supplemented to CHO-
K1 cells in culture while not compromising either glycosylation or biological activity 
(Mimura et al. 2001). More recently, Jeon et al reported that 1-2mM resulted in a 55% 
increase in human thrombopoietin (hTPO) productivity whereas 5-10mM was needed for a 
more cytotoxic effect to induce apoptosis (Jeon and Lee 2007).   
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Conversely, our results indicate that CHO cells overexpressing XIAP exhibited an increase 
in cell growth and higher viabilities than controls over extended time (usually 12-15 days) 
in various batch culture formats under apoptosis inducing conditions. This conflicting result 
may be due to a number of reasons. Kim et al used a regulated XIAP overexpression (Tet-
off-XIAP) construct tightly regulated by doxycycline, whereas for Sauerwald et al and 
ourselves, XIAP was constitutively overexpressed with both groups seeing increased 
viability (Sauerwald et al. 2006).  
Moreover, Sauerwald et al and Dorai et al used a XIAP variant, which retained the BIR 
domain but the C-terminal RING domain was absent (Dorai et al. 2009), whereas Liew et al 
and ourselves on the other hand used the full length XIAP transcript. We are unsure as to 
why we see contrasting results regarding growth and viability, however, it is more likely to 
be due to a different cell death mechanism such as rather than this XIAP transcript 
discrepancy, perhaps originating from mitochondrial membrane potential (MMP) as 
suggested by ( Kim and Lee 2009) (Liew et al. 2010). For instance, it is now accepted that 
apoptosis does not function alone in determining the fate of a cell (Booth et al. 2014). 
Several death initiator and effector molecules, signalling pathways and subcellular sites 
have been identified as key mediators in both processes, either by constituting common 
modules or alternatively by functioning as a switch allowing cells to decide which route to 
take (Nikoletopoulou et al. 2013), therefore we can assume that the interplay between these 
processes and molecules can alter phenotypes perhaps leading to the varying results 
observed among publications. 
Originally, the function of many of these apoptotic pathway proteins was believed to be 
binding the mitochondria and regulating apoptosis through modulation of mitochondria 
permeability. Mitochondria are at the core of all apoptosis pathways and are effectively 
targets themselves for cell engineering, owing to their essential role in aerobic respiration. 
Mitochondrial proteins called SMACs (small mitochondria-derived activator of caspases), 
bind to IAPs and deactivate them (Eschenburg et al. 2012). Furthermore, apoptosis pathway 
proteins in other organelles, other than mitochondria, within the cell may also both 
modulate apoptosis and metabolism adding to the potential for apoptosis-independent 
phenotype variations (Majors et al. 2007). 
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Our efforts did not examine caspase activity or mitochondrial membrane potential, 
however, we examined cell behaviour over longer culture periods in comparison. For 
example, Liew et al only tested cell behaviour over 5 days, viability of their control cells 
dropped to 40% after 2 days of serum deprivation, with the XIAP expressing cells 
maintaining up to 90% viability (Liew et al. 2010). We have shown that this impact can be 
extended to longer durations, mirroring those used in commercial bioprocesses. 
 
6.3: XIAP overexpression is directly linked to anti-apoptotic behaviour in CHO 
Cellular death can be divided into apoptosis, autophagy and necrosis. Apoptosis is 
morphologically and biochemically distinct from necrosis or autophagy and can be treated 
as a separate process (Krysko et al. 2008). For our analysis we did not focus on autophagy 
or necrosis, however, we are aware that all three processes and the crosstalk between them 
are important to understanding overall cell death behaviour.  
Having observed beneficial phenotypes attributed to XIAP overexpression in CHO cell 
clones, we wanted to examine if this specifically correlated with cellular apoptosis levels. 
We tested XIAP clone 12 in attached and suspension culture once again, and used the 
Nexin® assay to measure cells undergoing different stages of apoptosis (Figure 4.2.5.1). 
The most obvious impact was a tendency for cells to reach higher cell densities as expected, 
but also to be somewhat resistant to apoptosis later in culture – despite tending to be more 
prone to apoptosis earlier (Figure 4.2.5.1). We were unsure as to the reason for this 
observation: is it dosage dependant? In other words, is there too much XIAP being 
expressed earlier in culture from the plasmid coupled with the already relatively high 
endogenous levels of XIAP in CHO cells shown from the initial western result (Figure 
4.1.4).  
Although, XIAP is often overexpressed in cancer cells, where it plays a key role in survival 
and also promotes invasiveness, the extracellular signals and intracellular pathways 
regulating its expression and activity remain poorly understood. We also do not know if 
XIAP expression is fluctuating or is being constitutively expressed at any given point in 
time within CHO cells.  
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To estimate the dosage/expression of XIAP at various stages of batch culture would be 
interesting and mapping the XIAP levels over a timecourse may answer this question. For 
example, Gu et al demonstrated that the upregulation of XIAP protein levels is regulated by 
MDM2 at the translational level. 
This was interesting as the MDM2 promoter was one of our candidate inducible promoters 
identified from project 1, and we have shown that MDM2 gene expression is controlled by 
a temperature sensitive promoter. The MDM2 protein has been shown to physically interact 
with the IRES of the XIAP 5'-UTR, and to positively regulate XIAP IRES activity. This 
XIAP IRES-dependent translation was significantly increased in MDM2-transfected cells 
where MDM2 accumulated in the cytoplasm (Gu et al. 2009). Although project 1 focuses 
on the MDM2 promoter, rather than the MDM2 protein, it begs the question, what happens 
to XIAP levels post-temperature shift? Knowing that MDM2 transcription is activated – i.e: 
presumably more MDM2 protein, then would XIAP protein translation be increased or 
even impacted due to this? Is it the same biochemical pathway or a closed circuit? 
Interesting, but further study would be necessary to establish its relevance to CHO cell 
culture. 
It should be noted that, comparing apoptosis values between clone 12 and RFP-Control cell 
populations was difficult, owing to the RFP-Control samples having much lower cell 
densities over all timepoints. Clone 12 cultures presumably depleted the media quicker than 
RFP-Control as a result. This may be the reason for the observation that during early-mid 
culture, the control cells were less inclined to become apoptotic due to ample carbon source 
availability and limited waste product accumulation. One the other hand however, once 
both cultures had depleted the media and culture conditions had deteriorated the presence 
of excess XIAP conferred a survival advantage on the engineered cells. XIAP was deemed 
to have a direct link to apoptosis resistance over all timepoints tested but was found to only 
be statistically significantly at later stages of culture (9-12 days) (Figure 4.2.5.1).  
In summary, these experiments have suggested that XIAP is potentially a target for 
apoptosis engineering in advanced culture when overexpressed in CHO cells.  
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6.4: Targeting XIAP with siRNA reverses the beneficial phenotypes 
To provide additional evidence of XIAPs role in the observed phenotypic changes we used 
a siRNA targeting XIAP. By knocking down XIAP we expected to reverse the 
survival/growth benefit exhibited by clone 12, and to see if XIAP was responsible for these 
changes, in two different suspension formats (Figures 4.2.6.1 and 4.2.6.2). 
The data showed that targeting XIAP by RNAi significantly impacted the growth and 
viability of both XIAP clone 12 as well as the CHO-K1 cell line (Figure 4.2.6.1). The 
CHO-K1 cell line was tested in parallel as it was shown previously that XIAP expression 
was relatively high in actively growing CHO-K1 cells. Are the above normal XIAP levels 
seen a reason for CHO cells to be robust and resilient as is the general consensus?  
As regards to cell viability, the impact of XIAP knockdown was seen as early as day 2 in 
both cell lines in 24-well and 2mL formats. For growth, this impact was not shown to be 
significant at day 2 in culture for either cell line nor suspension culture format, but was by 
days 4 and 6. The viability of CHO-K1 cells on day 6 transfected with siXIAP dropped 5% 
lower than the siVCP treated cells which highlighted that treatment with siRNAs targeting 
XIAP really does hinder the viability phenotype compared to the siNeg control treated 
cells. VCP is a well-established RNAi control in the NICB labs, which obliterates CHO 
cells in culture when knocked down. The fact that XIAP knockdown caused a more potent 
effect is striking. 
In conclusion, we saw that XIAP depletion through RNAi caused a reverse in phenotypic 
effect on both the XIAP clone 12 and parental CHO-K1 cell densities compared to a siNeg 
control. Late culture exhibited the most significant cell count changes overall and by day 6 
the XIAP knockdown was more obvious from the western blot also (Figure 4.2.6.3) thus 
confirming the functional role of XIAP in impacting cell growth, survival and resistance to 
apoptosis. Other groups have reported comparative results of XIAP knockdown affecting 
growth and apoptosis sensitivity in human cancer cells, for example, Shi et al showed that 
luteolin (a dietary flavonoid commonly found in some medicinal plants) sensitizes TRAIL-
induced apoptosis through down-regulation of XIAP (Shi et al. 2005). 
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Spee et al reported that specific down-regulation of XIAP with RNAi enhances the 
sensitivity of canine tumor cell-lines to TRAIL and doxorubicin thereby reducing growth 
(Spee et al. 2006). Furthermore, Cho et al investigated the effect of GTP-binding proteins 
(Gαs) on apoptosis triggered by cisplatin and its underlying molecular mechanism in 
cervical cancer cells and showed XIAP knockdown by siRNA augmented apoptosis. They 
concluded that Gαs inhibit cisplatin-induced apoptosis by increasing transcription of XIAP 
and by decreasing degradation of XIAP protein in HeLa cervical cancer cells (Cho et al. 
2014). 
Clonal heterogeneity is always a concern when studying CHO cell behaviour (Dahodwala 
et al. 2012) (Ghorbaniaghdam et al. 2014). Therefore, we investigated the possibility that 
the phenotypes observed throughout the growth and viability timecourse assays were a 
result of a single clonal effect of XIAP overexpression, having focused on one particular 
clone (Clone 12) for the majority of the batch runs. As our results show, clone 12 exhibited 
higher cell densities while remaining healthier over extended culture, than the control 
(RFP) mixed populations up to 9-15 days and across varying culture formats.   
Having isolated 3 more clones overexpressing XIAP (5, 10 and 11), we grew them over 15 
days alongside clone 12 and the RFP-Control cells in a repeat experiment. All 3 clones 
perform in a similar fashion to clone 12 in 24-well suspension format (Figure 4.2.3.1.1 A), 
and suggested that initial observations for clone 12 were not due to a clonal specific 
anomaly.  
Clonal variation among CHO cells has been analysed using transcriptomics by a group in-
house to understand the mechanisms underlying bioprocess phenotypes; they focused on 
clonal growth rate variation during CHO cell line development. Using differential 
expression and correlation analysis they identified a high priority group of 416 transcripts 
(190 upregulated; 226 downregulated) associated with growth rate, highlighting the 
heterogeneity among clones when generating producer cell lines (Doolan et al. 2013). 
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6.5: Effect of XIAP overexpression on productivity 
Bioprocess engineering often focuses on growth/proliferation strategies to improve 
productivity as seen in a review by Kumar et al, for example; the role of cyclin dependent 
kinases (CDKs) and temperature shift to control the growth pathways/transitions while Bi 
et al, show that the average cell volume of arrested cells was approximately fourfold greater 
than that of proliferating cells (Bi, Shuttleworth and Al-Rubeai 2004) (Kumar, Gammell 
and Clynes 2007). Alternatively, yields can be improved by targeting pathways, for 
example, mTOR kinase signally pathway {{22 Dreesen,I.A. 2010;}}, in order to increase 
CHO cell specific productivity, while examples of  targeting pathways/genes via miRNAs 
is becoming more prevalent (Park et al. 2012) (Strotbek et al. 2013) (Fischer et al. 2014). 
The improvements in culture behaviour shown by the XIAP overexpressing clones during 
this project ultimately translated into improved yield of various types of recombinant 
protein products both transiently and in stable producer lines. In lieu of this we also 
examined whether XIAP engineering impacted cell-specific productivity of SEAP, EPO 
and IgG.  
It was shown that XIAP overexpression had no significant impact on cell-specific SEAP 
productivity however volumetric SEAP yield was increased (Figure 4.2.7.1.1). Therefore, 
the increase in SEAP yield must be due to the higher clone 12 cell numbers. EPO protein 
levels were shown via western blot to be increased in clone 12 cells compared to the RFP-
Control cells over 14 days in culture (Figure 4.2.7.2.1). From a bioprocess point of view, 
this validated that using an XIAP stable cell line (clone 12) versus a control CHO-K1 cell 
line was better in producing EPO and could be used to increase product titres. We also 
converted EPO band intensities to numerical values via densitometry analysis and found 
that EPO levels were higher in XIAP clone 12 samples on days 4, 7 and 12 compared to 
RFP-Control samples (Figure 4.2.7.2.2). This analysis provided further quantitative 
evidence that clone 12 cells did indeed produce more EPO than the RFP-Control cells. 
There are a few reports on the link between XIAP expression and productivity. Becker et al 
reported that co-expression of both XBP-1 and XIAP genes resulted in a higher titer of IgG 
in a serum-free medium than expression of either gene singularly (Becker et al. 2010). 
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Similar studies have shown that overexpressing anti-apoptotic genes such as, Aven and 
E1B-19k also increased survival and resistance to apoptosis, with reduced annexin-V 
binding compared to controls (Nivitchanyong et al. 2007) (Dorai et al. 2010). Similarly, 
Figueroa et al found that stable transfected pools of CHO cells engineered to express either 
Aven or E1B-19K alone were found to survive 1-2 days longer than the parent cell line 
following glucose deprivation while the expression of both genes in concert increased cell 
survival by 3 days. In their spinner flask batch studies, a clonal isolate engineered to 
express both anti-apoptosis genes exhibited a longer operating lifetime and higher final 
monoclonal antibody (MAb) titer.  
Much like what we reported for EPO, SEAP and IgG titers, they found that maximum titers 
of MAb were increased by 40-55% in bioreactors containing cells expressing both Aven 
and E1B-19K compared to cells expressing each singularly. Furthermore, as with our 
findings, these increases in volumetric productivity arose primarily due to enhancements in 
viable cell density over the course of the fed-batch culture period since the specific 
productivities for the cells expressing anti-apoptosis genes were comparable or slightly 
lower than the control CHO cells (Figueroa et al. 2007). 
So one thing is apparent, co-expressing anti-apoptotic genes appear to be more beneficial 
overall. This was encouraging from our perspective as we only concentrated on one gene, 
however, there might be opportunity for further improvement if we were to express another 
anti-apoptotic gene in CHO cells, along with XIAP.  
Tey et al found that exposure of CHO cells to ammonia toxicity via thymidine treatment 
revealed the relative robustness of Bcl-2 transfected cells. Growth was arrested by 
treatment with 4 mM thymidine, Bcl-2 overexpressing cells exhibit a viability of over 80% 
after 5 days in culture, compared to only 40% in the control cell line (Tey et al. 2000). 
Interestingly, measuring titers of a chimeric antibody they reported that under growth-
arrested conditions, there was no major difference in specific productivity of the antibody 
between the two cell lines, this was analogous to our IgG results.  
One aspect which we may have overlooked in comparison is that they showed that the 
mean level of Bcl-2 expression in the overexpressing population also declined significantly, 
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presumably reflecting the exhaustion of precursors for protein synthesis following nutrient 
depletion. We did not monitor XIAP expression levels over time like they did so we do not 
know how XIAP behaved as time progressed. Conducting and experiment to capture XIAP 
expression levels over extended culture, using gene expression analysis via qRT-PCR may 
provide this answer. 
Dorai et al, also experimented in overexpressing E1B-19K, Aven, and more specifically a 
mutant of XIAP (EAX197), they saw a reduction in caspase 3 activity of at least 60% and a 
170% enhancement in mitochondrial membrane potential (MMP) compared to controls 
when treated with staurosporine (inhibitor of protein kinases through the prevention of ATP 
binding to the kinase) (Dorai et al. 2009). The capacity of the apoptotic resistant cell lines 
to consume lactate was exploited by cultivating them in a ‘high’ glucose medium 
containing 15 g/L (60 mM glucose) in which apoptotic resistant cell lines exhibited lower 
maximum lactate (1.8 g/L) compared to control cell lines which accumulated 
concentrations of lactate (2.2 g/L) that subsequently appeared to be deleterious for growth. 
They also reported titers of a therapeutic antibody product expressed in the said apoptotic 
resistant cell line in ‘high’ glucose medium, titers reached 690 mg/L in apoptotic resistant 
cells compared to 390 mg/L for a cell line derived from a control host cell line. This was 
the first example in the literature in which manipulation of the apoptosis pathway led to an 
altered nutrient consumption profile of CHO cells in culture (Dorai et al. 2009). 
Furthermore, cells arrested in G1 phase can exhibit more specific productivity (Qp) as 
shown by groups Hackl et al, and Sanchez et al. Over expressing miR-7 arrested CHO cell 
growth for a period of 96 hours leading to increases in normalised productivity per cell 
albeit less than temperature shift studies carried out similarly. With the latter showing that 
using a novel sponge decoy approach was able to divert (soak up) endogenous miR-7, and 
they further showed that the reverse of this phenotype could increase maximum viable cell 
density, leading to increases in productivity (Hackl et al. 2012) (Sanchez et al. 2013).  
Enzymes, such as proteases and sialidases, accumulate in batch bioreactors. These enzymes 
are known to be detrimental to the quality of recombinant glycoproteins. Therefore, product 
quality in bioprocessing is another issue that frequently causes concerns, this is often made 
worse by manipulation of an otherwise predetermined natural process, be it an endogenous 
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gene/pathway or external environment change. For example, temperature shift or osmotic 
stress were both explored regarding the impact they cause on product quality when 
producing tissue type plasminogen activator (tPa) (Clark, Chaplin and Harcum 2004) (Han 
et al. 2010). Recently, Yang et al found that using perfusion seed cultures can optimise 
capacity utilization and improve process efficiency by increasing volumetric productivity 
while maintaining or improving product quality. They used three different CHO cell lines 
producing Fc fusion proteins and monoclonal antibodies and where titers were increased 
there was no significant deterioration in product quality (Yang et al. 2014). 
Therefore, it is reasonable to believe that any undertaking which may cause cellular stress, 
leads to unwanted cell death, often resulting in cell debris in culture media for example 
after degradation. As a result, care must be taken to ensure product quality is not 
compromised. Stressed conditions that can be shown to exhibit beneficial phenotypes such 
as growth and productivity as shown by Yoon et al, with EPO production, can invariably 
lead to stressed reactions by the cells used such as; loss of sialyation and formation of 
inclusion bodies affecting protein quality once undergone downstream processing. 
Therefore, increases in production, minus introducing a manipulation step causing cellular 
stress could obviously provide an improved route to increase productivity (Yoon, Hwang 
and Lee 2004).  
This is why we believe that the overexpression of XIAP in stable clone 12 especially, can 
be useful in a process setting. Clone 12 displayed two beneficial bioprocess phenotypes 
(increased growth rate and decreased apoptosis) that presumably do not put a transfection 
or any additional stress load onto the cells at a gene level and can be used as a productivity 
cell line in its natural state (with scope to make perhaps further adjustments to improve the 
cell line further). 
In conclusion, these results, demonstrate that XIAP overexpression in CHO lines can be 
beneficial in increasing productivity of therapeutic and reporter proteins, while keeping 
genetic manipulation to a minimum.  It would be interesting to combine the findings from 
each Project to investigate the temporal overexpression of XIAP later in culture in response 
to temperature shift, by placing it downstream of the promoters identified in project 1. 
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6.6: Targeting XIAP using  ncRNAs as a route to CHO cell engineering 
MicroRNAs are strongly implicated in the global regulation of gene expression, and 
consequently affect diverse metabolic pathways across many species. This characteristic 
makes miRNAs promising targets for cell engineering, while a key advantage of miRNAs, 
in contrast to most cell-engineering approaches that rely on overexpression of regulatory 
proteins for example, is that they do not compete for the translational machinery that is 
required to express the recombinant product (Muller et al. 2008) (Hackl et al. 2011). 
Therefore, the second part of project 2 considered the possibility of whether XIAP (from 
CHO and human) is subject to miRNA regulation, with a view to increasing productivity 
via interplay between miRNA and gene expression. 
The cancer project referred to earlier, not only identified XIAP expression as being 
correlated with proliferation rate and invasiveness potential of a panel of Glioblastoma 
(GBM) cell lines but also that XIAP was a direct target of miR-23b (Figure 4.3.1.2). 
Additionally, along with miR-23b, recently other miRNAs have also been shown to target 
XIAP such as miR-130, miR-24, miR-7 and miR-519d (Zhang et al. 2013) (Xie et al. 2013) 
(Liu et al. 2013a) (Pang et al. 2014). Furthermore, miRNA targeting could be an attractive 
route to regulate XIAP without exogenous expression derived from plasmid transfections. 
Over the last decade, approaches using other small RNAs i.e: siRNAs, which target XIAP 
have shown immediate impacts on human cancer cell phenotypes such as decreased 
viability and growth. Often the goal of such siRNA or miRNA based approaches is to 
sensitize cancerous cells by knocking down an important gene and simultaneously adding 
chemotherapeutic agents such as doxorubicin and TRAIL (McManus et al. 2004) (Spee et 
al. 2006), analogous to the findings of Shi et al, whereby they showed that luteolin (a 
dietary flavonoid) treatment sensitizes cells to TRAIL-induced apoptosis through down-
regulation of XIAP in HeLa cells (Shi et al. 2005). Our group also observed that XIAP 
targeting by a miRNA (in our case miR-23b) sensitized GBM cells to docetaxel treatment 
(unpublished data).  
Similarly, Pang et al found recently that miR-519d was also capable of sensitizing ovarian 
cancer cells to cisplatin-induced cell death by targeting the XIAP transcript and suppressing 
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cellular proliferation, suggesting that miR-519d plays a tumor-suppressive role in human 
ovarian cancer (Pang et al. 2014). 
The fact that such an important regulatory protein like XIAP can be targeted by siRNAs 
and miRNAs provides the basis for the second part of this project, which focused on the 
miR-Capture technique. This technique was used to identify potential miRNAs that may 
bind to XIAP mRNA and thus allow us to consider an alternative engineering option for 
XIAP regulation and will be addressed in more detail in the next section.    
 
6.7: MiR-Capture - to identify miRNAs targeting predetermined mRNAs 
Although the miR-Capture technique was described previous by (Hassan et al. 2013), it was 
never utilised in CHO before. By performing the XIAP mRNA capture method we wanted 
to establish a connection between  XIAP overexpression engineering (shown from the first 
part of this project) and miRNA engineering (more specifically the miRNAs that interact 
with XIAP) in CHO and human, with a view to potentially improve bioprocessing 
characteristics overall. Having realised XIAP manipulation can impact on CHO cells, 
knowing the miRNAs which regulate XIAP from both species, might provide an alternative 
method of controlling endogenous XIAP expression and see which miRNAs are common 
between species.  
By carrying out a novel MiR-Capture technique, our aims were two-fold. Firstly, to further 
validate the interaction between XIAP and ‘real’ miRNAs via bona fide validation using an 
affinity capture technique. It is well known that existing software algorithms for prediction 
of microRNA-mRNA interactions suffer from considerable false positive rates. A recent 
study by Maccani et al highlighted the urgent need for reliable CHO-specific microRNA 
target prediction tools and experimentally validated target databases in order to facilitate 
functional analysis of high-throughput microRNA expression data in CHO cells (Maccani 
et al. 2014). Secondly, we were afforded an opportunity to investigate and compare human 
(SNB-19) versus CHO XIAP mRNA homologues to test if they interact with a similar sub-
set of miRNAs and complete the first study of its type using CHO specific sample lysates. 
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This would also be interesting as the mRNA transcripts for CHO and human (SNB-19) are 
quite different in size but are reasonably conserved (>60%) at a DNA level. 
Investigating this would not only provide better primary understanding of the molecular 
mechanisms of XIAP expression control by miRNAs, but also potentially identify 
alternative ‘upstream’ routes to manipulating XIAP levels in given cell types without 
necessarily overexpressing the protein as an exogenous transgene. In other words, if we 
could identify miRNAs that regulate XIAP then they in turn might be used as future tools 
to alter endogenous XIAP levels. As briefly mentioned, the advantage of this approach, 
from a bioprocessing perspective, is that miRNA-based engineering avoids the added 
metabolic burden of translating another competing transgene (XIAP in this case). For 
example, by depleting the levels of a miRNA known to repress XIAP, the expression of the 
endogenous XIAP protein should increase.  
We are witnessing a shift from gene engineering to miRNA engineering with recent 
publications substantiating this, for example, Strotbek et al performed a genome wide 
functional miRNA screen by transient transfection of CHO cells stably expressing an IgG1 
antibody (CHO-IgG1). They identified 9 human miRNAs that improved productivity, 
whilst retaining product quality, not only of the CHO-IgG1 cells but also of CHO cells 
expressing recombinant human serum albumin (HSA), hinting that miRNAs can act in a 
product-independent manner  (Strotbek et al. 2013).  
This would appear beneficial as the opposite was reported recently by Maccani et al 
regarding exogenous gene expression, they suggested that the reaction of CHO cells to 
heterologous protein expression is strongly product- and/or clone-specific (Maccani et al. 
2014), though our data using XIAP does not support this observation. Encouragingly 
however, our broad analysis identified both an anti-apoptotic gene target and numerous 
miRNA targets from the miR-Capture.   
Jadhav et al also reported on the effect of various miRNAs transiently and stably 
transfected into CHO cells and their impact on various phenotypes. They found that CHO 
cells stably engineered with miR-17 exhibited both enhanced growth performance and a 2-
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fold increase in specific productivity, which resulted in a 3-fold overall increase in EPO 
titer (Jadhav et al. 2014).  
Interestingly, from our analysis, miR-17 was pulled down with XIAP in the CHO-K1 
lysate, but not in the SNB-19 lysate (Figure 4.3.5.2). However, careful annotation of the 
3’UTR of CHO-XIAP (Figures 4.1.3.1 and 4.1.3.2) revealed a substantially shorter (~2kb) 
sequence than in human and indeed other rodent species (Figure 4.1.3.3), therefore this may 
be partially attributed to miR-17 or indeed any orthologous miRNA not being present in the 
CHO sequence, as miR-17 is predicted to bind the human XIAP 3’UTR at nucleotide 
positions 5069 and 5677. In other words, due to the disparity between human and CHO 
XIAP 3’UTR sequences and the fact that the sequences match at interspersed regions 
(Figure 4.1.3.3), there was no way to fully elucidate or map the presence or lack thereof of 
certain miRNAs without further functional validation irrespective of in silico prediction. 
Equally constraining is that currently all prediction software haven’t been fully updated to 
contain CHO miRNA information. 
The miR-Capture technique was optimised to pulldown XIAP mRNA specifically along 
with miRNAs bound to it; this was followed by a comparison between CHO and human 
cell lines to identify miRNAs targeting XIAP. Four miRNAs were identified common to 
both cell lines [miR-124, miR-877, miR-526b*, miR-760]. None of the 4 miRNAs detected 
in both cell lines have previously been associated with XIAP or CHO in the literature but 
all were predicted to bind to XIAP in silico (Table 4.3.5.2).  
Furthermore, there were also 12 more miRNAs detected in the SNB-19 capture, and 
obvious questions would be to ask, can this discrepancy in miRNAs detected between both 
cell lines be explained by the differences in CHO-XIAP sequence versus the human-XIAP 
sequence? And does the 2kb difference in sequence size account for more miRNA binding 
as we envisaged? To help interpret the results of the miR-Capture, we compiled a table 
dividing up the lists of miRNAs into various categories depending on which samples they 
were detected (or not detected)  (Table 6.7).  
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Table 6.7: Categories of miRNAs from miR-Capture experiment. Six scenarios of why 
miRNAs made the list from figure 4.3.5.2. * denotes an exception where miRNA may have 
been pulled down but wasn’t detected in the total lysate. 
Categories of miR-Capture miRNA detection: 
In total lysate Predicted in silico Pulled down Ex: miR-124 
In total lysate Predicted in silico Not pulled down Ex: miR-24 
In total lysate Not predicted in silico Pulled down Ex: miR-135a* 
In total lysate Not predicted in silico Not pulled down Ex: miR-553 
Not in total lysate* Predicted in silico Pulled down Ex: miR-323-3p 
Not in total lysate* Not Predicted in silico Pulled down Ex: miR-801 
 
Various miRNAs predicted to bind XIAP may not have been detected because they simply 
were not detected in the cell lysates. We can check this by looking at the TLDA output for 
the total capture sample for a given miRNA. For example, as shown, miR-222 was detected 
in the SNB-19 total and XIAP-capture lysates, additionally it was detected in the CHO total 
lysate but not in the CHO XIAP-capture or indeed the non-specific oligo capture. In this 
case miR-222 was present in CHO cells extracted at that point in time but was not pulled 
down in the capture. It would be interesting to repeat the entire experiment with SNB-19 
and CHO-K1 cells at various time points of culture and see if the milieu of miRNAs differ 
from what was observed here.  
On the contrary, 6 miRNAs (miR-135a*, miR-768-3p, miR-801, miR-923, miR-20a and 
miR-572) were detected from the pulldown but were not predicted to bind to XIAP in silico 
which again highlights the frailties of computational approaches (Figure 6.7). For example 
upon inspection, the levels of miR-135* were found to be relatively high in total, NSO and 
capture XIAP lysates compared to other miRNAs that were predicted to bind in silico. This 
observation may have been due to non-canonical miRNA-mRNA binding which is not 
detectable using current prediction algorithms but has been demonstrated to occur in nature 
(Li and Yao 2012) (Pasquinelli 2012). 
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Figure 6.7: Venn diagram showing number of miRNAs predicted to bind in silico versus 
miRNAs that were actually pulled down and detected from the miR-Capture and 
overlapping miRNAs. 
 
Once the miR-Capture was completed, we performed a literature search to link some of the 
most promising miRNAs, starting with the four common ones and their involvement with 
growth and apoptosis regardless of cell type.  
MiR-124 featured in recent publications regarding reductions in growth of human cancer 
cells. Zhang et al found that ectopic expression of miR-124 in transplanted HT1197 cells 
resulted in the retardation of tumor growth in mouse tumor xenografts, and the expression 
of miR-124 and CDK4 showed an obvious inverse correlation in these xenograft tissues 
suggesting that miR-124 can arrest cell cycle and restrain the growth of bladder cancer by 
targeting CDK4 directly (Zhang et al. 2014). Additionally, Silber et al found that targeted 
delivery of miRNA-124 to glioblastoma multiforme tumor cells inhibited proliferation of 
the cells and in parallel induced differentiation of brain tumor stem cells and therefore may 
be therapeutically efficacious for the treatment of this disease (Silber et al. 2008). 
MiR-526b* was reported as a placental specific miRNA in numerous studies (Miura et al. 
2010) (Kotlabova, Doucha and Hromadnikova 2011) and more recently was shown to be 
involved in fetal growth restriction (FGR). The expression levels of six other placenta-
specific miRNAs including miR-526b* (hsa-miR-518b, hsa-miR-1323, hsa-miR-516b, hsa-
miR-515-5p, hsa-miR-520h, hsa-miR-519d), were significantly lower in placentas from 
FGR pregnancies than in placentas from uncomplicated pregnancies (Higashijima et al. 
2013). These other miRNAs listed were not identified from our miR-Capture, in other 
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words, were not co-captured with XIAP and miR-526b*. As growth was affected by miR-
526b* in an opposite fashion (shown to be less expressed) than say miR-124 which when 
highly expressed inhibits growth of cancer cells as mentioned previously, thus it was 
interesting that miR-526b* was moderately expressed in both cell lines. Mir-877 expression 
was not related to growth phenotypes but rather found to be associated with paclitaxel-
induced apoptosis in hepatocellular carcinoma cells (HCC) (Yan et al. 2013). 
Interestingly, miR-23b was not detected in the XIAP pulldown which was somewhat 
surprising as previous results suggested it targets XIAP. It has been shown by Garcia et al, 
that two properties of this miR-23b may explain this finding. Their analysis uses seed-
pairing stability (SPS) and high target-site abundance (TA) and miR-23b was shown to 
have unusually weak seed regions (an abundance of A/U bases), low SPS and high TA 
(Garcia et al. 2011). Therefore, miR-23b may not bind strongly enough to be pulled down 
during the miR-Capture procedure. Of course it could also simply be explained by the fact 
that even in the total lysate samples miR-23b was not detectable. Many miRNAs that were 
not detected in the capture lysates were detected in the total lysates – as would be expected 
using a technique that is specific for one mRNA target. Other miRNAs that were predicted 
to bind to XIAP but not captured by miR-Capture such as; miR-130a (Zhang et al. 2013), 
miR-7 (Liu et al. 2013a), miR-519d (Pang et al. 2014), miR-220c (Ren et al. 2014), and 
miR-24 (Xie et al. 2013) have all been reported as regulating XIAP, largely in human 
cancer cell types. 
For in silico prediction we used the mirWalk database as it scans all other existing 
databases such as TargetScan® and miRanda®, and allowed us to search the entire mRNA 
sequence, whereas most other miRNA prediction databases are restricted to the 3’UTR 
region. The database contains information based on predicted miRNAs as well as 
frequently being updated when functionally validated miRNAs are published in the 
literature (Dweep et al. 2011). MirWalk specifically uses a prediction approach whereby it 
identifies a strong seed region and ‘walks out’ to identify more complementary sequence 
and then assigns a score based on this affinity. In other words, miRNAs such as miR-135a* 
may not be predicted based on the binding criteria of the mirWalk software.  
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Recent publications have reviewed the extent of these wide-ranging binding criteria (see 
Figure 1.14.1) allowing deeper understanding of the rules used by miRNAs for the 
recognition and regulation of targets in vivo. Pasquinelli reviews several methods that are 
now available for identifying miRNA target sites and stated that the mere presence of a 
miRNA-binding site is insufficient for predicting target regulation. Furthermore, regulation 
of targets by miRNAs is subject to various levels of control, and recent developments have 
presented a new twist; targets can reciprocally control the level and function of miRNAs 
(Pasquinelli 2012). Curiously, target–sequence interactions can also stimulate miRNA 
degradation. It has been shown in D. melanogaster and in human cells that extensive 
pairing between a miRNA and its target site can induce 3′ end trimming of the miRNA 
(Ameres et al. 2010). It remains to be seen whether this may be the case for some miRNAs 
targeting XIAP here, subsequently reducing the detected captured output, for example in 
the SNB-19 capture, miR-221 was not captured, but its family member miR-222 was. The 
apparent flexibility in animal miRNA-targeting rules suggests that factors beyond their sole 
pairing capacity may mediate functional interactions in vivo (Grimson et al. 2007). In other 
words, the complexity may be so varied that understanding miRNAs via combinations of 
bioinformatics and capture methods may not wholly satisfy validation of every miRNA. 
Another aspect is co-expression of the mRNA and miRNA in question at a given point in 
time, for example, XIAP mRNA expression may differ grossly between stages of culture, 
and any in silico predicted miRNA target may not be present at the same stage. 
Additionally, folding of the XIAP mRNA may confer various secondary structures which 
may not facilitate access to a particular miRNA binding site. Furthermore, under different 
states of stress and culture conditions mRNA binding protein occupancy may differ and 
block access to the sequence. One way to examine this would be to run multiple captures at 
various culture/growth stages.  
In addition, it would be interesting to use other techniques (Table 1.14.1), to compare the 
miRNAs detected between techniques. The most commonly used methods to identify 
miRNA:mRNA interactions via argonaute (Ago) protein binding are HITS-CLIP and PAR-
CLIP, both of which have produced interesting results. As PAR-CLIP and HITS-CLIP 
results accumulated, Yang et al conceptualised a novel database, starBase (sRNA target 
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Base), which they have developed to facilitate the comprehensive exploration of miRNA-
target interaction maps from CLIP-Seq and Degradome-Seq data. They established 
approximately 400,000 and approximately 66,000 miRNA-target regulatory relationships 
from CLIP-Seq and Degradome-Seq data, respectively (Yang et al. 2011). Recently, 
starBase version 2.0 was established with many updates including interactive web 
implementations to provide visualisation, analysis and downloading of the aforementioned 
large-scale data sets (Li et al. 2014). 
However, unlike miR-Capture both CLIP techniques are in vitro-based which may not fully 
reflect the complexity of in vivo interactions. Other methods, similar in approach to miR-
Capture have been developed which can be used to identify miRNAs that regulate a single 
mRNA of interest. One method uses luciferase 3’UTR reporter genes with which individual 
miRNAs must be co-transfected into a cell line (Wu et al. 2010). This method suffers from 
some limitations, it can be laborious especially when bioinformatic screening predicts 
multiple potential regulatory miRNAs and it is limited to 3’UTR targeting only, with 
miRNAs targeting CDS and 5’UTR regions going unaccounted for. 
Interestingly, the miR-17-92 cluster members (miR-17, miR-19b and miR-20a) were all 
detected in the CHO capture lysate (Table 4.3.5.2). The fact that only some of the cluster 
members were detected was somewhat unexpected as the cluster was reported to be highly 
expressed in many cell types including Neuro- and Glio-blastoma (Hayashita et al. 2005) 
(Mestdagh et al. 2010), from which SNB-19 cells were derived. Additionally, as this 
clusters promoter was identified in the first project in this thesis, it was encouraging that 
these miRNAs appeared to be highly expressed in healthy, unstressed CHO cells, and 
therefore under the control of a moderate to strong promoter. This was partial justification 
to using the miR-17-92 cluster promoter even though the functional analysis wasn’t overly 
striking, but as mentioned it was highly unlikely we isolated the fully functional promoter 
region from the outset. 
MiR-222 was detected in the SNB-19 capture lysate and has been reported to be often co-
expressed with miR-221 (Howe, Cochrane and Richer 2012); however miR-221 was not 
present in SNB-19 or indeed CHO pulldowns (Table 4.3.5.2). Recently, Li et al found that 
knocking down the miR-221/222 cluster, significantly increased radiation-sensitivity of 
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Glioblastoma cells which they are normally highly resistant to. Notably, combined anti-
miR-221/222 and radiation therapy remarkably inhibited tumor growth compared with anti-
miR-221/222 or radiotherapy alone in a subcutaneous mouse model (Li et al. 2014a). It 
may be interesting to explore the knockdown of miR-222 in both cell lines as a comparison 
and expose them to radiation, based on miR-222 only being pulled down in our 
glioblastoma SNB-19 lysates.  
Interestingly, miR-8/200 and miR-221/222 families play crucial opposing roles that affect 
the differentiation state of breast cancers and have been shown to be expressed at higher 
levels in highly invasive basal-like breast cancer (BLBC) cells than in non-invasive luminal 
cells  (Howe et al. 2012), (Li et al. 2014b). This could go some way towards explaining as 
to why miR-222 was detected in the invasive human GBM SNB-19 cell line and not in the 
CHO XIAP pulldown. 
Reports in the literature have associated XIAP with certain miRNAs that are involved in 
carcinogenesis pathways and apoptosis regulation. From in vivo data, Ren et al indicated 
that the overexpression of miR-200c significantly inhibited tumor growth and increased the 
rate of apoptosis. Western blot analysis also demonstrated that the expression of XIAP was 
markedly reduced and that caspase-3 was highly activated by the overexpression of 
miR-200c (Ren et al. 2014). In addition, Xie et al suggested a novel mechanism by which 
miR-24 directly modulates the apoptosis threshold in cancer cells via downregulation of 
XIAP expression, and may be useful in order to overcome apoptosis resistance in cancer 
cells (Xie et al. 2013). 
In conclusion, while other studies have used this capture affinity technique for other mRNA 
targets such as; alpha-1 antitrypsin (AAT), interleukin-8 (IL-8) and secretory leucoprotease 
inhibitor (SLP1) (Hassan et al. 2013), this is the first miR-Capture study of this type done 
in CHO cells and the first capture study on an anti-apoptotic gene. 
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6.8: Functional validation of specific miRNAs from miR-Capture 
We presented an alternative validated method to identify multiple miRNAs targeting a 
predetermined mRNA. Our data showed 40 miRNAs in total, that may be cell specific, plus 
4 common and that co-elute with XIAP mRNA transcript in two cell types. From this target 
list (Table 4.3.5.2), two miRNAs were chosen for each cell line (miR-124, miR-19b for 
CHO and miR124, miR-222 for SNB-19) for functional validation.  
Each of these miRNAs were shown to be more abundant after single-plex Taqman assays, 
with miR-124 in the SNB-19 cells being the most abundant (~2.5-fold) compared to the 
non-specific oligo (NSO) treated SNB-19 cells. The other 3 miRNAs had similar fold 
increases (~1.8-1.9-fold) (Figure 4.3.6.1). Similarly, Chi et al validated genome-wide 
interaction maps for miR-124 and its target mRNAs after using the HITS-CLIP approach 
(Chi et al. 2009). 
All four showed a functional impact on XIAP expression to varying degrees when 
measured using qRT-PCR, treatment with pre-miR mimics for overexpression, western 
blotting and GFP-reporter 3’UTR knockdown analysis. 
XIAP 3’UTR GFP-reporter assay was performed to see the effect of miRNAs had on GFP 
expression levels. Surprisingly, miR-19b caused a very small reduction in GFP expression 
in CHO cells although it was significant (Figure 4.3.6.1.2 A). This was interesting because 
miR-19b was not detected from the human miR-Capture yet was shown to target human 
XIAP 3’UTR sequence. Maybe miR-19b does not bind that efficiently to the human XIAP 
mRNA and hence was not captured in the human lysate. 
Overall using the human XIAP 3’UTR sequence, it was shown that co-transfection of a 
pGFP (xiap3) vector with various pre-miR mimics resulted in modest reductions of GFP 
expression in both cell lines (Figure 4.3.6.1.2). This was presumably due to the miRNAs 
binding to locations on the XIAP 3’UTR as shown by RNAhybrid™ (Figure 4.3.6.1.1) and 
therefore impacting on GFP expression levels. As only the human XIAP 3’UTR (3.7kb) 
was examined for 3’UTR reporter gene targeting, repeat studies involving the exact CHO 
XIAP 3’UTR would prove beneficial.  
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The transfected miR-222 mimics induced a ~55% reduction in XIAP RQ in SNB-19 cells 
and had the most striking impact (Figure 4.3.6.3). The miR-222 mimics were included as a 
transfection control in CHO cells, as this miRNA was expected not to cause a change in 
XIAP expression based on it not being captured i.e: targeting XIAP endogenously, and 
indeed it showed no significant effect (Figure 4.3.6.3 A).  
The western blotting results did appear to correlate with the mimic transfection results for 
the CHO cells, both miR-124 and miR-19b showed reduced XIAP protein levels compared 
to the cells only and PM- control samples (Figure 4.3.6.4). However, in the SNB-19 cells, 
they did not correlate. For example, miR-222 transfected cells did not seem to have a 
reduction in XIAP protein and infact only the combination of miR-124 and miR-222 caused 
an impact on XIAP protein level (Figure 4.3.6.3 B). 
Transfecting pre-miR mimics into both cell lines resulted in varying amounts of XIAP 
knockdown measured as relative quantity (RQ). Hassan et al also observed varied results in 
their functional studies post-capture; they reported small percentage knockdown by anti-
miRs and suggest that using higher concentrations of anti-miRs may cause more substantial 
functional effects on alpha-1 antitrypsin (AAT) knockdown and we suggest the same for 
XIAP. Conversely, they highlighted that some miRNAs that were co-captured with AAT 
caused an effect on 3’UTR reporter gene studies but did not have a functional effect on 
AAT mRNA or protein levels (Hassan et al. 2013). Our results in fact show the opposite in 
some cases, for example, we had moderate but significant knockdown of XIAP mRNA 
levels by miR-124 mimics when transfected in SNB-19 cells, yet from the 3’UTR GFP 
reporter assay we saw slight knockdown but it was not significant (Figure 4.3.6.1.2). 
In summary, this novel technique combined with TLDA analysis, presents a simple 
efficient method to identify native interacting miRNAs targeting the whole sequence of an 
mRNA transcript. If used together with more stringent prediction programs and more 
sensitive specific assays for elucidation of miRNA biogenesis and functionality, this 
method is likely to significantly advance miRNA research.  
Ultimately what does this mean for protein production and how might we apply our 
findings in a bioreactor setting? For one we have identified 4 miRNAs that target both 
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CHO and human XIAP, these miRNAs could be stably overexpressed individually or in 
combination in CHO clones to examine their effects on cell growth, recombinant protein 
productivity and product quality much like Loh et al did for miRs-17, -19b, -20a, and -92a 
(Loh et al. 2014). Since miRNAs suppress mRNA translation, we hypothesized that up-
regulating miR-124 for example or indeed any miRNA identified by miR-Capture could 
inhibit endogenous XIAP and induce apoptosis as a result, i.e: they may be pro-apoptotic. 
Therefore by targeting these miRNA or using sponge decoys we might promote XIAP 
expression leading to even better phenotypes as shown from our data.  Furthermore, there is 
a high probability that these miRNAs may target more than one anti-apoptotic gene in both 
species which may increase the impact on apoptosis regulation further. For example, Druz 
et al found that miR-466h affects the apoptotic pathway by targeting at least 5 anti-
apoptotic genes in unison (Druz et al. 2011).  
Out of interest we checked other apoptotic related genes Bcl-2 and Aven for predicted 
binding sites of the four miRNAs identified from the miR-Capture. The Bcl-2 gene was 
shown to contain binding sites for miR-124 and miR-760, with miR-526* and miR-877 
sites not being predicted. MiR-124 was the only miRNA out of the four that also contained 
bind sites in the 3’UTR of the Aven gene. Therefore, with the help of more extensive 
validation, miR-124 may be shown to regulate a host of anti-apoptotic genes, not just XIAP 
as we showed in section 4.3.6.  
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6.9: Conclusions – Project 2 
 The anti-apoptotic gene XIAP plays important roles in survival and apoptosis in 
CHO in both adherent and suspension culture.  
 Stable overexpression of XIAP in CHO single cell clones caused increased growth 
rates, higher viabilities and resistance to apoptosis which enabled them to grow to 
higher cell densities compared to controls.  
 There were 4 clones which displayed these phenotypes to slightly varying levels, 
while clone 12 exhibited the most striking difference compared to the controls. 
 Day 9 spent media induced a morphological change in the tested cell lines in 
attached culture, and it was impactful on cellular viability in early culture for XIAP 
clone 12 and control populations. 
 Functional validation studies showed that the phenotypes (increased growth and 
viability) exhibited by overexpressing XIAP could be reversed by specifically 
knocking down XIAP using RNAi in two CHO cell lines (CHO-K1 parental and 
CHO stable XIAP clone 12).  
 The beneficial phenotypes displayed were adjudged not to be a clonal irregularity, 
as stable XIAP clones 5, 10 and 11 also displayed these phenotypes albeit to slightly 
varying degrees.  
 Regarding productivity, the stable XIAP clone 12 outperformed the RFP-Control 
cell line in all 3 reporter productivity assays [EPO, SEAP and IgG].  
 Other XIAP observations showed that it was; under control of miR-23b regulation 
in Glioma (Figure 4.3.1.2) and expressed highly in various CHO cell lines (Figure 
4.1.4).  
 A novel miRNA affinity capture ‘miR-Capture’ technique was shown to pulldown 
cognate miRNAs targeting XIAP. This was revealed in two separate mammalian 
cell types (CHO and human).  
 There were 40 miRNAs identified (26 in human and 14 in CHO) as being enriched 
between the capture oligo and control. As expected, more miRNAs were detected in 
the human XIAP mRNA presumably owing to it being 2113nt longer in sequence 
size. 
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 Of the 40 miRNAs detected, 4 miRNA were common between Human (SNB-19) 
and CHO (K1), these were [miR-124, miR-877, miR526b*, miR-760]. None had 
previous affiliation to XIAP in the literature.  
 The absence of 6 miRNAs predicted to bind XIAP in silico highlighted the 
discrepancies seen between software prediction methods and functional studies.  
 MiR-124 was validated as a true target of XIAP in both cell lines, while further 
validation is needed for the three other common miRNA targets. 
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6.10: Project 2 - Future work 
6.10.1: Cell-adhesion analysis 
From the abnormal morphology seen in the XIAP clone 12 cells under the microscope in 
extended culture under harsh conditions (Section 4.2.1) led us to believe that the elongated 
spiral morphology was responsible for survival in harsh conditions. Although not wholly 
relevant to biopharma production, we recommend for future experimentation to test for cell 
adhesion molecules (CAMs) such as integrins, selectins, CD44 and N-cadherin under 
flow/shear conditions. Several families of adhesion receptors have been identified (Albelda 
and Buck 1990). The different adhesive properties of our CHO cells may be reflected by 
different expression profiles of several CAMs and it would be interesting to analyse CAMs 
over time to see if they are responsible for increased survival. For example, in cancer cells, 
these CAMs have been associated with the growth and metastatic behaviour in several 
malignant entities such as neuroblastoma (Schwankhaus et al. 2014). One way of testing is 
by using a Laminar flow adhesion assay using IBIDI microslides VI (IBIDI, Munich, 
Germany) connected to a syringe pump (Model 100 Series; kdScientific, Holliston, 
Massachusetts, USA) and measure cell movement with an inverted microscope and validate 
with qRT-PCR. 
 
6.10.2: Clonal variation in XIAP clones 
The process of clonal cell line generation has inherent pitfalls. For example, random 
integration of the experimental vector/transgene can result in various genetic phenotypes 
such as intensity of expression potentially due to insertional mutagenesis and/or copy 
number variation. Vesuna and Winnard et al, also showed that random integration and 
amplification can interfere with the regulation of endogenous genes while potentially 
creating variation leading to chromosomal instability and karyotype alteration (Winnard et 
al. 2006) (Vesuna et al. 2006). 
Although care was taken to include a panel to test clonal variation in CHO cells expressing 
stable XIAP, only 13 clones survived after 3 months of selective pressure due to 
contamination and other technical issues. Although four clones progressed to the apoptosis 
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experiments and were deemed sufficient for an unbiased study, ideally more clones would 
be investigated to establish the full extent of the XIAP effect as well as to identify 
potentially better clones for future work. 
 
6.10.3: Analysis of metabolite utilisation and waste accumulation 
There is scope for analyzing the interdependence of the apoptotic cellular machinery with 
metabolism and waste formation (ammonia and lactate) to provide greater flexibility to 
mammalian bioreactor process development. Dorai and colleagues provided the first study 
pushing these boundaries into apoptosis mediated metabolite and waste interplay. They 
showed that overexpression of anti-apoptotic genes E1B-19K, Aven, and a mutant of XIAP 
(EAX197), resulted in beneficial traits including improved lactate clearance (>1.8g/L) and 
lower ammonia accumulation compared to host cell controls (Dorai et al. 2009) (Dorai et 
al. 2010). It would be interesting to assess the XIAP clones in terms of these metabolic 
activities. 
 
6.10.5: MiR-Capture improvements 
As it is a relatively novel technique, there is scope for improvement in the miR-Capture 
technique. An example would be to optimise the formaldehyde crosslinking step to try 
isolate bound miRNAs more efficiently. Additionally, it would be an interesting exercise to 
repeat the miR-Capture for other anti- and pro-apoptotic genes to see if there is a 
commonality of miRNAs pulled down which may target more than one apoptotic related 
gene/mRNA.  
Finally, as this was a novel technique, many steps can be altered which may be beneficial 
or in the contrary detrimental to the success of the miR-Capture process. For example, there 
were many washing steps with Catherine greens labs continuously experimenting to 
increase the efficiency and reproducibility of the technique. Therefore, multiple repeats of 
the technique using different arrangements of washing agents and exposure times may be 
useful in detecting more miRNAs (as some may simply not be bound to the XIAP mRNA 
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strongly enough using an oligo hook) and as a result, may have been undetected form the 
protocol we used. We could also compare the set of miRNAs after each miR-Capture. 
 
6.10.6: Are other anti-apoptotic genes targeted by the XIAP miR-Capture miRNAs 
As mentioned previously in section 6.8, it would be interesting to see if the four miRNAs 
identified as common or indeed any miRNA detected from the miR-Capture from either 
species affect the regulation of other anti-apoptotic genes. We were limited to in silico 
prediction only but we suggest validation using premir and antagomir to overexpress or 
knock down various miRNAs which are predicted to bind XIAP and a range of other 
related genes. In other words, by performing miR-Capture on other anti-apoptotic genes we 
would like to see if they are controlled by an overlapping set of miRNAs.  
 
6.10.7: XIAP 3’UTR reporter assay 
The XIAP 3’UTR reporter functional assay showed the decrease in GFP expression 
resulting from a co-transfection of a GFP construct containing a 3.7 kb sequence of the 
human XIAP 3’UTR with various miRNA mimics (Figure 4.3.6.1.2).  
For future work we recommend isolating the CHO XIAP equivalent (~3.7 kb) and clone to 
the GFP plasmid and repeat the assay. It would be beneficial to see effect after co-
transfection of the GFP- XIAP 3’UTR construct and various mimics in CHO cells, the 
experiment as it wasn’t originally specific for CHO. This was based on the hypothesis that 
different cell lines have potentially different levels of endogenous miRNAs, however, it 
must be noted that identifying and isolating the CHO 3’UTR sequence was not possible at 
the time of designing the experiment. With the release of the draft CHO sequence this is 
now possible. 
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6.10.8: Use the promoters from project 1 to control XIAP transgene expression 
To amalgamate both projects, we suggest using the temperature sensitive promoters 
identified from project 1 to drive competitive inhibitors of miRNAs ‘miRNA sponges’ in 
order to repress the set of miRNAs which control XIAP, and hence increase XIAP 
expression late in culture for example, to delay the onset of apoptosis. MiRNA sponges are 
transcripts which usually function under the control of a strong promoter, so we suggest 
using our strong CHO endogenous promoters which would be an attractive means for 
controlling XIAP expression coupled with a temperature inducible means of altering 
expression. 
Similarly, we could use sponges’ specific to the subset of miRNAs which regulate XIAP 
and engineer stable CHO cells to reduce these miRNAs and potentially get the same 
phenotypes as we saw from the XIAP overexpression experiments.  
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7.2: Appendix 
 
Final Primer Design for functional promoters 
  Primer order name:         Nucleotide sequence 5’-------3’                                     
                             MdM2.370 F:                    aattggtaccGTTAACAGGTGCCTGTCTCC 
  MdM2.370 R:                      aattctcgagTGGCCTACAAGTAGGGGAGAA 
    SSu72.654 F:                     aattggtaccACAGGGTTTCTCCTGATGAGCT 
                 SSu72.654 R:                    aattctcgagGACCGTCCGCGCTACCCA 
Cirbp.(828cho) F:        aataggtaccCCTTCCATGGCATGCTTGAGAC 
  Cirbp.(828cho) R:          attaagatctGTGCACACACCACAGATATTTGC 
                     Cirbp.(889mouse) F:      aataggtaccCCTTCCATGGCATGCTTGAGAC 
                     Cirbp.(889mouse) R:                  ataaagatctGAGTCCCGCCTGATATACTCC 
                  miR17-92.733 (cho) F:                    aattggtaccTAGCAGCACCCGAAGCTTTGC 
                  miR17-92.733 (cho) R:                   aattctcgagTCCATCAGTCTCCAGTCTCACA 
                miR17-92.992 (mouse) F:              aattggtaccTTCCACCCAATACATTGTTGCC 
                miR17-92.992 (mouse) R:             attaagatctGTCACAGCTTCAGTCCCAAG * 
Table 7.2.1: Designed primer sequences and order annotation for promoters used for 
functional reporter assays. * denotes a Bglii site due to existence of a Xho1 site being 
present within the 992bp sequence which would hinder cloning downstream otherwise. 
 
Mouse (backup) primers 
See supplementary CD (large file). 
FACS sector breakdown: 
 
GFP med + #Events GFP med + FITC-A Mean GFP med + FITC-A Median GFP top + #Events GFP top + FITC-A Mean GFP top + FITC-A Median Cells #Events
polyA_37 114 8847 7403 2 36550 36550 10488
polyA_31 691 10969 8695 56 43005 39594 10430
MDM_37 605 11556 9125 250 99225 81201 10621
MDM_31 1785 13285 11483 1348 96817 76647 10139
SSU-600_37 725 11272 8862 223 77062 59105 10289
SSU-600_31 827 13162 11308 580 95099 78151 7012
SSU-19_37 1181 11801 9427 411 86169 68126 10634
SSU-19_31 991 13736 12169 778 99066 78425 5923
Cir7-CHO_37 1555 12479 10249 712 82958 62600 10909
Cir7-CHO_31 715 13429 11345 660 104750 88985 5415
mir17-92M_37 275 11259 8810 116 87094 69770 6080
mir17-92M_31 654 12822 10804 363 94559 71786 5517
mir17-92C_37 129 10350 8003 11 40183 36737 6162
mir17-92C_31 434 11243 8999 44 43374 40080 5817
CMV_37 1047 12233 9762 490 77572 60498 10656
CMV_31 415 13244 11206 622 111499 96864 3740
Cir7-M_37 1318 12114 9672 543 86725 67638 11142
Cir7-M_31 851 12764 10223 683 102273 85866 5719
MED TOP
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RT-qPCR – Actinomycin D experiments – mRNA stability 
Table 7.2.2: Copy No. and CT calculations for 3 priority genes standard curves. 
 
Cirbp SSu72 MDM2
dil CT copy no dil CT copy no dil CT copy no
10 -1 95500000000 10 -1 61100000000 10 -1 16000000000
10 -2 9550000000 10 -2 6110000000 10 -2 1600000000
10 -3 955000000 10 -3 611000000 10 -3 160000000
10 -4 95500000 10 -4 61100000 10 -4 16000000
10 -5 14.2 9550000 10 -5 15.7 6110000 10 -5 14.6 1600000
10 -6 17.2 955000 10 -6 18.7 611000 10 -6 17.8 160000
10 -7 20.2 95500 10 -7 21.7 61100 10 -7 20.9 16000
10 -8 23.2 9550 10 -8 24.7 6110 10 -8 24.0 1600
10 -9 26.2 955 10 -9 27.6 611 10 -9 27.2 160
10 -10 29.2 95.5 10 -10 30.6 61.1 10 -10 30.3 16
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Figure 7.2.3: Logarithmic standard curves and line equation for each priority gene. 
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Figure 7.2.4: Copy number calculation via RT-qPCR for decay rate (-k) determination of 3 
gene specific mRNAs tested over 3 timepoints [3, 6, 24h]. CHO-K1 cells cultured over 24 
hours in 6-well plate format and subjected to treatment (W + W/O ActD). Note: The 24h 
ActD samples do not reach zero, the values were calculated to be 668, 299 and 2 copies 
respectively. 
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Table 7.2.5: Decay rates and half-life of gene transcripts between 3 timepoints post-
actinomycin D treatment of CHO-K1 cells. (A) Values estimated from figure 6.2.2.1 
results. 
 
 
Table 7.2.6: Details for GFP gene amplicon with standards used for calibration curve in red 
(10^5-10^10). For investigating CMV viral promoter stability and mRNA transcript level at 
31
o
C. 
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Figure 7.2.7: Standard curve generated by qPCR from primers specific to the GFP 
amplicon (252bp) diluted by serial dilution (range from 10
5
 to 10
10
). Sample CT plots 
measured in triplicate and averaged. The cycle difference between each order of magnitude 
corresponds to ~2.81 CT. 
 
p27 results appendices 
Table 7.2.8: Attached p27 cell number reduction % results 
 
 
 
 
Attached
% drop % of 100 % of pTATA
71.0 29.0 10.6
81.6 18.4 0.0
39.6 60.4 42.1
54.4 45.6 27.3
47.0 53.0 34.7
26.0 74.0 55.6
30.4 69.6 51.2
75.4 24.6 6.2
80.1 19.9 1.5
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Table 7.2.9: Suspension p27 cell number reduction % results 
 
Table 7.2.10: Single cell clonal population labels – from FACS sorting. 
 
 
 
 
 
 
Suspension
% drop % of 100 % of pTATA
61.1 38.9 15.3
76.4 23.6 0.0
60.1 39.9 16.2
31.1 68.9 45.2
37.3 62.7 39.0
35.7 64.3 40.7
28.2 71.8 48.2
56.0 44.0 20.4
62.8 37.2 13.5
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7.3: Project 2 - Appendices 
XIAP sequences – Human and CHO: 
CHO-scaffold 4366 
>gi|350538686|ref|NM_001246801.1| Cricetulus griseus X-linked inhibitor 
of apoptosis (Xiap), mRNA 
GGTGGACAAGTCCTATTTTCAAGAGAAGATGACTTTTAACAGTTTTGAAGGATCTAGAACTTGTGTACCTGCA
GACACCAATAAGGATGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACATTTGCTAACTTTCCAAGTAGTA
GTCCTGTTTCAGCATCAACCTTGGCACGAGCAGGGTTTCTTTATACTGGTGAAGGAGATACTGTGCAGTGCTT
TAGTTGTCACGCGGCAGTGGATAGATGGCAGTACGGAGACTCAGCTGTTGGAAGACACAGGCAAATATCCCCA
AATTGCAGATTTATCAATGGTTTTTATTTTGAAAACAGTGCCACACAGGCTACAAATCCTGGTATCCAAAATG
GCCAGTACAAAGCTGAAAACTATGTGGGAAACAGAAATCATTTTGCTCTTGACAGGCCATCTGAGACTCATGC
AGATTATCTTTTGAGAACTGGACAGGTTGTAGATATTTCAGATACCATATACCCGAGGAACCCTGCCATGTGT
AGTGAAGAAGCCAGGCTGAAGTCCTTTCAGAACTGGCCAGACTATGCCCACTTAACCCCCAGAGAGTTGGCCA
GTGCTGGACTGTACTACACAGGGATTGATGATCAAGTGCAGTGCTTTTGCTGTGGTGGGAAACTGAAAAATTG
GGAACCCTGTGATCGTGCCTGGTCAGAACACAGGAGACACTTTCCCAATTGCTTCTTTGTTTTGGGCCGGAAT
GTTAATGTTCGGAGTGAATCTGGTGTGAGTTCTGATAGGAATTTCCCCAATTCGGCAAATTCTCCAAGAAATC
CAGCCATGGCAGAATATGAAGCACGGATCATTACTTTTGGAACATGGATATACTCAGTTAACAAGGAGCAGCT
TGCAAGAGCTGGATTTTATGCTTTAGGTGAAGGTGATAAGGTGAAGTGCTTTCACTGTGGAGGAGGGCTCACA
GATTGGAAGCCAAGTGAAGACCCTTGGGAACAGCATGCGAAGTGGTACCCAGGGTGTAAATATCTATTGGATG
AGAAGGGGCAAGAATATATAAATAATATTCATTTAACCCATTCACTTGGAGAATCTTTGGTAAGAACTGCTGA
AAAAACACCTTCACTAACTAAAAGAATTGATGATACCATCTTCCAGAATCCTATGGTACAAGAAGCTATACGA
ATGGGATTCAGTTTCAGGGACATTAAGAAAACAATGGAAGAAAAGATCCAAACATCTGGGAGCAGCTATCTGT
CCCTTGAGGTTCTGATTGCAGATCTAGTGAGTGCTCAGAAAGATAATACACAGGATGAGTCAAGTCAGACTTC
ATTGCAGAAAGACATCAGTACGGAAGAGCAGCTGAGGCGCCTACAAGAAGAGAAGCTTTGCAAAATCTGCATG
GATAGAAATATTGCTGTAGTTTTTGTTCCTTGTGGACATCTGGTCACTTGTAAACAGTGTGCTGAAGCAGTTG
ACAAATGTCCCATGTGCTACACAATCATTACCTTCAAACAAAAAATTTTTATGTCTTAA*TTGAGAGCAACAG
TAGGCATGTTATGTTC 
 
Next scaffold….. 
>gi|344164155|gb|JH000910.1|:604800-712033 Cricetulus griseus cell 
line CHO-K1 unplaced genomic scaffold scaffold4333, whole genome 
shotgun sequence – rev compl 
miR-17 predicted binding site in Targetscan 
CAGTGTTTGAATGAATTTAAACAACAAACCCTCAAACTAGTATATGTTGTTTTTCTCTTTGTGCAG
ACATCAGTACGGAAGAGCAGCTGAGGCGCCTACAAGAAGAGAAGCTTTGCAAAATCTGCATGGATA
GAAATATTGCTGTAGTTTTTGTTCCTTGTGGACATCTGGTCACTTGTAAACAGTGTGCTGAAGCAG
TTGACAAATGTCCCATGTGCTACACAATCATTACCTTCAAACAAAAAATTTTTATGTCTTAA* 
....TTGAGAGCAACAGTAGGCATGTTATACTCTTCTTACTCTAATTGAATGTGTGATGTGAGCAA
ACTTTAAGTAATCAGCATTGCATTCCATTAGCATCTGCTGCCAAGTGGAAACAAATGTTAACAGCA
CTGGTACTGTCTAAACTTTGGATTTCTGGAACTTTCAGGTTATTAGCTATATCGTTTATCCAGTTT
TTTACTCAATTAAAGCCTTAGACAAAGAAGCATTTAATATTATAACTTTTCACCTTGTGTATTTGT
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AGTACACTGACTTGATTTCTATGTGTAAGTGAATTAATCACTATCATTTTTCATTCCTTTTGGATA
AGCTTAACAAATGGAGTGTTCTGTATAAGCAGGGAGATTTGAGTTAATCTACCCATTCACTTGCTC
TGTTTATTGTGAACAGAGAATACACTGTTCCACACTGGTGGGAGGATAAACATTGGTTTGTAGATG
TTTGTGTCTGTGTTTTGGATTCTGTCCATTTTCTTTCAAATTTATAAACATACTTGTATGAATGGT
TTTTTAAGTGATTTTGCCATCTCCCAAAAGATATTTAATGGTAAACTGCTTATCTAACCAGCATAT
ACTAACATGGAAAGACAACAAAGATATATTAAGTGTAAATTACAAATGGCAAAACACTATGTATAG
TTTGAGCCAAATCAAGGTGTGAATTTTATATCTGTATAGGACAAAAAAGAGTTGGAAAGATATGCA
TCATACTCTTAAATATGTTTTTTTCTTGAGGGGGGTGGGGGTATGGGTCTTTGAGGGGCTTATAGG
AGCCCTTCTTTTTTCATTTTGTTCTGTTTGAAGTTTATATAAGTATGTATTACTTTTATATAATCA
GAATTTTTAGAAATATTGTACTGATTTAAAGGCTTAGGCATGTTCAAACGTCTGCAAAACTACTTA
TTGCTCAGTTTTAGTTTTTCTAATCCAAGAAGGCAGGCCAGTTGACTTTCTGGTGCCAATGTGAAA
TTTAAATGTTTTTGTTTTACCTGCTTTGTGGATAGAAAATATTTCTGAGTGGTAGTTTTCTGACAG
GTAGACCATGTCTTCTTATCTTGTTTCAAAATAAGTATTTCTGATTTTGTAAAATGAAATATAAAA
TATTGTCTCAGATCTTCCAATTAATTAGTAAGGATTCATCCTTAATCCTTGCTAGTTTAAGCCTGC
CTAAGTCACTTTACTAAAAGATCTTTGTTAACCCAGTATTTTAAACATTTGTCTGCTTATGTAGGT
AAAAGTAGAAGCATGTTTGTATGCTGCTTGTAGTTTTAGTGACAGCTTTCCATGTTGAAATTCTCA
TGTCATTTTGTGTCCTAAAAGTTTCATGTGAGTTTTTACTGTTAGGAAGATTAAGATGTATATAGT
ACAGAATGGTAAGTCTCTAATTGTTTTATGTTTGTTTGTTTCTTGACTAGTAATAGTAGTAAATAC
TTTAAAAATATTTTCTCAAGATCCTTAAGAACTCTTGGAAATTGTAACATACTGACAAGAGTAGTT
GTTTAAATACTTCTAACAACTTGTATAAGAGTCAATATGAATAAAATCCAGCTAAATGCTTCATAG
AACACAGGATTTACCCTAAACAATTATCATAATGGACCTCTTACAGAGACTCTAGTCTGTTTTACT
ACAGAGCACAGTTTGAGAGTGAAACTGTTACAATTTAGATTTTTGTTGTATTTTCTAAGAGAAAGA
ATATTGTTAGGTTCTCCTAACTTCTGTTGACTACTATGGTAAGTGGTGTCATTTTAATTGCAAATT
TAAATAGAAATTAACAGAATTAAGTACATTCCCTTTTTTTCTTTGCTTTTTCATGAAAATCCTTAG
TTCTTTACATTGTCTCCTACTTAGGTTCAGTTGTATAGTCGAACTTAATCTAAATTGACTAAGGTT
TAAATTTAAATTTACGTTTAAAGCATTCCACAGGGGATAAAAGTGTTAATTTAAAAAAAAAATGTT
CCCTAAGACACTTCAGGTACAAGTCACGTAGGTAGTGTGTTTAATCTAGCTGTTAGCCAAGGATTC
AAGGACTGAATTGTTTTTGAATAAGGCTTTTCTTGTTCTGGGAGCCTCAGTTCATTAAAACTCTCC
TTTTAAAACTTGTGTGCTGAGAGTTAAGCAAGACCTCTTTTTTTTTTTTTTTTTGTCTTCATGAGT
TGCGAAATTGAATTCATGAAGCTGATGTGGCTAACAAGTTTATTTTAAGAATTGTTTAGAAAATGC
TGTTGCTTCGGGTTCTTAAAATCACAGCATTCCAACTCTAATCAAGTTGTTGGAGACTTACCAGAG
TTGGACTGAGCTCACACTAAAATAAAAAAAACAAAACCAAAAAAAAAAAAAAAACCCTCACTGGAT
TCTTTCCATATAGCTGTGTAAAAAATTGGTCACTTGGAAGGTCAAAATATAACCAGATCCAAATCA
CCCACCCCAGACAGTTCTCAGCATCTGTGTATTGATGTTCTGTTCTGTATAAAGTTCACTCTAGGA
TTTTGAAGTAGCCATGTATTTTACTACTTATTAATTGTCATGTGAAATTTGAAGTTCTTCTGTAAT
AAATAGTTAATTTTATTTGTAATTTACTGTGCTAATCAAAATTTTTGTGTTTGGCATTAAGTAAAC
ACAGTTTATTTGATTAATGGCTTAGTATTCCCTTTCCTTCTAGATTTTTGCCTCTTCCTTTGGTTA
GGGGTAGAGGTGAGGTGAGTGTAGTAAGTGAATATAATGTGATTTGGCTATGTTGTTATGACATTT
GTTTTGTTGTTTAAAATGTGTATTCTTTTCTGTTTTAGTAGATAAAATCTATTATCTTGAGCTCTC
TGAATGGAAACTACCATCCCAGCATTAGCTGCATTTATTGTTCCCATTAGACCTAAATCGTTTTAC
TTGTGACTGCCCAGGTACTGAGTAAGAGAAGAGGAGAGATGAAATAGATTGCAGGTTGTTGCTGTT
AGAGGAATAAGAAAATGGAGAAATACTTGACGACATTTTAGTCAAATCTCTTTTTAAAAAGGTAGC
CATATAGGCTTCACAATCTGAGGTCATATCTCCAGAACCCACATAAAAGCTGGGTGCACTAGCCCC
AAGCATCTGTAATCCGGGAATGCCTCCATGAAACAGGAAGCAGATAGGAGACGGGCCAGAAGCTAA
CTTGGCTTAGGCATTAGCCAAGAGACCCTGTTAAGGTAGGAAGGTTGTCCTTTGGGTTATCTGCCC
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TCTAATGTGCATCATGATAGGCATCCACCTATACTCGGACACACACACAAAAGAAAAAAAACAAAA
AGTAGCTATCTGTATAATAAGACTATTACCTTAACCATTTTATCCAAGGTGATGGAATTCAACTCA
AGGAGAACACACCTTAATTGTTTTAAATGTTAACTCTCAACCTAAAACTTTTTTTTTTTCCAGGAC
AGAGTTTCTCTATGTAGCCCAGGCTGTACTCAAACATCAGCAACCCTCTGCCTCTGCCTCTGCCTC
TGCCTCTGGAGTGCTGGGATTAAAGGTGCATGCCACTACAGCCCAGATTCATCCTAAAAACTCGTA
GGCCTTCCATGGGTTCTCCTTGATAGAGGACTTGGACTAAAGCTTAATAGACCGCCTGGAAAGATA
ACTCAGCCACTAAGAGTACTTGCTGCTTCTGCAGAGGACCAAAGTTCAGTTCCCAGCACCCAACGG
GGTGGCTTACAACTGCATATTAGCTCCAGCTTCAGTCTATCTAGTGCCCTCTTTTGGCCTCCATGG
GCACCTACATGCATGTGCATATATATAAACATACACACATTACACATAAAATAAAAATAATCCTTT
TTTTTTTTGGTTTTTCGAGACAGGGTTTCTCTGTGGCTTTGGAGACTGTCCTGGAACTAGCTCTTG
TAGACCAGGCTGGCCTCGAACTCACAGAGATCTGCCTCCCTCTGCCTCCCTGGAATTAAAGGCGTA
CGCCACCAACGCCCAGCAAATAAAAATAATCTTTAAAGCTTAAACAAAACTGGTATATTTACTTTT
TGTCACTGTTACTTGTTTCTCTGGATGCTTCTTAGAAAAGTTCCAGACTATCAGCTAGAAATGACC
TCGGAGAGTAGCTTATTCACAGCACACCACCCTCATTTTATCATTGCGATAGACCCTTTACTGGCA
CATGCTTTGAAGTTGGAAAACCCCTTACCACACCGGCTACCTGTCCTGGGAAGTCTCCGATGTTTA
TTTTTCAGCAGTTCATTCCATTATACTCGAATTTTCACTACACAGTAAATGATACTTTATAACTGT
TACAGTAGGACAACCCCTAATACTTTTAAATTAAGTAATATGCCGTTAATGCTTGAGTGGTAGAGT
TCTCATTTGGAGGCTCAGGTTTGTAGATGTTTGGCATTTACTGTGTGCTTATGTATCATGTAGCAT
TTAAGATTACTGTGTAAGTTTATTTTATCACTCTATCAATACCAACAAGCTTGCATTTTAAATTTG
ATGTTAATAATGGCTTTAATGTAGTTTCTGGTTTTGGATTTTTTTTTTATTATGCTTCACCTGACA
GAATGACCCATTCTTTTATCTTTGTGTTAGTTTTGTGAATACTTATGTTAAGAGTTTTGAGACAGA
ATACTATATTTGTGAATATAATTTTATGGCTTTTTTTCATTTAGTGGATACCTTTCAGTATGGAGA
TCTATGAAAATTGCTTTCTGCGCTATAATCTGTCCTTTGTTGTAGATTAAAGCTTATTTTTCTGTG
AATAAGACTTATCAATAAAGCACTATTCTTTAAA 
 
>xiap-Human     NM_001167.2 
TTTCCAGATTGGGGCTCGGGCCGCGCCTCCTCCGGGACCCTCCCCTTGGACCGAGCCGATCGCCGCGGGG 
CAGTTCGGGCCGGCTGTCCTGGCGCGAAAAGGTGGACAAGTCCTATTTTCAAGAGAAGATGACTTTTAAC 
AGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAATAAGGAAGAAGAATTTGTAGAAGAGTTTA 
ATAGATTAAAAACTTTTGCTAATTTTCCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGG 
GTTTCTTTATACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGATGGCAA 
TATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGCAGATTTATCAACGGCTTTTATC 
TTGAAAATAGTGCCACGCAGTCTACAAATTCTGGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCT 
GGGAAGCAGAGATCATTTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGTGAAGAAGCTAGATTAA 
AGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACCCCAAGAGAGTTAGCAAGTGCTGGACTCTACTA 
CACAGGTATTGGTGACCAAGTGCAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGAT 
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CGTGCCTGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAATCTTAATATTC 
GAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAATTCAACAAATCTTCCAAGAAATCCATC 
CATGGCAGATTATGAAGCACGGATCTTTACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTT 
GCAAGAGCTGGATTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGGCTAA 
CTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTATCCAGGGTGCAAATATCTGTT 
AGAACAGAAGGGACAAGAATATATAAACAATATTCATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGA 
ACTACTGAGAAAACACCATCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAG 
AAGCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAAATTCAGATATCTGG 
GAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTAGTGAATGCTCAGAAAGACAGTATGCAAGAT 
GAGTCAAGTCAGACTTCATTACAGAAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGA 
AGCTTTGCAAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTAGTCACTTG 
TAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACAGTCATTACTTTCAAGCAAAAAATT 
TTTATGTCTTAA...stop codon    3'UTR---> 
            TCTAACTCTATAGTAGGCATGTTATGTTGTTCTTATTACCCTGATTGAATGTGTGATG 
TGAACTGACTTTAAGTAATCAGGATTGAATTCCATTAGCATTTGCTACCAAGTAGGAAAAAAAATGTACA 
TGGCAGTGTTTTAGTTGGCAATATAATCTTTGAATTTCTTGATTTTTCAGGGTATTAGCTGTATTATCCA 
TTTTTTTTACTGTTATTTAATTGAAACCATAGACTAAGAATAAGAAGCATCATACTATAACTGAACACAA 
TGTGTATTCATAGTATACTGATTTAATTTCTAAGTGTAAGTGAATTAATCATCTGGATTTTTTATTCTTT 
TCAGATAGGCTTAACAAATGGAGCTTTCTGTATATAAATGTGGAGATTAGAGTTAATCTCCCCAATCACA 
TAATTTGTTTTGTGTGAAAAAGGAATAAATTGTTCCATGCTGGTGGAAAGATAGAGATTGTTTTTAGAGG 
TTGGTTGTTGTGTTTTAGGATTCTGTCCATTTTCTTTTAAAGTTATAAACACGTACTTGTGCGAATTATT 
TTTTTAAAGTGATTTGCCATTTTTGAAAGCGTATTTAATGATAGAATACTATCGAGCCAACATGTACTGA 
CATGGAAAGATGTCAAAGATATGTTAAGTGTAAAATGCAAGTGGCAAAACACTATGTATAGTCTGAGCCA 
GATCAAAGTATGTATGTTTTTAATATGCATAGAACAAAAGATTTGGAAAGATATACACCAAACTGTTAAA 
TGTGGTTTCTCTTCGGGGAGGGGGGGATTGGGGGAGGGGCCCCAGAGGGGTTTTATAGGGGCCTTTTCAC 
TTTCTACTTTTTTCATTTTGTTCTGTTCGAATTTTTTATAAGTATGTATTACTTTTGTAATCAGAATTTT 
TAGAAAGTATTTTGCTGATTTAAAGGCTTAGGCATGTTCAAACGCCTGCAAAACTACTTATCACTCAGCT 
TTAGTTTTTCTAATCCAAGAAGGCAGGGCAGTTAACCTTTTTGGTGCCAATGTGAAATGTAAATGATTTT 
ATGTTTTTCCTGCTTTGTGGATGAAAAATATTTCTGAGTGGTAGTTTTTTGACAGGTAGACCATGTCTTA 
TCTTGTTTCAAAATAAGTATTTCTGATTTTGTAAAATGAAATATAAAATATGTCTCAGATCTTCCAATTA 
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ATTAGTAAGGATTCATCCTTAATCCTTGCTAGTTTAAGCCTGCCTAAGTCACTTTACTAAAAGATCTTTG 
TTAACTCAGTATTTTAAACATCTGTCAGCTTATGTAGGTAAAAGTAGAAGCATGTTTGTACACTGCTTGT 
AGTTATAGTGACAGCTTTCCATGTTGAGATTCTCATATCATCTTGTATCTTAAAGTTTCATGTGAGTTTT 
TACCGTTAGGATGATTAAGATGTATATAGGACAAAATGTTAAGTCTTTCCTCTACCTACATTTGTTTTCT 
TGGCTAGTAATAGTAGTAGATACTTCTGAAATAAATGTTCTCTCAAGATCCTTAAAACCTCTTGGAAATT 
ATAAAAATATTGGCAAGAAAAGAAGAATAGTTGTTTAAATATTTTTTAAAAAACACTTGAATAAGAATCA 
GTAGGGTATAAACTAGAAGTTTAAAAATGCTTCATAGAACGTCCAGGGTTTACATTACAAGATTCTCACA 
ACAAACCTATTGTAGAGGTGAGTAAGGCATGTTACTACAGAGGAAAGTTTGAGAGTAAAACTGTAAAAAA 
TTATATTTTTGTTGTACTTTCTAAGAGAAAGAGTATTGTTATGTTCTCCTAACTTCTGTTGATTACTACT 
TTAAGTGATATTCATTTAAAACATTGCAAATTTATTTTATTTATTTAATTTTCTTTTTGAGATGGAGTCT 
TGCTTGTCACCCAGGCTGGAGTGCAGTGGAGTGATCTCTGCTCACTGCAACCTCCGCCTTCTGGGTTCAA 
GCGATTCTCGTGCCTCAGCTTCCTGAGTAGCTGGAATTACAGGCAGGTGCCACCATGCCCGACTAATTTT 
TTTTTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGTATCAAACTCCTGACCTCAAGAG 
ATCCACTCGCCTTGCCCTCCCAAAGTGCTGGGATTACAGGCTTGAGCCACCACGCCCGGCTAAAACATTG 
CAAATTTAAATGAGAGTTTTAAAAATTAAATAATGACTGCCCTGTTTCTGTTTTAGTATGTAAATCCTCA 
GTTCTTCACCTTTGCACTGTCTGCCACTTAGTTTGGTTATATAGTCATTAACTTGAATTTGGTCTGTATA 
GTCTAGACTTTAAATTTAAAGTTTTCTACAAGGGGAGAAAAGTGTTAAAATTTTTAAAATATGTTTTCCA 
GGACACTTCACTTCCAAGTCAGGTAGGTAGTTCAATCTAGTTGTTAGCCAAGGACTCAAGGACTGAATTG 
TTTTAACATAAGGCTTTTCCTGTTCTGGGAGCCGCACTTCATTAAAATTCTTCTAAAACTTGTATGTTTA 
GAGTTAAGCAAGACTTTTTTTCTTCCTCTCCATGAGTTGTGAAATTTAATGCACAACGCTGATGTGGCTA 
ACAAGTTTATTTTAAGAATTGTTTAGAAATGCTGTTGCTTCAGGTTCTTAAAATCACTCAGCACTCCAAC 
TTCTAATCAAATTTTTGGAGACTTAACAGCATTTGTCTGTGTTTGAACTATAAAAAGCACCGGATCTTTT 
CCATCTAATTCCGCAAAAATTGATCATTTGCAAAGTCAAAACTATAGCCATATCCAAATCTTTTCCCCCT 
CCCAAGAGTTCTCAGTGTCTACATGTAGACTATTCCTTTTCTGTATAAAGTTCACTCTAGGATTTCAAGT 
CACCACTTATTTTACATTTTAGTCATGCAAAGATTCAAGTAGTTTTGCAATAAGTACTTATCTTTATTTG 
TAATAATTTAGTCTGCTGATCAAAAGCATTGTCTTAATTTTTGAGAACTGGTTTTAGCATTTACAAACTA 
AATTCCAGTTAATTAATTAATAGCTTTATATTGCCTTTCCTGCTACATTTGGTTTTTTCCCCTGTCCCTT 
TGATTACGGGCTAAGGTAGGGTAGAGTGGGTGTAGTGAGTGTATATAATGTGATTTGGCCCTGTGTATTA 
TGATATTTTGTTATTTTTGTTGTTATATTATTTACATTTCAGTAGTTGTTTTTTGTGTTTCCATTTTAGT 
GGATAAAATTTGTATTTTGAACTATGAATGGAGACTACCGCCCCAGCATTAGTTTCACATGATATACCCT 
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TTAAACCCGAATCATTGTTTTATTTCCTGATTACACAGGTGTTGAATGGGGAAAGGGGCTAGTATATCAG 
TAGGATATACTATGGGATGTATATATATCATTGCTGTTAGAGAAATGAAATAAAATGGGGCTGGGCTCAG 
TGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCAGGTGGATCACGAGGTCAGGAGATCGAGA 
CCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAAACAGAAAATTAGCCGGGCGTGGTGGCGGG 
CGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGGAGGCAGAGCTTGCA 
GTGAGCCGAGATCTCGCCACTGCACTCCAGCCTGGGCAACAGAGCAAGACTCTGTCTCAAAAAAAAAAAA 
AAAAGAAATAAGAAAATGGGAAGCAATATTTGACATAGTTCTTTTTAGTCAAATCTACTTGTTAAAAAAA 
GGGTAGCAGTTTATTCATCTGTGAAAGGAAAATAATACTTATCTTACAAGGTTGCAAGAGCTCAAGGAGA 
CCATGTATGTAAAGTTCCTGCTGTAAATATGAACTCCCATCCTAATACCCTTTTACCTCTCTGTGGGTTT 
GTCTTGACCTGGAAATTTGGGCTAAAACTTAGAAAAAATTCTTACATGATAACTCAGTGATGCTTACTCA 
TAGTTTTTGGTGTTTCTCATAGATAAGATATAAATCAGCTGGGCGCGGTGGCTCATGCCTGTAATCCCAG 
CACTTTGGGAGGCCGAGGCGGGCAGATCACCTGAGGTCGGGAGGTCGAGACCAGCCTGACCAACATGGAG 
AAACCCCGTCTCTACTAAAAATACAAAATTAGCTGGGCGTGGTGGCTCATGCCTGTAATCCCAGCTACTT 
GGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGGTTGTGGTGAGCGAAGATCGTGCCATT 
GCACTCCAGCCTGGGCAACAAGAGCAAAACTCTGTCTCAAAAAAAAAAAAAGATATAAATCACAATAAAT 
AAATAGGTCAATACAAATGTTAGCCAGGCGTGGTGGCACATGCCCATAGTCGCAGCTACTCTGGAGGCAG 
AGGCAGGAGGATCACTTGAGCCCATGAATTTGAGGCAGCAGTGAGCTATGATTGTGCCACTGTACTCCAG 
TCTGGGTGACAGAGTGAGACCCCATCTCTAAATAAATAGGTCAAACCCTTAAAAATATTTAAATTCTTAA 
AAAATTGAAAAGATTATTCTTCTCAAATTTAGTTGAGCTTTCTAAGAGAAGCAATTGGCTTTTTCCCACT 
TCAATAATCATTTTCAGTTTGACTCATACAGTTAACACAATGTGAATTTCTTCCTCAGCATAACAGAGTT 
ATAGAATGACAGGGCTGGAAGTGACCTTAGAGAGTATCCAGTTCTTTCATTTTACAGGTGAGGCAACTGA 
GACTCAAAGGTGATGTAATTTGTGCAAAGATTATAGCTAATTAGTAGCAGAGCCCTGACTGGGACATAGT 
TTGAAGGTGAAAAACTTCACCAAGCTACCTTTCTTGAAAGGTCCAAATGTTTATGTTTTCAACTACTCTT 
TCCACTGTACCATAACTTTCACTACATATTAAATGACACTTTATAACTAATATAATAGGACAATCATCAA 
TGCATATATAGCCAGCCCTTCATATCTGTGGGTTTTGCATCCATGGATTCAACCAAGGAGGAATTGAAAA 
CACTGAGAAAAAAAAAAAAGACCACACAATAAAAAAAAAAAATACAAAATAATACAAAGAAAAAGCCAA
A 
ATTGTCATACTGTTGTTAAGCAACAGTATAACAACTATTTACATAGCATTAAGGTTGGTGCAAAAATGCA 
AAAAAAAAAAAAGCAATTATTTTTAAACCAACCTAATATATTGTATTAGGTATTAAAGTCATCTGGACAT 
GAATTAAAGTATATGATGCCAGCCTGGACAAAAGGCAAAACCCTGTCTCTACAAAAAATACAAAAATTAG 
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CTGGGCATGGTGGTGTGTGCCTGTAGTCCTGGCTACTCCGGAGCCTGAGGTGGGAGGATCGCTTGAGTCT 
GGGAGGCAGAGGCTGCATTGAGCTATGATCATGGCACTGCATTCCAGCCTGGGTGACAGTGCAAGACCTT 
GTCTCAGAATAAATAAAGTATGTGATGAAGATGTGCATACATTATATGCAAATACTGTTTTTTTTTTTTT 
TAATTTAAACAGTCTCACTGTGTTGCCCAGGATGGAGTGCAATGGCACAATCTTGGCTCATGGCAAACTC 
TGCCTCGCAAGCAGCTGGGACTACAGGCATGCTCCACGGTGCCCAGTTAATTTTTTTTGTATTCTTAGTA 
GAGACAGGGTTTCACCATGTTGGCCAGGCTAGTCTTGAATTTCTGACCTCAAGTGATTCATCTCCCAAAG 
TGCTGGGATTACAGGCGTGAGCCACCACGGCCGGCTAATTTTTGTATTTTTTAGTAGTGACTGGTTTCGC 
GGTGTTGACCAGGCTGGTCTCGAACTCCTGATCTCAGGTGATCTGCCTGCCTCGGCCTCACAAAGTGCTG 
GGATTACAGGTGTGAACCACTGCTCCCGGCCTTGTGTGATTTTATCTAAGGGACTTAAGCGTCCTCAGGT 
CCTAGGGGGTCGTGAAACCAAAACCCCAGGGATAGCAAGGGACAATTGTATCTTCAAAGTAGACAAATGG 
CGCCGGGCACGGTGGCTCACGCCTGTAATCCCAGCAGTTTCCGAGGCTGAGGCAGGCGGCTCACCTGAGG 
TCAGGAGTTGGAGACCAGCCTGGCCAACATGCTGAAACCCTGTCTGTACAAAAATACAAAAATAGCTGGG 
CATGGTGGCGCATGCCTGTAGTCCCAGCTACTAGAGCGACTGAGGCAGGAGAATTGCTTGAACCTGGGAG 
GCGGAGGTTGCAGGGAGCCAAGATGGCGCCACCGCACTCCAGCCTAGGTGATAGAGTGAGACTCCCTCTC 
AAAAACAAAACAAAACAAAAAAATTAGACAAATGCTACATTAATGTTTGGGTGGTCAGATTCTACTTTGA 
ATCTGAAGTTTGCAGATATGCCTATAGATTTTTGGAGTTTACCACTTTCTTATTCTGTATCATTAATGTA 
ATATTTTAAATTACTATATATGTTACCATTTTTCTGGATTTAGTAAGAAATTTGCAGTTTTGGTTTGATG 
TAACAAGGGTTTTAATGTAATTTATGTTAGATTTTGCATTTTTTTCATTACTGTTATATTTTAACCTGAC 
TGACTGATCTAATTGTATTAGTATTGTGAATAATCATGTGAAATGTTTTGAGACAGAGTACTATATTTGT 
GAATATAATTTTATGGTTTTTTTCACTTAGAACCTTTCTGTGTGGAAAACTAAGAAAATTGCTTTCTGCT 
GTATAATCTGGCATTCATTGTAGATTAAAGCTTATTTTTCTGTGAATAAAACGTATTCAATAAAATACTA 
TTCTTTAAAATTA…end of transcript 
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Full Alignment: ClustalW: CHO v Human comparison 
CHO=6300bp ---- Human=8413bp  
Identity matrix % = 81.01% 
CHO-XIAP        ------------------------------------------------------------ 
human-XIAP      TTTCCAGATTGGGGCTCGGGCCGCGCCTCCTCCGGGACCCTCCCCTTGGACCGAGCCGAT 60 
                                                                             
 
CHO-XIAP        ----------------------------------------GGTGGACAAGTCCTATTTTC 20 
human-XIAP      CGCCGCGGGGCAGTTCGGGCCGGCTGTCCTGGCGCGAAAAGGTGGACAAGTCCTATTTTC 120 
                                                        ******************** 
 
CHO-XIAP        AAGAGAAGATGACTTTTAACAGTTTTGAAGGATCTAGAACTTGTGTACCTGCAGACACCA 80 
human-XIAP      AAGAGAAGATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCA 180 
                ************************************ ******************** ** 
 
CHO-XIAP        ATAAGGATGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACATTTGCTAACTTTCCAA 140 
human-XIAP      ATAAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTTCCAA 240 
                ******* *********************************** ******** ******* 
 
CHO-XIAP        GTAGTAGTCCTGTTTCAGCATCAACCTTGGCACGAGCAGGGTTTCTTTATACTGGTGAAG 200 
human-XIAP      GTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTATACTGGTGAAG 300 
                ** **********************  ********************************* 
 
CHO-XIAP        GAGATACTGTGCAGTGCTTTAGTTGTCACGCGGCAGTGGATAGATGGCAGTACGGAGACT 260 
human-XIAP      GAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGATGGCAATATGGAGACT 360 
                ******* **** *************** ** ** ** *********** ** ******* 
 
CHO-XIAP        CAGCTGTTGGAAGACACAGGCAAATATCCCCAAATTGCAGATTTATCAATGGTTTTTATT 320 
human-XIAP      CAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGCAGATTTATCAACGGCTTTTATC 420 
                **** *************** ** ************************* ** ******  
 
CHO-XIAP        TTGAAAACAGTGCCACACAGGCTACAAATCCTGGTATCCAAAATGGCCAGTACAAAGCTG 380 
human-XIAP      TTGAAAATAGTGCCACGCAGTCTACAAATTCTGGTATCCAGAATGGTCAGTACAAAGTTG 480 
                ******* ******** *** ******** ********** ***** ********** ** 
 
CHO-XIAP        AAAACTATGTGGGAAACAGAAATCATTTTGCTCTTGACAGGCCATCTGAGACTCATGCAG 440 
human-XIAP      AAAACTATCTGGGAAGCAGAGATCATTTTGCCTTAGACAGGCCATCTGAGACACATGCAG 540 
                ******** ****** **** **********  * ***************** ******* 
 
CHO-XIAP        ATTATCTTTTGAGAACTGGACAGGTTGTAGATATTTCAGATACCATATACCCGAGGAACC 500 
human-XIAP      ACTATCTTTTGAGAACTGGGCAGGTTGTAGATATATCAGACACCATATACCCGAGGAACC 600 
                * ***************** ************** ***** ******************* 
 
CHO-XIAP        CTGCCATGTGTAGTGAAGAAGCCAGGCTGAAGTCCTTTCAGAACTGGCCAGACTATGCCC 560 
human-XIAP      CTGCCATGTATAGTGAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTC 660 
                ********* ************ **  * ***************************** * 
 
CHO-XIAP        ACTTAACCCCCAGAGAGTTGGCCAGTGCTGGACTGTACTACACAGGGATTGATGATCAAG 620 
human-XIAP      ACCTAACCCCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAG 720 
                ** ******* ******** ** *********** *********** **** *** **** 
 
CHO-XIAP        TGCAGTGCTTTTGCTGTGGTGGGAAACTGAAAAATTGGGAACCCTGTGATCGTGCCTGGT 680 
human-XIAP      TGCAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCCTGGT 780 
                ************* ******** ******************** **************** 
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CHO-XIAP        CAGAACACAGGAGACACTTTCCCAATTGCTTCTTTGTTTTGGGCCGGAATGTTAATGTTC 740 
human-XIAP      CAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAATCTTAATATTC 840 
                *********** ********** *************************** ***** *** 
 
CHO-XIAP        GGAGTGAATCTGGTG---TGAGTTCTGATAGGAATTTCCCCAATTCGGCAAATTCTCCAA 797 
human-XIAP      GAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAATTCAACAAATCTTCCAA 900 
                * ********** **   ********************** *****  *****  ***** 
 
CHO-XIAP        GAAATCCAGCCATGGCAGAATATGAAGCACGGATCATTACTTTTGGAACATGGATATACT 857 
human-XIAP      GAAATCCATCCATGGCAGATTATGAAGCACGGATCTTTACTTTTGGGACATGGATATACT 960 
                ******** ********** *************** ********** ************* 
 
CHO-XIAP        CAGTTAACAAGGAGCAGCTTGCAAGAGCTGGATTTTATGCTTTAGGTGAAGGTGATAAGG 917 
human-XIAP      CAGTTAACAAGGAGCAGCTTGCAAGAGCTGGATTTTATGCTTTAGGTGAAGGTGATAAAG 1020 
                ********************************************************** * 
 
CHO-XIAP        TGAAGTGCTTTCACTGTGGAGGAGGGCTCACAGATTGGAAGCCAAGTGAAGACCCTTGGG 977 
human-XIAP      TAAAGTGCTTTCACTGTGGAGGAGGGCTAACTGATTGGAAGCCCAGTGAAGACCCTTGGG 1080 
                * ************************** ** *********** **************** 
 
CHO-XIAP        AACAGCATGCGAAGTGGTACCCAGGGTGTAAATATCTATTGGATGAGAAGGGGCAAGAAT 1037 
human-XIAP      AACAACATGCTAAATGGTATCCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAAT 1140 
                **** ***** ** ***** ******** ******** ** **  ******* ******* 
 
CHO-XIAP        ATATAAATAATATTCATTTAACCCATTCACTTGGAGAATCTTTGGTAAGAACTGCTGAAA 1097 
human-XIAP      ATATAAACAATATTCATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGA 1200 
                ******* ************** **********  ** * * *********** **** * 
 
CHO-XIAP        AAACACCTTCACTAACTAAAAGAATTGATGATACCATCTTCCAGAATCCTATGGTACAAG 1157 
human-XIAP      AAACACCATCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAG 1260 
                ******* ********** ************************ **************** 
 
CHO-XIAP        AAGCTATACGAATGGGATTCAGTTTCAGGGACATTAAGAAAACAATGGAAGAAAAGATCC 1217 
human-XIAP      AAGCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAAATTC 1320 
                **************** ********** ************** ****** ***** ** * 
 
CHO-XIAP        AAACATCTGGGAGCAGCTATCTGTCCCTTGAGGTTCTGATTGCAGATCTAGTGAGTGCTC 1277 
human-XIAP      AGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTAGTGAATGCTC 1380 
                * * *********** ****   ** ************ *************** ***** 
 
CHO-XIAP        AGAAAGATAATACACAGGATGAGTCAAGTCAGACTTCATTGCAGAAAGACATCAGTACGG 1337 
human-XIAP      AGAAAGACAGTATGCAAGATGAGTCAAGTCAGACTTCATTACAGAAAGAGATTAGTACTG 1440 
                ******* * **  ** *********************** ******** ** ***** * 
 
CHO-XIAP        AAGAGCAGCTGAGGCGCCTACAAGAAGAGAAGCTTTGCAAAATCTGCATGGATAGAAATA 1397 
human-XIAP      AAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGCAAAATCTGTATGGATAGAAATA 1500 
                ********** ******** ***** ******************** ************* 
 
CHO-XIAP        TTGCTGTAGTTTTTGTTCCTTGTGGACATCTGGTCACTTGTAAACAGTGTGCTGAAGCAG 1457 
human-XIAP      TTGCTATCGTTTTTGTTCCTTGTGGACATCTAGTCACTTGTAAACAATGTGCTGAAGCAG 1560 
                ***** * *********************** ************** ************* 
 
CHO-XIAP        TTGACAAATGTCCCATGTGCTACACAATCATTACCTTCAAACAAAAAATTTTTATGTCTT 1517 
human-XIAP      TTGACAAGTGTCCCATGTGCTACACAGTCATTACTTTCAAGCAAAAAATTTTTATGTCTT 1620 
                ******* ****************** ******* ***** ******************* 
 
CHO-XIAP        AATGAGAG-CAACAGTAGGCATGTTATACTCTTCTTACT---CTAATTGAATGTGTGATG 1573 
human-XIAP      AATCTAACTCTATAGTAGGCATGTTATGTTGTTCTTATTACCCTGATTGAATGTGTGATG 1680 
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                ***   *  * * **************  * ****** *   ** *************** 
 
CHO-XIAP        TGAGCAAACTTTAAGTAATCAGCATTGCATTCCATTAGCATCTGCTGCCAAGTGG--AAA 1631 
human-XIAP      TGAACTGACTTTAAGTAATCAGGATTGAATTCCATTAGCATTTGCTACCAAGTAGGAAAA 1740 
                *** *  *************** **** ************* **** ****** *  *** 
 
CHO-XIAP        CAAATGTTAACAGCACTGGTACTGTC-------TAAACTTTGGATTTCTGGAACTTTCAG 1684 
human-XIAP      AAAATGTACATGGCAGTGTTTTAGTTGGCAATATAATCTTTGAATTTCTTGATTTTTCAG 1800 
                 ******  *  *** ** *   **        *** ***** ****** **  ****** 
 
CHO-XIAP        GTTATTAGCTATATCGTTTATCCAGTTTT---TTACTCAATTAAAGCCTTAGACAAAGAA 1741 
human-XIAP      GGTATTAGCTGTATTATCCATTTTTTTTACTGTTATTTAATTGAAACCATAGACTAAGAA 1860 
                * ******** ***  *  **    ***    *** * **** ** ** ***** ***** 
 
CHO-XIAP        ------GCATTTAATATTATAACTTTTCACCTTGTGTATTTGTAGTACACTGACTTGATT 1795 
human-XIAP      TAAGAAGCATC--ATACTATAACTGAACACAATGTGTATTCATAGTATACTGATTTAATT 1918 
                      ****   *** *******   ***  ********  ***** ***** ** *** 
 
CHO-XIAP        TCTATGTGTAAGTGAATTAATCACTATCATTTTTCATTCCTTTTGGATAAGCTTAACAAA 1855 
human-XIAP      TCTAAGTGTAAGTGAATTAATCATCTGGATTTTTTATTCTTTTCAGATAGGCTTAACAAA 1978 
                **** ******************     ****** **** ***  **** ********** 
 
CHO-XIAP        TGGAGTGTTCTGTATA--AGCAGGGAGATTTGAGTTAATCTACCCATTCACTTGCTCTGT 1913 
human-XIAP      TGGAGCTTTCTGTATATAAATGTGGAGATTAGAGTTAATCTCCCCAATCACATAATTTGT 2038 
                *****  *********  *    ******* ********** **** **** *  * *** 
 
CHO-XIAP        TTATTGTGAACAGAGAATACACTGTTCCACACTGGTGGGAGGATAAACATTGGTTTGTAG 1973 
human-XIAP      TTTGTGTGAAAAAGGAATAAATTGTTCCATGCTGGTGGAAAGATAGAGATTG-TTTTTAG 2097 
                **  ****** *  ***** * *******  ******* * **** * **** *** *** 
 
CHO-XIAP        ATGTTTGTGTCTGTGTTTT-GGATTCTGTCCATTTTCTTTCAAATTTATAAACA--TACT 2030 
human-XIAP      AGGTTGGTTGTTGTGTTTTAGGATTCTGTCCATTTTCTTTTAAAGTTATAAACACGTACT 2157 
                * *** **   ******** ******************** *** *********  **** 
 
CHO-XIAP        TGTATGAATGGTTTTTT--AAGTGATTTTGCCATCTCCCAAAAGATATTTAATGGTAAAC 2088 
human-XIAP      TGTGCGAATTATTTTTTTAAAGTGATTT-GCCATTTTTGAAAGCGTATTTAATGATAGAA 2216 
                ***  ****  ******  ********* ***** *   ***   ********* ** *  
 
CHO-XIAP        TGCTTATCTAACCAGCATATACTAACATGGAAAGACAACAAAGATATATTAAGTGTAAAT 2148 
human-XIAP      TACT-ATCGAGCCAACATGTACTGACATGGAAAGATGTCAAAGATATGTTAAGTGTAAAA 2275 
                * ** *** * *** *** **** ***********   ********* ***********  
 
CHO-XIAP        TACAAATGGCAAAACACTATGTATAGTTTGAGCCAAATCAAGGTGTGAATTTTAT--ATC 2206 
human-XIAP      TGCAAGTGGCAAAACACTATGTATAGTCTGAGCCAGATCAAAGTATGTATGTTTTTAATA 2335 
                * *** ********************* ******* ***** ** ** ** ** *  **  
 
CHO-XIAP        TGTATAGGACAAAAAAGAGTTGGAAAGATATGCATCATACTCTTAAATATGTTTTTTTCT 2266 
human-XIAP      TGCATAGAACAAAA--GATTTGGAAAGATATACACCAAACTGTTAAATGTGGTTTCTCTT 2393 
                ** **** ******  ** ************ ** ** *** ****** ** *** *  * 
 
CHO-XIAP        TGAGGGGGGTGGG-----GGTATGGGTCTTTGAGGGGCTT-ATAGGAGCCCTT------- 2313 
human-XIAP      CGGGGAGGGGGGGATTGGGGGAGGGGCCCCAGAGGGGTTTTATAGGGGCCTTTTCACTTT 2453 
                 * ** *** ***     ** * *** *   ****** ** ***** *** **        
 
CHO-XIAP        ---CTTTTTTCATTTTGTTCTGTTTGAAGTTTATATAAGTATGTATTACTTTTATATAAT 2370 
human-XIAP      CTACTTTTTTCATTTTGTTCTGTTCGAATTTTTTATAAGTATGTATTACTTTTGTA--AT 2511 
                   ********************* *** *** ******************** **  ** 
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CHO-XIAP        CAGAATTTTTAGAAA-TATTGTACTGATTTAAAGGCTTAGGCATGTTCAAACGTCTGCAA 2429 
human-XIAP      CAGAATTTTTAGAAAGTATTTTGCTGATTTAAAGGCTTAGGCATGTTCAAACGCCTGCAA 2571 
                *************** **** * ****************************** ****** 
 
CHO-XIAP        AACTACTTATTGCTCAGTTTTAGTTTTTCTAATCCAAGAAGGCAGGCCAGTTGAC-TTTC 2488 
human-XIAP      AACTACTTATCACTCAGCTTTAGTTTTTCTAATCCAAGAAGGCAGGGCAGTTAACCTTTT 2631 
                **********  ***** **************************** ***** ** ***  
 
CHO-XIAP        TGGTGCCAATGTGAAATTTAAATGTTTTT--GTTTTACCTGCTTTGTGGATAGAAAATAT 2546 
human-XIAP      TGGTGCCAATGTGAAATGTAAATGATTTTATGTTTTTCCTGCTTTGTGGATGAAAAATAT 2691 
                ***************** ****** ****  ***** **************  ******* 
 
CHO-XIAP        TTCTGAGTGGTAGTTTTCTGACAGGTAGACCATGTCTTCTTATCTTGTTTCAAAATAAGT 2606 
human-XIAP      TTCTGAGTGGTAGTTTTTTGACAGGTAGACCATGTCT---TATCTTGTTTCAAAATAAGT 2748 
                ***************** *******************   ******************** 
 
CHO-XIAP        ATTTCTGATTTTGTAAAATGAAATATAAAATATTGTCTCAGATCTTCCAATTAATTAGTA 2666 
human-XIAP      ATTTCTGATTTTGTAAAATGAAATATAAAATAT-GTCTCAGATCTTCCAATTAATTAGTA 2807 
                ********************************* ************************** 
 
CHO-XIAP        AGGATTCATCCTTAATCCTTGCTAGTTTAAGCCTGCCTAAGTCACTTTACTAAAAGATCT 2726 
human-XIAP      AGGATTCATCCTTAATCCTTGCTAGTTTAAGCCTGCCTAAGTCACTTTACTAAAAGATCT 2867 
                ************************************************************ 
 
CHO-XIAP        TTGTTAACCCAGTATTTTAAACATTTGTCTGCTTATGTAGGTAAAAGTAGAAGCATGTTT 2786 
human-XIAP      TTGTTAACTCAGTATTTTAAACATCTGTCAGCTTATGTAGGTAAAAGTAGAAGCATGTTT 2927 
                ******** *************** **** ****************************** 
 
CHO-XIAP        GTATGCTGCTTGTAGTTTTAGTGACAGCTTTCCATGTTGAAATTCTCATGTCATTTTGTG 2846 
human-XIAP      GTACACTGCTTGTAGTTATAGTGACAGCTTTCCATGTTGAGATTCTCATATCATCTTGTA 2987 
                ***  ************ ********************** ******** **** ****  
 
CHO-XIAP        TCCTAAAAGTTTCATGTGAGTTTTTACTGTTAGGAAGATTAAGATGTATATAGTACAGAA 2906 
human-XIAP      TCTTAAA-GTTTCATGTGAGTTTTTACCGTTAGGATGATTAAGATGTATATAGGACAAAA 3046 
                ** **** ******************* ******* ***************** *** ** 
 
CHO-XIAP        TGGTAAGTCTCTAATTGTTTTATGTTTGTTTGTTTCTTGACTAGTAATAGTAGTAAATAC 2966 
human-XIAP      TGTTAAGTCTTTCCTCTACCTACATTTGTTT---TCTTGGCTAGTAATAGTAGTAGATAC 3103 
                ** ******* *  *     **  *******   ***** *************** **** 
 
CHO-XIAP        TTTAAAAATA----TTTTCTCAAGATCCTTAAGAACTCTTGGAAATTGTAACA-TACTGA 3021 
human-XIAP      TTCTGAAATAAATGTTCTCTCAAGATCCTTAAAACCTCTTGGAAATTATAAAAATATTGG 3163 
                **   *****    ** *************** * ************ *** * ** **  
 
CHO-XIAP        CAAGAG--------TAGTTGTTTAAATACTTCTAACAA----CTTGTATAAGAGTCAATA 3069 
human-XIAP      CAAGAAAAGAAGAATAGTTGTTTAAATATTTTTTAAAAAACACTTGAATAAGAATCAGTA 3223 
                *****         ************** ** * * **    **** ****** *** ** 
 
CHO-XIAP        TGA-ATAAAATCCAGCT----AAATGCTTCATAGAACA--CAGGATTTACCCTAAACAAT 3122 
human-XIAP      GGGTATAAACTAGAAGTTTAAAAATGCTTCATAGAACGTCCAGGGTTTACATTACAAGAT 3283 
                 *  ***** *  *  *    ****************   **** *****  ** *  ** 
 
CHO-XIAP        TATCATAATGGACCTCTTACAGAGACTC-TAGTCTGTTTTACTACAGAGCACAGTTTGAG 3181 
human-XIAP      TCTCACAACAAACCTATTGTAGAGGTGAGTAAGGCATGTTACTACAGAGGAAAGTTTGAG 3343 
                * *** **   **** **  ****     **     * *********** * ******** 
 
CHO-XIAP        AGTGAAACTGTTACAATTTAGATTTTTGTTGTATTTTCTAAGAGAAAGAATATTGTTAGG 3241 
human-XIAP      AGTAAAACTGTAAAAAATTATATTTTTGTTGTACTTTCTAAGAGAAAGAGTATTGTTATG 3403 
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                *** ******* * ** *** ************ *************** ******** * 
 
CHO-XIAP        TTCTCCTAACTTCTGTTGACTACTATGGTAAGTGGTGT-CATTTTAA---TTGCAAATTT 3297 
human-XIAP      TTCTCCTAACTTCTGTTGATTACTACTTTAAGTGATATTCATTTAAAACATTGCAAATTT 3463 
                ******************* *****   ****** * * ***** **   ********** 
 
CHO-XIAP        A--------------------------AATAGAAATT----------------------- 3308 
human-XIAP      ATTTTATTTATTTAATTTTCTTTTTGAGATGGAGTCTTGCTTGTCACCCAGGCTGGAGTG 3523 
                *                           ** **   *                        
 
CHO-XIAP        -AACAGAAT--------------------------------------------------- 3316 
human-XIAP      CAGTGGAGTGATCTCTGCTCACTGCAACCTCCGCCTTCTGGGTTCAAGCGATTCTCGTGC 3583 
                 *   ** *                                                    
 
CHO-XIAP        ----------TAAGTA------------------------CATTCCC--------TTTTT 3334 
human-XIAP      CTCAGCTTCCTGAGTAGCTGGAATTACAGGCAGGTGCCACCATGCCCGACTAATTTTTTT 3643 
                          * ****                        *** ***        ***** 
 
CHO-XIAP        TTCTTT------------------------------------------------------ 3340 
human-XIAP      TTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGTATCAAACTCCTGACC 3703 
                ** ***                                                       
 
CHO-XIAP        ----------------------------------------------GCTT---------- 3344 
human-XIAP      TCAAGAGATCCACTCGCCTTGCCCTCCCAAAGTGCTGGGATTACAGGCTTGAGCCACCAC 3763 
                                                              ****           
 
CHO-XIAP        ------------------------------------------------------------ 
human-XIAP      GCCCGGCTAAAACATTGCAAATTTAAATGAGAGTTTTAAAAATTAAATAATGACTGCCCT 3823 
                                                                             
 
CHO-XIAP        -TTTC---------ATGAAAATCCTTAGTTCTTTAC------ATTGTCTCCTACTTAGGT 3388 
human-XIAP      GTTTCTGTTTTAGTATGTAAATCCTCAGTTCTTCACCTTTGCACTGTCTGCCACTTAG-T 3882 
                 ****         *** ******* ******* **      * ***** * ****** * 
 
CHO-XIAP        TCAGTTGTATAGTCGAACTTAATCTAAATT--GACTAAGGTTTAAATTTAAATTTACGTT 3446 
human-XIAP      TTGGTTATATAGTCA---TTAACTTGAATTTGGTCT---GTATAGTCTAGACTTTAAATT 3936 
                *  *** *******    ****  * ****  * **   ** **   *  * ****  ** 
 
CHO-XIAP        TAAAGCATTCCACA-GGGGATAAAAGTGTTAATTTAAAAAAAAAATGTTCCCTAAGACAC 3505 
human-XIAP      TAAAGTTTTCTACAAGGGGAGAAAAGTGTTAAAATTTTTAAAATATGTTTTCCAGGACAC 3996 
                *****  *** *** ***** ***********  *    **** *****  * * ***** 
 
CHO-XIAP        TTCAGGTACAAGTCACGTAGGTAGTGTGTTTAATCTAGCTGTTAGCCAAGGATTCAAGGA 3565 
human-XIAP      TTCACTTCCAAGTCAGGTAGGTAGT----TCAATCTAGTTGTTAGCCAAGGACTCAAGGA 4052 
                ****  * ******* *********    * ******* ************* ******* 
 
CHO-XIAP        CTGAATTGTTTTTGAATAAGGCTTTTCTTGTTCTGGGAGCCTCAGTTCATTAAAACTCTC 3625 
human-XIAP      CTGAATTGTTTTAACATAAGGCTTTTCCTGTTCTGGGAGCCGCACTTCATTAAAATT--- 4109 
                ************   ************ ************* ** ********** *    
 
CHO-XIAP        CTTTTAAAACTTGTGTGCTGAGAGTTAAGCAAGACCTCTTTTTTTTTTTTTTTTTGTCTT 3685 
human-XIAP      CTTCTAAAACTTGTATGTTTAGAGTTAAGCAAGAC---------TTTTTTTCTTCCTCTC 4160 
                *** ********** ** * ***************         ******* **  ***  
 
CHO-XIAP        CATGAGTTGCGAAATTGAATTCATGAAGCTGATGTGGCTAACAAGTTTATTTTAAGAATT 3745 
human-XIAP      CATGAGTTGTGAAATTTAATGCACAACGCTGATGTGGCTAACAAGTTTATTTTAAGAATT 4220 
                ********* ****** *** **  * ********************************* 
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CHO-XIAP        GTTTAGAAAATGCTGTTGCTTCGGGTTCTTAAAATCAC--AGCATTCCAACT-CTAATCA 3802 
human-XIAP      GTTTAGAAA-TGCTGTTGCTTCAGGTTCTTAAAATCACTCAGCACTCCAACTTCTAATCA 4279 
                ********* ************ ***************  **** ******* ******* 
 
CHO-XIAP        AGTTGTTGGAGACTTACCAGAGTTGGACTGAGCTCACACTAAAATAAAAAAAACAAAACC 3862 
human-XIAP      AATTTTTGGAGACTTAACAGCATTTGTCTGTGTTTGAACTA---TAAAAAG--------- 4327 
                * ** *********** ***  ** * *** * *   ****   ******           
 
CHO-XIAP        AAAAAAAAAAAAAAAACCCTCACTGGATTCTTTCCATATAGCTGTGTAAAAAATTGGTCA 3922 
human-XIAP      --------------------CACCGGATCTTTTCCATCTAATTCCGCAAAAA-TTGATCA 4366 
                                    *** ****  ******* **  *  * ***** *** *** 
 
CHO-XIAP        CTTGGAAGGTCAAAA-TATAACCAGATCCAAATCA---CCCACCCCAGACAGTTCTCAGC 3978 
human-XIAP      TTTGCAAAGTCAAAACTATAGCCATATCCAAATCTTTTCCCCCTCCCAAGAGTTCTCAGT 4426 
                 *** ** ******* **** *** *********    *** * **  * *********  
 
CHO-XIAP        ATCTGTGTATTGA-TGTTC-TGTTCTGTATAAAGTTCACTCTAGGATTTTGAAGTAGCCA 4036 
human-XIAP      GTCTACATGTAGACTATTCCTTTTCTGTATAAAGTTCACTCTAGGATTTC-AAGTCACCA 4485 
                 ***   * * ** * *** * ***************************  ****  *** 
 
CHO-XIAP        TGTATTTTACTACTTATTAATTGTCATGTGAAATTTGAAGTTCTTCTGTAATAAATAGTT 4096 
human-XIAP      CTTATTTTACATTTTA------GTCATGCAAAGATTCAAGTAGTTTTGCAATAAGTACTT 4539 
                  ********   ***      ******  **  ** ****  ** ** ***** ** ** 
 
CHO-XIAP        AATTTTATTTGTAAT---TTACTGTGCTAATCAAAA------------TTTTTGTG---- 4137 
human-XIAP      ATCTTTATTTGTAATAATTTAGTCTGCTGATCAAAAGCATTGTCTTAATTTTTGAGAACT 4599 
                *  ************   *** * **** *******            ****** *     
 
CHO-XIAP        ---TTTGGCATT----AAGTAAACACAGTTTATTTGATTAATGGCTTAGTATTCCCTTTC 4190 
human-XIAP      GGTTTTAGCATTTACAAACTAAATTCCAGTTAATTAATTAATAGCTTTATATTGCCTTTC 4659 
                   *** *****    ** ****  *   *** ** ****** ****  **** ****** 
 
CHO-XIAP        CTTCTA-----GATTTTTGCCTCT--TCCTTTGGTTAGGGGTAGAGGTGAGGT-----GA 4238 
human-XIAP      CTGCTACATTTGGTTTTTTCCCCTGTCCCTTTGATTACGGGCTAAGGTAGGGTAGAGTGG 4719 
                ** ***     * ***** ** **   ****** *** ***   ****  ***     *  
 
CHO-XIAP        GTGTAGTAAGTGAATATAATGTGATTTGGCTATGT-TGTTATGACATTTG-----TTTTG 4292 
human-XIAP      GTGTAGTGAGTGTATATAATGTGATTTGGCCCTGTGTATTATGATATTTTGTTATTTTTG 4779 
                ******* **** *****************  *** * ****** ****      ***** 
 
CHO-XIAP        TTGTT-TAAAATGTGTATTCT-----------------TTTCTGTTTTAGTAGATAAAAT 4334 
human-XIAP      TTGTTATATTATTTACATTTCAGTAGTTGTTTTTTGTGTTTCCATTTTAGTGGATAAAAT 4839 
                ***** **  ** *  ***                   ****  ******* ******** 
 
CHO-XIAP        CTATTATCTTGAGCTCTCTGAATGGAAACTACCATCCCAGCATTAGCTGCATTTATTGTT 4394 
human-XIAP      TTGT-ATTTTGAACTA--TGAATGGAGACTACCGCCCCAGCATTAGTTTCACATGATATA 4896 
                 * * ** **** **   ******** ******  *********** * **  *  * *  
 
CHO-XIAP        CCCATTAGACCTAAATC---GTTTTACTTG-TGACTGCCCAGGTACTGAGTAAGAGAAGA 4450 
human-XIAP      CCCTTTAAACCCGAATCATTGTTTTATTTCCTGATTACACAGGTGTTGAATGGGGAAAGG 4956 
                *** *** ***  ****   ****** **  *** * * *****  *** *  *  ***  
 
CHO-XIAP        GGAGAG-------ATGAAATAGATTGCAGGTTGT-----------TGCTGTTAGAGGAAT 4492 
human-XIAP      GGCTAGTATATCAGTAGGATATACTATGGGATGTATATATATCATTGCTGTTAGAGAAAT 5016 
                **  **        *   *** * *   ** ***           *********** *** 
 
CHO-XIAP        AAGA--AAATGGAGAAATACTTGACG----ACATTT-TAGTCAAATCTCTTT-------T 4538 
human-XIAP      GAAATAAAATGGGGCTGGGCTCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCT 5076 
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                 * *  ****** *     **    *    **   * ** **  * * ****       * 
 
CHO-XIAP        TAAAAAGGTAG-----------------------CCATATAGGCTTCACAATCTGAGGTC 4575 
human-XIAP      GAGGCAGGTGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTA-ACACGGTGAAACC 5135 
                 *   **** *                       ****   ****  ***   ***   * 
 
CHO-XIAP        ATATCTCCAG-AACCCACATAAAA---GCTGGGTG----------CAC---TAGCCCCAA 4618 
human-XIAP      CCGTCTCTACTAAAAAACAGAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAG 5195 
                   **** *  **   *** ****   ** *** *          * *   *** ****  
 
CHO-XIAP        GCATC------------------------TGT-AATCCGGGAA--------TGC------ 4639 
human-XIAP      CTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGGAGGCAGAGCTTGCAGTGAG 5255 
                  *                          *** ** ******         ***       
 
CHO-XIAP        -------------------CTCCA---TGA--AACAGG---------------------A 4654 
human-XIAP      CCGAGATCTCGCCACTGCACTCCAGCCTGGGCAACAGAGCAAGACTCTGTCTCAAAAAAA 5315 
                                   *****   **   *****                      * 
 
CHO-XIAP        AGCAGATAGGAGACGGGCCA----GAAGCTA-ACTTGGCTTAGGCATT---AGCCAAGAG 4706 
human-XIAP      AAAAAAAAAGAAATAAGAAAATGGGAAGCAATATTTGACATAGTTCTTTTTAGTCAAATC 5375 
                *  * * * ** *   *  *    ***** * * *** * ***   **   ** ***    
 
CHO-XIAP        ACCCTGTTAA------GGTAG----------------GAAGG-----------TTGTCCT 4733 
human-XIAP      TACTTGTTAAAAAAAGGGTAGCAGTTTATTCATCTGTGAAAGGAAAATAATACTTATCTT 5435 
                  * ******      *****                *** *           ** ** * 
 
CHO-XIAP        ------TTG--------------GGTTATCTG---------CCCTCT---AATGTG---- 4757 
human-XIAP      ACAAGGTTGCAAGAGCTCAAGGAGACCATGTATGTAAAGTTCCTGCTGTAAATATGAACT 5495 
                      ***              *   ** *          **  **   *** **     
 
CHO-XIAP        --CATCATGATAGGCATCCACCTAT----------------ACTCGGACACACACACAAA 4799 
human-XIAP      CCCATCCTAATACCCTTTTACCTCTCTGTGGGTTTGTCTTGACCTGGAAATTTGGGCTAA 5555 
                  **** * ***  * *  **** *                **  *** *      * ** 
 
CHO-XIAP        AG---AAAAAAAAC--------AAAAA-----------------GTAGCTATCTGTAT-- 4829 
human-XIAP      AACTTAGAAAAAATTCTTACATGATAACTCAGTGATGCTTACTCATAGTTTTTGGTGTTT 5615 
                *    * ******          * **                  *** * *  ** *   
 
CHO-XIAP        ------AATAAGA-----------------------CTATTACCT-TAACC-----ATTT 4854 
human-XIAP      CTCATAGATAAGATATAAATCAGCTGGGCGCGGTGGCTCATGCCTGTAATCCCAGCACTT 5675 
                       ******                       **  * *** *** *     * ** 
 
CHO-XIAP        T----------------------ATCCAAGGT-----GATGGAATTCAACTCAA------ 4881 
human-XIAP      TGGGAGGCCGAGGCGGGCAGATCACCTGAGGTCGGGAGGTCGAGACCAGCCTGACCAACA 5735 
                *                      * *  ****     * * **   ** *   *       
 
CHO-XIAP        -GGAGAACACACCTTAATTGTTTTAAATG-----TTAACT-----------CTCA-ACCT 4923 
human-XIAP      TGGAGAA-ACCCCGTCTCTACTAAAAATACAAAATTAGCTGGGCGTGGTGGCTCATGCCT 5794 
                 ****** ** ** *   *  *  ****      *** **           ****  *** 
 
CHO-XIAP        AAAA------CTTTTT--------------------TTTTTT----CCAGGA--CAGAGT 4951 
human-XIAP      GTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGG 5854 
                  **      **  **                    *   **    ******  * ***  
 
CHO-XIAP        TTCT-----------------CTAT-GTAGCCCAGGCTGTACTCAAACATCAGCAACCCT 4993 
human-XIAP      TTGTGGTGAGCGAAGATCGTGCCATTGCACTCCAGCCTGGGC---AACAAGAGCAAAACT 5911 
                ** *                 * ** * *  **** ***  *   ****  *****  ** 
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CHO-XIAP        CTGCCTC----------------------------------------------------- 5000 
human-XIAP      CTGTCTCAAAAAAAAAAAAAGATATAAATCACAATAAATAAATAGGTCAATACAAATGTT 5971 
                *** ***                                                      
 
CHO-XIAP        -------------------TGCCTCT-GCCTCTGC--CTCTGGAGT-----GCTGGG--- 5030 
human-XIAP      AGCCAGGCGTGGTGGCACATGCCCATAGTCGCAGCTACTCTGGAGGCAGAGGCAGGAGGA 6031 
                                   ****  * * * * **  ********      ** **     
 
CHO-XIAP        ----------------ATTAAAGGT-GCA--------------TGCCACTACAGCCCAG- 5058 
human-XIAP      TCACTTGAGCCCATGAATTTGAGGCAGCAGTGAGCTATGATTGTGCCACTGTACTCCAGT 6091 
                                ***  ***  ***              *******  *  ****  
 
CHO-XIAP        -------------------------------------------------------ATTCA 5063 
human-XIAP      CTGGGTGACAGAGTGAGACCCCATCTCTAAATAAATAGGTCAAACCCTTAAAAATATTTA 6151 
                                                                       *** * 
 
CHO-XIAP        ---TCCTAAAAACTCG--------------------------TAGGCCTTCCA------- 5087 
human-XIAP      AATTCTTAAAAAATTGAAAAGATTATTCTTCTCAAATTTAGTTGAGCTTTCTAAGAGAAG 6211 
                   ** ****** * *                          *  ** *** *        
 
CHO-XIAP        ----TGGGTTCTCC-----TTGATAG--------AG---GACTTGGAC---TAA------ 5118 
human-XIAP      CAATTGGCTTTTTCCCACTTCAATAATCATTTTCAGTTTGACTCATACAGTTAACACAAT 6271 
                    *** ** * *     *  ***         **   ****   **   ***       
 
CHO-XIAP        ---------------AGCTTAATAGACC-------------GCCTGGAA----------- 5139 
human-XIAP      GTGAATTTCTTCCTCAGCATAACAGAGTTATAGAATGACAGGGCTGGAAGTGACCTTAGA 6331 
                               *** *** ***               * ******            
 
CHO-XIAP        -----------------------------AGATAACTCAGCCACTAAG------------ 5158 
human-XIAP      GAGTATCCAGTTCTTTCATTTTACAGGTGAGGCAACTGAGACTCAAAGGTGATGTAATTT 6391 
                                             **  **** ** * * ***             
 
CHO-XIAP        ---------------------AGTA----------------------------------- 5162 
human-XIAP      GTGCAAAGATTATAGCTAATTAGTAGCAGAGCCCTGACTGGGACATAGTTTGAAGGTGAA 6451 
                                     ****                                    
 
CHO-XIAP        ---CTT------GCTGC--TTCTGCAGAGGACCAAA-GTTCA-GTTCCCAGC-AC----- 5203 
human-XIAP      AAACTTCACCAAGCTACCTTTCTTGAAAGGTCCAAATGTTTATGTTTTCAACTACTCTTT 6511 
                   ***      *** *  ****  * *** ***** *** * ***  ** * **      
 
CHO-XIAP        CCAACG-----------------------GGGTGGC---TTACAACTG-CATATTAGCTC 5236 
human-XIAP      CCACTGTACCATAACTTTCACTACATATTAAATGACACTTTATAACTAATATAATAGGAC 6571 
                ***  *                          ** *   *** ****   *** ***  * 
 
CHO-XIAP        CAGCTTCAGTC--TATCTAGT--GCCCTCT-----------TTTGGCCTCCATGGG---- 5277 
human-XIAP      AATCATCAATGCATATATAGCCAGCCCTTCATATCTGTGGGTTTTGCATCCATGGATTCA 6631 
                 * * *** *   *** ***   *****             *** ** *******      
 
CHO-XIAP        -------------------CAC------------------CTACA--------------- 5285 
human-XIAP      ACCAAGGAGGAATTGAAAACACTGAGAAAAAAAAAAAAGACCACACAATAAAAAAAAAAA 6691 
                                   ***                  * ***                
 
CHO-XIAP        -TGCA--------------------------TGTGCATAT---------------ATATA 5303 
human-XIAP      ATACAAAATAATACAAAGAAAAAGCCAAAATTGT-CATACTGTTGTTAAGCAACAGTATA 6750 
                 * **                          *** ****                 **** 
 
CHO-XIAP        A-----ACATACACA-CATTA-----------------CACATAAAATAAAAATAATCCT 5340 
human-XIAP      ACAACTATTTACATAGCATTAAGGTTGGTGCAAAAATGCAAAAAAAAAAAAAGCAATTAT 6810 
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                *     *  **** * *****                 ** * **** ****  ***  * 
 
CHO-XIAP        TTTTT------------------TTTTTGGTTTT-------TCGAGACAGGGTTTC---T 5372 
human-XIAP      TTTTAAACCAACCTAATATATTGTATTAGGTATTAAAGTCATCTGGACATGAATTAAAGT 6870 
                ****                   * ** *** **       **  **** *  **    * 
 
CHO-XIAP        CTGTGGC-----TTTGGAGA------------CTGTCCT-------------GGAACTAG 5402 
human-XIAP      ATATGATGCCAGCCTGGACAAAAGGCAAAACCCTGTCTCTACAAAAAATACAAAAATTAG 6930 
                 * **         **** *            *****                 ** *** 
 
CHO-XIAP        CT-----------------CTTGTAGACCAGGCTGGCCTCGAACTCA------------- 5432 
human-XIAP      CTGGGCATGGTGGTGTGTGCCTGTAGTCCTGGCTACTCCGGAGCCTGAGGTGGGAGGATC 6990 
                **                 * ***** ** ****   *  ** *                 
 
CHO-XIAP        ----------------CAGAGAT-----------------------CTGCCTCCC--TCT 5451 
human-XIAP      GCTTGAGTCTGGGAGGCAGAGGCTGCATTGAGCTATGATCATGGCACTGCATTCCAGCCT 7050 
                                *****                         **** * **   ** 
 
CHO-XIAP        G---------------CCTC--CCTGGAAT---TAAAG----------------GCGTAC 5475 
human-XIAP      GGGTGACAGTGCAAGACCTTGTCTCAGAATAAATAAAGTATGTGATGAAGATGTGCATAC 7110 
                *               ***   *   ****   *****                ** *** 
 
CHO-XIAP        GCCAC---CAA------------------------------------------CGCCCAG 5490 
human-XIAP      ATTATATGCAAATACTGTTTTTTTTTTTTTTAATTTAAACAGTCTCACTGTGTTGCCCAG 7170 
                   *    ***                                           ****** 
 
CHO-XIAP        CA---AATAAAA----ATAATCTT---------TAAA----GCTT---AAACAA----AA 5523 
human-XIAP      GATGGAGTGCAATGGCACAATCTTGGCTCATGGCAAACTCTGCCTCGCAAGCAGCTGGGA 7230 
                 *   * *  **    * ******          ***    ** *   ** **      * 
 
CHO-XIAP        CT---GGTATATT-----------------TACTTTTTGT-------------------- 5543 
human-XIAP      CTACAGGCATGCTCCACGGTGCCCAGTTAATTTTTTTTGTATTCTTAGTAGAGACAGGGT 7290 
                **   ** **  *                 *  *******                     
 
CHO-XIAP        --CAC--TGTTA-----------CTTG--TTTCT-------------------------- 5560 
human-XIAP      TTCACCATGTTGGCCAGGCTAGTCTTGAATTTCTGACCTCAAGTGATTCATCTCCCAAAG 7350 
                  ***  ****            ****  *****                           
 
CHO-XIAP        --CTGGA-------------------------------------TGCTTCTTAGAAA--- 5578 
human-XIAP      TGCTGGGATTACAGGCGTGAGCCACCACGGCCGGCTAATTTTTGTATTTTTTAGTAGTGA 7410 
                  ****                                      *  ** **** *     
 
CHO-XIAP        --AGTTCCAGACTATCAGCTAGA---------AA----TGACCTCGGA-GAGTAGCTTAT 5622 
human-XIAP      CTGGTTTCGCGGTGTTGACCAGGCTGGTCTCGAACTCCTGATCTCAGGTGATCTGCCTGC 7470 
                   *** *    * *   * **          **    *** *** *  **   ** *   
 
CHO-XIAP        -------TCACA-------------------GCACACCACC-CTC-------------AT 5642 
human-XIAP      CTCGGCCTCACAAAGTGCTGGGATTACAGGTGTGAACCACTGCTCCCGGCCTTGTGTGAT 7530 
                       *****                   *   *****  ***             ** 
 
CHO-XIAP        TTTATC--------------------------------ATTGCGA---TAGACCCTT--- 5664 
human-XIAP      TTTATCTAAGGGACTTAAGCGTCCTCAGGTCCTAGGGGGTCGTGAAACCAAAACCCCAGG 7590 
                ******                                 * * **    * * **      
 
CHO-XIAP        --TACT--GGCACA--TG---CTTTGAAGTTGGAAAAC--CCCTTACCACACCGGCT--- 5710 
human-XIAP      GATAGCAAGGGACAATTGTATCTTCAAAGTAGACAAATGGCGCCGGGCACGGTGGCTCAC 7650 
                  **    ** ***  **   ***  **** *  ***   * *    ***   ****    
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CHO-XIAP        ACCTGT--CCTGGGAAGTCTCCGATGTT-------------TATTTT---TCAGCAGTT- 5751 
human-XIAP      GCCTGTAATCCCAGCAGTTTCCGAGGCTGAGGCAGGCGGCTCACCTGAGGTCAGGAGTTG 7710 
                 *****   *   * *** ***** * *              *  *    **** ****  
 
CHO-XIAP        -----CATTC----CATTATACTCGAATTTTCACTACACAGTAA---------------- 5786 
human-XIAP      GAGACCAGCCTGGCCAACATGCTGAAACCCTGTCTGTACAAAAATACAAAAATAGCTGGG 7770 
                     **  *    **  ** **  **   *  **  ***  **                 
 
CHO-XIAP        -ATGATA--------CTTTA----TAACTGTTA------------CAGTAGGAC------ 5815 
human-XIAP      CATGGTGGCGCATGCCTGTAGTCCCAGCTACTAGAGCGACTGAGGCAGGAGAATTGCTTG 7830 
                 *** *         ** **     * **  **            *** ** *        
 
CHO-XIAP        AACC------------------------------------------------CCTA---- 5823 
human-XIAP      AACCTGGGAGGCGGAGGTTGCAGGGAGCCAAGATGGCGCCACCGCACTCCAGCCTAGGTG 7890 
                ****                                                ****     
 
CHO-XIAP        ATA-----------CTTTT---------------------AAATTAAGTAATATGC--CG 5849 
human-XIAP      ATAGAGTGAGACTCCCTCTCAAAAACAAAACAAAACAAAAAAATTAGACAA-ATGCTACA 7949 
                ***           * * *                     ******   ** ****  *  
 
CHO-XIAP        TTAATGCTTGAGTGGTAGAGTTCTCATTTGGAGGCTCAGGTTTGTAGATGT--------- 5900 
human-XIAP      TTAATGTTTGGGTGGTCAGATTCT-ACTTTGAATCTGAAGTTTGCAGATATGCCTATAGA 8008 
                ****** *** *****    **** * ** **  ** * ***** **** *          
 
CHO-XIAP        ---TTGGCATTTACTGTGTGCTTAT---GTATCAT----GTAGCATTTAAGATTACTGTG 5950 
human-XIAP      TTTTTGGAGTTTACCACTTTCTTATTCTGTATCATTAATGTAATATTTTAAATTACTATA 8068 
                   ****  *****    * *****   *******    ***  **** * ****** *  
 
CHO-XIAP        TAAGTTTATTTTATCACTCTATCAATACCAACAAGCTTGCATTTTAAATTTGATGTTAAT 6010 
human-XIAP      TATGTT-ACCATTTTTCTGGATT--TAGTAAGAAATTTGCAGTTTTGGTTTGATGT-AAC 8124 
                ** *** *   * *  **  **   **  ** **  ***** ***   ******** **  
 
CHO-XIAP        AATGGCTTTAATGTAGTTTCTG----GTTTTGGATTTTTTTT----TTATTATGCTTCA- 6061 
human-XIAP      AAGGGTTTTAATGTAATTTATGTTAGATTTTGCATTTTTTTCATTACTGTTATATTTTAA 8184 
                ** ** ********* *** **     ***** ********      * ****  ** *  
 
CHO-XIAP        CCTGACAGAATGACCCATTCTTTTATCTTTGTGTTAGTTTTGTGAATACTTATGTTAAGA 6121 
human-XIAP      CCTGACTGACTGATCTAAT----------TGTATTAGTATTGTGAATAATCATGTGAAAT 8234 
                ****** ** *** * * *          *** ***** ********* * **** **   
 
CHO-XIAP        GTTTTGAGACAGAATACTATATTTGTGAATATAATTTTATGGCTTTTTTTCATTTAGTGG 6181 
human-XIAP      GTTTTGAGACAGAGTACTATATTTGTGAATATAATTTTATGG-TTTTTTTCACTTAG--- 8290 
                ************* **************************** ********* ****    
 
CHO-XIAP        ATACCTTTCAGTATGGAGATCTATGAAAATTGCTTTCTGCGCTATAATCTGTCCTTTGTT 6241 
human-XIAP      -AACCTTTCTGTGTGGAAAACTAAGAAAATTGCTTTCTGCTGTATAATCTGGCATTCATT 8349 
                  ******* ** **** * *** ****************  ********* * **  ** 
 
CHO-XIAP        GTAGATTAAAGCTTATTTTTCTGTGAATAAGACTTAT-CAATAAAGCACTATTCTTTAAA 6300 
human-XIAP      GTAGATTAAAGCTTATTTTTCTGTGAATAAAACGTATTCAATAAAATACTATTCTTTAAA 8409 
                ****************************** ** *** *******  ************* 
 
CHO-XIAP        ---- 
human-XIAP      ATTA 8413 
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Mir-Capture - Dissociation curve analysis: 
 
Figure 7.12: Human (SNB-19) and CHO XIAP and GAPDH melt curves after qPCR analysis post-
naked capture (no formaldehyde fixing step). GAPDH melting temperature peaks are similar and sit on 
top of each other for both species unlike the XIAP amplicons which had separate dissociation 
temperatures. 
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Figure 7.13: (A) Human (SNB-19 and CHO) XIAP melt curves after qPCR analysis post-full capture. 
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Figure 7.14: (B) Human (SNB-19 and CHO) RPLOP melt curves after qPCR analysis 
post-full capture. 
 
